Additional O O
iron B-drug B-drug
significantly O O
inhibited O O
the O O
absorption O O
of O O
cobalt B-drug B-drug
in O O
both O O
dietary O O
cobalt B-drug B-drug
treatments O O
. O O

It O O
is O O
not O O
clear O O
whether O O
this O O
was O O
due O O
to O O
the O O
combination O O
of O O
therapy O O
. O O

increased O O
creatine O O

A O O
number O O
of O O
substances O O
affect O O
glucose O O
metabolism O O
and O O
may O O
require O O
insulin B-drug O
dose O O
adjustment O O
and O O
particularly O O
close O O
monitoring O O
. O O

Beta-adrenergic B-group B-group
receptor I-group I-group
antagonists I-group I-group
( O O
beta-blockers B-group B-group
) O O
and O O
BROVANA B-brand B-brand
may O O
interfere O O
with O O
the O O
effect O O
of O O
each O O
other O O
when O O
administered O O
concurrently O O
. O O

Based O O
on O O
the O O
chemical O O
resemblance O O
of O O
itraconazole B-drug B-drug
and O O
ketoconazole B-drug B-drug
, O O
coadministration O O
of O O
astemizole B-drug B-drug
with O O
itraconazole B-drug B-drug
is O O
contraindicated O O
. O O

Unless O O
really O O
needed O O
, O O
agents O O
which O O
may O O
enhance O O
the O O
risk O O
of O O
hemorrhage O O
should O O
be O O
discontinued O O
prior O O
to O O
initiation O O
of O O
Lovenox B-brand B-brand
Injection O O
therapy O O
. O O

With O O
the O O
morning O O
dose O O
of O O
ceftibuten B-drug B-drug
on O O
day O O
6 O O
, O O
each O O
volunteer O O
received O O
a O O
single O O
intravenous O O
infusion O O
of O O
theophylline B-drug B-drug
( O O
4 O O
mg/kg O O
) O O
. O O

Ways O O
of O O
improving O O
the O O
adequacy O O
of O O
the O O
treatment O O
of O O
psychotic O O
patients O O
with O O
neuroleptics B-group B-group
are O O
discussed O O
. O O

May O O
interact O O
with O O
wthionamide O B-drug
( O O
Trecator-SC B-brand B-brand
) O O
and O O
isoniazid B-drug B-drug
( O O
Nydrazid B-brand B-brand
) O O
. O O

The O O
drugs O O
that O O
inhibit O O
cytochrome O O
P450 O O
2D6 O O
include O O
some O O
that O O
are O O
not O O
metabolized O O
by O O
the O O
enzyme O O
( O O
quinidine B-drug B-drug
; O O

Methadone B-drug B-drug
: O O
Coadministration O O
of O O
amprenavir B-drug B-drug
and O O
methadone B-drug B-drug
can O O
decrease O O
plasma O O
levels O O
of O O
methadone B-drug B-drug
. O O

N-methyllevallorphan B-drug_n B-drug_n
( O O
5 O O
mg/kg O O
, O O
s.c O O
. O O
) O O

Studies O O
showed O O
that O O
diltiazem B-drug B-drug
increased O O
the O O
AUC O O
of O O
midazolam B-drug B-drug
and O O
triazolam B-drug B-drug
by O O
3-4 O O
fold O O
and O O
the O O
Cmax O O
by O O
2-fold O O
, O O
compared O O
to O O
placebo O O
. O O

AMEVIVE B-brand B-brand
is O O
not O O
indicated O O
for O O
pediatric O O
patients O O
. O O

If O O
pregnancy O O
occurs O O
in O O
a O O
patient O O
or O O
partner O O
of O O
a O O
patient O O
during O O
treatment O O
or O O
during O O
the O O
6 O O
months O O
after O O
treatment O O
cessation O O
, O O
such O O
cases O O
should O O
be O O
reported O O
to O O
the O O
COPEGUS B-brand B-brand
Pregnancy O O
Registry O O
at O O
1-800-526-6367 O O
. O O

. O O

Steady-state O O
bosentan B-drug B-drug
plasma O O
concentrations O O
were O O
3- O O
to O O
4-fold O O
higher O O
than O O
in O O
the O O
absence O O
of O O
cyclosporine B-drug B-drug
A I-drug O
. O O

This O O
response O O
has O O
been O O
attributed O O
to O O
inhibition O O
of O O
renal O O
prostaglandin O O
synthesis O O
. O O

Therefore O O
, O O
it O O
should O O
be O O
used O O
in O O
caution O O
in O O
patients O O
receiving O O
such O O
agents O O
. O O

this O O
did O O
not O O
interfere O O
with O O
its O O
effect O O
. O O

Based O O
on O O
the O O
results O O
of O O
these O O
studies O O
, O O
it O O
is O O
concluded O O
that O O
azithromycin B-drug B-drug
may O O
be O O
safely O O
coadministered O O
with O O
both O O
zidovudine B-drug B-drug
and O O
dideoxyinosine B-drug B-drug
. O O

Hypotension O O
- O O
Patients O O
on O O
Diuretic O B-group
Therapy O O
: O O
Patients O O
on O O
diuretics B-group B-group
, O O
and O O
especially O O
those O O
in O O
whom O O
diuretic O B-group
therapy O O
was O O
recently O O
instituted O O
, O O
may O O
occasionally O O
experience O O
an O O
excessive O O
reduction O O
of O O
blood O O
pressure O O
after O O
initiation O O
of O O
therapy O O
with O O
PRINIVIL B-brand B-brand
. O O

Metformin B-drug B-drug
: O O
In O O
a O O
single-dose O O
interaction O O
study O O
in O O
NIDDM O O
subjects O O
, O O
decreases O O
in O O
glyburide B-drug B-drug
AUC O O
and O O
Cmax O O
were O O
observed O O
, O O
but O O
were O O
highly O O
variable O O
. O O

. O O

The O O
bioavailability O O
of O O
the O O
capsule O O
formulation O O
of O O
cefprozil B-drug B-drug
was O O
not O O
affected O O
when O O
administered O O
5 O O
minutes O O
following O O
an O O
antacid B-group B-group
. O O

Therefore O O
, O O
when O O
using O O
these O O
blocking O B-group
agents O I-group
to O O
treat O O
hypertension O O
, O O
patients O O
should O O
be O O
observed O O
carefully O O
in O O
order O O
to O O
confirm O O
that O O
the O O
desired O O
therapeutic O O
effect O O
has O O
been O O
obtained O O
. O O

This O O
interaction O O
was O O
not O O
accompanied O O
by O O
ECG O O
changes O O
and O O
its O O
clinical O O
significance O O
is O O
not O O
known O O
. O O

Veratrum B-group B-group
alkaloids I-group I-group
: O O
Amphetamines B-group B-group
inhibit O O
the O O
hypotensive O O
effect O O
of O O
veratrum B-group B-group
alkaloids I-group I-group
. O O

aBased O O
on O O
reports O O
of O O
narcotic O B-group
withdrawal O O
syndrome O O
in O O
patients O O
treated O O
with O O
nevirapine B-drug B-drug
and O O
methadone B-drug B-drug
concurrently O O
, O O
and O O
evidence O O
of O O
decreased O O
plasma O O
concentrations O O
of O O
methadone B-drug B-drug
. O O

The O O
administration O O
of O O
naproxen B-drug B-drug
may O O
result O O
in O O
increased O O
urinary O O
values O O
for O O
17-ketogenic O O
steroids O O
because O O
of O O
an O O
interaction O O
between O O
the O O
drug O O
and/or O O
its O O
metabolites O O
with O O
m-dinitrobenzene O B-drug_n
used O O
in O O
this O O
assay O O
. O O

these O O
enzymes O O
would O O
therefore O O
not O O
be O O
expected O O
to O O
be O O
inhibited O O
in O O
clinical O O
use O O
. O O

The O O
reduced O O
risk O O
of O O
adverse O O
events O O
and O O
therapeutic O O
superiority O O
compared O O
with O O
haloperidol B-drug B-drug
and O O
risperidone B-drug B-drug
in O O
the O O
treatment O O
of O O
negative O O
and O O
depressive O O
symptoms O O
support O O
the O O
choice O O
of O O
olanzapine B-drug B-drug
as O O
a O O
first-line O O
option O O
in O O
the O O
management O O
of O O
schizophrenia O O
in O O
the O O
acute O O
phase O O
and O O
for O O
the O O
maintenance O O
of O O
treatment O O
response O O
. O O

In O O
a O O
study O O
of O O
12 O O
schizophrenic O O
patients O O
coadministered O O
oral O O
haloperidol B-drug B-drug
and O O
rifampin B-drug B-drug
, O O
plasma O O
haloperidol B-drug B-drug
levels O O
were O O
decreased O O
by O O
a O O
mean O O
of O O
70 O O
% O O
and O O
mean O O
scores O O
on O O
the O O
Brief O O
Psychiatric O O
Rating O O
Scale O O
were O O
increased O O
from O O
baseline O O
. O O

Co-administration O O
with O O
antifungal B-group B-group
agents I-group I-group
such O O
as O O
ketoconazole B-drug B-drug
or O O
itraconazole B-drug B-drug
is O O
not O O
recommended O O
. O O

Leucovorin B-drug B-drug
may O O
enhance O O
the O O
toxicity O O
of O O
5-fluorouracil B-drug O
. O O

Laboratory O O
Tests O O
Pregnancy O O
Test O O
Female O O
patients O O
of O O
childbearing O O
potential O O
must O O
have O O
negative O O
results O O
from O O
2 O O
urine O O
or O O
serum O O
pregnancy O O
tests O O
with O O
a O O
sensitivity O O
of O O
at O O
least O O
25 O O
mIU/mL O O
before O O
receiving O O
the O O
initial O O
Accutane B-brand B-brand
prescription O O
. O O

The O O
drugs O O
that O O
inhibit O O
cytochrome O O
P450 O O
2D6 O O
include O O
some O O
that O O
are O O
not O O
metabolized O O
by O O
the O O
enzyme O O
( O O
quinidine B-drug B-drug
; O O

Mineral B-drug O
oil I-drug O
interferes O O
with O O
the O O
absorption O O
of O O
fat-soluble B-group B-group
vitamins I-group I-group
, O O
including O O
vitamin B-group B-group
D I-group I-group
preparations I-group I-group
. O O

Digoxin B-drug B-drug
half-life O O
of O O
elimination O O
was O O
prolonged O O
from O O
34 O O
+/- O O
13 O O
to O O
40 O O
+/- O O
16 O O
hours O O
( O O
p O O
less O O
than O O
0.05 O O
) O O
. O O

Therefore O O
, O O
based O O
on O O
these O O
in O O
vitro O O
data O O
, O O
estazolam B-drug B-drug
is O O
very O O
unlikely O O
to O O
inhibit O O
the O O
biotransformation O O
of O O
other O O
drugs O O
metabolized O O
by O O
these O O
CYP O O
isoforms O O

The O O
biochemical O O
toxicology O O
of O O
1,3-difluoroacetone B-drug_n B-drug_n
, O O
a O O
known O O
metabolite O O
of O O
the O O
major O O
ingredient O O
of O O
the O O
pesticide O O
Gliftor B-drug_n B-brand
( O O
1,3-difluoro-2-propanol B-drug_n B-drug_n
) O O
, O O
was O O
investigated O O
in O O
vivo O O
and O O
in O O
vitro O O
. O O

No O O
pharmacokinetic O O
interaction O O
was O O
identified O O
. O O

Alprazolam B-drug B-drug
: O O
When O O
fluvoxamine B-drug B-drug
maleate I-drug I-drug
( O O
100 O O
mg O O
qd O O
) O O
and O O
alprazolam B-drug B-drug
( O O
1 O O
mg O O
q.d O O
. O O
were O O
co-administered O O
to O O
steady O O
state O O
, O O
plasma O O
concentration O O
and O O
other O O
pharmacokinetics O O
parameters O O
( O O
AUC O O
, O O
Cmax O O
, O O
T1/2 O O
, O O
) O O
of O O
alprazolam B-drug B-drug
were O O
approximately O O
twice O O
those O O
observed O O
when O O
alprazolam B-drug B-drug
was O O
administered O O
alone O O
; O O

Drug/Laboratory O O
Test O O
Interactions O O
No O O
clinically O O
significant O O
changes O O
in O O
the O O
results O O
of O O
clinical O O
laboratory O O
tests O O
have O O
been O O
observed O O

Certain O O
drugs O O
tend O O
to O O
produce O O
hyperglycemia O O
and O O
may O O
lead O O
to O O
loss O O
of O O
blood O O
glucose O O
control O O
. O O

These O O
compounds O O
are O O
metabolized O O
through O O
various O O
cytochrome O O
P450 O O
isozymes O O
including O O
CYP1A2 O O
, O O
CYP2C9 O O
, O O
CYP2C19 O O
, O O
CYP2D6 O O
, O O
and O O
CYP3A O O
. O O

Efavirenz B-drug B-drug

The O O
pharmacokinetics O O
of O O
fenofibric B-drug_n B-drug
acid I-drug_n I-drug
were O O
not O O
significantly O O
affected O O
by O O
atorvastatin B-drug B-drug

Acebutolol B-drug B-drug
, O O
atenolol B-drug B-drug
, O O
and O O
nadolol B-drug B-drug
( O O
low O O
hepatic O O
clearance O O
or O O
no O O
first-pass O O
metabolism O O
) O O
are O O
unlikely O O
to O O
be O O
affected O O
. O O

The O O
drugs O O
that O O
inhibit O O
cytochrome O O
P450 O O
2D6 O O
include O O
some O O
that O O
are O O
not O O
metabolized O O
by O O
the O O
enzyme O O
( O O
quinidine B-drug B-drug
; O O

Drugs O O
Demonstrated O O
to O O
be O O
CYP O O
3A O O
Inhibitors O O
of O O
Possible O O
Clinical O O
Significance O O
on O O
the O O
Basis O O
of O O
Clinical O O
Studies O O
Involving O O
Alprazolam B-drug B-drug
( O O
caution O O
is O O
recommended O O
during O O
coadministration O O
with O O
alprazolam B-drug B-drug
) O O
: O O
Coadministration O O
of O O
fluoxetine B-drug B-drug
with O O
alprazolam B-drug B-drug
increased O O
the O O
maximum O O
plasma O O
concentration O O
of O O
alprazolam B-drug B-drug
by O O
46 O O
% O O
, O O
decreased O O
clearance O O
by O O
21 O O
% O O
, O O
increased O O
half-life O O
by O O
17 O O
% O O
, O O
and O O
decreased O O
measured O O
psychomotor O O
performance O O
. O O

The O O
serum O O
androgen O O
concentrations O O
of O O
estradiol B-drug B-drug
+ O O
endotoxin-treated B-drug_n O
rats O O
did O O
not O O
change O O
significantly O O
, O O
while O O
those O O
of O O
endotoxin-treated B-drug_n O
rats O O
dropped O O
to O O
30-40 O O
% O O

The O O
mechanism O O
for O O
this O O
interaction O O
is O O
unknown O O
. O O

Sucralfate B-drug B-drug
should O O
not O O
be O O
taken O O
within O O
2 O O
hours O O
of O O
FACTIVE B-brand B-brand
. O O

Diltiazem B-drug B-drug
, O O
nifedipine B-drug B-drug
, O O
verapamil B-drug B-drug

In O O
contrast O O
, O O
atropine B-drug B-drug
increased O O
the O O
amplitudes O O
of O O
components O O
P1 O O
and O O
P2 O O
, O O
while O O
decreasing O O
components O O
N1 O O
, O O
N2 O O
and O O
N3 O O
for O O
varying O O
durations O O
of O O
time O O
. O O

Clindamycin B-drug B-drug
has O O
been O O
shown O O
to O O
have O O
neuromuscular O O
blocking O O
properties O O
that O O
may O O
enhance O O
the O O
action O O
of O O
other O O
neuromuscular B-group B-group
blocking I-group I-group
agents I-group I-group
. O O

No O O
drug O O
interactions O O
of O O
clinical O O
importance O O
have O O
been O O
identified O O
. O O

Prior O O
administration O O
of O O
succinylcholine B-drug B-drug
has O O
no O O
clinically O O
important O O
effect O O
on O O
the O O
neuromuscular O O
blocking O O
action O O
of O O
NUROMAX B-brand B-brand
. O O

Imipramine B-drug B-drug
hydrochloride I-drug I-drug
may O O
potentiate O O
the O O
effects O O
of O O
CNS B-group B-group
depressant I-group I-group
drugs I-group I-group
. O O

SUSTIVA B-brand B-brand
has O O
the O O
potential O O
to O O
decrease O O
plasma O O
concentrations O O
of O O
itraconazole B-drug B-drug
and O O
ketoconazole B-drug B-drug
. O O

Since O O
symptoms O O
of O O
anticholinesterase O O
overdose O O
( O O
cholinergic O O
crisis O O
) O O
may O O
mimic O O
underdosage O O
( O O
myasthenic O O
weakness O O
) O O
, O O
their O O
condition O O
may O O
be O O
worsened O O
by O O
the O O
use O O
of O O
this O O
drug O O
. O O

Since O O
the O O
effect O O
of O O
AMEVIVE B-brand B-brand
on O O
pregnancy O O
and O O
fetal O O
development O O
, O O
including O O
immune O O
system O O
development O O
, O O
is O O
not O O
known O O
, O O
health O O
care O O
providers O O
are O O
encouraged O O
to O O
enroll O O
patients O O
currently O O
taking O O
AMEVIVE B-brand B-brand
who O O
become O O
pregnant O O
into O O
the O O
Biogen O B-brand
Pregnancy O O
Registry O O
by O O
calling O O
1-866-AMEVIVE B-brand O
( O O
1-866-263-8483 O O
) O O
. O O

Myocardial O O
injury O O
, O O
including O O
myocardial O O
infarction O O
, O O
myocarditis O O
, O O
ventricular O O
hypokinesia O O
, O O
and O O
severe O O
rhabdomyolysis O O
appear O O
to O O
be O O
increased O O
in O O
patients O O
receiving O O
PROLEUKIN B-brand B-brand
and O O
interferon-alfa B-drug B-drug
concurrently O O
. O O

In O O
comparison O O
to O O
saline O O
values O O
, O O
all O O
three O O
agents O O
produced O O
reliable O O
increases O O
in O O
peak O O
latency O O
for O O
most O O
of O O
the O O
components O O
, O O
with O O
only O O
N3 O O
showing O O
no O O
effects O O
. O O

Understanding O O
the O O
breadth O O
of O O
systemic O O
antimicrobial B-group B-group
agents I-group I-group
available O O
for O O
use O O
by O O
the O O
dermatologist O O
and O O
their O O
associated O O
side-effect O O
profiles O O
and O O
drug O O
interactions O O
allows O O
the O O
clinician O O
to O O
offer O O
patients O O
optimal O O
care O O
in O O
the O O
management O O
of O O
cutaneous O O
infectious O O
disease O O
. O O

Studies O O
in O O
humans O O
show O O
that O O
the O O
absorption O O
of O O
chlorothiazide B-drug B-drug
as O O
reflected O O
in O O
urinary O O
excretion O O
is O O
markedly O O
decreased O O
even O O
when O O
administered O O
one O O
hour O O
before O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
. O O

Anticoagulants B-group B-group
( O O
Oral O O
) O O
: O O
The O O
hypoprothrombinemic O O
effect O O
of O O
anticoagulants B-group B-group
may O O
be O O
potentiated O O
, O O
apparently O O
by O O
increased O O
catabloism O O
of O O
vitamin O O
K-dependent O O
clotting O O
factors O O
. O O

Boric B-drug B-drug
acid I-drug I-drug
may O O
interact O O
with O O
the O O
idoxuridine B-drug B-drug
preparation O O
causing O O
a O O
gritty O O
substance O O
to O O
form O O
or O O
may O O
interact O O
with O O
the O O
preservative O O
in O O
the O O
idoxuridine B-drug B-drug
preparation O O
causing O O
a O O
toxic O O
effect O O
in O O
the O O
eye O O
. O O

Although O O
inhibition O O
of O O
CYP O O
3A4/5 O O
by O O
OXC B-drug B-drug_n
and O O
MHD B-drug_n B-drug_n
did O O
occur O O
at O O
high O O
concentrations O O
, O O
it O O
is O O
not O O
likely O O
to O O
be O O
of O O
clinical O O
significance O O
. O O

The O O
dosage O O
of O O
these O O
drugs O O
or O O
others O O
with O O
a O O
similar O O
metabolism O O
may O O
need O O
to O O
be O O
modified O O
if O O
they O O
are O O
administered O O
concomitantly O O
with O O
nilutamide B-drug B-drug
. O O

Lastly O O
local O O
use O O
of O O
the O O
mucocutaneous O O
and O O
cytoprotective O O
properties O O
of O O
magnesium B-drug B-drug
is O O
still O O
valid O O
, O O
in O O
cardioplegic B-drug O
solutions I-drug O
and O O
for O O
preservation O O
of O O
transplants O O
particularly O O
. O O

Furosemide B-drug B-drug
may O O
decrease O O
arterial O O
responsiveness O O
to O O
norepinephrine B-drug B-drug
. O O

efavirenz I-drug B-drug
concentration O O

In O O
a O O
Phase O O
I O O
trial O O
using O O
escalating O O
doses O O
of O O
TAXOL B-brand B-brand
( O O
110-200 O O
mg/m2 O O
) O O
and O O
cisplatin B-drug B-drug
( O O
50 O O
or O O
75 O O
mg/m2 O O
) O O
given O O
as O O
sequential O O
infusions O O
, O O
myelosuppression O O
was O O
more O O
profound O O
when O O
TAXOL B-brand B-brand
was O O
given O O
after O O
cisplatin B-drug B-drug
than O O
with O O
the O O
alternate O O
sequence O O
( O O
ie O O
, O O
TAXOL B-brand B-brand
before O O
cisplatin B-drug B-drug
) O O
. O O

-adrenergic O B-group
Blockers O I-group
: O O
-adrenergic O B-group
blockers O I-group
may O O
weaken O O
or O O
antagonise O O
the O O
effect O O
of O O
FORADIL B-brand B-brand
. O O

The O O
key O O
to O O
maximizing O O
therapy O O
lies O O
in O O
individualizing O O
it O O
as O O
much O O
as O O
possible O O
. O O

In O O
clinical O O
studies O O
with O O
PROPECIA B-brand B-brand
( O O
finasteride B-drug B-drug
, O O
1 O O
mg O O
) O O
in O O
men O O
18-41 O O
years O O
of O O
age O O
, O O
the O O
mean O O
value O O
of O O
serum O O
prostate-specific O O
antigen O O
( O O
PSA O O
) O O
decreased O O
from O O
0.7 O O
ng/mL O O
at O O
baseline O O
to O O
0.5 O O
ng/mL O O
at O O
Month O O
12 O O
. O O

The O O
patient O O
had O O
been O O
receiving O O
simvastatin B-drug B-drug
for O O
approximately O O
six O O
months O O
. O O

Ergot-containing B-group O
drugs O O
have O O
been O O
reported O O
to O O
cause O O
prolonged O O
vasospastic O O
reactions O O
. O O

Poor O O
metabolizers O O
have O O
higher O O
than O O
expected O O
lasma O O
concentrations O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
( O O
TCAs B-group B-group
) O O
when O O
given O O
usual O O
doses O O
. O O

The O O
concomitant O O
use O O
of O O
alcohol B-drug B-drug
or O O
other O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
may O O
have O O
an O O
additive O O
effect O O
. O O

Antiarrhythmics B-drug B-group
: O O
Other O O
antiarrhythmic B-drug B-group
drugs O I-group
, O O
such O O
as O O
quinidine B-drug B-drug
, O O
procainamide B-drug B-drug
, O O
disopyramide B-drug B-drug
, O O
and O O
phenytoin B-drug B-drug
, O O
have O O
been O O
used O O
concurrently O O
with O O
amiodarone B-drug B-drug
. O O

However O O
, O O
because O O
nafarelin B-drug B-drug
acetate I-drug I-drug
is O O
a O O
peptide O O
that O O
is O O
primarily O O
degraded O O
by O O
peptidase O O
and O O
not O O
by O O
cytochrome O O
P-450 O O
enzymes O O
, O O
and O O
the O O
drug O O
is O O
only O O
about O O
80 O O
% O O
bound O O
to O O
plasma O O
proteins O O
at O O
4 O O
C O O
, O O
drug O O
interactions O O
would O O
not O O
be O O
expected O O
to O O
occur O O
. O O

However O O
, O O
since O O
there O O
is O O
an O O
increased O O
risk O O
of O O
bleeding O O
with O O
Xigris B-brand B-brand
, O O
caution O O
should O O
be O O
employed O O
when O O
Xigris B-brand B-brand
is O O
used O O
with O O
other O O
drugs O O
that O O
affect O O
hemostasis O O
. O O

In O O
addition O O
, O O
new O O
cases O O
of O O
diabetes O O
have O O
been O O
diagnosed O O
during O O
retinoid B-group O
therapy O O
, O O
including O O
diabetic O O
ketoacidosis O O
. O O

On O O
the O O
contrary O O
, O O
neurotensin B-drug_n B-drug_n
and O O
tuftsin B-drug_n O
were O O
agonists O O
in O O
induction O O
of O O
analgesia O O
. O O

A O O
chemically O O
similar O O
drug O O
in O O
this O O
class O O
produced O O
optic O O
nerve O O
degeneration O O
( O O
Wallerian O O
degeneration O O
of O O
retinogeniculate O B-drug
fibers O O
) O O
in O O
clinically O O
normal O O
dogs O O
in O O
a O O
dose-dependent O O
fashion O O
at O O
a O O
dose O O
that O O
produced O O
plasma O O
drug O O
levels O O
about O O
30 O O
times O O
higher O O
than O O
the O O
mean O O
drug O O
level O O
in O O
humans O O
taking O O
the O O
highest O O
recommended O O
dose O O
. O O

- O O
Furazolidone B-drug B-drug
( O O
e.g. O O
, O O
Furoxone B-brand B-brand
) O O
or O O

Concomitant O O
administration O O
of O O
diltiazem B-drug B-drug
with O O
carbamazepine B-drug B-drug
has O O
been O O
reported O O
to O O
result O O
in O O
elevated O O
serum O O
levels O O
of O O
carbamazepine B-drug B-drug
( O O
40 O O
% O O
to O O
72 O O
% O O
increase O O
) O O
, O O
resulting O O
in O O
toxicity O O
in O O
some O O
cases O O
. O O

In O O
single O O
and O O
multiple O O
dose O O
studies O O
in O O
healthy O O
subjects O O
receiving O O
both O O
warfarin B-drug B-drug
and O O
rofecoxib B-drug B-drug
, O O
prothrombin O O
time O O
( O O
measured O O
as O O
INR O O
) O O
was O O
increased O O
by O O
approximately O O
8 O O
% O O
to O O
11 O O
% O O
. O O

Pharmacokinetic O O
studies O O
indicate O O
that O O
administration O O
of O O
disulfiram B-drug B-drug
or O O
diazepam B-drug B-drug
does O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
acamprosate B-drug B-drug
. O O

Therefore O O
, O O
agents O O
affecting O O
sympathetic O O
activity O O
( O O
e.g. O O
, O O
ganglionic B-group B-group
blocking I-group I-group
agents I-group I-group
or O O
adrenergic B-group B-group
neuron I-group I-group
blocking I-group I-group
agents I-group I-group
) O O
should O O
be O O
used O O
with O O
caution O O
. O O

Reports O O
in O O
the O O
literature O O
suggest O O
that O O
plasma O O
levels O O
of O O
doxorubicin B-drug B-drug
( O O
and O O
its O O
active O O
metabolite O O
doxorubicinol B-drug_n B-drug
) O O
may O O
be O O
increased O O
when O O
paclitaxel B-drug B-drug
and O O
doxorubicin B-drug B-drug
are O O
used O O
in O O
combination O O
. O O

The O O
concomitant O O
use O O
of O O
H2 B-group B-group
blockers I-group I-group
or O O
proton B-group B-group
pump I-group I-group
inhibitors I-group I-group
with O O
SPRYCEL B-brand B-brand
is O O
not O O
recommended O O
. O O

The O O
results O O
indicate O O
that O O
a O O
statistically O O
significant O O
difference O O
exists O O
between O O
the O O
excreted O O
levels O O
of O O
homocysteine O O
in O O
the O O
urine O O
of O O
both O O
control O O
and O O
levonorgestrel-treated B-drug O
rats O O
and O O
the O O
levels O O
shown O O
by O O
rats O O
treated O O
with O O
ethynyl B-drug B-drug
estradiol I-drug I-drug
. O O

The O O
IV O O
methylprednisolone B-drug B-drug
dose O O
should O O
be O O
reduced O O
by O O
approximately O O
25 O O
% O O
, O O
and O O
the O O
oral O O
methylprednisolone B-drug B-drug
dose O O
should O O
be O O
reduced O O
by O O
approximately O O
50 O O
% O O
when O O
coadministered O O
with O O
Aprepitant B-drug B-drug
to O O
achieve O O
exposures O O
of O O
methylprednisolone B-drug B-drug
similar O O
to O O
those O O
obtained O O
when O O
it O O
is O O
given O O
without O O
Aprepitant B-drug B-drug
. O O

Simultaneous O O
use O O
of O O
activated B-group O
prothrombin I-group O
complex I-group O
concentrates I-group O
or O O
prothrombin B-group O
complex I-group O
concentrates I-group O
should O O
be O O
avoided O O
. O O

Digoxin B-drug B-drug
did O O
not O O
affect O O
BREVIBLOC B-brand B-brand
pharmacokinetics O O
. O O

Urinary B-drug O
acidifying I-drug O
agents O O
decrease O O
blood O O
levels O O
and O O
increase O O
excretion O O
of O O
amphetamines B-group B-group
. O O

Antibiotics B-group B-group
( O O
ampicillin B-drug B-drug
, O O
tetracycline B-drug B-drug
) O O
: O O
Pregnancy O O
has O O
been O O
reported O O
following O O
concomitant O O
use O O
, O O
however O O
, O O
pharmacokinetic O O
studies O O
have O O
not O O
shown O O
consistent O O
effects O O
with O O
these O O
antibiotics B-group B-group
on O O
plasma O O
concentrations O O
of O O
synthetic B-group B-group
steroids I-group I-group
. O O

The O O
second O O
pregnancy O O
test O O
( O O
a O O
confirmation O O
test O O
) O O
should O O
be O O
done O O
during O O
the O O
first O O
5 O O
days O O
of O O
the O O
menstrual O O
period O O
immediately O O
preceding O O
the O O
beginning O O
of O O
Accutane B-brand B-brand
therapy O O
. O O

However O O
, O O
total O O
mucosal O O
accumulation O O
of O O
As B-drug_n B-drug_n
( I-drug_n I-drug_n
V I-drug_n I-drug_n
) I-drug_n O
and O O
that O O
transferred O O
to O O
the O O
body O O
increase O O
in O O
a O O
linear O O
logarithmic O O
fashion O O
from O O
0.05 O O
to O O
5 O O
mm O O
As B-drug_n O
( I-drug_n B-drug_n
V I-drug_n I-drug_n
) I-drug_n O
. O O

Information O O
on O O
concurrent O O
usage O O
of O O
atenolol B-drug B-drug
and O O
aspirin B-brand B-brand
is O O
limited O O
. O O

In O O
order O O
to O O
avoid O O
the O O
occurrence O O
of O O
severe O O
hypersensitivity O O
reactions O O
, O O
all O O
patients O O
treated O O
with O O
TAXOL B-brand B-brand
should O O
be O O
premedicated O O
with O O
corticosteroids B-group B-group
( O O
such O O
as O O
dexamethasone B-drug B-drug
) O O
, O O
diphen-hydramine O B-drug
and O O
H2 B-group B-group
antagonists I-group I-group
( O O
such O O
as O O
cimetidine B-drug B-drug
or O O
ranitidine B-drug B-drug
) O O
. O O

Patients O O
in O O
a O O
clinical O O
study O O
who O O
were O O
on O O
established O O
therapy O O
with O O
sulfasalazine B-drug B-drug
, O O
to O O
which O O
ENBREL B-brand B-brand
was O O
added O O
, O O
were O O
noted O O
to O O
develop O O
a O O
mild O O
decrease O O
in O O
mean O O
neutrophil O O
counts O O
in O O
comparison O O
to O O
groups O O
treated O O
with O O
either O O
ENBREL B-brand B-brand
CI O O
or O O
sulfasalazine B-drug B-drug
alone O O
. O O

It O O
is O O
concluded O O
from O O
these O O
results O O
that O O
the O O
modulatory O O
effect O O
of O O
glycine B-drug B-drug
is O O
evidently O O
a O O
later O O
developmental O O
acquisition O O
( O O
after O O
day O O
15 O O
of O O
incubation O O
) O O
in O O
the O O
embryogenesis O O
of O O
NMDA-ergic O O
activation O O
of O O
spontaneous O O
motility O O
in O O
chick O O
embryos O O
similarly O O
as O O
glycinergic O O
inhibition O O
. O O

If O O
TRANXENE B-brand B-brand
is O O
to O O
be O O
combined O O
with O O
other O O
drugs O O
acting O O
on O O
the O O
central O O
nervous O O
system O O
, O O
careful O O
consideration O O
should O O
be O O
given O O
to O O
the O O
pharmacology O O
of O O
the O O
agents O O
to O O
be O O
employed O O
. O O

Plasma O O
concentrations O O
of O O
cyclosporine B-drug B-drug
should O O
therefore O O
be O O
closely O O
monitored O O
, O O
and O O
its O O
dosage O O
reduced O O
accordingly O O
, O O
in O O
patients O O
treated O O
with O O
nicardipine B-drug B-drug
. O O

Excessive O O
ethanol B-drug B-drug
ingestion O O
should O O
be O O
avoided O O
because O O
a O O
psychotic O O
reaction O O
has O O
been O O
reported O O
. O O

There O O
is O O
thus O O
an O O
enhancement O O
effect O O
of O O
PGF2alpha B-drug B-drug
upon O O
the O O
reaction O O
of O O
placental O O
vessels O O
to O O
oxytocin B-drug B-drug
in O O
vitro O O
. O O

Azithromycin B-drug B-drug

or O O
- O O
over-the-counter O O
cough O O
, O O
cold O O
, O O
allergy O O
, O O
or O O
weight O O
loss O O
medications O O
. O O

DESIGN O O
: O O
Open-label O O
, O O
three-phase O O
, O O
sequential O O
study O O
. O O

Adenosine B-drug O
effects O O
are O O
potentiated O O
by O O
dipyridamole B-drug B-drug
. O O

Aerosol O O
particles O O
of O O
budesonide B-drug B-drug
were O O
generated O O
from O O
an O O
ethanol B-drug B-drug
solution O O
, O O
dried O O
, O O
and O O
collected O O
by O O
a O O
cascade O O
impactor O O
for O O
characterization O O
or O O
by O O
a O O
liquid O O
impinger O O
for O O
dissolution O O
experiments O O
. O O

Colestipol B-drug B-drug

STUDY O O
OBJECTIVE O O
: O O
To O O
evaluate O O
the O O
effect O O
of O O
fluoxetine B-drug B-drug
on O O
the O O
pharmacokinetics O O
and O O
cardiovascular O O
safety O O
of O O
cisapride B-drug B-drug
at O O
steady O O
state O O
in O O
healthy O O
men O O
. O O

However O O
, O O
current O O
evidence O O
suggests O O
that O O
isoniazid B-drug B-drug
does O O
induce O O
P-450IIE1 O O
, O O
a O O
mixed-function O O
oxidase O O
enzyme O O
that O O
appears O O
to O O
generate O O
the O O
toxic O O
metabolites O O
, O O
in O O
the O O
liver O O
. O O

Nelfinavir B-drug B-drug
is O O
an O O
inhibitor O O
of O O
CYP3A O O
( O O
cytochrome O O
P450 O O
3A O O
) O O
. O O

The O O
vasodilating O O
effects O O
of O O
nitroglycerin B-drug B-drug
may O O
be O O
additive O O
with O O
those O O
of O O
other O O
vasodilators B-group B-group
. O O

The O O
hatching O O
of O O
miracidia O O
from O O
eggs O O
was O O
inhibited O O
by O O
concentrations O O
of O O
1000-10000 O O
microg/l O O
of O O
single O O
metals O O
. O O

Phenytoin B-drug B-drug
decreases O O
serum O O
amiodarone O B-drug
levels O O
. O O

The O O
effect O O
of O O
orally O O
ingested O O
peginterferon B-drug B-drug
or O O
ribavirin B-drug B-drug
from O O
breast O O
milk O O
on O O
the O O
nursing O O
infant O O
has O O
not O O
been O O
evaluated O O
. O O

Vardenafil B-drug B-drug
dose O O
should O O
not O O
exceed O O
a O O
maximum O O
of O O
2.5 O O
mg O O
in O O
a O O
24-hour O O
period O O
in O O
patients O O
receiving O O
concomitant O O
indinavir B-drug B-drug
therapy O O
. O O

therefore O O
, O O
caution O O
should O O
be O O
used O O
when O O
administering O O
CYP3A4 O O
inhibitors O O
with O O
IRESSA B-brand B-brand
. O O

Therefore O O
, O O
the O O
simultaneous O O
administration O O
of O O
these O O
drugs O O
should O O
be O O
avoided O O
. O O

Non-selective B-group B-group
MAO I-group I-group
inhibitors I-group I-group
including O O
tranylcypromine B-drug B-drug
sulfate I-drug I-drug
, O O
phenelzine B-drug B-drug
sulfate I-drug I-drug
, O O
and O O
pargyline B-drug B-drug
HC1 O O
: O O
Concomitant O O
use O O
of O O
L-tyrosine B-drug B-drug
and O O
non-selective O B-group
MAO B-group I-group
inhibitors I-group I-group
may O O
cause O O
hypertension O O
. O O

Acetaminophen B-drug B-drug
had O O
no O O
effect O O
on O O
plasma O O
levels O O
of O O
diflunisal B-drug B-drug
. O O

However O O
, O O
in O O
patients O O
treated O O
with O O
oral O O
carbonic B-group B-group
anhydrase I-group I-group
inhibitors I-group I-group
, O O
rare O O
instances O O
of O O
drug O O
interactions O O
have O O
occurred O O
with O O
high-dose O O
salicylate B-drug B-group
therapy O O
. O O

Immunosuppressive B-group B-group
Drugs I-group I-group
, O O
Fibric B-group B-group
Acid I-group I-group
Derivatives I-group I-group
, O O
Niacin B-drug B-drug
( O O
Nicotinic B-drug B-drug
Acid I-drug I-drug
, O O
Erythromycin B-drug B-drug
, O O
Azole B-group B-group
Antifungals I-group I-group
: O O
Skeletal O O
Muscle O O
. O O

Further O O
, O O
these O O
results O O
confirm O O
that O O
the O O
diabetic O O
Chinese O O
hamster O O
's O O
alpha O B-drug
and O O
beta O O
cells O O
respond O O
normally O O
to O O
theophylline B-drug B-drug
, O O
but O O
are O O
relatively O O
insensitive O O
to O O
glucose B-drug O
. O O

Patients O O
treated O O
with O O
acebutolol B-drug B-drug
plus O O
catecholamine B-group O
depletors I-group O
should O O
, O O
therefore O O
, O O
be O O
observed O O
closely O O
for O O
evidence O O
of O O
marked O O
bradycardia O O
or O O
hypotension O O
which O O
may O O
present O O
as O O
vertigo O O
, O O
syncope/presyncope O O
, O O
or O O
orthostatic O O
changes O O
in O O
blood O O
pressure O O
without O O
compensatory O O
tachycardia O O
. O O

Thus O O
, O O
the O O
hypothesis O O
of O O
Gibaldi O B-brand
et O O
al O O
. O O

This O O
has O O
been O O
observed O O
with O O
CLINITEST O O
reagent O O
tablets O O

For O O
patients O O
with O O
amenorrhea O O
, O O
the O O
second O O
test O O
should O O
be O O
done O O
at O O
least O O
11 O O
days O O
after O O
the O O
last O O
act O O
of O O
unprotected O O
sexual O O
intercourse O O
( O O
without O O
using O O
2 O O
effective O O
forms O O
of O O
contraception O O
) O O
. O O

No O O
interactions O O
have O O
been O O
observed O O
with O O
beta-receptor B-group B-group
blockers I-group I-group
, O O
calcium B-group B-group
antagonists I-group I-group
, O O
thiazide O B-group
and O O
loop B-group B-group
diuretics I-group I-group
and O O
ACE B-group B-group
inhibitors I-group I-group
. O O

These O O
experiences O O
have O O
been O O
characterized O O
by O O
flushing O O
, O O
rash O O
, O O
peripheral O O
edema O O
, O O
nausea O O
, O O
and O O
headache O O
. O O

Modification O O
of O O
toxin B-drug_n B-drug_n
A I-drug_n I-drug_n
with O O
diethyl B-drug_n B-drug
pyrocarbonate I-drug_n I-drug
abolished O O
both O O
its O O
cytotoxic O O
activity O O
and O O
the O O
ability O O
of O O
the O O
toxin O O
to O O
bind O O
Zn-Sepharose O O
gel O O
. O O

Flurbiprofen B-drug B-drug
pretreatment O O
attenuated O O
the O O
hypotensive O O
effect O O
of O O
a O O
single O O
dose O O
of O O
propranolol B-drug B-drug
but O O
not O O
atenolol B-drug B-drug
. O O

Conclusions O O
and O O
the O O
types O O
of O O
studies O O
which O O
support O O
these O O
conclusions O O
are O O
given O O
for O O
each O O
major O O
section O O
. O O

Thiazide B-group B-group
Diuretics I-group I-group
: O O
The O O
reports O O
that O O
the O O
concomitant O O
use O O
of O O
allopurinol B-drug B-drug
and O O
thiazide B-group B-group
diuretics I-group I-group
may O O
contribute O O
to O O
the O O
enhancement O O
of O O
allopurinol B-drug B-drug
toxicity O O
in O O
some O O
patients O O
have O O
been O O
reviewed O O
in O O
an O O
attempt O O
to O O
establish O O
a O O
cause-and-effect O O
relationship O O
and O O
a O O
mechanism O O
of O O
causation O O
. O O

Concurrent O O
administration O O
of O O
vasopressor B-group B-group
drugs I-group I-group
( O O
for O O
the O O
treatment O O
of O O
hypotension O O
related O O
to O O
obstetric O O
blocks O O
) O O
and O O
ergot-type B-group B-group
oxytocic I-group I-group
drugs I-group I-group
may O O
cause O O
severe O O
, O O
persistent O O
hypertension O O
or O O
cerebrovascular O O
accidents O O
. O O

For O O
example O O
, O O
when O O
vitamin B-group B-group
K I-group I-group
antagonists I-group I-group
are O O
administered O O
concomitantly O O
with O O
nilutamide B-drug B-drug
, O O
prothrombin O O
time O O
should O O
be O O
carefully O O
monitored O O
and O O
if O O
necessary O O
, O O
the O O
dosage O O
of O O
vitamin B-group B-group
K I-group I-group
antagonists I-group I-group
should O O
be O O
reduced O O
. O O

Theophylline B-drug B-drug
: O O
Grepafloxacin B-drug B-drug
is O O
a O O
competitive O O
inhibitor O O
of O O
the O O
metabolism O O
of O O
theophylline B-drug B-drug
. O O

However O O
, O O
the O O
absolute O O
number O O
of O O
alcohol-related B-drug O
deaths O O
is O O
far O O
greater O O
than O O
the O O
number O O
of O O
deaths O O
in O O
amphetamine B-drug B-drug
or O O
heroin B-drug_n B-drug
users O O
. O O

Phenytoin/Phenobarbital B-drug O
: O O
The O O
coadministration O O
of O O
phenytoin B-drug B-drug
or O O
phenobarbital B-drug B-drug
will O O
not O O
affect O O
plasma O O
concentrations O O
of O O
vitamin B-group B-group
D I-group I-group
, O O
but O O
may O O
reduce O O
endogenous O O
plasma O O
levels O O
of O O
calcitriol/ergocalcitriol B-drug B-drug
by O O
accelerating O O
metabolism O O
. O O

In O O
the O O
presence O O
of O O
these O O
methylxanthines B-group B-group
, O O
larger O O
doses O O
of O O
adenosine B-drug B-drug
may O O
be O O
required O O
or O O
adenosine B-drug B-drug
may O O
not O O
be O O
effective O O
. O O

Gastrointestinal O O
: O O
Nausea O O
( O O
4-12 O O
% O O
) O O
, O O
constipation O O
( O O
2-6 O O
% O O
) O O
; O O

If O O
a O O
diuretic B-group B-group
is O O
also O O
used O O
, O O
the O O
risk O O
of O O
lithium O B-drug
toxicity O O
may O O
be O O
increased O O
. O O

The O O
administration O O
of O O
epinephrine B-drug B-drug
should O O
be O O
avoided O O
in O O
the O O
treatment O O
of O O
drug O O
induced O O
hypotension O O
because O O
of O O
a O O
possible O O
reverse O O
epinephrine B-drug O
effect O O
. O O

The O O
blood O O
pressure O O
( O O
carotid O O
cannulation O O
) O O
decreased O O
along O O
with O O
the O O
core O O
temperature O O
. O O

The O O
decrease O O
in O O
temperature O O
began O O
within O O
20 O O
minutes O O
after O O
ethanol B-drug B-drug
administration O O
, O O
reaching O O
a O O
maximal O O
decrease O O
between O O
60 O O
and O O
120 O O
minutes O O
post O O
ethanol B-drug B-drug
. O O

Aripiprazole B-drug B-drug
dose O O
should O O
be O O
reduced O O
to O O
one-half O O
of O O
its O O
normal O O
dose O O
when O O
concomitant O O
administration O O
of O O
quinidine B-drug B-drug
with O O
aripiprazole B-drug B-drug
occurs O O
. O O

Dose O O
adjustment O O
is O O
not O O
recommended.Levetiracetam B-drug O
had O O
no O O
effect O O
on O O
plasma O O
concentrations O O
of O O
carbamazepine B-drug B-drug
, O O
valproate B-drug B-drug
, O O
topiramate B-drug B-drug
, O O
or O O
lamotrigine B-drug B-drug
. O O

Peripheral O O
mononuclear O O
cells O O
were O O
also O O
collected O O
for O O
quantitation O O
of O O
phosphorylated O O
zidovudine B-drug B-drug
. O O

Dose O O
adjustments O O
of O O
either O O
class O O
of O O
agents O O
may O O
be O O
necessary O O
. O O

In O O
the O O
present O O
study O O
, O O
it O O
is O O
proposed O O
that O O
the O O
opioids B-group B-group
applied O O
to O O
supraspinal O O
brain O O
sites O O
produced O O
their O O
analgesic O O
effects O O
by O O
the O O
activation O O
of O O
different O O
descending O O
pain O O
inhibitory O O
systems O O
. O O

Warfarin B-drug B-drug
: O O
The O O
effect O O
of O O
valdecoxib B-drug B-drug
on O O
the O O
anticoagulant O O
effect O O
of O O
warfarin B-drug B-drug
( O O
1 O O
- O O
8 O O
mg/day O O
) O O
was O O
studied O O
in O O
healthy O O
subjects O O
by O O
coadministration O O
of O O
BEXTRA B-brand B-brand
40 O O
mg O O
BID O O
for O O
7 O O
days O O
. O O

While O O
mean O O
INR O O
values O O
were O O
only O O
slightly O O
increased O O
with O O
coadministration O O
of O O
valdecoxib B-drug B-drug
, O O
the O O
day-to-day O O
variability O O
in O O
individual O O
INR O O
values O O
was O O
increased O O
. O O

The O O
preservation O O
of O O
the O O
microtubules O O
was O O
improved O O
when O O
D2O O O
was O O
present O O
in O O
the O O
incubation O O
medium O O
. O O

With O O
simultaneous O O
dosing O O
of O O
Vardenafil B-drug B-drug
10 O O
mg O O
and O O
terazosin B-drug B-drug
10 O O
mg O O
, O O
6 O O
of O O
8 O O
subjects O O
experienced O O
a O O
standing O O
systolic O O
blood O O
pressure O O
of O O
less O O
than O O
85 O O
mm O O
Hg O O
. O O

Lithium B-drug B-drug
: O O
Inhibition O O
of O O
renal O O
lithium B-drug B-drug
clearance O O
, O O
leading O O
to O O
an O O
increase O O
in O O
plasma O O
lithium B-drug B-drug
concentration O O
, O O
has O O
been O O
reported O O
with O O
some O O
prostaglandin O B-group
synthesis-inhibiting O I-group
drugs O I-group
. O O

Drugs O O
that O O
reduce O O
the O O
number O O
of O O
blood O O
platelets O O
by O O
causing O O
bone O O
marrow O O
depression O O
( O O
such O O
as O O
antineoplastic B-group B-group
agents I-group I-group
) O O
or O O
drugs O O
which O O
inhibit O O
platelet O O
function O O
( O O
eg O O
, O O
aspirin B-brand B-brand
and O O
other O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
, O O
dipyridamole B-drug B-drug
, O O
hydrochloroquine B-drug B-drug
, O O
clofibrate B-drug B-drug
, O O
dextran B-drug B-drug
) O O
may O O
increase O O
the O O
bleeding O O
tendency O O
produced O O
by O O
anticoagulants B-group B-group
without O O
altering O O
prothrombin O O
time O O
determinations O O
. O O

Monitoring O O
for O O
amiodarone B-drug B-drug
toxicity O O
and O O
serial O O
measurement O O
of O O
amiodarone B-drug B-drug
serum O O
concentration O O
during O O
concomitant O O
protease B-group B-group
inhibitor I-group I-group
therapy O O
should O O
be O O
considered O O
. O O

Interactions O O
with O O
Fruit O O
Juices O O
Fruit O O
juices O O
such O O
as O O
grapefruit O O
, O O
orange O O
and O O
apple O O
may O O
reduce O O
the O O
bioavailability O O
and O O
exposure O O
of O O
fexofenadine B-drug B-drug
. O O

The O O
effects O O
of O O
oral O O
neomycin B-drug B-drug
on O O
ACTH B-group B-drug
induced O O
hypertension O O
were O O
examined O O
in O O
conscious O O
sheep O O
. O O

Cardiovascular O O
disease O O
is O O
a O O
common O O
comorbidity O O
and O O
a O O
major O O
cause O O
of O O
mortality O O
in O O
patients O O
with O O
chronic O O
renal O O
disease O O
. O O

Patients O O
taking O O
warfarin B-drug B-drug
or O O
other O O
coumarin-derivative B-group B-group
anticoagulants I-group I-group
should O O
be O O
monitored O O
regularly O O
for O O
changes O O
in O O
prothrombin O O
time O O
or O O
INR O O

Risk O O
of O O
Anaphylactic O O
Reaction O O
: O O
Although O O
it O O
is O O
known O O
that O O
patients O O
on O O
beta-blockers B-group B-group
may O O
be O O
refractory O O
to O O
epinephrine B-drug B-drug
in O O
the O O
treatment O O
of O O
anaphylactic O O
shock O O
, O O
beta-blockers B-group B-group
can O O
, O O
in O O
addition O O
, O O
interfere O O
with O O
the O O
modulation O O
of O O
allergic O O
reaction O O
and O O
lead O O
to O O
an O O
increased O O
severity O O
and/or O O
frequency O O
of O O
attacks O O
. O O

- O O
Increased O O
thyroid-binding O O
globulin O O
( O O
TBG O O
) O O
leading O O
to O O
in-creased O O
circulating O O
total O O
thyroid O O
hormone O O
; O O

Serum O O
digoxin B-drug B-drug
levels O O
using O O
an O O
125I-labelled O O
antigen O O
: O O
Validation O O
of O O
method O O
and O O
observations O O
on O O
cardiac O O
patients O O
. O O

There O O
are O O
no O O
known O O
drug O O
interactions O O
with O O
LEUSTATIN B-brand B-brand
Injection O O
. O O

This O O
cluster O O
of O O
metabolic O O
abnormalities O O
has O O
been O O
termed O O
the O O
insulin O O
resistance O O
or O O
cardiovascular O O
dysmetabolic O O
syndrome O O
. O O

Deferasirox B-drug B-drug
should O O
be O O
taken O O
on O O
an O O
empty O O
stomach O O
30 O O
minutes O O
before O O
eating O O
. O O

As O O
DIFFERIN B-brand B-brand
Gel O O
has O O
the O O
potential O O
to O O
produce O O
local O O
irritation O O
in O O
some O O
patients O O
, O O
concomitant O O
use O O
of O O
other O O
potentially O O
irritating O O
topical O O
products O O
( O O
medicated O O
or O O
abrasive O O
soaps O O
and O O
cleansers O O
, O O
soaps O O
and O O
cosmetics O O
that O O
have O O
a O O
strong O O
drying O O
effect O O
, O O
and O O
products O O
with O O
high O O
concentrations O O
of O O
alcohol O B-drug
, O O
astringents O B-group
, O O
spices O O
or O O
lime O O
) O O
should O O
be O O
approached O O
with O O
caution O O
. O O

To O O
investigate O O
the O O
effects O O
of O O
antimicrobial O O
combinations O O
of O O
GL B-drug_n B-drug_n
with O O
four O O
kinds O O
of O O
antibiotics B-group B-group
( O O
ampicillin B-drug B-drug
, O O
cefazolin B-drug B-drug
, O O
oxytetracycline B-drug B-drug
and O O
chloramphenicol B-drug B-drug
) O O
, O O
the O O
fractional O O
inhibitory O O
concentration O O
index O O
( O O
FICI O O
) O O
was O O
determined O O
by O O
checkerboard O O
assay O O
for O O
each O O
strain O O
. O O

Effect O O
of O O
Clonazepam B-drug B-drug
on O O
the O O
Pharmacokinetics O O
of O O
Other O O
Drugs O O
: O O
Clonazepam B-drug B-drug
does O O
not O O
appear O O
to O O
alter O O
the O O
pharmacokinetics O O
of O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
or O O
phenobarbital B-drug B-drug
. O O

Excystment O O
in O O
vitro O O
was O O
only O O
significantly O O
affected O O
by O O
cercariae O O
exposed O O
to O O
cadmium/zinc O O
mixtures O O
whilst O O
encysting O O
. O O

Hypokalemia O O
may O O
increase O O
susceptibility O O
to O O
cardiac O O
arrhythmias O O
in O O
patients O O
treated O O
with O O
digitalis B-group B-group
. O O

Lamivudine B-drug B-drug
: O O
In O O
vitro O O
studies O O
in O O
peripheral O O
blood O O
mononuclear O O
cells O O
, O O
U937 O O
and O O
Molt-4 O O
cells O O
revealed O O
that O O
lamivudine B-drug B-drug
significantly O O
inhibited O O
zalcitabine B-drug B-drug
phosphorylation O O
in O O
a O O
dose O O
dependent O O
manner O O
. O O

Therefore O O
, O O
precaution O O
should O O
be O O
taken O O
when O O
coadministration O O
is O O
necessary O O
. O O

as O O
judged O O
by O O
increased O O
serum O O
enzyme O O
activities O O
and O O
increased O O
incidence O O
of O O
hepatic O O
necrosis O O
. O O

Caution O O
should O O
be O O
exercised O O
if O O
an O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitor I-group I-group
is O O
administered O O
concomitantly O O
with O O
drugs O O
that O O
may O O
decrease O O
the O O
levels O O
or O O
activity O O
of O O
endogenous O B-group
steroid O I-group
hormones O I-group
, O O
such O O
as O O
ketoconazole B-drug B-drug
, O O
spironolactone B-drug B-drug
, O O
and O O
cimetidine B-drug B-drug
. O O

Inhibitors O O
of O O
CYP2D6 O O
: O O
Because O O
CYP2D6 O O
is O O
involved O O
in O O
duloxetine B-drug B-drug
metabolism O O
, O O
concomitant O O
use O O
of O O
duloxetine B-drug B-drug
with O O
potent O O
inhibitors O O
of O O
CYP2D6 O O
may O O
result O O
in O O
higher O O
concentrations O O
of O O
duloxetine B-drug B-drug
. O O

Ketoconazole B-drug B-drug
: O O
Co-administration O O
of O O
200 O O
mg O O
twice-daily O O
ketoconazole B-drug B-drug
with O O
aliskiren B-drug B-drug
resulted O O
in O O
an O O
approximate O O
80 O O
% O O
increase O O
in O O
plasma O O
levels O O
of O O
aliskiren B-drug B-drug
. O O

The O O
pharmacokinetic O O
variables O O
for O O
digoxin B-drug B-drug
were O O
determined O O
after O O
a O O
1.0 O O
mg O O
intravenous O O
dose O O
of O O
digoxin B-drug B-drug
in O O
each O O
subject O O
, O O
before O O
and O O
after O O
oral O O
amiodarone B-drug B-drug
, O O
400 O O
mg O O
daily O O
for O O
3 O O
weeks O O
. O O

Drugs O O
That O O
Interfere O O
With O O
Hemostasis O O
( O O
NSAIDs B-group B-group
, O O
Aspirin B-brand B-brand
, O O
Warfarin B-drug B-drug
, O O
etc O O
. O O
) O O

Rat O O
kidney O O
homogenates O O
supplemented O O
with O O
coenzyme O O
A O O
, O O
ATP O O
, O O
oxaloacetate O B-drug
, O O
and O O
Mg2+ O O
converted O O
1,3-difluoroacetone B-drug_n B-drug_n
to O I-drug_n
( B-drug_n I-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-erythro-fluorocitrate I-drug_n I-drug_n
in O O
vitro O O
. O O

mefenamic B-drug B-drug
acid I-drug I-drug
; O O

Genitourinary O O
: O O
Urinary O O
frequency O O
( O O
2-6 O O
% O O
) O O
; O O

Human O O
pharmacokinetics O O
data O O
indicate O O
that O O
oral O O
ketoconazole B-drug B-drug
potently O O
inhibits O O
the O O
metabolism O O
of O O
cisapride B-drug B-drug
resulting O O
in O O
a O O
mean O O
eight-fold O O
increase O O
in O O
AUC O O
of O O
cisapride B-drug B-drug
. O O

Ketoconazole B-drug B-drug
at O O
400 O O
mg O O
daily O O
( O O
the O O
maximum O O
approved O O
prescription O O
dose O O
) O O
co-administered O O
with O O
TIKOSYN B-brand B-brand
( O O
500 O O
mcg O O
BID O O
) O O
for O O
7 O O
days O O
has O O
been O O
shown O O
to O O
increase O O
dofetilide B-drug B-drug
Cmax O O
by O O
53 O O
% O O
in O O
males O O
and O O
97 O O
% O O
in O O
females O O
, O O
and O O
AUC O O
by O O
41 O O
% O O
in O O
males O O
and O O
69 O O
% O O
in O O
females O O
. O O

Any O O
agent O O
that O O
alters O O
thyroid O O
hormone O O
synthesis O O
, O O
secretion O O
, O O
distribution O O
, O O
effect O O
on O O
target O O
tissues O O
, O O
metabolism O O
, O O
or O O
elimination O O
may O O
alter O O
the O O
optimal O O
therapeutic O O
dose O O
of O O
levothyroxine B-drug B-drug
sodium O I-drug
. O O

Cysteine B-drug B-drug
conjugation O O
at O O
3.6 O O
, O O
5.3 O O
and O O
7.3 O O
% O O
( O O
m/m O O
) O O
resulted O O
in O O
R-values O O
of O O
1.4 O O
, O O
1.7 O O
and O O
1.8 O O
, O O
respectively O O
. O O

Monoamine B-group B-group
Oxidase I-group I-group
Inhibitors I-group I-group
: O O
Coadministration O O
of O O
moclobemide B-drug B-drug
resulted O O
in O O
a O O
27 O O
% O O
decrease O O
in O O
almotriptan B-drug B-drug
clearance O O
and O O
an O O
increase O O
in O O
Cmax O O
of O O
approximately O O
6 O O
% O O
. O O

GI O O
Motility O O
Agent O O
: O O
cisapride* B-drug B-drug
CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and/or O O
life-threatening O O
reactions O O
such O O
as O O
cardiac O O
arrhythmias O O
. O O

However O O
, O O
increasing O O
use O O
of O O
such O O
preparations O O
to O O
control O O
symptoms O O
indicates O O
deterioration O O
of O O
asthma O O
control O O
and O O
the O O
need O O
to O O
reassess O O
the O O
patient O O
s O O
therapy O O
. O O

Concomitant O O
administration O O
of O O
FACTIVE B-brand B-brand
and O O
calcium B-drug B-drug
carbonate I-drug I-drug
, O O
cimetidine B-drug B-drug
, O O
omeprazole B-drug B-drug
, O O
or O O
an O O
estrogen/progesterone B-group B-drug
oral O O
contraceptive B-group B-group
produced O O
minor O O
changes O O
in O O
the O O
pharmacokinetics O O
of O O
gemifloxacin B-drug B-drug
, O O
which O O
were O O
considered O O
to O O
be O O
without O O
clinical O O
significance O O
. O O

Interaction O O
with O O
Food O O
See O O
CLINICAL O O
PHARMACOLOGY O O
, O O
Pharmacokinetics O O
and O O
Metabolism O O
. O O

5-HT3 B-group B-group
antagonists I-group I-group
: O O
In O O
clinical O O
drug O O
interaction O O
studies O O
, O O
aprepitant B-drug B-drug
did O O
not O O
have O O
clinically O O
important O O
effects O O
on O O
the O O
pharmacokinetics O O
of O O
ondansetron B-drug B-drug
or O O
granisetron B-drug B-drug
. O O

Use O O
lowest O O
possible O O
dose O O
of O O
atorvastatin B-drug B-drug
with O O
careful O O
monitoring O O
, O O
or O O
consider O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
that O O
are O O
not O O
primarily O O
metabolized O O
by O O
CYP3A4 O O
, O O
such O O
as O O
pravastatin B-drug B-drug
, O O
fluvastatin B-drug B-drug
, O O
or O O
rosuvastatin B-drug B-drug
in O O
combination O O
with O O
CRIXIVAN B-brand B-brand
. O O

Patients O O
who O O
have O O
been O O
treated O O
with O O
MAO B-group B-group
inhibitors I-group I-group
within O O
two O O
to O O
three O O
weeks O O
prior O O
to O O
the O O
administration O O
of O O
dopamine B-drug B-drug
HCl I-drug I-drug
should O O
receive O O
initial O O
doses O O
of O O
dopamine B-drug B-drug
HCl I-drug I-drug
no O O
greater O O
than O O
one-tenth O O
( O O
1/10 O O
) O O
of O O
the O O
usual O O
dose O O
. O O

There O O
is O O
considerable O O
evidence O O
suggesting O O
that O O
histaminergic O O
and O O
serotoninergic O O
central O O
pathways O O
are O O
involved O O
in O O
nociception O O
and O O
that O O
antihistaminic B-group B-group
drugs O I-group
can O O
modulate O O
their O O
responses O O
( O O
1 O O
) O O
. O O

Glyburide B-drug B-drug
: O O
Glyburide B-drug B-drug
is O O
a O O
CYP O O
2C9 O O
substrate O O
. O O

The O O
concomitant O O
use O O
of O O
nitrofurantoin B-drug B-drug
is O O
not O O
recommended O O
since O O
nitrofurantoin B-drug B-drug
may O O
antagonize O O
the O O
antibacterial O O
effect O O
of O O
Norfloxacin B-drug B-drug
in O O
the O O
urinary O O
tract O O
. O O

Use O O
of O O
a O O
nonhormonal B-group B-group
contraceptive I-group I-group
product I-group I-group
is O O
recommended O O
. O O

The O O
hypotensive O O
effect O O
of O O
sodium B-drug B-drug
nitroprusside I-drug I-drug
is O O
augmented O O
by O O
that O O
of O O
most O O
other O O
hypotensive B-group O
drugs I-group O
, O O
including O O
ganglionic B-group B-group
blocking I-group I-group
agents I-group I-group
, O O
negative O O
inotropic O B-group
agents O I-group
, O O
and O O
inhaled O O
anesthetics B-group B-group
. O O

GABITRIL B-brand B-brand
is O O
considered O O
to O O
be O O
a O O
non-enzyme O O
inducing O O
AED B-group B-group
. O O

The O O
following O O
drugs O O
have O O
been O O
coadministered O O
with O O
Kerlone B-brand B-brand
and O O
have O O
not O O
altered O O
its O O
pharmacokinetics O O
: O O
cimetidine B-drug B-drug
, O O
nifedipine B-drug B-drug
, O O
chlorthalidone B-drug B-drug
, O O
and O O
hydrochlorothiazide B-drug B-drug
. O O

AUCss O O
( O O
0-12h O O
) O O
( O O
Extent O O
of O O
systemic O O
exposure O O
) O O

Although O O
concomitant O O
use O O
of O O
Clozapine B-drug B-drug
and O O
carbamazepine B-drug B-drug
is O O
not O O
recommended O O
, O O
it O O
should O O
be O O
noted O O
that O O
discontinuation O O
of O O
concomitant O O
carbamazepine B-drug B-drug
administration O O
may O O
result O O
in O O
an O O
increase O O
in O O
Clozapine B-drug B-drug
plasma O O
levels O O
. O O

Sildenafil B-drug B-drug

Therefore O O
, O O
coagulation O O
indices O O
should O O
be O O
monitored O O
to O O
maintain O O
the O O
desired O O
anticoagulant O O
effect O O
. O O

Data O O
from O O
studies O O
to O O
date O O
show O O
that O O
disease O O
states O O
, O O
underlying O O
conditions O O
, O O
and O O
concomitantly O O
administered O O
highly O O
protein-bound O O
drugs O O
have O O
essentially O O
no O O
effect O O
on O O
etodolac B-drug B-drug
pharmacokinetics O O
. O O

Warfarin B-drug B-drug
: O O
Increased O O
INR O O
( O O
International O O
Normalized O O
Ratio O O
) O O
when O O
ARAVA B-brand B-brand
and O O
warfarin B-drug B-drug
were O O
co-administered O O
has O O
been O O
rarely O O
reported O O
. O O

The O O
mechanism O O
for O O
this O O
interaction O O
probably O O
is O O
adsorption O O
of O O
nitrofurantoin B-drug B-drug
onto O O
the O O
surface O O
of O O
magnesium B-drug B-drug
trisilicate I-drug I-drug
. O O

An O O
oral O O
glucose B-drug O
overload O O
of O O
1 O O
ml O O
of O O
a O O
50 O O
% O O
glucose B-drug O
solution O O
was O O
given O O
to O O
rats O O
and O O
blood O O
glucose O O
was O O
determined O O
after O O
30 O O
, O O
60 O O
and O O
90 O O
min O O
. O O

Caution O O
should O O
be O O
exercised O O
when O O
imipramine B-drug B-drug
hydrochloride I-drug I-drug
is O O
used O O
with O O
agents O O
that O O
lower O O
blood O O
pressure O O
. O O

Rifampin B-drug B-drug

There O O
is O O
the O O
possibility O O
of O O
precipitating O B-group
anticonvulsant O I-group
drug O I-group
toxicity O O
. O O

Because O O
of O O
possible O O
additive O O
effects O O
with O O
other O O
carbonic B-group B-group
anhydrase I-group I-group
inhibitors I-group I-group
, O O
concomitant O O
use O O
is O O
not O O
advisable O O
. O O

certain O O
tetracyclic B-group B-group
antidepressants I-group I-group
( O O
such O O
as O O
maprotiline B-drug B-drug
) O O
; O O

Nonsteroidal B-drug B-group
Antiinflammatory I-drug I-group
Agents O I-group
: O O
Aspirin B-drug B-brand
is O O
contraindicated O O
in O O
patients O O
who O O
are O O
hypersensitive O O
to O O
nonsteroidal B-drug B-group
anti-inflammatory I-drug I-group
agents O I-group
. O O

There O O
are O O
no O O
data O O
that O O
conclusively O O
establish O O
whether O O
the O O
concomitant O O
administration O O
of O O
Mefloquineuine O O
and O O
the O O
above O O
listed O O
agents O O
has O O
an O O
effect O O
on O O
cardiac O O
function O O
. O O

especially O O
if O O
these O O
patients O O
are O O
extensive O O
metabolizers O O
. O O

These O O
drugs O O
include O O
the O O
thiazides B-group B-group
and O O
other O O
diuretics B-group B-group
, O O
corticosteroids B-group B-group
, O O
phenothiazines B-group B-group
, O O
thyroid B-group B-group
products I-group I-group
, O O
estrogens B-group B-group
, O O
oral O O
contraceptives B-group B-group
, O O
phenytoin B-drug B-drug
, O O
nicotinic B-drug B-drug
acid I-drug I-drug
, O O
sympathomimetics B-group B-group
, O O
calcium B-group B-group
channel-blocking I-group I-group
drugs I-group I-group
, O O
and O O
isoniazid B-drug B-drug
. O O

Thus O O
, O O
concentrations O O
which O O
have O O
been O O
obtained O O
in O O
vivo O O
clinically O O
in O O
patients O O
with O O
normal O O
renal O O
function O O
are O O
considerably O O
lower O O
than O O
the O O
in O O
vitro O O
concentrations O O
found O O
to O O
induce O O
abnormalities O O
in O O
platelet O O
function O O
tests O O
. O O

In O O
psoriatic O O
arthritis O O
clinical O O
trials O O
, O O
concomitant O O
medications O O
included O O
MTX B-drug B-drug
in O O
approximately O O
half O O
of O O
the O O
patients O O
as O O
well O O
as O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
, O O
folic B-drug B-drug
acid I-drug I-drug
and O O
corticosteroids B-group B-group
. O O

Coadministration O O
with O O
valdecoxib B-drug B-drug
increased O O
exposure O O
of O O
omeprazole B-drug B-drug
( O O
AUC O O
) O O
by O O
46 O O
% O O
. O O

Coadministration O O
in O O
HIV-infected O O
individuals O O
with O O
a O O
history O O
of O O
injection O O
drug O O
use O O
resulted O O
in O O
decreased O O
plasma O O
levels O O
of O O
methadone B-drug B-drug
and O O
signs O O
of O O
opiate B-group B-group
withdrawal O O
. O O

Saquinavir B-drug B-drug

The O O
appropriate O O
doses O O
for O O
this O O
combination O O
, O O
with O O
respect O O
to O O
efficacy O O
and O O
safety O O
, O O
have O O
not O O
been O O
established O O
. O O

Dose O O
reduction O O
of O O
CRIXIVAN B-brand B-brand
to O O
600 O O
mg O O
every O O
8 O O
hours O O
is O O
recommended O O
when O O
administering O O
itraconazole B-drug B-drug
concurrently O O
. O O

Carbamazepine B-drug B-drug
: O O
Felbatol B-brand B-brand
causes O O
a O O
decrease O O
in O O
the O O
steady-state O O
carbamazepine B-drug B-drug
plasma O O
concentrations O O
and O O
an O O
increase O O
in O O
the O O
steady-state O O
carbamazepine B-drug_n B-drug
epoxide I-drug_n O
plasma O O
concentration O O
. O O

Glucose O B-drug
: O O
Some O O
patients O O
receiving O O
Accutane B-brand B-brand
have O O
experienced O O
problems O O
in O O
the O O
control O O
of O O
their O O
blood O O
sugar O O
. O O

Products O O
containing O O
calcium B-drug B-drug
and O O
other O O
multivalent O O
cations O O
( O O
such O O
as O O
aluminum B-drug B-drug
, O O
magnesium B-drug B-drug
, O O
iron B-drug B-drug
) O O
are O O
likely O O
to O O
interfere O O
with O O
absorption O O
of O O
Ibandronate B-drug B-drug
. O O

Antacids B-group B-group
: O O
The O O
concomitant O O
administration O O
of O O
antacids B-group B-group
has O O
no O O
apparent O O
effect O O
on O O
the O O
extent O O
of O O
absorption O O
of O O
Lodine B-brand B-brand
. O O

INDOCIN B-brand B-brand
and O O
triamterene B-drug B-drug
should O O
not O O
be O O
administered O O
together O O
. O O

However O O
, O O
hydrocortisone B-drug B-drug
pretreatment O O
did O O
not O O
affect O O
any O O
of O O
the O O
physiological O O
, O O
behavioral O O
, O O
or O O
subjective O O
effects O O
of O O
d-amphetamine B-drug B-drug
. O O

Depending O O
on O O
the O O
fraction O O
of O O
drug O O
metabolized O O
by O O
P450 O O
2D6 O O
, O O
the O O
increase O O
in O O
plasma O O
concentration O O
may O O
be O O
small O O
, O O
or O O
quite O O
large O O
( O O
8-fold O O
increase O O
in O O
plasma O O
AUC O O
of O O
the O O
TCA O B-group
) O O
. O O

The O O
resulting O O
increase O O
in O O
nitrofurantoin B-drug B-drug
serum O O
levels O O
may O O
increase O O
toxicity O O
, O O
and O O
the O O
decreased O O
urinary O O
levels O O
could O O
lessen O O
its O O
efficacy O O
as O O
a O O
urinary O O
tract O O
antibacterial B-group B-group
. O O

In O O
pigeons O O
, O O
naloxone B-drug B-drug
did O O
not O O
systematically O O
alter O O
the O O
effects O O
of O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
, O I-drug_n
( B-drug_n I-drug_n
+ I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
or O O
PCP B-drug_n B-drug_n
. O O

A O O
group O O
of O O
patients O O
who O O
had O O
had O O
a O O
new O O
acute O O
episode O O
despite O O
seemingly O O
adequate O O
treatment O O
were O O
selected O O
. O O

Hypotension O O
was O O
more O O
likely O O
to O O
occur O O
if O O
the O O
calcium B-group B-group
antagonist I-group I-group
were O O
a O O
dihydropyridine B-group O
derivative I-group O
, O O
e.g. O O
, O O
nifedipine B-drug B-drug
, O O
while O O
left O O
ventricular O O
failure O O
and O O
AV O O
conduction O O
disturbances O O
, O O
including O O
complete O O
heart O O
block O O
, O O
were O O
more O O
likely O O
to O O
occur O O
with O O
either O O
verapamil B-drug B-drug
or O O
diltiazem B-drug B-drug
. O O

In O O
the O O
warfarin B-drug B-drug
study O O
, O O
vardenafil B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
prothrombin O O
time O O
or O O
other O O
pharmacodynamic O O
parameters O O
. O O

In O O
a O O
chronic O O
toxicity O O
study O O
, O O
cynomolgus O O
monkeys O O
were O O
dosed O O
weekly O O
for O O
52 O O
weeks O O
with O O
intravenous O O
alefacept B-drug B-drug
at O O
1 O O
mg/kg/dose O O
or O O
20 O O
mg/kg/dose O O
. O O

However O O
, O O
serious O O
opportunistic O O
infections O O
have O O
not O O
been O O
observed O O
, O O
and O O
no O O
complications O O
have O O
specifically O O
been O O
attributed O O
to O O
lymphocytopenia O O
. O O

Adenosine O B-drug
3':5'-cyclic O I-drug
phosphate O I-drug
in O O
turn O O
controls O O
levels O O
of O O
free O O
calcium O O
ions O O
in O O
platelets O O
and O O
regulates O O
calcium-dependent O O
reactions O O
. O O

Accordingly O O
, O O
renal O O
function O O
should O O
be O O
closely O O
monitored O O
in O O
these O O
patients O O
and O O
, O O
in O O
the O O
event O O
of O O
relevant O O
significant O O
changes O O
in O O
laboratory O O
parameters O O
, O O
bezafibrate B-drug B-drug
should O O
, O O
if O O
necessary O O
, O O
be O O
discontinued O O

Aspirin B-brand B-brand
: O O
In O O
normal O O
volunteers O O
, O O
a O O
small O O
decrease O O
in O O
diflunisal B-drug B-drug
levels O O
was O O
observed O O
when O O
multiple O O
doses O O
of O O
diflunisal B-drug B-drug
and O O
aspirin B-brand B-brand
were O O
administered O O
concomitantly O O
. O O

Clonazepam B-drug B-drug
would O O
be O O
useful O O
in O O
cases O O
with O O
potential O O
risk O O
of O O
hypoglycemia O O
. O O

6 O O
. O O

In O O
vitro O O
metabolism O O
studies O O
have O O
demonstrated O O
that O O
tizoxanide B-drug B-drug
has O O
no O O
significant O O
inhibitory O O
effect O O
on O O
cytochrome O O
P450 O O
enzymes O O
. O O

This O O
may O O
indicate O O
that O O
ibuprofen B-drug B-drug
could O O
enhance O O
the O O
toxicity O O
of O O
methotrexate B-drug B-drug
. O O

FLEXERIL B-brand B-brand
may O O
have O O
life-threatening O O
interactions O O
with O O
MAO B-group B-group
inhibitors I-group I-group
. O O

acanthus O O
. O O

0.001 O O
. O O

In O O
an O O
in O O
vitro O O
study O O
, O O
cytochrome O O
P450 O O
isozymes O O
1A2 O O
, O O
2A6 O O
, O O
2C9 O O
, O O
2C19 O O
, O O
2D6 O O
, O O
2E1 O O
, O O
and O O
3A4 O O
were O O
not O O
inhibited O O
by O O
exposure O O
to O O
cevimeline B-drug B-drug
. O O

ZEBETA B-brand B-brand
should O O
not O O
be O O
combined O O
with O O
other O O
beta-blocking B-group B-group
agents I-group I-group
. O O

The O O
safety O O
and O O
efficacy O O
of O O
PROLEUKIN B-brand B-brand
in O O
combination O O
with O O
any O O
antineoplastic B-group B-group
agents I-group I-group
have O O
not O O
been O O
established O O
. O O

Nevertheless O O
, O O
the O O
effects O O
of O O
Mefloquine B-drug B-drug
on O O
travelers O O
receiving O O
comedication O O
, O O
particularly O O
diabetics O O
or O O
patients O O
using O O
anticoagulants B-group B-group
, O O
should O O
be O O
checked O O
before O O
departure O O
. O O

In O O
contrast O O
, O O
nucleophosmin/B23 O O
in O O
serum-deprived O O
ras-transformed O O
( O O
RAS-3T3 O O
) O O
cells O O
was O O
as O O
stable O O
as O O
that O O
in O O
serum-supplemented O O
NIH-3T3 O O
or O O
RAS-3T3 O O
cells O O
. O O

Patients O O
using O O
CYP3A4 O O
metabolized O O
statins B-group O
should O O
have O O
cholesterol O O
levels O O
monitored O O
after O O
TRACLEER B-brand B-brand
is O O
initiated O O
to O O
see O O
whether O O
the O O
statin B-group O
dose O O
needs O O
adjustment O O
. O O

Due O O
to O O
its O O
nephrotoxicity O O
, O O
gentamicin B-drug B-drug
may O O
cause O O
abnormal O O
renal O O
uptake O O
to O O
be O O
seen O O
on O O
99mTc-MDP B-drug O
bone O O
scintigraphy O O
. O O

Paroxetine B-drug B-drug
: O O
Coadministration O O
of O O
single O O
doses O O
of O O
eszopiclone B-drug B-drug
3 O I-drug
mg O O
and O O
paroxetine B-drug B-drug
20 O O
mg O O
daily O O
for O O
7 O O
days O O
produced O O
no O O
pharmacokinetic O O
or O O
pharmacodynamic O O
interaction O O
. O O

More O O
than O O
600 O O
Parkinsons O O
disease O O
patients O O
in O O
clinical O O
trials O O
have O O
used O O
selegiline B-drug B-drug
in O O
combination O O
with O O
entacapone B-drug B-drug
and O O
levodopa/dopa B-drug B-group
decarboxylase B-group I-group
inhibitor I-group I-group
. O O

Lincomycin B-drug B-drug
has O O
been O O
shown O O
to O O
have O O
neuromuscular O O
blocking O O
properties O O
that O O
may O O
enhance O O
the O O
action O O
of O O
other O O
neuromuscular B-group B-group
blocking I-group I-group
agents I-group I-group
. O O

Antacids B-group B-group
, O O
Sucralfate B-drug B-drug
, O O
Metal O O
Cations O O
, O O
Multivitamins B-group B-group
Quinolones I-group I-group
form O O
chelates O O
with O O
alkaline O O
earth O O
and O O
transition O O
metal O O
cations O O
. O O

In O O
vitro O O
mixing O O
of O O
an O O
aminoglycoside B-group B-group
with O O
beta-lactamtype O B-group
antibiotics B-group I-group
( O O
penicillins B-group B-group
or O O
cephalosporins B-group B-group
) O O
may O O
result O O
in O O
a O O
significant O O
mutual O O
inactivation O O
. O O

When O O
given O O
in O O
a O O
dose O O
of O O
50 O O
mg/kg O O
, O O
sandimmune B-brand B-brand
produced O O
no O O
statistically O O
significant O O
effect O O
on O O
the O O
duration O O
of O O
hexanal-induced O B-drug
sleep O O
in O O
mice O O
. O O

Although O O
trough O O
citalopram B-drug B-drug
plasma O O
levels O O
were O O
unaffected O O
, O O
given O O
the O O
enzyme-inducing O O
properties O O
of O O
carbamazepine B-drug B-drug
, O O
the O O
possibility O O
that O O
carbamazepine B-drug B-drug
might O O
increase O O
the O O
clearance O O
of O O
escitalopram B-drug B-drug
should O O
be O O
considered O O
if O O
the O O
two O O
drugs O O
are O O
coadministered O O
. O O

BREVIBLOC B-brand B-brand
concentrations O O
were O O
equivocally O O
higher O O
when O O
given O O
with O O
warfarin B-drug B-drug
, O O
but O O
this O O
is O O
not O O
likely O O
to O O
be O O
clinically O O
important O O
. O O

Propranolol B-drug B-drug
: O O
In O O
a O O
single O O
dose O O
study O O
in O O
normal O O
volunteers O O
, O O
coadministration O O
of O O
propranolol B-drug B-drug
had O O
a O O
small O O
effect O O
on O O
the O O
rate O O
but O O
no O O
effect O O
on O O
the O O
extent O O
of O O
isradipine B-drug B-drug
bioavailability O O
. O O

Antipsychotic B-group B-group
drugs I-group I-group
such O O
as O O
phenothiazines B-group B-group
or O O
haloperidol B-drug B-drug
; O O

Sumatriptan B-drug B-drug
and O O
D.H.E B-brand B-brand
. I-brand O
45 I-brand B-drug
( O O
dihydroergotamine B-drug B-drug
mesylate I-drug I-drug
) O O
Injection O O
, O O
USP O O
should O O
not O O
be O O
taken O O
within O O
24 O O
hours O O
of O O
each O O
other.. O O

Use O O
With O O
Ribavirin B-drug B-drug
Ribavirin I-drug I-drug
is O O
genotoxic O O
and O O
mutagenic O O
. O O

Corticosteroids B-group B-group
may O O
also O O
potentiate O O
the O O
replication O O
of O O
some O O
organisms O O
contained O O
in O O
live B-group O
attenuated I-group B-group
vaccines I-group I-group
. O O

If O O
the O O
TARCEVA B-brand B-brand
dose O O
is O O
adjusted O O
upward O O
, O O
the O O
dose O O
will O O
need O O
to O O
be O O
reduced O O
upon O O
discontinuation O O
of O O
rifampicin B-drug B-drug
or O O
other O O
inducers O O
. O O

Dexamethasone B-drug B-drug
: O O
Steady-state O O
trough O O
concentrations O O
of O O
albendazole B-drug B-drug
sulfoxide I-drug I-drug
were O O
about O O
56 O O
% O O
higher O O
when O O
8 O O
mg O O
dexamethasone B-drug B-drug
was O O
coadministered O O
with O O
each O O
dose O O
of O O
albendazole B-drug B-drug
( O O
15 O O
mg/kg/day O O
) O O
in O O
eight O O
neurocysticercosis O O
patients O O
. O O

Dexbrompheniramine B-drug B-drug
can O O
interact O O
with O O
alcohol B-drug B-drug
or O O
other O O
CNS B-group B-group
depressants I-group I-group
( O O
may O O
potentiate O O
the O O
CNS O O
depressant O O
effects O O
of O O
either O O
these O O
medications O O
or O O
antihistamines B-group B-group
) O O
, O O
anticholinergics B-group B-group
or O O
other O O
medications O O
with O O
anticholinergic O O
activity O O
( O O
anticholinergic O O
effects O O
may O O
be O O
potentiated O O
when O O
these O O
medications O O
are O O
used O O
concurrently O O
with O O
antihistamines B-group B-group
) O O
, O O
and O O
monoamine B-group B-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
( O O
concurrent O O
use O O
with O O
antihistamines B-group B-group
may O O
prolong O O
and O O
intensify O O
the O O
anticholinergic O O
and O O
CNS O O
depressant O O
effects O O
of O O
antihistamines B-group B-group
) O O
. O O

COPEGUS B-brand B-brand
therapy O O
is O O
contraindicated O O
in O O
women O O
who O O
are O O
pregnant O O
and O O
in O O
the O O
male O O
partners O O
of O O
women O O
who O O
are O O
pregnant O O
. O O

A O O
similar O O
association O O
, O O
though O O
less O O
marked O O
, O O
has O O
been O O
suggested O O
with O O
barbiturates B-group B-group
, O O
phenylbutazone B-drug B-drug
, O O
phenytoin B-drug B-drug
sodium I-drug I-drug
, O O
carbamazepine B-drug B-drug
, O O
griseofulvin B-drug B-drug
, O O
topiramate B-drug B-drug
, O O
and O O
possibly O O
with O O
ampicillin B-drug B-drug
and O O
tetracyclines B-group B-group
72 O O
. O O

In O O
a O O
parallel O O
group O O
drug O O
interaction O O
study O O
comparing O O
the O O
intravenous O O
prodrug O O
form O O
of O O
valdecoxib B-drug B-drug
at O O
40 O O
mg O O
BID O O
( O O
n=10 O O
) O O
vs O O
placebo O O
( O O
n=9 O O
) O O
, O O
valdecoxib B-drug B-drug
had O O
no O O
effect O O
on O O
in O O
vitro O O
aspirin-mediated B-brand O
inhibition O O
of O O
arachidonate- O O
or O O
collagen-stimulated O O
platelet O O
aggregation O O
. O O

Protein O O
Binding O O
: O O
Entacapone B-drug B-drug
is O O
highly O O
protein O O
bound O O
( O O
98 O O
% O O
) O O
. O O

Patients O O
taking O O
warfarin B-drug B-drug
should O O
be O O
monitored O O
regularly O O
for O O
changes O O
in O O
prothrombin O O
time O O
or O O
INR O O
. O O

The O O
potential O O
effects O O
of O O
INDOCIN B-brand B-brand
and O O
potassium-sparing B-group B-group
diuretics I-group I-group
on O O
potassium O O
kinetics O O
and O O
renal O O
function O O
should O O
be O O
considered O O
when O O
these O O
agents O O
are O O
administered O O
concurrently O O
. O O

Indinavir B-drug B-drug

Rifampin B-drug B-drug
significantly O O
decreased O O
the O O
AUC O O
( O O
ss O O
) O O
of O O
amprenavir B-drug B-drug
by O O
82 O O
% O O
, O O
but O O
amprenavir B-drug B-drug
had O O
no O O
effect O O
on O O
rifampin B-drug B-drug
pharmacokinetics O O
. O O

Similarly O O
, O O
ethanol B-drug B-drug
decreased O O
the O O
rate O O
of O O
elimination O O
of O O
Antizol B-brand B-brand
( O O
by O O
approximately O O
50 O O
% O O
) O O
by O O
the O O
same O O
mechanism O O
. O O

Monoamine B-group B-group
Oxidase I-group I-group
Inhibitors I-group I-group
and O O
Tricyclic B-group B-group
Antidepressants I-group I-group
: O O
FORADIL B-brand B-brand
should O O
be O O
administered O O
with O O
extreme O O
caution O O
in O O
patients O O
being O O
treated O O
with O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
or O O
tricyclic B-group B-group
antidepressants I-group I-group
because O O
the O O
action O O
of O O
formoterol B-drug B-drug
on O O
the O O
cardiovascular O O
system O O
may O O
be O O
potentiated O O
by O O
these O O
agents O O
. O O

1200-2400 O O
up O O
to O O
40 O O
% O O
increase3 O O
[ O O
CI O O
: O O
12 O O
% O O
increase O O
, O O
60 O O
% O O
increase O O
] O O

Drug O O
interaction O O
studies O O
have O O
not O O
been O O
performed O O
with O O
Soliris B-brand B-brand
. O O

Itraconazole B-drug B-drug

Organic O O
nitrates B-group B-group
- O O
L-arginine B-drug B-drug
supplements O O
theoretically O O
may O O
potentiate O O
the O O
effects O O
of O O
organic O O
nitrates B-drug B-group
if O O
taken O O
concomitantly O O
. O O

However O O
, O O
in O O
vivo O O
drug O O
interaction O O
studies O O
of O O
ketoconazole B-drug B-drug
with O O
vitamin B-group B-group
D I-group I-group
have O O
not O O
been O O
investigated O O
. O O

The O O
tolerability O O
of O O
NNRTIs B-group B-group
appears O O
generally O O
good O O
with O O
few O O
individuals O O
discontinuing O O
in O O
clinical O O
studies O O
as O O
a O O
result O O
of O O
adverse O O
drug O O
events O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
: O O
The O O
administration O O
of O O
CEFOTAN B-brand B-brand
may O O
result O O
in O O
a O O
false O O
positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
using O O
Clinitest O O
, O O
Benedicts O O
solution O O
, O O
or O O
Fehlings O O
solution O O
. O O

Coadministration O O
of O O
oral O O
contraceptives B-group B-group
increased O O
the O O
maximum O O
plasma O O
concentration O O
of O O
alprazolam B-drug B-drug
by O O
18 O O
% O O
, O O
decreased O O
clearance O O
by O O
22 O O
% O O
, O O
and O O
increased O O
half-life O O
by O O
29 O O
% O O
. O O

The O O
therapeutic O O
efficacy O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
may O O
be O O
compromised O O
in O O
these O O
patients O O
when O O
cimetidine B-drug B-drug
is O O
discontinued O O
. O O

Drugs O O
Metabolized O O
by O O
CYP2D6 O O
: O O
Duloxetine B-drug B-drug
is O O
a O O
moderate O O
inhibitor O O
of O O
CYP2D6 O O
. O O

In O O
renal O O
and O O
cardiac O O
transplant O O
recipients O O
, O O
a O O
reduction O O
of O O
cyclosporine B-drug B-drug
dose O O
ranging O O
from O O
15 O O
% O O
to O O
48 O O
% O O
was O O
necessary O O
to O O
maintain O O
cyclosporine B-drug B-drug
trough O O
concentrations O O
similar O O
to O O
those O O
seen O O
prior O O
to O O
the O O
addition O O
of O O
diltiazem B-drug B-drug
. O O

Catecholamine-depleting O O
drugs O O
( O O
e.g. O O
, O O
reserpine B-drug B-drug
) O O
may O O
have O O
an O O
additive O O
effect O O
when O O
given O O
with O O
beta-blocking B-drug B-group
agents O I-group
. O O

Morphine B-drug B-drug
pharmacokinetic O O
parameter O O
values O O
were O O
not O O
affected O O
by O O
administration O O
of O O
Neurontin B-brand B-brand
2 O O
hours O O
after O O
morphine B-drug B-drug
. O O

Concurrent O O
administration O O
of O O
vasopressor B-group B-group
drugs I-group I-group
and O O
of O O
ergot-type B-group B-group
oxytocic I-group I-group
drugs I-group I-group
may O O
cause O O
severe O O
, O O
persistent O O
hypertension O O
or O O
cerebrovascular O O
accidents O O
. O O

. O O

If O O
phenytoin B-drug B-drug
or O O
other O O
hepatic O O
enzyme O O
inducers O O
are O O
taken O O
concurrently O O
with O O
Norpace B-brand B-brand
or O O
Norpace B-brand B-brand
CR I-brand O
, O O
lower O O
plasma O O
levels O O
of O O
disopyramide B-drug B-drug
may O O
occur O O
. O O

Ketoconazole B-drug B-drug
( O O
200 O O
mg O O
once O O
daily O O
) O O
produced O O
a O O
10-fold O O
increase O O
in O O
vardenafil B-drug B-drug
AUC O O
and O O
a O O
4-fold O O
increase O O
in O O
Cmax O O
when O O
co-administered O O
with O O
Vardenafil B-drug B-drug
( O O
5 O O
mg O O
) O O
in O O
healthy O O
volunteers O O
. O O

As O O
most O O
entacapone B-drug B-drug
excretion O O
is O O
via O O
the O O
bile O O
, O O
caution O O
should O O
be O O
exercised O O
when O O
drugs O O
known O O
to O O
interfere O O
with O O
biliary O O
excretion O O
, O O
glucuronidation O O
, O O
and O O
intestinal O O
beta-glucuronidase O O
are O O
given O O
concurrently O O
with O O
entacapone B-drug B-drug
. O O

Limited O O
PK O O
and/or O O
PD O O
studies O O
investigating O O
possible O O
interactions O O
between O O
anagrelide B-drug B-drug
and O O
other O O
medicinal O O
products O O
have O O
been O O
conducted O O
. O O

Cimetidine B-drug B-drug
( O O
300 O O
mg O O
qid O O
) O O
+103 O O
% O O
+ O O
6 O O
% O O

Nursing O O
Mothers O O

Coadministration O O
of O O
NIZORAL B-brand B-brand
Tablets O O
and O O
drugs O O
primarily O O
metabolized O O
by O O
the O O
cytochrome O O
P450 O O
3A4 O O
enzyme O O
system O O
may O O
result O O
in O O
increased O O
plasma O O
concentrations O O
of O O
the O O
drugs O O
that O O
could O O
increase O O
or O O
prolong O O
both O O
therapeutic O O
and O O
adverse O O
effects O O
. O O

CYP2D6 O O
inhibitors O O
- O O
Atomoxetine B-drug B-drug
is O O
primarily O O
metabolized O O
by O O
the O O
CYP2D6 O O
pathway O O
to O O
4-hydroxyatomoxetine B-drug_n B-drug_n
. O O

Antacid B-group B-group
: O O
When O O
atorvastatin B-drug B-drug
and O O
Maalox B-brand B-brand
TC I-brand I-brand
suspension O O
were O O
coadministered O O
, O O
plasma O O
concentrations O O
of O O
atorvastatin B-drug B-drug
decreased O O
approximately O O
35 O O
% O O
. O O

Erythromycin B-drug B-drug
and O O
clarithromycin B-drug B-drug
( O O
and O O
possibly O O
other O O
macrolide B-group B-group
antibiotics I-group I-group
) O O
and O O
tetracycline B-drug B-drug
may O O
increase O O
digoxin B-drug B-drug
absorption O O
in O O
patients O O
who O O
inactivate O O
digoxin B-drug B-drug
by O O
bacterial O O
metabolism O O
in O O
the O O
lower O O
intestine O O
, O O
so O O
that O O
digitalis B-group B-group
intoxication O O
may O O
result O O
. O O

Concurrent O O
administration O O
of O O
a O O
TNF B-group B-group
antagonist I-group I-group
with O O
ORENCIA B-brand B-brand
has O O
been O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
serious O O
infections O O
and O O
no O O
significant O O
additional O O
efficacy O O
over O O
use O O
of O O
the O O
TNF B-group B-group
antagonists I-group I-group
alone O O
. O O

Central B-group B-group
nervous I-group I-group
system I-group I-group
depressant I-group I-group
( O O
CNS O O
) O O
drugs O O
including O O
alcohol B-drug B-drug
, O O
antidepressants B-group B-group
, O O
antihistamines B-group B-group
, O O
antipsychotics B-group B-group
, O O
blood O O
pressure O O
medications O O
( O O
reserpine B-drug B-drug
, O O
methyldopa B-drug B-drug
, O O
beta-blockers B-group B-group
) O O
, O O
motion O O
sickness O O
medications O O
, O O
muscle B-group B-group
relaxants I-group I-group
, O O
narcotics B-group B-group
, O O
sedatives B-group B-group
, O O
sleeping O O
pills O O
and O O
tranquilizers B-group B-group

Magnesium B-drug B-drug
: O O
Magnesium-containing B-drug B-drug
preparations O O
( O O
eg O O
, O O
antacids B-group B-group
) O O
may O O
cause O O
hypermagnesemia O O
and O O
should O O
therefore O O
not O O
be O O
taken O O
during O O
therapy O O
with O O
vitamin B-group B-group
D I-group I-group
by O O
patients O O
on O O
chronic O O
renal O O
dialysis O O
. O O

Patients O O
receiving O O
these O O
drugs O O
concurrently O O
should O O
be O O
monitored O O
for O O
a O O
potential O O
drug O O
interaction O O
. O O

Concomitant O O
use O O
of O O
other O O
5-HT1B/1D O B-group
agonists O I-group
within O O
24 O O
hours O O
of O O
FROVA B-brand B-brand
treatment O O
is O O
not O O
recommended O O
. O O

This O O
change O O
was O O
not O O
considered O O
clinically O O
significant O O
and O O
no O O
dose O O
adjustment O O
is O O
needed O O
when O O
ketoconazole B-drug B-drug
and O O
VIRACEPT B-brand B-brand
are O O
coadministered O O
. O O

Interactions O O
for O O
vitamin B-group B-group
D I-group I-group
analogues O I-group
( O O
Vitamin B-drug B-drug
D2 I-drug I-drug
, O O
Vitamin B-drug B-drug
D3 I-drug I-drug
, O O
Calcitriol B-drug B-drug
, O O
and O O
Calcidiol B-drug B-drug
) O O
: O O
Cholestyramine B-drug B-drug
: O O
Cholestyramine B-drug B-drug
has O O
been O O
reported O O
to O O
reduce O O
intestinal O O
absorption O O
of O O
fat B-group B-group
soluble I-group I-group
vitamins I-group I-group
; O O

Considering O O
that O O
the O O
involvement O O
of O O
reactive O O
oxygen O O
species O O
( O O
ROS O O
) O O
has O O
been O O
implicated O O
in O O
the O O
toxicity O O
of O O
various O O
pesticides O O
, O O
this O O
study O O
was O O
designed O O
to O O
investigate O O
the O O
possibility O O
of O O
oxidative O O
stress O O
induction O O
by O O
cypermethrin B-drug B-drug
, O O
a O O
Type B-drug_n B-group
II I-drug_n I-group
pyrethroid I-drug_n I-group
. O O

Digoxin B-drug B-drug
: O O
Rofecoxib B-drug B-drug
75 O O
mg O O
once O O
daily O O
for O O
11 O O
days O O
does O O
not O O
alter O O
the O O
plasma O O
concentration O O
profile O O
or O O
renal O O
elimination O O
of O O
digoxin B-drug B-drug
after O O
a O O
single O O
0.5 O O
mg O O
oral O O
dose O O
. O O

Endocrine O O
Function O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
interfere O O
with O O
cholesterol O O
synthesis O O
and O O
theoretically O O
might O O
blunt O O
adrenal O O
and/or O O
gonadal O O
steroid O O
production O O
. O O

Other O O
Drugs O O
: O O
In O O
small O O
groups O O
of O O
patients O O
( O O
7-10/interaction O O
study O O
) O O
, O O
the O O
concomitant O O
administration O O
of O O
azathioprine B-drug B-drug
, O O
gold B-group B-drug
, O O
chloroquine B-drug B-drug
, O O
D-penicillamine B-drug B-drug
, O O
prednisolone B-drug B-drug
, O O
doxycycline B-drug B-drug
, O O
or O O
digitoxin B-drug B-drug
did O O
not O O
significantly O O
affect O O
the O O
peak O O
levels O O
and O O
AUC O O
values O O
of O O
diclofenac B-drug B-drug
. O O

4 O O
. O O

In O O
clinical O O
studies O O
, O O
coadministration O O
of O O
WelChol B-brand B-brand
with O O
atorvastatin B-drug B-drug
, O O
lovastatin B-drug B-drug
, O O
or O O
simvastatin B-drug B-drug
did O O
not O O
interfere O O
with O O
the O O
lipid-lowering O O
activity O O
of O O
the O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitor I-group I-group
. O O

The O O
latency O O
to O O
loss O O
of O O
the O O
righting O O
reflex O O
and O O
duration O O
of O O
sleep O O
time O O
were O O
recorded O O
while O O
the O O
rats O O
were O O
kept O O
in O O
sound-attenuating O O
chambers O O
. O O

The O O
concurrent O O
use O O
of O O
these O O
drugs O O
is O O
not O O
recommended O O
. O O

There O O
are O O
no O O
known O O
drug/drug O O
interactions O O
with O O
chlorambucil B-drug B-drug
. O O

In O O
the O O
first O O
study O O
, O O
concomitant O O
administration O O
of O O
0.2 O O
mg O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
and O O
12 O O
g O O
cholestyramine B-drug B-drug
resulted O O
in O O
decreases O O
of O O
more O O
than O O
22 O O
% O O
for O O
AUC O O
and O O
40 O O
% O O
for O O
Cmax O O
when O O
compared O O
to O O
dosing O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
alone O O
. O O

PTX B-drug_n O
caused O O
the O O
release O O
of O O
norepinephrine O B-drug
from O O
the O O
muscle O O
. O O

Although O O
glucocorticoids B-group B-group
have O O
been O O
shown O O
to O O
reduce O O
PROLEUKIN-induced B-brand B-brand
side O O
effects O O
including O O
fever O O
, O O
renal O O
insufficiency O O
, O O
hyperbilirubinemia O O
, O O
confusion O O
, O O
and O O
dyspnea O O
, O O
concomitant O O
administration O O
of O O
these O O
agents O O
with O O
PROLEUKIN B-brand B-brand
may O O
reduce O O
the O O
antitumor O O
effectiveness O O
of O O
PROLEUKIN B-brand B-brand
and O O
thus O O
should O O
be O O
avoided O O
. O O
12 O O
Beta-blockers B-group B-group
and O O
other O O
antihypertensives B-group B-group
may O O
potentiate O O
the O O
hypotension O O
seen O O
with O O
PROLEUKIN B-brand B-brand
. O O

Combination O O
therapy O O
should O O
be O O
administered O O
with O O
caution O O
, O O
especially O O
in O O
immunocompromised O O
patients O O
. O O

CPK O O
: O O
Some O O
patients O O
undergoing O O
vigorous O O
physical O O
activity O O
while O O
on O O
Accutane B-brand B-brand
therapy O O
have O O
experienced O O
elevated O O
CPK O O
levels O O
; O O

We O O
obtained O O
evidence O O
that O O
increased O O
stability O O
of O O
nucleophosmin/B23 O O
is O O
involved O O
in O O
antiapoptotic O O
effect O O
of O O
ras O O
during O O
serum O O
deprivation O O
. O O

In O O
a O O
controlled O O
clinical O O
trial O O
, O O
a O O
20 O O
% O O
reduction O O
of O O
the O O
phenytoin B-drug B-drug
dose O O
at O O
the O O
initiation O O
of O O
Felbatol B-brand B-brand
therapy O O
resulted O O
in O O
phenytoin B-drug B-drug
levels O O
comparable O O
to O O
those O O
prior O O
to O O
Felbatol B-brand B-brand
administration O O
. O O

The O O
percentage O O
of O O
drug O O
binding O O
in O O
each O O
preparation O O
was O O
calculated O O
. O O

Thus O O
, O O
the O O
results O O
suggest O O
that O O
cypermethrin B-drug B-drug
exposure O O
of O O
rats O O
results O O
in O O
free O O
radical-mediated O O
tissue O O
damage O O
, O O
as O O
indicated O O
by O O
elevated O O
cerebral O O
and O O
hepatic O O
lipid O O
peroxidation O O
, O O
which O O
was O O
prevented O O
by O O
allopurinol B-drug B-drug
and O O
Vitamin B-drug B-drug
E I-drug I-drug
. O O

Two O O
retrospective O O
studies O O
were O O
conducted O O
in O O
1992 O O
( O O
75 O O
cases O O
) O O
and O O
in O O
1993 O O
( O O
51 O O
cases O O
) O O
. O O

use O O
potassium B-drug B-drug
supplements O O
if O O
necessary O O
. O O

In O O
addition O O
, O O
the O O
beneficial O O
effects O O
of O O
levodopa B-drug B-drug
in O O
Parkinsons O O
disease O O
have O O
been O O
reported O O
to O O
be O O
reversed O O
by O O
phenytoin B-drug B-drug
and O O
papaverine B-drug B-drug
. O O

No O O
effects O O
were O O
evident O O
on O O
excystment O O
rates O O
of O O
cyst-exposed O O
parasites O O
. O O

These O O
included O O
seven O O
cerebrovascular O O
accidents O O
, O O
six O O
sudden O O
cardiac O O
deaths O O
, O O
three O O
cases O O
of O O
hyperpyrexia O O
, O O
eight O O
poisonings O O
of O O
uncertain O O
mechanism O O
and O O
seven O O
cases O O
of O O
medical O O
complications O O
of O O
intravenous O O
injection O O
; O O

The O O
interval O O
between O O
the O O
administration O O
of O O
COLESTID B-brand B-brand
Tablets O O
and O O
any O O
other O O
medication O O
should O O
be O O
as O O
long O O
as O O
possible O O
. O O

Administration O O
of O O
diltiazem B-drug B-drug
hydrochloride I-drug I-drug
with O O
digoxin B-drug B-drug
in O O
24 O O
healthy O O
male O O
subjects O O
increased O O
plasma O O
digoxin B-drug B-drug
concentrations O O
approximately O O
20 O O
% O O
. O O

positive O O
antinuclear O O

The O O
atorvastatin B-drug B-drug
Cmax O O
values O O
were O O
not O O
significantly O O
affected O O
by O O
fenofibrate B-drug B-drug
. O O

None O O
Reported O O

one O O
patient O O
died O O
with O O
severe O O
hypocalcemia O O
. O O

DIGOXIN B-drug B-drug
: O O
Plasma O O
digoxin B-drug B-drug
levels O O
and O O
digoxin B-drug B-drug
clearance O O
at O O
steady-state O O
were O O
not O O
affected O O
by O O
co-administration O O
of O O
0.2 O O
mg O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
. O O

Tricyclic B-group B-group
antidepressants I-group I-group
( O O
amitriptyline B-drug B-drug
, O O
imipramine B-drug B-drug
, O O
nortriptyline B-drug B-drug
) O O
: O O
Metabolism O O
may O O
be O O
inhibited O O
by O O
combination B-group B-group
hormonal I-group I-group
contraceptives I-group I-group
, O O
increasing O O
plasma O O
levels O O
of O O
antidepressant B-group B-group
; O O

CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and/or O O
life-threatening O O
reactions O O
such O O
as O O
cardiac O O
arrhythmias O O
. O O

Drugs O O
Decreasing O O
Heparin B-drug B-drug
Effect O O
: O O
Digitalis B-group B-group
, O O
tetracyclines B-group B-group
, O O
nicotine B-drug B-drug
, O O
or O O
antihistamines B-group B-group
may O O
partially O O
counteract O O
the O O
anticoagulant O O
action O O
of O O
heparin B-drug B-drug
sodium I-drug I-drug
. O O

Lack O O
of O O
interaction O O
between O O
levofloxacin B-drug B-drug
and O O
oxycodone B-drug B-drug
: O O
pharmacokinetics O O
and O O
drug O O
disposition O O
. O O

substrates O O
, O O
in O O
vitro O O
data O O
suggest O O
similar O O
effects O O
of O O
grepafloxacin B-drug B-drug
in O O
CYP3A4 O O
mediated O O
metabolism O O
and O O
theophylline B-drug B-drug
metabolism O O
. O O

Development O O
and O O
pharmacology O O
of O O
fluvastatin B-drug B-drug
. O O

Choose O O
particular O O
low O O
doses O O
of O O
these O O
drugs O O
. O O

Treatment O O
of O O
both O O
parental O O
and O O
resistant O O
MCF-7 O O
cells O O
with O O
TAM B-drug_n O
induces O O
apoptosis O O
and O O
clusterin O B-drug
. O O

Phenothiazines B-group B-group
and O O
butyrophenones B-group B-group
may O O
reduce O O
or O O
reverse O O
the O O
pressor O O
effect O O
of O O
epinephrine B-drug B-drug
. O O

. O O

No O O
dose O O
adjustment O O
of O O
bosentan B-drug B-drug
is O O
necessary O O
, O O
but O O
increased O O
effects O O
of O O
bosentan B-drug B-drug
should O O
be O O
considered O O
. O O

Urinary O O
alkalinizing O O
agents O O
( O O
acetazolamide B-drug B-drug
, O O
some O O
thiazides B-group B-group
) O O
increase O O
the O O
concentration O O
of O O
the O O
non-ionized O O
species O O
of O O
the O O
amphetamine B-drug B-drug
molecule O O
, O O
thereby O O
decreasing O O
urinary O O
excretion O O
. O O

Cyclophosphamide B-drug B-drug

It O O
is O O
suggested O O
that O O
in O O
patients O O
receiving O O
dopamine B-drug B-drug
HCl I-drug I-drug
, O O
alternatives O O
to O O
phenytoin B-drug B-drug
should O O
be O O
used O O
if O O
anticonvulsant B-group B-group
therapy O O
is O O
needed O O
. O O

Similarly O O
, O O
saquinavir B-drug B-drug
might O O
also O O
modify O O
the O O
pharmacokinetics O O
of O O
other O O
drugs O O
that O O
are O O
substrates O O
for O O
CYP3A4 O O
or O O
Pgp O O
. O O

5 O O
. O O

Hepatotoxicity O O
Asymptomatic O O
increases O O
in O O
liver O O
transaminases O O
have O O
been O O
observed O O
in O O
TARCEVA B-brand B-brand
treated O O
patients O O
; O O

On O O
the O O
other O O
hand O O
, O O
surprisingly O O
, O O
green B-drug O
tea I-drug O
gallocatechins I-drug O
, O O
( O B-drug_n
- O I-drug_n
) O I-drug_n
-epigallocatechin-3-O-gallate O I-drug_n
and O O
theasinensin O B-drug
A O I-drug
, O O
potently O O
enhanced O O
the O O
promoter O O
activity O O
( O O
182 O O
and O O
247 O O
% O O
activity O O
at O O
1 O O
microM O O
, O O
respectively O O
) O O
. O O

N=12 O O
) O O
administration O O
. O O

Appropriate O O
doses O O
for O O
this O O
combination O O
arenot O O
established O O
, O O
but O O
an O O
increase O O
in O O
thedosage O O
of O O
saquinavir B-drug B-drug
may O O
be O O
required O O
. O O

In O O
screening O O
patients O O
suspected O O
of O O
having O O
a O O
pheochromocytoma O O
and O O
being O O
treated O O
with O O
labetalol B-drug B-drug
HCl I-drug I-drug
, O O
a O O
specific O O
method O O
, O O
such O O
as O O
a O O
high O O
performance O O
liquid O O
chromatographic O O
assay O O
with O O
solid O O
phase O O
extraction O O
( O O
e.g. O O
, O O
J O O
Chromatogr O O
385:241,1987 O O
) O O
should O O
be O O
employed O O
in O O
determining O O
levels O O
of O O
catecholamines O O
. O O

MICs O O
of O O
vancomycin B-drug B-drug
against O O
67 O O
% O O
of O O
resistant O O
clinical O O
isolates O O
and O O
a O O
type O O
strain O O
of O O
enterococci O O
were O O
lowered O O
from O O
> O O
250 O O
microg O O
mL O O
( O O
-1 O O
) O O
to O O
1 O O

however O O
, O O
14-OH O O
metabolite O O
concentrations O O
were O O
increased.Because O O
clarithromycin B-drug B-drug
active O O
metabolite O O
has O O
reduced O O
activity O O
against O O
Mycobacteriumavium-intracellulare O O
complex O O
, O O
overallactivity O O
against O O
this O O
pathogen O O
may O O
bealtered O O
. O O

The O O
magnitude O O
of O O
interaction O O
at O O
other O O
doses O O
is O O
not O O
known O O
. O O

Anastrozole B-drug B-drug
did O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
antipyrine B-drug B-drug
. O O

The O O
results O O
of O O
a O O
study O O
of O O
coadministration O O
of O O
ethambutol B-drug B-drug
( O O
50 O O
mg/kg O O
) O O
with O O
an O O
aluminum B-drug B-drug
hydroxide I-drug I-drug
containing O O
antacid B-group B-group
to O O
13 O O
patients O O
with O O
tuberculosis O O
showed O O
a O O
reduction O O
of O O
mean O O
serum O O
concentrations O O
and O O
urinary O O
excretion O O
of O O
ethambutol B-drug B-drug
of O O
approximately O O
20 O O
% O O
and O O
13 O O
% O O
, O O
respectively O O
, O O
suggesting O O
that O O
the O O
oral O O
absorption O O
of O O
ethambutol B-drug B-drug
may O O
be O O
reduced O O
by O O
these O O
antacid B-group B-group
products I-group O
. O O

No O O
formal O O
studies O O
to O O
evaluate O O
drug O O
interactions O O
with O O
bexarotene B-drug B-drug
have O O
been O O
conducted O O
. O O

However O O
, O O
there O O
has O O
been O O
one O O
report O O
of O O
prolonged O O
prothrombin O O
time O O
when O O
buspirone B-drug B-drug
was O O
added O O
to O O
the O O
regimen O O
of O O
a O O
patient O O
treated O O
with O O
warfarin B-drug B-drug
. O O

Interactions O O
for O O
vitamin B-group B-group
D I-group I-group
analogues I-group I-group
( O O
Vitamin B-drug B-drug
D2 I-drug I-drug
, O O
Vitamin B-drug B-drug
D3 I-drug I-drug
, O O
Calcitriol B-drug B-drug
, O O
and O O
Calcidiol B-drug B-drug
) O O
: O O
Cholestyramine B-drug B-drug
: O O
Cholestyramine B-drug B-drug
has O O
been O O
reported O O
to O O
reduce O O
intestinal O O
absorption O O
of O O
fat B-group B-group
soluble I-group I-group
vitamins I-group I-group
; O O

- O O
Drug/Laboratory O O
Test O O
Interactions O O
: O O
Thiazides B-group B-group
should O O
be O O
discontinued O O
before O O
carrying O O
out O O
tests O O
for O O
parathyroid O O
function O O
. O O

Conversion O O
could O O
be O O
affected O O
by O O
alterations O O
in O O
the O O
level O O
of O O
phosphatase O O
activity O O
, O O
but O O
given O O
the O O
abundance O O
and O O
wide O O
distribution O O
of O O
phosphatases O O
in O O
the O O
body O O
it O O
is O O
unlikely O O
that O O
drugs O O
would O O
affect O O
this O O
activity O O
enough O O
to O O
affect O O
conversion O O
of O O
fosphenytoin B-drug B-drug
to O O
phenytoin B-drug B-drug
. O O

For O O
example O O
, O O
diuretics B-group B-group
( O O
e.g. O O
, O O
thiazides B-group B-group
) O O
may O O
activate O O
the O O
renin-angiotensin-aldosterone O O
system O O
. O O

Corticosteroids B-group B-group
and O O
Corticotropin B-drug B-drug
( O O
ACTH B-group B-drug
) O O
: O O
may O O
potentiate O O
amphotericin B-drug B-drug
B- O O
induced O O
hypokalemia O O
which O O
may O O
predispose O O
the O O
patient O O
to O O
cardiac O O
dysfunction O O
. O O

Sedatives B-group B-group
and O O
tranquilizers B-group B-group
( O O
e.g. O O
, O O
diazepam B-drug B-drug
) O O
. O O

If O O
these O O
drugs O O
are O O
to O O
be O O
used O O
in O O
the O O
initial O O
treatment O O
of O O
severe O O
malaria O O
, O O
Mefloquine B-drug B-drug
administration O O
should O O
be O O
delayed O O
at O O
least O O
12 O O
hours O O
after O O
the O O
last O O
dose O O
. O O

Drug O O
Name O O

Because O O
antacids B-group B-group
may O O
interfere O O
with O O
the O O
absorption O O
of O O
anticholinergic B-group B-group
agents I-group I-group
, O O
simultaneous O O
use O O
of O O
these O O
drugs O O
should O O
be O O
avoided O O
. O O

anemia O O

Single O O
doses O O
of O O
either O O
cholestyramine B-drug B-drug
or O O
colestipol B-drug B-drug
resins B-group B-group
bind O O
the O O
hydrochlorothiazide B-drug B-drug
and O O
reduce O O
its O O
absorption O O
from O O
the O O
gastrointestinal O O
tract O O
by O O
up O O
to O O
85 O O
and O O
43 O O
percent O O
, O O
respectively O O
. O O

Differences O O
in O O
iron B-drug B-drug
balance O O
were O O
only O O
observed O O
between O O
both O O
dietary O O
concentrations O O
, O O
showing O O
a O O
higher O O
absolute O O
but O O
a O O
lower O O
relative O O
absorption O O
as O O
well O O
as O O
retention O O
in O O
the O O
groups O O
fed O O
further O O
Fe B-drug B-drug
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Terfenadine B-drug B-drug
: O O
No O O
clinically O O
significant O O
changes O O
occurred O O
in O O
heart O O
rate O O
or O O
corrected O O
QT O O
intervals O O
, O O
or O O
in O O
terfenadine B-drug B-drug
metabolite O O
or O O
lomefloxacin B-drug B-drug
pharmacokinetics O O
, O O
during O O
concurrent O O
administration O O
of O O
lomefloxacin B-drug B-drug
and O O
terfenadine B-drug B-drug
at O O
steady-state O O
in O O
28 O O
healthy O O
males O O
. O O

No O O
other O O
drug O O
interactions O O
are O O
known O O
. O O

Ketorolac B-drug B-drug
is O O
highly O O
bound O O
to O O
human O O
plasma O O
protein O O
( O O
mean O O
99.2 O O
% O O
) O O
. O O

Although O O
BETAGAN B-brand B-brand
used O O
alone O O
has O O
little O O
or O O
no O O
effect O O
on O O
pupil O O
size O O
, O O
mydriasis O O
resulting O O
from O O
concomitant O O
therapy O O
with O O
BETAGAN B-brand B-brand
and O O
epinephrine B-drug B-drug
may O O
occur O O
. O O

Use O O
of O O
PRINIVIL B-brand B-brand
with O O
potassium-sparing B-group B-group
diuretics I-group I-group
( O O
e.g. O O
, O O
spironolactone B-drug B-drug
, O O
triamterene B-drug B-drug
, O O
or O O
amiloride B-drug B-drug
) O O
, O O
potassium B-drug B-drug
supplements O O
, O O
or O O
potassium-containing O B-drug
salt O O
substitutes O O
may O O
lead O O
to O O
significant O O
increases O O
in O O
serum O O
potassium O O
. O O

Ketoconazole I-drug B-drug

Blood O O
sampling O O
for O O
the O O
pharmacokinetics O O
of O O
everolimus B-drug B-drug
and O O
cyclosporine B-drug B-drug
was O O
performed O O
on O O
day O O
1 O O
, O O
on O O
weeks O O
1 O O
, O O
2 O O
, O O
3 O O
, O O
and O O
4 O O
, O O
and O O
on O O
months O O
2 O O
, O O
3 O O
, O O
6 O O
, O O
9 O O
, O O
and O O
12 O O
. O O

No O O
formal O O
clinical O O
studies O O
have O O
been O O
conducted O O
to O O
assess O O
if O O
there O O
is O O
an O O
interactive O O
effect O O
on O O
bone O O
loss O O
between O O
phenytoin B-drug B-drug
and O O
Accutane B-brand B-brand
. O O

Analysis O O
of O O
the O O
concentration O O
of O O
budesonide B-drug B-drug
following O O
ultracentrifugation O O
indicated O O
that O O
there O O
is O O
rapid O O
equilibration O O
of O O
budesonide B-drug B-drug
between O O
the O O
Survanta B-brand B-brand
and O O
aqueous O O
phase O O
. O O

The O O
immediate O O
release O O
, O O
but O O
not O O
the O O
coat-core O O
formulation O O
of O O
nisoldipine B-drug B-drug
increased O O
plasma O O
quinidine B-drug B-drug
concentrations O O
by O O
about O O
20 O O
% O O
. O O

Because O O
busulfan B-drug B-drug
is O O
eliminated O O
from O O
the O O
body O O
via O O
conjugation O O
with O O
glutathione O B-drug
, O O
use O O
of O O
acetaminophen B-drug B-drug
prior O O
to O O
( O O
72 O O
hours O O
) O O
or O O
concurrent O O
with O O
BUSULFEX B-brand B-brand
may O O
result O O
in O O
reduced O O
busulfan B-drug B-drug
clearance O O
based O O
upon O O
the O O
known O O
property O O
of O O
acetaminophen B-drug B-drug
to O O
decrease O O
glutathione O O
levels O O
in O O
the O O
blood O O
and O O
tissues O O
. O O

Response O O
to O O
Treatment O O
for O O
Anaphylactic O O
Reaction O O
: O O
While O O
taking O O
beta-blockers B-group B-group
, O O
patients O O
with O O
a O O
history O O
of O O
severe O O
anaphylactic O O
reaction O O
to O O
a O O
variety O O
of O O
allergens O O
may O O
be O O
more O O
reactive O O
to O O
repeated O O
challenge O O
, O O
either O O
accidental O O
, O O
diagnostic O O
, O O
or O O
therapeutic O O
. O O

Amphetamines B-group B-group
may O O
interfere O O
with O O
urinary O O
steroid O B-group
determinations O O
. O O

If O O
combination O O
therapy O O
is O O
initiated O O
or O O
withdrawn O O
in O O
conjunction O O
with O O
propranolol B-drug B-drug
, O O
an O O
adjustment O O
in O O
the O O
propranolol B-drug B-drug
dose O O
may O O
be O O
warranted O O
. O O

Other O O
than O O
with O O
probenecid B-drug B-drug
, O O
no O O
specific O O
clinical O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O

Alternate O O
or O O
additional O O
contraceptive O B-group
measures O O
should O O
be O O
used O O
during O O
therapy O O
with O O
VIRACEPT B-brand B-brand

Also O O
, O O
although O O
minimal O O
alterations O O
of O O
fluvastatin B-drug B-drug
clearance O O
in O O
patients O O
with O O
renal O O
insufficiency O O
are O O
anticipated O O
due O O
to O O
limited O O
renal O O
excretion O O
( O O
5 O O
% O O
) O O
, O O
a O O
study O O
in O O
this O O
patient O O
group O O
is O O
currently O O
underway O O
to O O
examine O O
this O O
further O O
. O O

However O O
, O O
neuromuscular O O
paralysis O O
may O O
be O O
potentiated O O
by O O
co-administration O O
or O O
overlapping O O
administration O O
of O O
different O O
botulinum B-group B-group
toxin I-group I-group
serotypes O I-group
. O O

The O O
effects O O
of O O
ruthenium B-drug_n B-drug_n
red I-drug_n I-drug_n
( O I-drug_n
RR B-drug_n I-drug_n
) O I-drug_n
on O O
inositol B-drug_n O
1,4,5-trisphosphate I-drug_n O
( O O
InsP B-drug_n B-drug_n
( I-drug_n I-drug_n
3 I-drug_n I-drug_n
) I-drug_n I-drug_n
) I-drug_n I-drug_n
-induced O O
responses O O
were O O
studied O O
in O O
rat O O
bone O O
marrow O O
megakaryocytes O O
with O O
the O O
patch-clamp O O
whole-cell O O
recording O O
technique O O
in O O
combination O O
with O O
fura-2 O O
microfluorometry O O
. O O

Extended O O
Release O O
Tablets O O
: O O
Administration O O
of O O
nifedipine B-drug B-drug
with O O
digoxin B-drug B-drug
increased O O
digoxin B-drug B-drug
levels O O
in O O
9 O O
of O O
12 O O
normal O O
volunteers O O
. O O

Other O O
antihypertensive B-group B-group
drugs I-group I-group
: O O
additive O O
effect O O
or O O
potentiation O O
. O O

Unfortunately O O
, O O
folic B-drug B-drug
acid I-drug I-drug
will O O
not O O
correct O O
changes O O
in O O
the O O
nervous O O
system O O
that O O
result O O
from O O
vitamin O O
B12 O O
deficiency O O
. O O

These O O
effects O O
not O O
only O O
improve O O
insulin O O
sensitivity O O
and O O
glycemic O O
control O O
with O O
reduced O O
insulin O B-drug
requirements O O
, O O
but O O
also O O
have O O
potentially O O
favorable O O
effects O O
on O O
other O O
components O O
of O O
the O O
cardiovascular O O
dysmetabolic O O
syndrome O O
. O O

= O O
increase O O
; O O

No O O
rashes O O
were O O
reported O O
in O O
these O O
patients O O
. O O

The O O
data O O
presented O O
here O O
demonstrate O O
that O O
with O O
serial O O
pharmacokinetic O O
dosing O O
of O O
gentamicin B-drug B-drug
, O O
the O O
iatrogenic O O
alteration O O
caused O O
by O O
gentamicin B-drug B-drug
therapy O O
can O O
be O O
avoided O O
. O O

Ritonavir B-drug B-drug
and O O
indinavir B-drug B-drug
: O O
Upon O O
concomitant O O
administration O O
of O O
5 O O
mg O O
of O O
Vardenafil B-drug B-drug
with O O
600 O O
mg O O
BID O O
ritonavir B-drug B-drug
, O O
the O O
Cmax O O
and O O
AUC O O
of O O
ritonavir B-drug B-drug
were O O
reduced O O
by O O
approximately O O
20 O O
% O O
. O O

These O O
data O O
raise O O
the O O
question O O
of O O
whether O O
sertraline B-drug B-drug
is O O
the O O
best O O
choice O O
for O O
prolonged O O
use O O
for O O
diabetic O O
individuals O O
, O O
because O O
of O O
its O O
antihyperglycemic O O
effects O O
. O O

Due O O
to O O
the O O
considerable O O
variability O O
of O O
these O O
interactions O O
, O O
the O O
dosage O O
of O O
digoxin B-drug B-drug
should O O
be O O
individualized O O
when O O
patients O O
receive O O
these O O
medications O O
concurrently O O
. O O

increased O O
prothrombin O O
and O O
factors O O
VII O O
, O O
VIII O O
, O O
IX O O
, O O
and O O
X O O
; O O

Tablet O O
If O O
a O O
patient O O
receiving O O
clonidine B-drug B-drug
hydrochloride I-drug I-drug
is O O
also O O
taking O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
the O O
effect O O
of O O
clonidine B-drug B-drug
may O O
be O O
reduced O O
, O O
thus O O
necessitating O O
an O O
increase O O
in O O
dosage O O
. O O

As O O
a O O
consequence O O
, O O
when O O
INDOCIN B-brand B-brand
and O O
lithium B-drug B-drug
are O O
given O O
concomitantly O O
, O O
the O O
patient O O
should O O
be O O
carefully O O
observed O O
for O O
signs O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

Blood O O
Sugar O O
: O O
Some O O
patients O O
receiving O O
retinoids B-group B-group
have O O
experienced O O
problems O O
with O O
blood O O
sugar O O
control O O
. O O

Antifungals B-group B-group

avoid O O
use O O
if O O
possible O O
or O O
closely O O
monitor O O
cardiovascular O O
status O O
at O O
the O O
end O O
of O O
drug O O
interactions O O

Caffeine B-drug B-drug
Theobromine I-drug I-drug
Grepafloxacin I-drug B-drug
, O O
like O O
other O O
quinolones B-group B-group
, O O
may O O
inhibit O O
the O O
metabolism O O
of O O
caffeine B-drug B-drug
and O O
theobromine B-drug B-drug
. O O

Clinical O O
studies O O
of O O
PEGASYS B-brand B-brand
alone O O
or O O
in O O
combination O O
with O O
COPEGUS B-brand B-brand
did O O
not O O
include O O
sufficient O O
numbers O O
of O O
subjects O O
aged O O
65 O O
or O O
over O O
to O O
determine O O
whether O O
they O O
respond O O
differently O O
from O O
younger O O
subjects O O
. O O

d-amphetamine B-drug B-drug
with O O
desipramine B-drug B-drug
or O O
protriptyline B-drug B-drug
and O O
possibly O O
other O O
tricyclics B-group B-group
cause O O
striking O O
and O O
sustained O O
increases O O
in O O
the O O
concentration O O
of O O
d-amphetamine B-drug B-drug
in O O
the O O
brain O O
; O O

RESULTS O O
: O O
Insulin B-drug B-drug
increased O O
renal O O
plasma O O
flow O O
and O O
fundus O O
pulsation O O
amplitude O O
but O O
not O O
the O O
glomerular O O
filtration O O
rate O O
. O O

During O O
concomitant O O
therapy O O
with O O
NSAIDs B-group B-group
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
signs O O
of O O
renal O O
failure O O
, O O
as O O
well O O
as O O
to O O
assure O O
diuretic O B-group
efficacy O O
. O O

Mixtures O O
should O O
not O O
be O O
administered O O
intravenously O O
. O O

Magnesium B-drug B-drug
: O O
Magnesium-containing B-drug B-drug
preparations O O
( O O
eg O O
, O O
antacids B-group B-group
) O O
may O O
cause O O
hypermagnesemia O O
and O O
should O O
therefore O O
not O O
be O O
taken O O
during O O
therapy O O
with O O
vitamin B-group B-group
D I-group I-group
by O O
patients O O
on O O
chronic O O
renal O O
dialysis O O
. O O

The O O
safety O O
of O O
using O O
STADOL B-brand B-brand
NS I-brand I-brand
and O O
IMITREX B-brand B-brand
( O O
sumatriptan B-drug B-drug
) O O
Nasal O O
Spray O O
during O O
the O O
same O O
episode O O
of O O
migraine O O
has O O
not O O
been O O
established O O
. O O

Cevimeline B-drug B-drug
should O O
be O O
administered O O
with O O
caution O O
to O O
patients O O
taking O O
beta B-group B-group
adrenergic I-group I-group
antagonists I-group I-group
, O O
because O O
of O O
the O O
possibility O O
of O O
conduction O O
disturbances O O
. O O

An O O
individual O O
who O O
is O O
stable O O
on O O
a O O
given O O
dose O O
of O O
TCAmay B-group B-group
become O O
abruptly O O
toxic O O
when O O
given O O
one O O
of O O
these O O
inhibiting O O
drugs O O
as O O
concomitant O O
therapy O O
. O O

Depending O O
on O O
the O O
fraction O O
of O O
drug O O
metabolized O O
by O O
P450 O O
2D6 O O
, O O
the O O
increase O O
in O O
plasma O O
concentration O O
may O O
be O O
small O O
, O O
or O O
quite O O
large O O
( O O
8 O O
fold O O
increase O O
in O O
plasma O O
AUC O O
of O O
the O O
TCA B-group B-group
) O O
. O O

No O O
interaction O O
with O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
imipramine B-drug B-drug
was O O
shown O O
in O O
a O O
single-dose O O
study O O
with O O
entacapone B-drug B-drug
without O O
coadministered O O
levodopa/dopa-decarboxylase B-drug O
inhibitor B-group O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
Effect O O
on O O
Blood O O
Coagulation O O
: O O
Diclofenac B-drug B-drug
increases O O
platelet O O
aggregation O O
time O O
but O O
does O O
not O O
affect O O
bleeding O O
time O O
, O O
plasma O O
thrombin O O
clotting O O
time O O
, O O
plasma O O
fibrinogen O O
, O O
or O O
factors O O
V O O
and O O
VII O O
to O O
XII O O
. O O

Such O O
patients O O
may O O
be O O
unresponsive O O
to O O
the O O
usual O O
doses O O
of O O
epinephrine B-drug B-drug
used O O
to O O
treat O O
the O O
allergic O O
reaction O O
. O O

This O O
diminution O O
is O O
not O O
sufficient O O
to O O
preclude O O
effectiveness O O
of O O
the O O
pressor O O
agent O O
for O O
therapeutic O O
use O O
. O O
) O O

Morphine B-drug B-drug
: O O
Combination O O
hormonal B-group B-group
contraceptives I-group I-group
may O O
increase O O
the O O
clearance O O
of O O
morphine B-drug B-drug
. O O

This O O
may O O
potentiate O O
and O O
prolong O O
hypnotic O O
and O O
sedative O O
effects O O
. O O

Ketoconazole B-drug B-drug
is O O
a O O
potent O O
inhibitor O O
of O O
the O O
cytochrome O O
P450 O O
3A4 O O
enzyme O O
system O O
. O O

Each O O
healthy O O
subject O O
( O O
N O O
= O O
10 O O
) O O
received O O
rofecoxib B-drug B-drug
( O O
75 O O
mg O O
once O O
daily O O
) O O
or O O
placebo O O
for O O
11 O O
days O O
in O O
a O O
double-blind O O
, O O
randomized O O
, O O
balanced O O
, O O
two-period O O
crossover O O
study O O
. O O

Since O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
is O O
an O O
anion B-group O
exchange I-group O
resin I-group B-group
, O O
it O O
may O O
have O O
a O O
strong O O
affinity O O
for O O
anions O O
other O O
than O O
the O O
bile O O
acids O O
. O O

In O O
such O O
cases O O
of O O
combined O O
treatment O O
, O O
the O O
dose O O
of O O
one O O
or O O
both O O
agents O O
should O O
be O O
reduced O O
. O O

Intracellular O O
resistance O O
to O O
thyroid B-group B-group
hormone I-group I-group
is O O
quite O O
rare O O
. O O

Drugs O O
that O O
suppress O O
the O O
immune O O
system O O
are O O
widely O O
used O O
. O O

Saquinavir B-drug B-drug
steady-state O O
Cmax O O
, O O
A.C. O O
and O O
Cmin O O
were O O
increased O O
21 O O
% O O
, O O
decreased O O
19 O O
% O O
, O O
and O O
decreased O O
48 O O
% O O
, O O
respectively O O
, O O
by O O
concomitant O O
amprenavir B-drug B-drug
. O O

Anticholinergics B-group B-group
antagonize O O
the O O
effects O O
of O O
antiglaucoma B-group B-group
agents I-group I-group
. O O

The O O
intake O O
of O O
furosemide B-drug B-drug
and O O
sucralfate B-drug B-drug
should O O
be O O
separated O O
by O O
at O O
least O O
two O O
hours O O
. O O

Patients O O
taking O O
digoxin B-drug B-drug
should O O
be O O
monitored O O
appropriately O O
. O O

For O O
this O O
reason O O
the O O
dose O O
of O O
adrenaline B-drug B-drug
should O O
be O O
restricted O O
and O O
an O O
antiarrhythmic B-group B-group
agent I-group I-group
administered O O
as O O
appropriate O O
. O O

On O O
the O O
other O O
hand O O
, O O
the O O
density O O
of O O
D2 O O
binding O O
sites O O
in O O
the O O
SST O O
and O O
the O O
RBC O O
mice O O
in O O
the O O
STR O O
was O O
significantly O O
increased O O
in O O
cocaine-treated B-drug B-drug
groups O O
without O O
change O O
in O O
Kd O O
. O O

This O O
study O O
investigated O O
the O O
role O O
of O O
neuronal O O
uptake O O
of O O
norepinephrine B-drug B-drug
( O O
uptake-1 O O
) O O
in O O
human O O
heart O O
failure O O
as O O
a O O
local O O
factor O O
for O O
altering O O
concentrations O O
of O O
norepinephrine O B-drug
at O O
the O O
cardiac O O
myocyte O O
membranes O O
. O O

In O O
clinical O O
trials O O
, O O
mean O O
decreases O O
of O O
1 O O
to O O
2 O O
mg/dL O O
were O O
observed O O
in O O
arthritic O O
patients O O
receiving O O
etodolac B-drug B-drug
( O O
600 O O
mg O O
to O O
1000 O O
mg/day O O
) O O
after O O
4 O O
weeks O O
of O O
therapy O O
. O O

Breakthrough O O
bleeding O O
has O O
been O O
reported O O

The O O
appropriate O O
doses O O
for O O
this O O
combination O O
, O O
with O O
respect O O
to O O
efficacy O O
and O O
safety O O
, O O
have O O
not O O
been O O
established O O
. O O

A O O
variety O O
of O O
toxic O O
neurological O O
effects O O
and O O
malignant O O
hyperpyrexia O O
can O O
occur O O
, O O
sometimes O O
with O O
fatal O O
results O O
. O O

Postoperative O O
respiratory O O
depression O O
may O O
be O O
enhanced O O
or O O
prolonged O O
by O O
these O O
agents O O
. O O

Both O O
groups O O
of O O
agents O O
increase O O
blood O O
levels O O
and O O
therefore O O
potentiate O O
the O O
actions O O
of O O
amphetamines B-group B-group
. O O

Therefore O O
, O O
monitoring O O
of O O
blood O O
glucose O O
is O O
recommended O O
when O O
these O O
agents O O
are O O
co-administered O O
. O O

Hypersensitivity O O
reactions O O
have O O
been O O
reported O O
in O O
patients O O
receiving O O
combination O O
regimens O O
containing O O
sequential O O
high O O
dose O O
PROLEUKIN B-brand B-brand
and O O
antineoplastic B-group B-group
agents I-group I-group
, O O
specifically O O
, O O
dacarbazine B-drug B-drug
, O O
cis-platinum B-drug B-drug
, O O
tamoxifen B-drug B-drug
and O O
interferon-alfa B-drug B-drug
. O O

Concurrent O O
administration O O
of O O
oxyphenbutazone B-drug B-drug
and O O
androgens B-group B-group
may O O
result O O
in O O
elevated O O
serum O O
levels O O
of O O
oxyphenbutazone B-drug B-drug
. O O

Increased O O
ectopic O O
pacemaker O O
activity O O
can O O
occur O O
when O O
pseudoephedrine B-drug B-drug
is O O
used O O
concomitantly O O
with O O
digitalis B-group B-group
. O O

When O O
concomitant O O
treatment O O
with O O
agents B-group O
with I-group O
b-blocking I-group B-group
properties I-group I-group
and O O
clonidine B-drug B-drug
is O O
to O O
be O O
terminated O O
, O O
the O O
b-blocking B-group B-group
agent I-group I-group
should O O
be O O
discontinued O O
first O O
. O O

Blunting O O
of O O
the O O
antihypertensive O O
effect O O
of O O
beta-adrenoceptor B-group B-group
blocking I-group I-group
agents I-group I-group
by O O
non-steroidal B-group B-group
antiinflammatory I-group I-group
drugs I-group I-group
including O O
INDOCIN B-brand B-brand
has O O
been O O
reported O O
. O O

Serious O O
cardiac O O
dysrhythmias O O
, O O
some O O
resulting O O
in O O
death O O
, O O
have O O
occurred O O
in O O
patients O O
receiving O O
terfenadine B-drug B-drug
concomitantly O O
with O O
other O O
macrolide B-group B-group
antibiotics I-group I-group
. O O

The O O
growth O O
of O O
Pseudomonas O O
aeruginosa O O
, O O
particularly O O
serotype O O
O11 O O
, O O
in O O
pentazocine B-drug B-drug
and O O
tripelennamine B-drug B-drug

There O O
is O O
strong O O
evidence O O
that O O
insulin O B-drug
resistance O O
is O O
involved O O
in O O
the O O
development O O
of O O
not O O
only O O
hyperglycemia O O
, O O
but O O
also O O
dyslipidemia O O
, O O
hypertension O O
, O O
hypercoagulation O O
, O O
vasculopathy O O
, O O
and O O
ultimately O O
atherosclerotic O O
cardiovascular O O
disease O O
. O O

Central B-group B-group
Nervous I-group I-group
System I-group I-group
Depressants I-group I-group
: O O
The O O
concomitant O O
use O O
of O O
DURAGESIC B-brand B-brand
( O O
fentanyl B-drug B-drug
transdermal O O
system O O
) O O
with O O
other O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
, O O
including O O
but O O
not O O
limited O O
to O O
other O O
opioids B-group B-group
, O O
sedatives B-group B-group
, O O
hypnotics B-group B-group
, O O
tranquilizers B-group B-group
( O O
e.g. O O
, O O
benzodiazepines B-group B-group
) O O
, O O
general O O
anesthetics B-group B-group
, O O
phenothiazines B-group B-group
, O O
skeletal B-group B-group
muscle I-group I-group
relaxants I-group I-group
, O O
and O O
alcohol B-drug B-drug
, O O
may O O
cause O O
respiratory O O
depression O O
, O O
hypotension O O
, O O
and O O
profound O O
sedation O O
, O O
or O O
potentially O O
result O O
in O O
coma O O
or O O
death O O
. O O

OBJECTIVE O O
: O O
Our O O
objective O O
was O O
to O O
examine O O
the O O
interaction O O
between O O
fluvoxamine B-drug B-drug
and O O
tolbutamide B-drug B-drug
to O O
confirm O O
that O O
fluvoxamine B-drug B-drug
inhibits O O
CYP2C9 O O
. O O

Abciximab B-drug B-drug
has O O
been O O
administered O O
to O O
patients O O
with O O
ischemic O O
heart O O
disease O O
treated O O
concomitantly O O
with O O
a O O
broad O O
range O O
of O O
medications O O
used O O
in O O
the O O
treatment O O
of O O
angina O O
myocardial O O
infarction O O
and O O
hypertension O O
. O O

Patients O O
receiving O O
insulin B-drug B-drug
or O O
oral O O
hypoglycemics B-group B-group
should O O
be O O
closely O O
watched O O
during O O
initiation O O
of O O
thyroid O O
replacement O O
therapy O O
. O O

No O O
data O O
for O O
saquinavir B-drug B-drug
. O O

N=48 O O
) O O
decreases O O
hydrocodone B-drug B-drug
( O O
10 O O
mg O O
; O O

Appropriate O O
laboratory O O
testing O O
should O O
be O O
considered O O
prior O O
to O O
initiating O O
combination O O
therapy O O
with O O
Amprenavir B-drug B-drug
and O O
ritonavir B-drug B-drug
and O O
at O O
periodic O O
intervals O O
or O O
if O O
any O O
clinical O O
signs O O
or O O
symptoms O O
of O O
hyperlipidemia O O
or O O
elevated O O
liver O O
function O O
tests O O
occur O O
during O O
therapy O O
. O O

Griseofulvin B-drug B-drug
: O O
Griseofulvin B-drug B-drug
may O O
induce O O
the O O
metabolism O O
of O O
combination B-group B-group
hormonal I-group I-group
contraceptives I-group I-group
causing O O
menstrual O O
changes O O
; O O

It O O
is O O
not O O
known O O
whether O O
other O O
progestational B-group B-group
contraceptives I-group I-group
, O O
such O O
as O O
implants O O
and O O
injectables O O
, O O
are O O
adequate O O
methods O O
of O O
contraception O O
during O O
acitretin B-drug B-drug
therapy O O
. O O

Because O O
heparin B-drug B-drug
, O O
aspirin B-brand B-brand
, O O
or O O
Activase B-brand B-brand
may O O
cause O O
bleeding O O
complications O O
, O O
careful O O
monitoring O O
for O O
bleeding O O
is O O
advised O O
, O O
especially O O
at O O
arterial O O
puncture O O
sites O O
. O O

There O O
is O O
no O O
pharmacokinetic O O
interaction O O
between O O
ethanol B-drug B-drug
and O O
flumazenil B-drug B-drug
. O O

This O O
is O O
demonstrated O O
for O O
cigarette O O
smokers O O
and O O
industrial O O
workers O O
involved O O
in O O
chemical O O
waste O O
incineration O O
. O O

Differences O O
in O O
clearance O O
between O O
patients O O
on O O
these O O
medications O O
( O O
at O O
any O O
occasion O O
in O O
the O O
study O O
) O O
and O O
those O O
off O O
medications O O
varied O O
between O O
-16 O O
% O O
and O O
+3 O O
% O O
. O O

The O O
adverse O O
effects O O
of O O
CAMPTOSAR B-brand B-brand
, O O
such O O
as O O
myelosuppression O O
and O O
diarrhea O O
, O O
would O O
be O O
expected O O
to O O
be O O
exacerbated O O
by O O
other O O
antineoplastic B-group B-group
agents I-group I-group
having O O
similar O O
adverse O O
effects O O
. O O

It O O
is O O
, O O
however O O
, O O
possible O O
that O O
concomitant O O
use O O
of O O
other O O
known O O
photosensitizing B-group O
agents I-group O
such O O
as O O
griseofulvin B-drug B-drug
, O O
thiazide B-group B-group
diuretics I-group I-group
, O O
sulfonylureas B-group B-group
, O O
phenothiazines B-group B-group
, O O
sulfonamides B-group B-group
and O O
tetracyclines B-group B-group
might O O
increase O O
the O O
photosensitivity O O
reaction O O
of O O
actinic O O
keratoses O O
treated O O
with O O
the O O
LEVULAN B-brand B-brand
KERASTICK I-brand B-brand
for O O
Topical O O
Solution O O
. O O

No O O
evaluation O O
of O O
EXTRANEALs B-brand B-brand
effects O O
on O O
the O O
cytochrome O O
P450 O O
system O O
was O O
conducted O O
. O O

These O O
increases O O
should O O
be O O
considered O O
when O O
selecting O O
an O O
oral O O
contraceptive B-group B-group
for O O
a O O
woman O O
taking O O
atorvastatin B-drug B-drug
. O O

Cimetidine B-drug B-drug
: O O
Cimetidine B-drug B-drug
has O O
been O O
reported O O
to O O
produce O O
clinically O O
significant O O
fluctuations O O
in O O
steady-state O O
serum O O
concentrations O O
of O O
various O O
tricyclic B-group B-group
antidepressants I-group I-group
. O O

In O O
patients O O
on O O
chronic O O
warfarin B-drug B-drug
therapy O O
, O O
the O O
prothrombin O O
time O O
( O O
INR O O
) O O
should O O
be O O
closely O O
monitored O O
in O O
the O O
2-week O O
period O O
, O O
particularly O O
at O O
7 O O
to O O
10 O O
days O O
, O O
following O O
initiation O O
of O O
the O O
3-day O O
regimen O O
of O O
Aprepitant B-drug B-drug
with O O
each O O
chemotherapy O O
cycle O O
. O O

Therefore O O
, O O
a O O
potent O O
effect O O
of O O
etofibrate B-drug B-drug
on O O
both O O
chylomicron O B-drug
lipolysis O O
and O O
remnant O O
removal O O
was O O
achieved O O
, O O
indicating O O
that O O
this O O
drug O O
can O O
be O O
used O O
to O O
improve O O
this O O
metabolism O O
in O O
future O O
prospective O O
studies O O
. O O

Antimycobacterial B-group O
: O O
rifampin B-drug B-drug

Patients O O
already O O
stabilized O O
on O O
valdecoxib B-drug B-drug
should O O
be O O
closely O O
monitored O O
for O O
loss O O
of O O
symptom O O
control O O
with O O
phenytoin B-drug B-drug
coadministration O O
. O O

There O O
were O O
26 O O
PI O O
with O O
drugs O O
of O O
low O O
intrinsic O O
value O O
( O O
7.6 O O
% O O
; O O
95 O O
% O O
CI O O
, O O
+/- O O
2.8 O O
) O O
. O O

Seizures O O
have O O
been O O
reported O O
in O O
patients O O
taking O O
another O O
quinolone B-group B-group
class I-group I-group
antimicrobial I-group I-group
and O O
the O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drug I-group I-group
fenbufen B-drug B-drug
concurrently O O
. O O

Monitoring O O
of O O
disopyramide B-drug B-drug
plasma O O
levels O O
is O O
recommended O O
in O O
such O O
concurrent O O
use O O
to O O
avoid O O
ineffective O O
therapy O O
. O O

Available O O
data O O
are O O
not O O
sufficient O O
, O O
however O O
, O O
to O O
predict O O
the O O
effects O O
of O O
concomitant O O
medication O O
on O O
patients O O
with O O
impaired O O
ventricular O O
function O O
or O O
cardiac O O
conduction O O
abnormalities O O
. O O

Withdrawal O O
of O O
rifampin B-drug B-drug
decreased O O
the O O
warfarin B-drug B-drug
requirement O O
by O O
50 O O
% O O
. O O

In O O
patients O O
who O O
have O O
received O O
general O O
anesthesia O O
utilizing O O
a O O
volatile O O
agent O O
known O O
to O O
sensitize O O
the O O
myocardium O O
to O O
catecholamines O O
, O O
administration O O
of O O
doxapram B-drug B-drug
should O O
be O O
delayed O O
until O O
the O O
volatile O O
agent O O
has O O
been O O
excreted O O
in O O
order O O
to O O
lessen O O
the O O
potential O O
for O O
arrhythmias O O
, O O
including O O
ventricular O O
tachycardia O O
and O O
ventricular O O
fibrillation O O
. O O

This O O
defect O O
in O O
the O O
failing O O
heart O O
can O O
be O O
mimicked O O
by O O
the O O
effects O O
of O O
uptake O O
blocking O O
agents O O
, O O
such O O
as O O
cocaine B-drug B-drug
and O O
desipramine B-drug B-drug
, O O
in O O
the O O
nonfailing O O
heart O O
only O O
. O O

Patients O O
treated O O
with O O
Nalfon B-brand B-brand
may O O
be O O
resistant O O
to O O
the O O
effects O O
of O O
loop B-group B-group
diuretics I-group I-group
. O O

In O O
Europe O O
, O O
Nimotop B-brand B-brand
was O O
observed O O
to O O
occasionally O O
intensify O O
the O O
effect O O
of O O
antihypertensive B-group B-group
compounds I-group I-group
taken O O
concomitantly O O
by O O
patients O O
suffering O O
from O O
hypertension O O
; O O

Inhibits O O
CYP2D6 O O
( O O
weak O O
) O O
. O O

Cholestyramine B-drug B-drug
, O O
an O O
anionic-binding O O
resin O B-group
, O O
has O O
a O O
considerable O O
effect O O
in O O
lowering O O
the O O
rate O O
and O O
extent O O
of O O
fluvastatin B-drug B-drug
bioavailability O O
. O O

Drugs O O
that O O
have O O
been O O
reported O O
to O O
diminish O O
oral O O
anticoagulant B-group B-group
response O O
, O O
ie O O
, O O
decreased O O
prothrom-bin O O
time O O
response O O
, O O
in O O
man O O
significantly O O
include O O
: O O
adrenocortical B-group B-group
steroids I-group I-group
; O O

Certain O O
concomitant O O
medications O O
( O O
such O O
as O O
rifampin B-drug B-drug
, O O
anticonvulsants B-group B-group
, O O
St O O
. O O

The O O
authors O O
investigated O O
the O O
possibility O O
of O O
a O O
similar O O
interaction O O
between O O
oxycodone B-drug B-drug
and O O
levofloxacin B-drug B-drug
. O O

The O O
successive O O
application O O
of O O
glycine B-drug B-drug
( O O
5 O O
or O O
10 O O
mg/kg O O
egg O O
weight O O
( O O
e.w O O
. O O
) O O

Combinations O O
of O O
clindamycin B-drug B-drug
and O O
gentamicin B-drug B-drug
were O O
indifferent O O
for O O
16 O O
and O O
synergistic O O
for O O
11 O O
of O O
the O O
resistant O O
strains O O
. O O

Concurrent O O
use O O
of O O
erythromycin B-drug B-drug
and O O
ergotamine B-drug B-drug
or O O
dihydroergotamine B-drug B-drug
has O O
been O O
associated O O
in O O
some O O
patients O O
with O O
acute O O
ergot O B-group
toxicity O O
characterized O O
by O O
severe O O
peripheral O O
vasospasm O O
and O O
dysesthesia O O
. O O

Triazolam B-drug B-drug
- O O
Combined O O
administration O O
of O O
racemic O O
citalopram B-drug B-drug
( O O
titrated O O
to O O
40 O O
mg/day O O
for O O
28 O O
days O O
) O O
and O O
the O O
CYP3A4 O O
substrate O O
triazolam B-drug B-drug
( O O
single O O
dose O O
of O O
0.25 O O
mg O O
) O O
did O O
not O O
significantly O O
affect O O
the O O
pharmacokinetics O O
of O O
either O O
citalopram B-drug B-drug
or O O
triazolam B-drug B-drug
. O O

Aprepitant B-drug B-drug
is O O
a O O
substrate O O
, O O
a O O
moderate O O
inhibitor O O
, O O
and O O
an O O
inducer O O
of O O
CYP3A4 O O
. O O

Due O O
to O O
highintersubject O O
variability O O
, O O
however O O
, O O
somepatients O B-group
may O O
experience O O
large O O
increases O O
inrifabutin B-drug B-drug
exposure O O
and O O
may O O
be O O
at O O
higher O O
riskfor O O
rifabutin O B-drug
toxicity O O
. O O

In O O
eight O O
experiments O O
the O O
perfusion O O
medium O O
contained O O
oxytocin B-drug B-drug
. O O

The O O
anticoagulant O O
effect O O
of O O
heparin B-drug B-drug
is O O
enhanced O O
by O O
concurrent O O
treatment O O
with O O
antithrombin B-drug O
III I-drug O
( O O
human O O
) O O
in O O
patients O O
with O O
hereditary O O
antithrombin O O
III O O
deficiency O O
. O O

After O O
multiple O O
dosing O O
, O O
interferon B-drug B-drug
beta-1a I-drug I-drug
( O O
AVONEX B-brand B-brand
30 O O
mcg O O
IM O O
once O O
weekly O O
) O O
reduced O O
TYSABRI B-brand B-brand
clearance O O
by O O
approximately O O
30 O O
% O O
. O O

Drug O O
interactions O O
between O O
NEUPOGEN B-brand B-brand
and O O
other O O
drugs O O
have O O
not O O
been O O
fully O O
evaluated O O
. O O

Fluconazole B-drug B-drug
, O O
an O O
inhibitor O O
of O O
P450 O O
2C9 O O
, O O
decreased O O
active O O
metabolite O O
concentration O O
and O O
increased O O
losartan B-drug B-drug
concentration O O
. O O

A O O
proposed O O
mechanism O O
for O O
the O O
potentiation O O
of O O
cAMP-mediated O O
acid O O
secretion O O
by O O
carbachol B-drug B-drug
. O O

Renal O O
Impairment O O
There O O
are O O
currently O O
no O O
clinical O O
studies O O
with O O
SPRYCEL B-brand B-brand
in O O
patients O O
with O O
impaired O O
renal O O
function O O
( O O
clinical O O
studies O O
have O O
excluded O O
patients O O
with O O
serum O O
creatinine O O
concentration O O
1.5 O O
times O O
the O O
upper O O
limit O O
of O O
the O O
normal O O
range O O
) O O
. O O

Limited O O
clinical O O
data O O
in O O
angina O O
patients O O
receiving O O
concomitant O O
bepridil B-drug B-drug
hydrochloride I-drug I-drug
and O O
digoxin B-drug B-drug
therapy O O
indicate O O
no O O
discernible O O
changes O O
in O O
serum O O
digoxin O B-drug
levels O O
. O O

FLEXERIL B-brand B-brand
may O O
enhance O O
the O O
effects O O
of O O
alcohol B-drug B-drug
, O O
barbiturates B-group B-group
, O O
and O O
other O O
CNS B-group B-group
depressants I-group I-group
. O O

Interactions O O
of O O
cobalt B-drug B-drug
and O O
iron B-drug B-drug
in O O
absorption O O
and O O
retention O O
. O O

Adenosine B-drug B-drug
: O O
Dipyridamole B-drug B-drug
has O O
been O O
reported O O
to O O
increase O O
the O O
plasma O O
levels O O
and O O
cardiovascular O O
effects O O
of O O
adenosine B-drug B-drug
. O O

Cholestyramine B-drug B-drug
and O O
colestipol B-drug B-drug
resins B-group B-group
: O O
Absorption O O
of O O
hydrochlorothiazide B-drug B-drug
is O O
impaired O O
in O O
the O O
presence O O
of O O
anionic B-group O
exchange I-group O
resins I-group B-group
. O O

Beta-adrenergic B-group B-group
Blocking I-group I-group
Agents I-group I-group
: O O
The O O
effect O O
of O O
flurbiprofen B-drug B-drug
on O O
blood O O
pressure O O
response O O
to O O
propranolol B-drug B-drug
and O O
atenolol B-drug B-drug
was O O
evaluated O O
in O O
men O O
with O O
mild O O
uncomplicated O O
hypertension O O
( O O
n O O
= O O
10 O O
) O O
. O O

methyldopa B-drug B-drug
; O O

Because O O
the O O
nitrosourea B-group B-group
CCNU B-drug B-drug
is O O
given O O
exclusively O O
by O O
the O O
oral O O
route O O
in O O
man O O
, O O
we O O
have O O
carried O O
out O O
studies O O
in O O
mice O O
on O O
the O O
antitumour O O
activity O O
, O O
acute O O
toxicity O O
and O O
pharmacokinetics O O
of O O
oral O O
CCNU B-drug B-drug
, O O
either O O
alone O O
or O O
in O O
combination O O
with O O
the O O
chemosensitizer O O
misonidazole B-drug_n O
. O O

Given O O
the O O
primary O O
CNS O O
effects O O
of O O
Anafranil B-brand B-brand
, O O
caution O O
is O O
advised O O
in O O
using O O
it O O
concomitantly O O
with O O
other O O
CNS-active O O
drugs O O
. O O

This O O
may O O
occur O O
because O O
diflunisal B-drug B-drug
competitively O O
displaces O O
coumarins B-group B-group
from O O
protein O O
binding O O
sites O O
. O O

In O O
vivo O O
studies O O
: O O
Cytochrome O O
P450 O O
Inhibitors O O

These O O
potential O O
drug O O
interactions O O
are O O
listed O O
in O O
Table O O
4 O O
. O O

It O O
is O O
recommended O O
not O O
to O O
exceed O O
a O O
single O O
2.5 O O
mg O O
Vardenafil B-drug B-drug
dose O O
in O O
a O O
24-hour O O
period O O
when O O
used O O
in O O
combination O O
with O O
indinavir B-drug B-drug
. O O

Because O O
severe O O
hypoglycemia O O
has O O
been O O
reported O O
in O O
patients O O
concomitantly O O
receiving O O
oral O O
miconazole B-drug B-drug
( O O
an O O
imidazole B-group B-group
) O O
and O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
, O O
such O O
a O O
potential O O
interaction O O
involving O O
the O O
latter O O
agents O O
when O O
used O O
concomitantly O O
with O O
ketoconazole B-drug B-drug
tablets O O
( O O
an O O
imidazole B-group B-group
) O O
can O O
not O O
be O O
ruled O O
out O O
. O O

The O O
oral O O
dexamethasone B-drug B-drug
doses O O
should O O
be O O
reduced O O
by O O
approximately O O
50 O O
% O O
when O O
coadministered O O
with O O
Aprepitant B-drug B-drug
, O O
to O O
achieve O O
exposures O O
of O O
dexamethasone B-drug B-drug
similar O O
to O O
those O O
obtained O O
when O O
it O O
is O O
given O O
without O O
Aprepitant B-drug B-drug
. O O

Beta-Blocking O B-group
Agents O I-group
A O O
pharmacokinetic O O
study O O
of O O
felodipine B-drug B-drug
in O O
conjunction O O
with O O
metoprolol B-drug B-drug
demonstrated O O
no O O
significant O O
effects O O
on O O
the O O
pharmacokinetics O O
of O O
felodipine B-drug B-drug
. O O

ROMAZICON B-brand B-brand
blocks O O
the O O
central O O
effects O O
of O O
benzodiazepines B-group B-group
by O O
competitive O O
interaction O O
at O O
the O O
receptor O O
level O O
. O O

Serum O O
Amylase O O
An O O
apparent O O
decrease O O
in O O
serum O O
amylase O O
activity O O
has O O
been O O
observed O O
in O O
patients O O
administered O O
EXTRANEAL B-brand B-brand
. O O

Therefore O O
, O O
if O O
concomitant O O
use O O
of O O
such O O
agents O O
is O O
indicated O O
, O O
they O O
should O O
be O O
given O O
with O O
caution O O
, O O
and O O
the O O
patient O O
's O O
serum O O
potassium O O
should O O
be O O
monitored O O
frequently O O
. O O

In O O
addition O O
, O O
certain O O
drugs O O
that O O
are O O
metabolized O O
by O O
this O O
isozyme O O
, O O
including O O
many O O
antidepressants B-group B-group
( O O
clozapine B-drug B-drug
, O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
, O O
and O O
others O O
) O O
, O O
may O O
inhibit O O
the O O
activity O O
of O O
this O O
isozyme O O
, O O
and O O
thus O O
may O O
make O O
normal O O
metabolizers O O
resemble O O
poor O O
metabolizers O O
with O O
regard O O
to O O
concomitant O O
therapy O O
with O O
other O O
drugs O O
metabolized O O
by O O
this O O
enzyme O O
system O O
, O O
leading O O
to O O
drug O O
interaction O O
. O O

increased O O
alkaline O O

Ethanol B-drug B-drug
or O O
Triazolam B-drug B-drug
: O O
No O O
significant O O
differences O O
were O O
observed O O
in O O
the O O
pharmacokinetics O O
of O O
triazolam B-drug B-drug
( O O
0.125 O O
mg O O
) O O
and O O
tiagabine B-drug B-drug
( O O
10 O O
mg O O
) O O
when O O
given O O
together O O
as O O
a O O
single O O
dose O O
. O O

Studies O O
have O O
demonstrated O O
that O O
pretreatment O O
with O O
isoniazid B-drug B-drug
potentiates O O
a O O
cetaminophen O B-drug
hepatoxicity O O
in O O
rats O O
. O O

Ibogaine B-drug_n B-drug_n
attenuates O O
, O O
but O O
18-MC B-drug_n B-drug_n
potentiates O O
, O O
the O O
acute O O
locomotor O O
effects O O
of O O
morphine B-drug B-drug
; O O

The O O
carbamazepine B-drug B-drug
steady-state O O
Cmin O O
decreased O O
31 O O
% O O
to O O
5 O O
1 O O
micrograms/mL O O
when O O
felbamate B-drug B-drug
( O O
3000 O O
mg/day O O
, O O
divided O O
into O O
three O O
doses O O
) O O
was O O
coadministered O O
. O O

Sodium B-drug B-drug
cephalothin I-drug I-drug
may O O
enhance O O
the O O
nephrotoxicity O O
of O O
Coly-Mycin B-brand B-brand
M I-brand O
Parenteral O O
. O O

magnesium B-drug B-drug
salts O O
; O O

The O O
gradual O O
withdrawal O O
of O O
guafacine B-drug B-drug
or O O
a O O
cardioselective B-group B-group
beta-blocker I-group I-group
could O O
be O O
substituted O O
. O O

Refer O O
to O O
the O O
package O O
insert O O
for O O
lithium B-drug B-drug
preparations O O
before O O
use O O
of O O
such O O
preparations O O
with O O
Hydrochlorothiazide B-drug B-drug
. O O

Therefore O O
, O O
if O O
theophylline B-drug B-drug
is O O
co-administered O O
with O O
fluvoxamine B-drug B-drug
maleate I-drug I-drug
, O O
its O O
dose O O
should O O
be O O
reduced O O
to O O
one O O
third O O
of O O
the O O
usual O O
daily O O
maintenance O O
dose O O
and O O
plasma O O
concentrations O O
of O O
theophylline B-drug B-drug
should O O
to O O
monitored O O
. O O

Caution O O
in O O
using O O
concomitant O O
drugs O O
such O O
as O O
beta-blockers B-group B-group
( O O
ophthalmic O O
and O O
systemic O O
) O O
, O O
anti-hypertensives B-group B-group
and/or O O
cardiac B-group B-group
glycosides I-group I-group
is O O
advised O O
. O O

Beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
may O O
also O O
interact O O
with O O
sympathomimetics B-group B-group
. O O

EDECRIN B-brand B-brand
may O O
increase O O
the O O
ototoxic O O
potential O O
of O O
other O O
drugs O O
such O O
as O O
aminoglycoside B-group B-group
and O O
some O O
cephalosporin B-group B-group
antibiotics I-group I-group
. O O

A O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
may O O
occur O O
with O O
copper O O
reduction O O
tests O O
( O O
Benedicts O O
or O O
Fehlings O O
solution O O
or O O
with O O
CLINITEST O O
tablets O O
) O O
, O O
but O O
not O O
with O O
enzyme-based O O
tests O O
for O O
glycosuria O O
( O O
e.g. O O
, O O
CLINISTIX O O
, O O
TES-TAPE O O
) O O
. O O

Immunosuppressants B-group B-group
: O O
cyclosporine B-drug B-drug
, O O
tacrolimus B-drug B-drug
, O O
sirolimus B-drug B-drug

Pentamidine B-drug B-drug
may O O
cause O O
hypoglycemia O O
, O O
which O O
may O O
sometimes O O
be O O
followed O O
by O O
hyperglycemia O O
. O O

quinine B-drug B-drug
; O O

This O O
effect O O
may O O
be O O
mediated O O
by O O
the O O
known O O
inhibition O O
of O O
hepatic O O
cytochrome O O
P- O O
450 O O
by O O
cimetidine B-drug B-drug
, O O
which O O
could O O
decrease O O
first O O
pass O O
metabolism O O
of O O
nimodipine B-drug B-drug
. O O

It O O
is O O
not O O
known O O
whether O O
this O O
potentiation O O
of O O
ampicillin B-drug B-drug
rashes O O
is O O
due O O
to O O
allopurinol B-drug B-drug
or O O
the O O
hyperuricemia O O
present O O
in O O
these O O
patients O O
. O O

Theophylline B-drug B-drug
: O O
Following O O
co-administration O O
of O O
two O O
250-mg O O
dirithromycin B-drug B-drug
tablets O O
administered O O
once O O
daily O O
with O O
200-mg O O
theophylline B-drug B-drug
tablets O O
administered O O
twice O O
daily O O
for O O
10 O O
days O O
to O O
14 O O
healthy O O
subjects O O
, O O
the O O
steady-state O O
plasma O O
concentration O O
of O O
theophylline B-drug B-drug
was O O
not O O
significantly O O
altered O O
. O O

These O O
reactions O O
have O O
also O O
been O O
reported O O
in O O
patients O O
who O O
have O O
discontinued O O
that O O
drug O O
and O O
have O O
been O O
started O O
on O O
a O O
MAOI B-group B-group
. O O

Zidovudine B-drug B-drug
: O O
There O O
is O O
no O O
significant O O
pharmacokinetic O O
interaction O O
between O O
ZDV B-drug B-drug
and O O
zalcitabine B-drug B-drug
which O O
has O O
been O O
confirmed O O
clinically O O
. O O

The O O
concomitant O O
use O O
of O O
transdermal O O
fentanyl B-drug B-drug
with O O
ritonavir B-drug B-drug
or O O
other O O
potent O O
3A4 O O
inhibitors O O
such O O
as O O
ketoconazole B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
troleandomycin B-drug B-drug
, O O
clarithromycin B-drug B-drug
, O O
nelfinavir B-drug B-drug
, O O
and O O
nefazadone O B-drug
may O O
result O O
in O O
an O O
increase O O
in O O
fentanyl B-drug B-drug
plasma O O
concentrations O O
. O O

Most O O
( O O
98 O O
% O O
) O O
of O O
plasma O O
doxazosin B-drug B-drug
is O O
protein O O
bound O O
. O O

Tetracycline B-drug B-drug
, O O
a O O
bacteriostatic B-group B-group
antibiotic I-group I-group
, O O
may O O
antagonize O O
the O O
bactercidal O O
effect O O
of O O
penicillin B-drug B-drug
and O O
concurrent O O
use O O
of O O
these O O
drugs O O
should O O
be O O
avoided O O
. O O

Specific O O
interaction O O
studies O O
have O O
demonstrated O O
the O O
following O O
: O O
Cyclosporine B-drug B-drug
A I-drug O
: O O
During O O
the O O
first O O
day O O
of O O
concomitant O O
administration O O
, O O
trough O O
concentrations O O
of O O
bosentan B-drug B-drug
were O O
increased O O
by O O
about O O
30-fold O O
. O O

This O O
has O O
been O O
demonstrated O O
in O O
view O O
, O O
however O O
, O O
the O O
clinical O O
significance O O
of O O
this O O
interaction O O
is O O
not O O
well O O
documented O O
. O O

Ketoconazole B-drug B-drug
( O O
400 O O
mg O O
once O O
daily O O
) O O

Conflicting O O
results O O
have O O
been O O
reported O O
regarding O O
the O O
effects O O
of O O
EPA B-drug B-drug
supplements O O
on O O
glycemic O O
control O O
in O O
non-diabetics O O
with O O
glucose O O
intolerance O O
, O O
and O O
those O O
with O O
type O O
2 O O
diabetes O O
. O O

Hematology O O
: O O
TAXOL B-brand B-brand
therapy O O
should O O
not O O
be O O
administered O O
to O O
patients O O
with O O
baseline O O
neutrophil O O
counts O O
of O O
less O O
than O O
1,500 O O
cells/mm3 O O
. O O

However O O
, O O
another O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitor I-group I-group
has O O
been O O
found O O
to O O
produce O O
a O O
less O O
than O O
two-second O O
increase O O
in O O
prothrombin O O
time O O
in O O
healthy O O
volunteers O O
receiving O O
low O O
doses O O
of O O
warfarin B-drug B-drug
. O O

Warfarin B-drug B-drug
: O O
Co-administration O O
of O O
bosentan B-drug B-drug
500 O O
mg O O
b.i.d O O
. O O
for O O
6 O O
days O O
decreased O O
the O O
plasma O O
concentrations O O
of O O
both O O
S-warfarin B-drug B-drug_n
( O O
a O O
CYP2C9 O O
substrate O O
) O O
and O O
R-warfarin B-drug B-drug_n
( O O
a O O
CYP3A4 O O
substrate O O
) O O
by O O
29 O O
and O O
38 O O
% O O
, O O
respectively O O
. O O

This O O
response O O
has O O
been O O
attributed O O
to O O
inhibition O O
of O O
renal O O
prostaglandin O O
synthesis O O
. O O

The O O
administration O O
of O O
local O O
anesthetic B-group B-group
solutions I-group O
containing O O
epinephrine B-drug B-drug
or O O
norepinephrine B-drug B-drug
to O O
patients O O
receiving O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
, O O
tricyclic B-group B-group
antidepressants I-group I-group
or O O
phenothiazines B-group B-group
may O O
produce O O
severe O O
, O O
prolonged O O
hypotension O O
or O O
hypertension O O
. O O

Acid O O
secretion O O
in O O
isolated O O
rabbit O O
gastric O O
glands O O
was O O
monitored O O
by O O
the O O
accumulation O O
of O O
[ O O
( O O
14 O O
) O O
C O O
] O O
aminopyrine B-drug B-drug
. O O

Antiarrhythmics B-group B-group
: O O
bepridil B-drug B-drug
, O O
lidocaine B-drug B-drug
( O O
systemic O O
) O O
and O O
quinidine B-drug B-drug

Therefore O O
, O O
when O O
INDOCIN B-brand B-brand
and O O
INDOCIN B-brand B-brand
. O O

decreased O O
levels O O
of O O
anti-factor O O
Xa O O
and O O
antithrombin B-drug O
III I-drug O
, O O
decreased O O
antithrombin B-drug O
III I-drug O
activity O O
; O O

Anticoagulant B-brand B-group
therapy O O
should O O
be O O
monitored O O
, O O
particularly O O
during O O
the O O
first O O
few O O
weeks O O
, O O
after O O
initiating O O
therapy O O
with O O
BEXTRA B-brand B-brand
in O O
patients O O
receiving O O
warfarin B-drug B-drug
or O O
similar O O
agents O O
. O O

Based O O
on O O
in O O
vitro O O
data O O
, O O
no O O
interaction O O
would O O
be O O
expected O O
with O O
drugs O O
whose O O
metabolism O O
is O O
dependent O O
upon O O
cytochrome O O
P450 O O
isozymes O O
1A1 O O
, O O
1A2,2A6,2B6,2D6,2E1 O O
, O O
or O O
3A4 O O
. O O

Ketoconazole B-drug B-drug
: O O
Coadministration O O
of O O
ketoconazole B-drug B-drug
with O O
VIRACEPT B-brand B-brand
resulted O O
in O O
a O O
35 O O
% O O
increase O O
in O O
nelfinavir B-drug B-drug
plasma O O
A.C O O
. O O

Moreover O O
, O O
additional O O
interaction O O
studies O O
with O O
niacin B-drug B-drug
and O O
propranolol B-drug B-drug
have O O
not O O
demonstrated O O
any O O
effect O O
on O O
fluvastatin B-drug B-drug
plasma O O
levels O O
, O O
and O O
administration O O
to O O
a O O
patient O O
population O O
chronically O O
receiving O O
digoxin B-drug B-drug
resulted O O
in O O
no O O
difference O O
in O O
the O O
extent O O
of O O
bioavailability O O
of O O
digoxin B-drug B-drug
relative O O
to O O
control O O
data O O
. O O

The O O
initiation O O
of O O
alcohol B-drug B-drug
or O O
nicotine B-drug B-drug
use O O
may O O
be O O
precipitated O O
by O O
similar O O
personality O O
characteristics O O
in O O
the O O
user O O
, O O
such O O
as O O
impulsivity O O
and O O
sensation O O
seeking O O
. O O

ZINECARD B-brand B-brand
does O O
not O O
influence O O
the O O
pharmacokinetics O O
of O O
doxorubicin B-drug B-drug
. O O

FORADIL B-brand B-brand
should O O
not O O
be O O
used O O
as O O
a O O
substitute O O
for O O
oral O O
or O O
inhaled O O
corticosteroids B-group B-group
. O O

dmPGE2 B-drug_n B-drug_n
( O O
0.1-1.0 O O
mg/kg O O
, O O
p.o O O
. O O
) O O

A O O
subset O O
( O O
3 O O
% O O
-10 O O
% O O
) O O
of O O
the O O
population O O
has O O
reduced O O
activity O O
of O O
certain O O
drug O O
metabolizing O O
enzymes O O
such O O
as O O
the O O
cytochrome O O
P450 O O
isozyme O O
P450 O O
2D6 O O
. O O

It O O
may O O
also O O
produce O O
artifactually O O
low O O
results O O
in O O
dexamethasone O B-drug
or O O
metyrapone O O
tests O O
. O O

- O O
Reduced O O
response O O
to O O
metyrapone O O
test O O

Potential O O
drug O O
interactions O O
for O O
doxylamine B-drug B-drug
include O O
, O O
increased O O
sedation O O
if O O
doxylamine B-drug B-drug
is O O
combined O O
with O O
other O O
CNS B-group B-group
depressant I-group I-group
drugs I-group I-group
. O O

Amprenavir B-drug B-drug
plus O O
rifabutin B-drug B-drug
was O O
poorly O O
tolerated O O
, O O
and O O
5 O O
of O O
11 O O
subjects O O
discontinued O O
therapy O O
. O O

Concurrent O O
administration O O
of O O
HEXALEN B-brand B-brand
and O O
antidepressants B-group B-group
of I-group O
the I-group O
MAO I-group B-group
inhibitor I-group I-group
class I-group I-group
may O O
cause O O
severe O O
orthostatic O O
hypotension.Cimetidine B-drug O
, O O
an O O
inhibitor O O
of O O
microsomal O O
drug O O
metabolism O O
, O O
increased O O
altretamines B-drug O
half-life O O
and O O
toxicity O O
in O O
a O O
rat O O
model O O
. O O

Anticholinesterases B-group B-group
: O O
Concomitant O O
use O O
of O O
anticholinesterase B-group B-group
agents I-group I-group
and O O
corticosteroids B-group B-group
may O O
produce O O
severe O O
weakness O O
in O O
patients O O
with O O
myasthenia O O
gravis O O
. O O

Such O O
information O O
assists O O
in O O
development O O
of O O
safe O O
dosing O O
regimens O O
, O O
prediction O O
of O O
abnormal O O
handling O O
of O O
drugs O O
in O O
states O O
of O O
disease O O
and O O
disorder O O
and O O
anticipation O O
of O O
drug O O
interactions O O
. O O

The O O
effect O O
of O O
administering O O
different O O
botulinum B-group B-group
neurotoxin I-group I-group
serotypes O O
at O O
the O O
same O O
time O O
or O O
within O O
several O O
months O O
of O O
each O O
other O O
is O O
unknown O O
. O O

In O O
some O O
patients O O
, O O
the O O
administration O O
of O O
a O O
non- B-group B-group
steroidal I-group I-group
antiinflammatory I-group I-group
agent I-group I-group
can O O
reduce O O
the O O
diuretic B-group B-group
, I-group O
natriuretic O O
, O O
and O O
antihypertensive O O
effects O O
of O O
loop O O
, O O
potassium- O O
sparing O O
and O O
thiazide B-group B-group
diuretics I-group I-group
. O O

Given O O
the O O
primary O O
CNS O O
effects O O
of O O
Clozapine B-drug B-drug
, O O
caution O O
is O O
advised O O
in O O
using O O
it O O
concomitantly O O
with O O
other O O
CNS-active O O
drugs O O
or O O
alcohol B-drug B-drug
. O O

This O O
suggests O O
that O O
an O O
interaction O O
of O O
aripiprazole B-drug B-drug
with O O
inhibitors O O
or O O
inducers O O
of O O
these O O
enzymes O O
, O O
or O O
other O O
factors O O
, O O
like O O
smoking O O
, O O
is O O
unlikely O O
. O O

Animal O O
reproduction O O
studies O O
, O O
however O O
, O O
are O O
not O O
always O O
predictive O O
of O O
human O O
response O O
and O O
there O O
are O O
no O O
adequate O O
and O O
well-controlled O O
studies O O
in O O
pregnant O O
women O O
. O O

Increased O O
plasma O O
HDL O O
and O O
HDL2 O O
cholesterol O O
subfraction O O
concentrations O O
, O O
reduced O O
LDL O O
cholesterol O O
concentration O O
, O O
increased O O
triglyceride O O
levels O O
. O O

The O O
urinary O O
excretion O O
of O O
meclofenamate B-drug B-drug
sodium I-drug I-drug
is O O
unaffected O O
by O O
aspirin B-brand B-brand
, O O
indicating O O
no O O
change O O
in O O
meclofenamate B-drug B-drug
sodium I-drug I-drug
absorption O O
. O O

Renal O O
function O O
should O O
be O O
monitored O O
carefully O O
if O O
high O O
doses O O
of O O
aminoglycosides B-group B-group
are O O
to O O
be O O
administered O O
with O O
MAXIPIME B-brand B-brand
because O O
of O O
the O O
increased O O
potential O O
of O O
nephrotoxicity O O
and O O
ototoxicity O O
of O O
aminoglycoside B-group B-group
antibiotics I-group I-group
. O O

Netilmicin B-drug B-drug
should O O
not O O
be O O
administered O O
concomitantly O O
with O O
potent O O
loop B-group B-group
diuretics I-group I-group
such O O
as O O
furosemide B-drug B-drug
and O O
ethacrynic B-drug B-drug
acid I-drug I-drug
as O O
the O O
potential O O
for O O
ototoxicity O O
is O O
enhanced O O
by O O
the O O
combination O O
. O O

When O O
warfarin B-drug B-drug
is O O
co-administered O O
with O O
nevirapine B-drug B-drug
, O O
anticoagulation O O
levels O O
should O O
be O O
monitored O O
frequently O O
. O O

Sucralfate B-drug B-drug
administered O O
2 O O
hours O O
before O O
lomefloxacin B-drug B-drug
resulted O O
in O O
a O O
slower O O
absorption O O
( O O
mean O O
C O O
max O O
decreased O O
by O O
30 O O
% O O
and O O
mean O O
T O O
max O O
increased O O
by O O
1 O O
hour O O
) O O
and O O
a O O
lesser O O
extent O O
of O O
absorption O O
( O O
mean O O
AUC O O
decreased O O
by O O
approximately O O
25 O O
% O O
) O O
. O O

Medication O O
is O O
rarely O O
needed O O
. O O

Liver O O
Function O O
Tests O O
: O O
Since O O
elevations O O
of O O
liver O O
enzymes O O
have O O
been O O
observed O O
during O O
clinical O O
trials O O
, O O
and O O
hepatitis O O
has O O
been O O
reported O O
, O O
pretreatment O O
and O O
follow-up O O
liver O O
function O O
tests O O
should O O
be O O
performed O O
at O O
weekly O O
or O O
biweekly O O
intervals O O
until O O
the O O
response O O
to O O
Accutane B-brand B-brand
has O O
been O O
established O O

Renal O O
function O O
should O O
be O O
carefully O O
monitored O O
, O O
especially O O
if O O
higher O O
dosages O O
of O O
the O O
aminoglycosides B-group B-group
are O O
to O O
be O O
administered O O
or O O
if O O
therapy O O
is O O
prolonged O O
, O O
because O O
of O O
the O O
potential O O
nephrotoxicity O O
and O O
ototoxicity O O
of O O
aminoglycosidic B-group B-group
antibiotics I-group I-group
. O O

A O O
case O O
report O O
of O O
one O O
patient O O
taking O O
amiodarone B-drug B-drug
200 O O
mg O O
and O O
indinavir B-drug B-drug
800 O O
mg O O
three O O
times O O
a O O
day O O
resulted O O
in O O
increases O O
in O O
amiodarone B-drug B-drug
concentrations O O
from O O
0.9 O O
mg/L O O
to O O
1.3 O O
mg/L O O
. O O

The O O
addition O O
of O O
tiagabine B-drug B-drug
in O O
a O O
limited O O
number O O
of O O
patients O O
in O O
three O O
well-controlled O O
studies O O
caused O O
no O O
systematic O O
changes O O
in O O
phenobarbital B-drug B-drug
or O O
primidone B-drug B-drug
concentrations O O
when O O
compared O O
to O O
placebo O O
. O O

Therefore O O
, O O
injection O O
of O O
these O O
agents O O
into O O
patients O O
receiving O O
thyroid B-group B-group
preparations I-group I-group
increases O O
the O O
risk O O
of O O
precipitating O O
coronary O O
insufficiency O O
especially O O
in O O
patients O O
with O O
coronary O O
artery O O
disease O O
. O O

Here O O
, O O
we O O
have O O
examined O O
whether O O
METH B-drug B-drug
administration O O
affects O O
expression O O
of O O
an O O
effector O O
IEG O O
arc O O
( O O
activity-regulated O O
, O O
cytoskeleton-associated O B-drug_n
) O O
that O O
encodes O O
a O O
protein O O
with O O
homology O O
to O O
spectrin O O
. O O

Lotensin B-brand B-brand
has O O
been O O
used O O
concomitantly O O
with O O
beta-adrenergic-blocking B-group B-group
agents I-group I-group
, O O
calcium-channel-blocking B-group B-group
agents I-group I-group
, O O
diuretics B-group B-group
, O O
digoxin B-drug B-drug
, O O
and O O
hydralazine B-drug B-drug
, O O
without O O
evidence O O
of O O
clinically O O
important O O
adverse O O
interactions O O
. O O

These O O
pharmacokinetic O O
effects O O
seen O O
during O O
diltiazem B-drug B-drug
coadministration O O
can O O
result O O
in O O
increased O O
clinical O O
effects O O
( O O
e.g. O O
, O O
prolonged O O
sodation O O
) O O
of O O
both O O
midazolam B-drug B-drug
and O O
triazolam B-drug B-drug
. O O

Combinations O O
of O O
clozapine B-drug B-drug
and O O
phencyclidine B-drug_n B-drug
: O O
effects O O
on O O
drug O O
discrimination O O
and O O
behavioral O O
inhibition O O
in O O
rats O O
. O O

No O O
drug O O
interaction O O
studies O O
were O O
performed O O
. O O

RESULTS O O
: O O
Everolimus B-drug B-drug
steady O O
state O O
was O O
reached O O
on O O
or O O
before O O
day O O
7 O O
, O O
with O O
a O O
median O O
3-fold O O
accumulation O O
of O O
drug O O
exposure O O
compared O O
with O O
that O O
after O O
the O O
first O O
postoperative O O
dose O O
. O O

The O O
binding O O
of O O
thyroxine O O
by O O
thyroxine-binding O O
prealbumin O O
( O O
TBPA O O
) O O
is O O
inhibited O O
by O O
salicylates B-group B-group

Warfarin B-drug B-drug
: O O
Eszopiclone B-drug B-drug
3 O I-drug
mg O O
administered O O
daily O O
for O O
5 O O
days O O
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
( O O
R O O
) B-drug O
- I-drug O
or I-drug O
( I-drug B-drug_n
S I-drug I-drug_n
) I-drug I-drug_n
-warfarin I-drug I-drug_n
, O O
nor O O
were O O
there O O
any O O
changes O O
in O O
the O O
pharmacodynamic O O
profile O O
( O O
prothrombin O O
time O O
) O O
following O O
a O O
single O O
25 O O
mg O O
oral O O
dose O O
of O O
warfarin B-drug B-drug

The O O
patient O O
continued O O
to O O
receive O O
intermittent O O
hemodialysis O O
until O O
his O O
death O O
from O O
infectious O O
complications O O
that O O
occurred O O
three O O
months O O
after O O
admission O O
. O O

Pharmacoeconomic O O
analyses O O
indicate O O
that O O
olanzapine B-drug B-drug
does O O
not O O
significantly O O
increase O O
, O O
and O O
may O O
even O O
decrease O O
, O O
the O O
overall O O
direct O O
treatment O O
costs O O
of O O
schizophrenia O O
, O O
compared O O
with O O
haloperidol B-drug B-drug
. O O

In O O
spite O O
of O O
the O O
absence O O
of O O
kidney O O
function O O
, O O
the O O
value O O
of O O
the O O
elimination O O
rate O O
constant O O
was O O
significantly O O
decreased O O
in O O
the O O
presence O O
of O O
probenecid B-drug B-drug
( O O
from O O
0.326 O O
to O O
0.263/h O O
) O O
. O O

Information O O
on O O
precautions O O
and O O
contraindications O O
, O O
indications O O
, O O
use O O
instructions O O
, O O
and O O
instructions O O
for O O
appropriate O O
actions O O
after O O
missing O O
a O O
pill O O
is O O
appended O O
. O O

Alcohol B-drug B-drug
: O O
Has O O
a O O
synergistic O O
effect O O
with O O
aspirin B-brand B-brand
in O O
causing O O
gastrointestinal O O
bleeding O O
. O O

Immunosuppressive B-group B-group
drugs I-group I-group
and O O
their O O
complications O O
. O O

Current O O
immunosuppressive O B-group
therapies O I-group
are O O
effective O O
but O O
can O O
be O O
associated O O
with O O
significant O O
adverse O O
reactions O O
. O O

In O O
addition O O
, O O
there O O
was O O
no O O
pharmacodynamic O O
interaction O O
as O O
a O O
result O O
of O O
coadministration O O
of O O
zaleplon B-drug B-drug
and O O
venlafaxine B-drug B-drug
ER O O
. O O

Increases O O
in O O
plasma O O
levels O O
of O O
tricyclic B-drug B-group
antidepressants I-drug I-group
, O O
and O O
in O O
the O O
frequency O O
and O O
severity O O
of O O
side O O
effects O O
, O O
particularly O O
anticholinergic B-drug O
, O O
have O O
been O O
reported O O
when O O
cimetidine B-drug B-drug
was O O
added O O
to O O
the O O
drug B-drug O
regimen O O
. O O

The O O
mechanism O O
of O O
resveratrol-induced B-drug_n B-drug
vasorelaxation O O
differs O O
in O O
the O O
mesenteric O O
resistance O O
arteries O O
of O O
lean O O
and O O
obese O O
rats O O
. O O

clinical O O
implications O O
are O O
unclear O O
. O O

When O O
the O O
muscle O O
was O O
exposed O O
to O O
the O O
potassium-depleted O O
solution O O
, O O
the O O
first O O
contractile O O
response O O
to O O
PTX B-drug_n B-drug_n
was O O
rather O O
potentiated O O
. O O

Addition O O
or O O
deletion O O
of O O
any O O
drug O O
from O O
the O O
therapeutic O O
regimen O O
of O O
patients O O
receiving O O
oral O O
anticoagulants B-group B-group
may O O
affect O O
patient O O
response O O
to O O
the O O
anticoagulant B-group B-group
. O O

Concomitant O O
use O O
of O O
agents O O
in O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
class I-group I-group
( O O
which O O
includes O O
Anafranil B-brand B-brand
) O O
with O O
drugs O O
that O O
can O O
inhibit O O
cytochrome O O
P450 O O
2D6 O O
may O O
require O O
lower O O
doses O O
than O O
usually O O
prescribed O O
for O O
either O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
agent I-group I-group
or O O
the O O
other O O
drug O O
. O O

Patients O O
receiving O O
other O O
narcotic B-group B-group
analgesics O I-group
, O O
general O O
anesthetics B-group B-group
, O O
phenothiazines B-group B-group
, O O
tranquilizers B-group B-group
, O O
sedative-hypnotics B-group B-group
, O O
tricyclic B-group B-group
antidepressants I-group I-group
or O O
other O O
CNS B-group B-group
depressants I-group I-group
( O O
including O O
alcohol B-drug B-drug
) O O
concomitantly O O
with O O
DILAUDID B-brand B-brand
may O O
exhibit O O
an O O
additive O O
CNS O O
depression O O
. O O

In O O
vitro O O
studies O O
of O O
human O O
CYP O O
enzymes O O
showed O O
that O O
entacapone B-drug B-drug
inhibited O O
the O O
CYP O O
enzymes O O
1A2 O O
, O O
2A6 O O
, O O
2C9 O O
, O O
2C19 O O
, O O
2D6 O O
, O O
2E1 O O
and O O
3A O O
only O O
at O O
very O O
high O O
concentrations O O
( O O
IC50 O O
from O O
200 O O
to O O
over O O
1000 O O
uM O O
; O O

900 O O

NSAIDs B-group B-group
: O O
In O O
in O O
vitro O O
studies O O
, O O
M1 O O
was O O
shown O O
to O O
cause O O
increases O O
ranging O O
from O O
13 O O
- O O
50 O O
% O O
in O O
the O O
free O O
fraction O O
of O O
diclofenac B-drug B-drug
and O O
ibuprofen B-drug B-drug
at O O
concentrations O O
in O O
the O O
clinical O O
range O O
. O O

The O O
appropriate O O
doses O O
for O O
this O O
combination O O
, O O
with O O
respect O O
to O O
efficacy O O
and O O
safety O O
, O O
have O O
not O O
been O O
established O O
. O O

Hydrochlorothiazide B-drug B-drug
: O O
In O O
normal O O
volunteers O O
, O O
concomitant O O
administration O O
of O O
diflunisal B-drug B-drug
and O O
hydrochlorothiazide B-drug B-drug
resulted O O
in O O
significantly O O
increased O O
plasma O O
levels O O
of O O
hydrochlorothiazide B-drug B-drug
. O O

Enhanced O O
theophylline B-drug B-drug
clearance O O
secondary O O
to O O
phenytoin B-drug B-drug
therapy O O
. O O

Glyburide B-drug B-drug
: O O
An O O
increased O O
risk O O
of O O
elevated O O
liver O O
aminotransferases O O
was O O
observed O O
in O O
patients O O
receiving O O
concomitant O O
therapy O O
with O O
glyburide B-drug B-drug
. O O

Concomitant O O
administration O O
of O O
an O O
aluminum-containing B-drug B-group
antacid B-group I-group
had O O
no O O
significant O O
effect O O
in O O
the O O
bioavailability O O
of O O
6MNA B-drug_n B-drug_n
. O O

When O O
such O O
drugs O O
are O O
administered O O
to O O
a O O
patient O O
receiving O O
MICRONASE B-brand B-brand
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
hypoglycemia O O
. O O

Although O O
the O O
interaction O O
between O O
almotriptan B-drug B-drug
and O O
other O O
potent O O
CYP3A4 O O
inhibitors O O
( O O
e.g. O O
, O O
itraconazole B-drug B-drug
, O O
ritonavir B-drug B-drug
, O O
and O O
erythromycin B-drug B-drug
) O O
has O O
not O O
been O O
studied O O
, O O
increased O O
exposures O O
to O O
almotriptan B-drug B-drug
may O O
be O O
expected O O
when O O
almotriptan B-drug B-drug
is O O
used O O
concomitantly O O
with O O
these O O
medications O O
. O O

Pretreatment O O
and O O
follow-up O O
measurements O O
should O O
be O O
obtained O O
under O O
fasting O O
conditions O O
. O O

Ergotamine B-drug B-drug
or O O
dihydroergotamine B-drug B-drug
acute O O
ergot O B-group
toxicity O O
characterized O O
by O O
severe O O
peripheral O O
vasospasm O O
and O O
dysesthesia O O
. O O

Interactions O O
with O O
Other O O
CNS O B-group
Agents O I-group
: O O
Concurrent O O
use O O
of O O
Levo-Dromoran B-brand B-brand
with O O
all O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
( O O
eg O O
, O O
alcohol B-drug B-drug
, O O
sedatives B-group B-group
, O O
hypnotics B-group B-group
, O O
other O O
opioids B-group B-group
, O O
general O O
anesthetics B-group B-group
, O O
barbiturates B-group B-group
, O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
phenothiazines B-group B-group
, O O
tranquilizers B-group B-group
, O O
skeletal B-group B-group
muscle I-group I-group
relaxants I-group I-group
and O O
antihistamines B-group B-group
) O O
may O O
result O O
in O O
additive O O
central O O
nervous O O
system O O
depressant O O
effects O O
. O O

Propantheline B-drug B-drug
and O O
diphenoxylate B-drug B-drug
, O O
by O O
decreasing O O
gut O O
motility O O
, O O
may O O
increase O O
digoxin B-drug B-drug
absorption O O
. O O

If O O
taken O O
1 O O
hour O O
before O O
indinavir B-drug B-drug
( O O
IDV B-drug O
) O O
, O O
didanosine B-drug B-drug
does O O
not O O
affect O O
IDV B-drug O
exposure O O
, O O
despite O O
persistent O O
buffering O O
effects O O
. O O

5 O O
. O O

cimetidine B-drug B-drug
) O O
and O O
many O O
that O O
are O O
substrates O O
for O O
P450 O O
2D6 O O
( O O
many O O
other O O
antidepressants B-group B-group
, O O
phenothiazines B-group B-group
, O O
and O O
the O O
Type B-group B-group
1C I-group I-group
antiarrhythmics I-group I-group
propafenone B-drug B-drug
and O O
flecainide B-drug B-drug
) O O
. O O

The O O
effect O O
of O O
concomitant O O
administration O O
of O O
fluconazole B-drug B-drug
and O O
glipizide B-drug B-drug
has O O
been O O
demonstrated O O
in O O
a O O
placebo-controlled O O
crossover O O
study O O
in O O
normal O O
volunteers O O
. O O

However O O
, O O
in O O
the O O
second O O
study O O
, O O
administration O O
of O O
12 O O
g O O
cholestyramine B-drug B-drug
1 O O
hour O O
before O O
the O O
evening O O
meal O O
and O O
0.3 O O
mg O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
approximately O O
4 O O
hours O O
after O O
the O O
same O O
evening O O
meal O O
resulted O O
in O O
a O O
decrease O O
in O O
the O O
cerivastatin B-drug O
AUC O O
of O O
less O O
than O O
8 O O
% O O
, O O
and O O
a O O
decrease O O
in O O
Cmax O O
of O O
about O O
30 O O
% O O
when O O
compared O O
to O O
dosing O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
alone O O
. O O

These O O
results O O
suggest O O
that O O
the O O
hepatoxicity O O
of O O
ethanol B-drug B-drug
in O O
alcoholic O B-drug
beverages O O
is O O
enhanced O O
by O O
interaction O O
with O O
its O O
congeners O O
and O O
acetaldehyde B-drug_n B-drug
; O O

It O O
is O O
now O O
clear O O
that O O
topoisomerase O O
activity O O
level O O
is O O
an O O
important O O
determinant O O
of O O
sensitivity O O
to O O
topo O O
drugs O O
. O O

( O O
See O O
CLINICAL O O
PHARMACOLOGY O O
) O O
Coadministration O O
of O O
Femara B-brand B-brand
and O O
tamoxifen B-drug B-drug
20 O O
mg O O
daily O O
resulted O O
in O O
a O O
reduction O O
of O O
letrozole B-drug B-drug
plasma O O
levels O O
by O O
38 O O
% O O
on O O
average O O
. O O

however O O
, O O
the O O
total O O
amount O O
of O O
6MNA B-drug_n B-drug_n
in O O
the O O
plasma O O
is O O
unchanged O O
. O O

Therefore O O
, O O
amiodarone B-drug B-drug
has O O
the O O
potential O O
for O O
interactions O O
with O O
drugs O O
or O O
substances O O
that O O
may O O
be O O
substrates O O
, O O
inhibitors O O
or O O
inducers O O
of O O
CYP3A4 O O
. O O

Neither O O
racemic O O
warfarin B-drug B-drug
nor O O
isradipine B-drug B-drug
binding O O
to O O
plasma O O
proteins O O
in O O
vitro O O
was O O
altered O O
by O O
the O O
addition O O
of O O
the O O
other O O
drug O O
. O O

These O O
agents O O
, O O
including O O
norfloxacin B-drug B-drug
, O O
ciprofloxacin B-drug B-drug
, O O
ofloxacin B-drug B-drug
, O O
enoxacin B-drug B-drug
, O O
and O O
lomefloxacin B-drug B-drug
, O O
have O O
been O O
extensively O O
studied O O
and O O
have O O
demonstrated O O
efficacy O O
and O O
safety O O
profiles O O
comparable O O
to O O
those O O
of O O
other O O
traditional O O
agents O O
for O O
the O O
treatment O O
of O O
complicated O O
or O O
uncomplicated O O
urinary O O
tract O O
infections O O
and O O
prostatitis O O
. O O

Furosemide B-drug B-drug
: O O
When O O
aliskiren B-drug B-drug
was O O
co-administered O O
with O O
furosemide B-drug B-drug
, O O
the O O
AUC O O
and O O
Cmax O O
of O O
furosemide B-drug B-drug
were O O
reduced O O
by O O
about O O
30 O O
% O O
and O O
50 O O
% O O
, O O
respectively O O
. O O

Treatment O O
with O O
antidepressant B-group B-group
drugs I-group I-group
can O O
directly O O
interfere O O
with O O
blood O O
glucose O O
levels O O
or O O
may O O
interact O O
with O O
hypoglycemic B-group B-group
agents I-group I-group
. O O

Ethinyl B-drug B-drug
Estradiol I-drug I-drug
and O O
Norethindrone B-drug B-drug
: O O
Coadministration O O
of O O
VIRACEPT B-brand B-brand
with O O
OVCON-35 B-brand B-brand
resulted O O
in O O
a O O
47 O O
% O O
decrease O O
in O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
and O O
an O O
18 O O
% O O
decrease O O
in O O
norethindrone B-drug B-drug
plasma O O
concentrations O O
. O O

- O O
Sulfoxone B-drug B-brand
( O O
e.g. O O
, O O
Diasone B-brand B-brand
) O O
or O O

The O O
8.5 O O
% O O
incidence O O
of O O
akathisia O O
, O O
however O O
, O O
is O O
within O O
the O O
range O O
reported O O
for O O
use O O
of O O
prochlorperazine B-drug B-drug
when O O
given O O
as O O
a O O
premedication O O
for O O
other O O
chemotherapies O O
. O O

- O O
a O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drug I-group I-group
( O O
NSAID B-group B-group
) O O
such O O
as O O
ibuprofen B-drug B-drug
( O O
Motrin B-brand B-brand
, O O
Advil B-brand B-brand
, O O
Nuprin B-brand B-brand
, O O
others O O
) O O
, O O
ketoprofen B-drug B-drug
( O O
Orudis B-brand B-brand
, O O
Orudis B-brand B-brand
KT I-brand O
, O O
Oruvail B-brand B-brand
) O O
, O O
diclofenac B-drug B-drug
( O O
Voltaren B-brand B-brand
, O O
Cataflam B-brand B-brand
) O O
, O O
etodolac B-drug B-drug
( O O
Lodine B-brand B-brand
) O O
, O O
indomethacin B-drug B-drug
( O O
Indocin B-brand B-brand
) O O
, O O
nabumetone B-drug B-drug
( O O
Relafen B-brand B-brand
) O O
, O O
oxaprozin B-drug B-drug
( O O
Daypro B-brand B-brand
) O O
, O O
and O O
naproxen B-drug B-drug
( O O
Anaprox B-brand B-brand
, O O
Naprosyn B-brand B-brand
, O O
Aleve B-brand B-brand
) O O
; O O

However O O
, O O
when O O
any O O
additional O O
drug O O
, O O
including O O
INDOCIN B-brand B-brand
, O O
is O O
added O O
to O O
the O O
treatment O O
of O O
patients O O
on O O
anticoagulant B-group B-group
therapy O O
, O O
the O O
patients O O
should O O
be O O
observed O O
for O O
alterations O O
of O O
the O O
prothrombin O O
time O O
. O O

Lorazepam B-drug B-drug
: O O
Coadministration O O
of O O
single O O
doses O O
of O O
eszopiclone B-drug B-drug
3 O I-drug
mg O O
and O O
lorazepam B-drug B-drug
2 O O
mg O O
did O O
not O O
have O O
clinically O O
relevant O O
effects O O
on O O
the O O
pharmacodynamics O O
or O O
pharmacokinetics O O
of O O
either O O
drug O O
. O O

Drug O O
Interaction O O
During O O
Pregnancy O O
: O O
Cromolyn B-drug B-brand
sodium I-drug I-drug
and O O
isoproterenol B-drug B-drug
were O O
studied O O
following O O
subcutaneous O O
injections O O
in O O
pregnant O O
mice O O
. O O

Symptoms O O
resolved O O
within O O
a O O
few O O
hours O O
. O O

The O O
threohydrobupropion B-drug_n O
metabolite O O
of O O
bupropion B-drug B-drug
does O O
not O O
appear O O
to O O
be O O
produced O O
by O O
the O O
cytochrome O O
P450 O O
isoenzymes O O
. O O

When O O
such O O
drugs O O
are O O
withdrawn O O
from O O
a O O
patient O O
receiving O O
DIABINESE B-brand B-brand
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
hypoglycemia O O
. O O

Concurrent O O
use O O
of O O
these O O
agents O O
should O O
generally O O
be O O
avoided O O
. O O

In O O
the O O
case O O
that O O
you O O
are O O
taking O O
digoxin B-drug B-drug
while O O
taking O O
aminosalicylic B-drug B-drug
acid I-drug I-drug
, O O
higher O O
doses O O
of O O
digoxin B-drug B-drug
may O O
be O O
needed O O
. O O

no O O
evidence O O
of O O
mutagenicity O O
was O O
observed O O
. O O

Further O O
, O O
in O O
rabbits O O
dosed O O
at O O
0.25 O O
mg/kg/day O O
( O O
about O O
one-half O O
the O O
human O O
dose O O
on O O
BSA O O
) O O
, O O
increases O O
in O O
placental O O
weight O O
and O O
post-implantation O O
loss O O
were O O
observed O O
but O O
, O O
there O O
were O O
no O O
observed O O
effects O O
on O O
fetal O O
development O O
. O O

The O O
following O O
are O O
examples O O
of O O
substances O O
that O O
may O O
reduce O O
the O O
blood-glucose-lowering O O
effect O O
of O O
insulin B-drug B-drug
: O O
corticosteroids B-group B-group
, O O
danazol B-drug B-drug
, O O
diuretics B-group B-group
, O O
sympathomimetic B-group B-group
agents I-group I-group
( O O
e.g. O O
, O O
epinephrine B-drug B-drug
, O O
albuterol B-drug B-drug
, O O
terbutaline B-drug B-drug
) O O
, O O
isoniazid B-drug B-drug
, O O
phenothiazine B-group B-group
derivatives I-group I-group
, O O
somatropin B-drug B-drug
, O O
thyroid B-group B-group
hormones I-group I-group
, O O
estrogens B-group B-group
, O O
progestogens B-group B-group
( O O
e.g. O O
, O O
in O O
oral O O
contraceptives B-group B-group
) O O
. O O

In O O
order O O
to O O
monitor O O
the O O
occurrence O O
of O O
myelotoxicity O O
, O O
it O O
is O O
recommended O O
that O O
frequent O O
peripheral O O
blood O O
cell O O
counts O O
be O O
performed O O
on O O
all O O
patients O O
receiving O O
TAXOL B-brand B-brand
. O O

Acid-base O O
and O O
electrolyte O O
alterations O O
were O O
not O O
reported O O
in O O
the O O
clinical O O
trials O O
with O O
brinzolamide B-drug B-drug
. O O

. O O

Albendazole B-drug B-drug
sulfoxide I-drug I-drug
plasma O O
concentrations O O
were O O
unchanged O O
4 O O
hours O O
after O O
dosing O O
. O O

HIV B-group B-group
Antiviral I-group I-group
Agents I-group I-group

Drugs O O
that O O
inhibit O O
or O O
Induce O O
CYP O O
2D6 O O
and O O
CYP O O
3A4 O O
may O O
affect O O
the O O
concentration O O
on O O
Aricept B-brand B-brand
. O O

The O O
optimal O O
dosing O O
interval O O
for O O
coadministration O O
with O O
VIDEX B-brand B-brand
should O O
be O O
determined O O
by O O
consulting O O
the O O
appropriate O O
quinolone B-group B-group
package O O
insert O O
. O O

Itraconazole B-drug B-drug
decreases O O
busulfan B-drug B-drug
clearance O O
by O O
up O O
to O O
25 O O
% O O
, O O
and O O
may O O
produce O O
AUCs O O
1500 O O
M O O
min O O
in O O
some O O
patients O O
. O O

Antacids B-group B-group
: O O
Concomitant O O
administration O O
of O O
antacids B-group B-group
containing O O
magnesium B-drug B-drug
or O O
aluminum B-drug B-drug
with O O
VIDEX B-brand B-brand
Chewable/Dispersible O O
Buffered O O
Tablets O O
or O O
Pediatric O O
Powder O O
for O O
Oral O O
Solution O O
may O O
potentiate O O
adverse O O
events O O
associated O O
with O O
the O O
antacid B-group B-group
components O I-group
. O O

This O O
article O O
will O O
describe O O
the O O
escalating O O
use O O
of O O
herbal O O
therapy O O
and O O
the O O
hazards O O
of O O
herbal O O
remedy O O
use O O
among O O
patients O O
. O O

Nelfinavir B-drug B-drug

Interferon O B-drug
induction O O
: O O
tool O O
for O O
establishing O O
interactions O O
among O O
homopolyribonucleotides O O
. O O

- O O
Pressor O B-group
amines O I-group
( O O
e.g. O O
, O O
norepinephrine B-drug B-drug
) O O
: O O
Possible O O
decreased O O
response O O
to O O
pressor O B-group
amines O I-group
but O O
not O O
sufficient O O
to O O
preclude O O
their O O
use O O

This O O
study O O
demonstrated O O
that O O
the O O
potent O O
cytochrome O O
P450 O O
enzyme-inducer O O
phenytoin B-drug B-drug
did O O
indeed O O
have O O
a O O
marked O O
effect O O
on O O
the O O
metabolism O O
of O O
quetiapine B-drug B-drug
, O O
resulting O O
in O O
a O O
5-fold O O
increase O O
in O O
clearance O O
when O O
administered O O
concomitantly O O
to O O
patients O O
with O O
DSM-IV-diagnosed O O
schizophrenia O O
, O O
schizoaffective O O
disorder O O
, O O
or O O
bipolar O O
disorder O O
. O O

Accordingly O O
, O O
when O O
diflunisal B-drug B-drug
is O O
administered O O
with O O
oral O O
anticoagulants B-group B-group
, O O
the O O
prothrombin O O
time O O
should O O
be O O
closely O O
monitored O O
during O O
and O O
for O O
several O O
days O O
after O O
concomitant O O
drug O O
administration O O
. O O

Imidazoles B-group O
( O O
e. O O
g. O O
, O O
ketoconazole B-drug B-drug
, O O
miconazole B-drug B-drug
, O O
clotrimazole B-drug B-drug
, O O
fluconazole B-drug B-drug
, O O
etc O O
. O O
) O O
: O O
in O O
vitro O O
and O O
animal O O
studies O O
with O O
the O O
combination O O
of O O
amphotericin B-drug B-drug
B I-drug I-drug
and O O
imidazoles B-group O
suggest O O
that O O
imidazoles B-group O
may O O
induce O O
fungal O O
resistance O O
to O O
amphotericin B-drug B-drug
B I-drug I-drug
. O O

Phenobarbital B-drug B-drug
: O O
Amphetamines B-group B-group
may O O
delay O O
intestinal O O
absorption O O
of O O
phenobarbital B-drug B-drug
; O O

Benzodiazepines B-group B-group

A O O
study O O
in O O
rats O O
to O O
assess O O
the O O
carcinogenic O O
potential O O
of O O
ribavirin B-drug B-drug
is O O
ongoing O O
. O O

Although O O
bupropion B-drug B-drug
is O O
not O O
metabolized O O
by O O
this O O
isoenzyme O O
, O O
bupropion B-drug B-drug
and O O
hydroxybupropion B-drug_n O
are O O
inhibitors O O
of O O
the O O
CYP2D6 O O
isoenzyme O O
in O O
vitro O O
. O O

Although O O
there O O
have O O
been O O
no O O
formal O O
interaction O O
studies O O
other O O
than O O
with O O
antipyrine B-drug B-drug
, O O
based O O
on O O
these O O
in O O
vivo O O
and O O
in O O
vitro O O
studies O O
, O O
it O O
is O O
unlikely O O
that O O
co-administration O O
of O O
a O O
1 O O
mg O O
dose O O
of O O
ARIMIDEX B-brand B-brand
with O O
other O O
drugs O O
will O O
result O O
in O O
clinically O O
significant O O
drug O O
inhibition O O
of O O
cytochrome O O
P450-mediated O O
metabolism O O
of O O
the O O
other O O
drugs O O
. O O

Probenecid B-drug B-drug
: O O
Probenecid B-drug B-drug
, O O
a O O
renal O O
tubular O O
secretion O O
blocking O O
agent O O
, O O
administered O O
at O O
a O O
dose O O
of O O
500 O O
mg O O
four O O
times O O
a O O
day O O
, O O
did O O
not O O
change O O
the O O
pharmacokinetics O O
of O O
levetiracetam B-drug B-drug
1000 O O
mg O O
twice O O
daily O O
. O O

18-MC B-drug_n B-drug_n
does O O
not O O
produce O O
these O O
effects O O
. O O

Plasma O O
levels O O
of O O
flecainide B-drug B-drug
have O O
been O O
reported O O
to O O
increase O O
in O O
the O O
presence O O
of O O
oral O O
amiodarone B-drug B-drug
; O O

No O O
increase O O
in O O
mortality O O
was O O
observed O O
in O O
patients O O
taking O O
digoxin B-drug B-drug
as O O
concomitant O O
medication O O
. O O

However O O
, O O
if O O
the O O
patients O O
thyroid O O
gland O O
has O O
sufficient O O
function O O
, O O
the O O
decreased O O
free O O
thyroxine B-drug B-drug
will O O
result O O
in O O
a O O
compensatory O O
increase O O
in O O
thyroxine O O
output O O
by O O
the O O
thyroid O O
. O O

The O O
drug O O
interaction O O
data O O
described O O
in O O
this O O
section O O
were O O
obtained O O
from O O
studies O O
involving O O
healthy O O
adults O O
and O O
adult O O
patients O O
with O O
epilepsy O O
. O O

Administration O O
of O O
repeat O O
doses O O
of O O
FACTIVE B-brand B-brand
had O O
no O O
effect O O
on O O
the O O
repeat O O
dose O O
pharmacokinetics O O
of O O
theophylline B-drug B-drug
, O O
digoxin B-drug B-drug
or O O
an O O
ethinylestradiol/levonorgestrol B-drug B-drug
oral O O
contraceptive B-group B-group
product I-group I-group
in O O
healthy O O
subjects O O
. O O

There O O
was O O
no O O
change O O
after O O
a O O
single O O
dose O O
of O O
PGF2alpha B-drug B-drug
. O O

Studies O O
in O O
vitro O O
show O O
that O O
caspofungin B-drug B-drug
acetate I-drug I-drug
is O O
not O O
an O O
inhibitor O O
of O O
any O O
enzyme O O
in O O
the O O
cytochrome O O
P450 O O
( O O
CYP O O
) O O
system O O
. O O

Salicylates-Salicylates B-group B-group
in O O
large O O
doses O O
may O O
inhibit O O
vitamin O O
K O O
epoxide O O
reductase O O
resulting O O
in O O
vitamin O B-group
K O I-group
deficiency O O
. O O

During O O
co-administration O O
, O O
systemic O O
levels O O
of O O
TMP B-drug O
and O O
SMX B-drug B-drug_n
were O O
essentially O O
unchanged O O
. O O

After O O
incubation O O
at O O
0 O O
degrees O O
C O O
for O O
4 O O
h O O
this O O
number O O
fell O O
to O O
2.3 O O
plus O O
or O O
minus O O
0.1 O O
S.E.M O O
. O O

- O O
Valproic B-drug B-drug
acid I-drug I-drug
( O O
e.g. O O
, O O
Depakene B-brand B-brand
) O O
Use O O
of O O
sulfapyridine B-drug B-drug
with O O
these O O
medicines O O
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
affecting O O
the O O
liver O O

Ketoconazole B-drug B-drug
tablets O O
may O O
alter O O
the O O
metabolism O O
of O O
cyclosporine B-drug B-drug
, O O
tacrolimus B-drug B-drug
, O O
and O O
methylprednisolone B-drug B-drug
, O O
resulting O O
in O O
elevated O O
plasma O O
concentrations O O
of O O
the O O
latter O O
drugs O O
. O O

- O O
The O O
action O O
of O O
sulphonylureas B-group B-group
and O O
insulin B-drug B-drug
may O O
be O O
enhanced O O
by O O
Bezalip B-brand B-brand
or O O
Bezalip B-brand B-brand
retard I-brand I-brand
. O O

However O O
, O O
these O O
studies O O
did O O
not O O
show O O
whether O O
ginsenosides-induced B-drug_n B-drug
inhibition O O
of O O
Ca O O
( O O
2+ O O
) O O
currents O O
discriminates O O
among O O
the O O
various O O
Ca O O
( O O
2+ O O
) O O
channel O O
subtypes O O
, O O
although O O
it O O
is O O
known O O
that O O
there O O
are O O
at O O
least O O
five O O
different O O
Ca O O
( O O
2+ O O
) O O
channel O O
subtypes O O
in O O
neuronal O O
cells O O
. O O

Concomitant O O
administration O O
of O O
erythromycin B-drug B-drug
and O O
digoxin B-drug B-drug
has O O
been O O
reported O O
to O O
result O O
in O O
elevated O O
digoxin B-drug B-drug
serum O O
levels O O
. O O

Differential O O
actions O O
of O O
intrathecal O O
naloxone B-drug B-drug
on O O
blocking O O
the O O
tail-flick O O
inhibition O O
induced O O
by O O
intraventricular O O
beta-endorphin B-drug_n B-drug
and O O
morphine B-drug B-drug
in O O
rats O O
. O O

While O O
taking O O
beta B-group B-group
blockers I-group I-group
, O O
patients O O
with O O
a O O
history O O
of O O
anaphylactic O O
reaction O O
to O O
a O O
variety O O
of O O
allergens O O
may O O
have O O
a O O
more O O
severe O O
reaction O O
on O O
repeated O O
challenge O O
, O O
either O O
accidental O O
, O O
diagnostic O O
or O O
therapeutic O O
. O O

Q4H O O
, O O
and O O
levofloxacin B-drug B-drug
, O O
500 O O
mg O O
p.o O O
. O O

Nonetheless O O
, O O
their O O
relevance O O
continues O O
to O O
be O O
demonstrated O O
by O O
the O O
dependence O O
of O O
each O O
agent O O
on O O
intact O O
liver O O
blood O O
flow O O
and O O
function O O
for O O
normal O O
rates O O
of O O
elimination O O
; O O

However O O
, O O
in O O
vitro O O
studies O O
have O O
shown O O
that O O
at O O
high O O
concentrations O O
( O O
7.4 O O
mMol/L O O
or O O
0.97 O O
mg/mL O O
and O O
greater O O
) O O
EACA B-drug O
inhibits O O
ADP O O
and O O
collagen-induced O O
platelet O O
aggregation O O
, O O
the O O
release O O
of O O
ATP O O
and O O
serotonin O O
, O O
and O O
the O O
binding O O
of O O
fibrinogen O O
to O O
the O O
platelets O O
in O O
a O O
concentration-response O O
manner O O
. O O

Use O O
with O O
Allopurinol B-drug B-drug
: O O
The O O
principal O O
pathway O O
for O O
detoxification O O
of O O
azathioprine B-drug B-drug
is O O
inhibited O O
by O O
allopurinol B-drug B-drug
. O O

Familial O O
hyper- O O
or O O
hypo-thyroxine-binding-globulinemias O O
have O O
been O O
described O O
. O O

Talk O O
to O O
your O O
doctor O O
if O O
you O O
are O O
taking O O
certain O O
antibiotics B-group B-group
such O O
as O O
erythromycin B-drug B-drug
, O O
clarithromycin B-drug B-drug
or O O
azithromycin B-drug B-drug
. O O

This O O
response O O
has O O
been O O
attributed O O
to O O
inhibition O O
of O O
renal O O
prostaglandin O O
synthesis O O
. O O

Guardians O O
of O O
children O O
who O O
have O O
been O O
prescribed O O
FORADIL B-brand B-brand
should O O
be O O
alerted O O
to O O
the O O
general O O
concern O O
regarding O O
asthma O O
therapy O O
compliance O O
, O O
especially O O
neglect O O
of O O
anti-inflammatory O O
therapy O O
and O O
overuse O O
of O O
short-acting B-group B-group
beta2-agonists I-group I-group
. O O

Injection O O
: O O
Lorazepam B-drug B-drug
injection O O
, O O
like O O
other O O
injectable O O
benzodiazepines B-group B-group
, O O
produces O O
depression O O
of O O
the O O
central O O
nervous O O
system O O
when O O
administered O O
with O O
ethyl B-drug B-drug
alcohol I-drug I-drug
, O O
phenothiazines B-group B-group
, O O
barbiturates B-group B-group
, O O
MAO B-group B-group
inhibitors I-group I-group
, O O
and O O
other O O
antidepressants.When B-group B-drug
scopolamine B-drug I-drug
is O O
used O O
concomitantly O O
with O O
injectable O O
lorazepam B-drug B-drug
, O O
an O O
increased O O
incidence O O
of O O
sedation O O
, O O
hallucinations O O
, O O
and O O
irrational O O
behavior O O
has O O
been O O
observed O O
. O O

Acidifying B-group B-group
agents I-group I-group
: O O
Gastrointestinal B-group B-group
acidifying I-group I-group
agents I-group I-group
( O O
guanethidine B-drug B-drug
, O O
reserpine B-drug B-drug
, O O
glutamic B-drug B-drug
acid I-drug I-drug
HCl I-drug I-drug
, O O
ascorbic B-drug B-drug
acid I-drug I-drug
, O O
fruit O O
juices O O
, O O
etc O O
. O O
) O O
lower O O
absorption O O
of O O
amphetamines B-group B-group
. O O

Positive O O
direct O O
and O O
indirect O O
antiglobulin O B-drug
( O O
Coombs O O
) O O
tests O O
have O O
occurred O O
; O O

Drugs O O
highly O O
bound O O
to O O
albumin O O
could O O
increase O O
the O O
unbound O O
fraction O O
of O O
fosphenytoin B-drug B-drug
. O O

The O O
concomitant O O
use O O
of O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
with O O
digitalis B-group B-group
and O O
calcium B-group B-group
antagonists O I-group
may O O
have O O
additive O O
effects O O
on O O
prolonging O O
atrioventricular O O
conduction O O
time O O
. O O

RESULTS O O
: O O
The O O
two O O
treatment O O
groups O O
were O O
well O O
matched O O
with O O
regard O O
to O O
patient O O
demographics O O
, O O
NHL O O
characteristics O O
, O O
HIV O O
status O O
, O O
and O O
treatment O O
, O O
i.e. O O
, O O
the O O
number O O
of O O
cycles O O
and O O
chemotherapy O O
dose O O
. O O

Avoid O O
the O O
concomitant O O
use O O
of O O
chlorprothixene B-drug B-drug
and O O
tramadol B-drug B-drug
( O O
Ultram B-brand B-brand
) O O
. O O

Coadministration O O
of O O
NIZORAL B-brand B-brand
Tablets O O
with O O
midazolam B-drug B-drug
or O O
triazolam B-drug B-drug
has O O
resulted O O
in O O
elevated O O
plasma O O
concentrations O O
of O O
the O O
latter O O
two O O
drugs O O
. O O

This O O
treatment O O
arm O O
was O O
discontinued O O
from O O
the O O
trial O O
. O O

No O O
dose O O
adjustment O O
is O O
necessary O O
. O O

An O O
in O O
vitro O O
effect O O
occurs O O
when O O
the O O
medication O O
interferes O O
with O O
the O O
assay O O
, O O
and O O
the O O
result O O
is O O
erroneous O O
and O O
can O O
not O O
be O O
interpreted O O
. O O

Ironically O O
, O O
benzodiazepines B-group B-group
are O O
often O O
used O O
in O O
the O O
treatment O O
of O O
heroin B-drug B-drug
addiction O O
while O O
they O O
cause O O
much O O
more O O
severe O O
withdrawal O O
symptoms O O
. O O

However O O
, O O
a O O
crossover O O
study O O
in O O
healthy O O
subjects O O
receiving O O
either O O
Tagamet B-brand B-brand
300 O O
mg O O
q.i.d O O
. O O
or O O
800 O O
mg O O
h.s O O
. O O
concomitantly O O
with O O
a O O
300 O O
mg O O
b.i.d O O
. O O
dosage O O
of O O
theophylline B-drug B-drug
( O O
Theo-Dur B-brand B-brand
, O O
Key O O
Pharmaceuticals O O
, O O
Inc. O O
) O O
demonstrated O O
less O O
alteration O O
in O O
steady-state O O
theophylline B-drug B-drug
peak O O
serum O O
levels O O
with O O
the O O
800 O O
mg O O
h.s O O
. O O
regimen O O
, O O
particularly O O
in O O
subjects O O
aged O O
54 O O
years O O
and O O
older O O
. O O

This O O
interaction O O
should O O
be O O
given O O
consideration O O
in O O
patients O O
taking O O
NSAIDs B-group B-group
concomitantly O O
with O O
ACE B-group B-group
inhibitors I-group I-group
. O O

cardiac B-group B-group
glycosides I-group I-group
; O O

Specific O O
studies O O
have O O
confirmed O O
these O O
effects O O
with O O
sevoflurane B-drug B-drug
, O O
isoflurane B-drug B-drug
, O O
propofol B-drug B-drug
, O O
alfentanil B-drug B-drug
, O O
and O O
midazolam B-drug B-drug
. O O

Anti-arrhythmics B-group B-group
and O O
tricyclic B-group B-group
anti-depressants I-group I-group
could O O
exaggerate O O
the O O
prolongation O O
of O O
the O O
QT O O
interval O O
observed O O
with O O
bepridil B-drug B-drug
hydrochloride I-drug I-drug
. O O

It O O
is O O
assumed O O
that O O
increased O O
interaction O O
between O O
3H-spiroperidol B-drug_n O
and O O
high O O
affinity O O
binding O O
sites O O
for O O
apomorphine B-drug B-drug
on O O
dopamine2- O O
and O O
serotonin2-receptors O O
underlies O O
the O O
antipsychotic O O
action O O
of O O
neuroleptics B-group B-group
after O O
their O O
prolonged O O
administration O O
. O O

The O O
most O O
commonly O O
occurring O O
drug O O
interactions O O
are O O
listed O O
below O O
: O O
- O O
Drugs O O
that O O
may O O
increase O O
plasma O O
phenytoin B-drug B-drug
concentrations O O
include O O
: O O
acute O O
alcohol B-drug B-drug
intake O O
, O O
amiodarone B-drug B-drug
, O O
chboramphenicol O B-drug
, O O
chlordiazepoxide B-drug B-drug
, O O
cimetidine B-drug B-drug
, O O
diazepam B-drug B-drug
, O O
dicumarol B-drug B-drug
, O O
disulfiram B-drug B-drug
, O O
estrogens B-group B-group
, O O
ethosuximide B-drug B-drug
, O O
fluoxetine B-drug B-drug
, O O
H2-antagonists B-group B-group
, O O
halothane B-drug B-drug
, O O
isoniazid B-drug B-drug
, O O
methylphenidate B-drug B-drug
, O O
phenothiazines B-group B-group
, O O
phenylbutazone B-drug B-drug
, O O
salicylates B-group B-group
, O O
succinimides B-group B-group
, O O
sulfonamides B-group B-group
, O O
tolbutamide B-drug B-drug
, O O
trazodone B-drug B-drug

If O O
they O O
do O O
occur O O
, O O
the O O
EPA B-drug B-drug
dose O O
should O O
be O O
lowered O O
or O O
discontinued O O
. O O

For O O
digoxin B-drug B-drug
AUC O O
( O O
0-infinity O O
) O O
, O O
AUC O O
( O O
0-24 O O
) O O
, O O
and O O
Cmax O O
, O O
the O O
geometric O O
mean O O
ratios O O
( O O
90 O O
% O O
confidence O O
interval O O
) O O
for O O
( O O
rofecoxib B-drug B-drug
+ O I-drug
digoxin/placebo B-drug I-drug
+ O O
digoxin B-drug B-drug
) O O
were O O
1.04 O O
( O O
0.94 O O
, O O
1.14 O O
) O O
, O O
1.02 O O
( O O
0.94 O O
, O O
1.09 O O
) O O
, O O
and O O
1.00 O O
( O O
0.91 O O
, O O
1.10 O O
) O O
, O O
respectively O O
. O O

washout O O
( O O
days O O
7-13 O O
) O O
; O O

In O O
a O O
study O O
in O O
which O O
patients O O
with O O
active O O
RA O O
were O O
treated O O
for O O
up O O
to O O
24 O O
weeks O O
with O O
concurrent O O
Kineret B-brand B-brand
and O O
etanercept B-drug B-drug
therapy O O
, O O
a O O
7 O O
% O O
rate O O
of O O
serious O O
infections O O
was O O
observed O O
, O O
which O O
was O O
higher O O
than O O
that O O
observed O O
with O O
etanercept B-drug B-drug
alone O O
( O O
0 O O
% O O
) O O
. O O

Because O O
Nalfon B-brand B-brand
has O O
not O O
been O O
shown O O
to O O
produce O O
any O O
additional O O
effect O O
beyond O O
that O O
obtained O O
with O O
aspirin B-brand B-brand
alone O O
and O O
because O O
aspirin B-brand B-brand
increases O O
the O O
rate O O
of O O
excretion O O
of O O
Nalfon B-brand B-brand
, O O
the O O
concomitant O O
use O O
of O O
Nalfon B-brand B-brand
and O O
salicylates B-group B-group
is O O
not O O
recommended O O
. O O

In O O
that O O
same O O
study O O
, O O
aspirin B-brand B-brand
alone O O
produced O O
a O O
marked O O
inhibition O O
in O O
platelet O O
aggregation O O
ex O O
vivo O O
. O O

When O O
used O O
concomitantly O O
, O O
anesthetics B-group B-group
and O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
should O O
be O O
titrated O O
carefully O O
. O O

When O O
estrogen B-group B-group
therapy O O
is O O
initiated O O
, O O
a O O
reduction O O
in O O
corticosteroid B-group B-group
dosage O O
may O O
be O O
required O O
, O O
and O O
increased O O
amounts O O
may O O
be O O
required O O
when O O
estrogen B-group B-group
is O O
terminated O O
. O O

In O O
neither O O
case O O
were O O
the O O
pharmacokinetics O O
of O O
sumatriptan B-drug B-drug
affected O O
by O O
coadministration O O
with O O
STADOL B-brand B-brand
NS I-brand I-brand
. O O

Some O O
cases O O
presented O O
with O O
features O O
resembling O O
neuroleptic O O
malignant O O
syndrome O O
. O O

Therefore O O
, O O
intake O O
of O O
supplemental O O
folic B-drug B-drug
acid I-drug I-drug
should O O
not O O
exceed O O
1000 O O
micrograms O O
( O O
g O O
, O O
sometimes O O
mcg O O
) O O
per O O
day O O
to O O
prevent O O
folic B-drug B-drug
acid I-drug I-drug
from O O
masking O O
symptoms O O
of O O
vitamin O O
B12 O O
deficiency O O
. O O

Xigris B-brand B-brand
present O O
in O O
plasma O O
samples O O
does O O
not O O
interfere O O
with O O
one-stage O O
factor O O
assays O O
based O O
on O O
the O O
PT O O
( O O
such O O
as O O
factor O O
II O O
, O O
V O I-drug_n
, O O
VII O O
, O O
and O O
X O O
assays O O
) O O
. O O

These O O
compounds O O
interfere O O
with O O
chemical O O
color O O
development O O
essential O O
to O O
the O O
analytical O O
procedures O O
. O O

GI O O
motility O O
agents O O
: O O
cisapride B-drug B-drug

Amprenavir B-drug B-drug
is O O
metabolized O O
in O O
the O O
liver O O
by O O
the O O
cytochrome O O
P450 O O
enzyme O O
system O O
. O O

At O O
least O O
14 O O
days O O
should O O
elapse O O
between O O
discontinuation O O
of O O
a O O
MAO B-group B-group
inhibitor I-group I-group
and O O
initiation O O
of O O
treatment O O
with O O
dexfenfluramine B-drug B-drug
. O O

Phenytoin B-drug B-drug
is O O
extensively O O
bound O O
to O O
serum O O
plasma O O
proteins O O
and O O
is O O
prone O O
to O O
competitive O O
displacement O O
. O O

the O O
third O O
group O O
( O O
SH/EA O O
) O O
was O O
treated O O
with O O
a O O
hydroalcoholic O B-drug
solution O O
of O O
ethanol B-drug B-drug
; O O

Administration O O
of O O
rifampin B-drug B-drug
concomitantly O O
with O O
oral O O
amiodarone B-drug B-drug
has O O
been O O
shown O O
to O O
result O O
in O O
decreases O O
in O O
serum O O
concentrations O O
of O O
amiodarone B-drug B-drug
and O O
desethylamiodarone B-drug B-drug
. O O

The O O
fluoroquinolones B-group B-group
are O O
also O O
extensively O O
used O O
in O O
urologic O O
surgery O O
. O O

Each O O
serum O O
without O O
the O O
other O O
added O O
drug O O
as O O
well O O
as O O
the O O
serum O O
supplemented O O
with O O
the O O
other O O
drug O O
at O O
the O O
three O O
concentrations O O
was O O
dialyzed O O
against O O
phosphate O O
buffer O O
. O O

endocrine O O
dysfunction O O
; O O

Quinolones B-group B-group
have O O
been O O
shown O O
to O O
interfere O O
with O O
the O O
metabolism O O
of O O
caffeine B-drug B-drug
. O O

Therefore O O
, O O
concurrent O O
use O O
of O O
Trileptal B-brand B-brand
with O O
hormonal B-group B-group
contraceptives I-group I-group
may O O
render O O
these O O
contraceptives B-group B-group
less O O
effective O O
. O O

In O O
controlled O O
clinical O O
trials O O
of O O
AUGMENTIN B-brand B-brand
XR I-brand I-brand
, O O
22 O O
patients O O
received O O
concomitant O O
allopurinol B-drug B-drug
and O O
AUGMENTIN B-brand B-brand
XR I-brand I-brand
. O O

Examples O O
of O O
Drugs O O
in O O
Which O O
Plasma O O
Concentrations O O
May O O
Be O O
Decreased O O
By O O
Co-administration O O
With O O
Nevirapine B-drug B-drug

Using O O
calcium B-drug B-drug
acetate I-drug I-drug
with O O
digitalis B-group B-group
glycosides I-group I-group
( O O
heart O O
medicine O O
) O O
may O O
cause O O
hypercalcemia O O
( O O
too O O
much O O
calcium B-drug B-drug
in O O
the O O
blood O O
) O O
, O O
which O O
could O O
increase O O
the O O
chance O O
of O O
developing O O
an O O
irregular O O
heartbeat O O
. O O

Fentanyl B-drug B-drug
Anesthesia O O
: O O
Severe O O
hypotension O O
has O O
been O O
reported O O
during O O
fentanyl B-drug B-drug
anesthesia O O
with O O
concomitant O O
use O O
of O O
a O O
beta B-group B-group
blocker I-group I-group
and O O
a O O
calcium B-group B-group
channel I-group I-group
blocker I-group I-group
. O O

Laboratory O O
Tests O O
If O O
significant O O
abnormal O O
laboratory O O
results O O
are O O
obtained O O
, O O
either O O
dosage O O
reduction O O
with O O
careful O O
monitoring O O
or O O
treatment O O
discontinuation O O
is O O
recommended O O
, O O
depending O O
on O O
clinical O O
judgement O O
. O O

reliable O O
estimates O O
of O O
the O O
prevalence O O
of O O
reduced O O
P450 O O
2D6 O O
isozyme O O
activity O O
among O O
Asian O O
, O O
African O O
and O O
other O O
populations O O
are O O
not O O
yet O O
available O O
. O O

Although O O
ROMAZICON B-brand B-brand
exerts O O
a O O
slight O O
intrinsic O O
anticonvulsant O O
effect O O
, O O
its O O
abrupt O O
suppression O O
of O O
the O O
protective O O
effect O O
of O O
a O O
benzodiazepine B-group B-group
agonist O I-group
can O O
give O O
rise O O
to O O
convulsions O O
in O O
epileptic O O
patients O O
. O O

In O O
healthy O O
volunteers O O
, O O
the O O
pharmacokinetics O O
of O O
a O O
1-mg O O
dose O O
of O O
butorphanol B-drug B-drug
administered O O
as O O
STADOL B-brand B-brand
NS I-brand I-brand
were O O
not O O
affected O O
by O O
the O O
coadministration O O
of O O
a O O
single O O
6-mg O O
subcutaneous O O
dose O O
of O O
sumatriptan B-drug B-drug
. O O

In O O
post-marketing O O
experience O O
, O O
bleeding O O
has O O
been O O
reported O O
in O O
patients O O
on O O
concomitant O O
treatment O O
with O O
anticoagulants B-group B-group
and O O
INDOCIN B-brand B-brand
. O O

Concurrent O O
administration O O
of O O
low-dose O O
dopamine B-drug B-drug
HCl I-drug I-drug
and O O
diuretic B-group B-group
agents I-group I-group
may O O
produce O O
an O O
additive O O
or O O
potentiating O O
effect O O
on O O
urine O O
flow O O
. O O

Maximal O O
hypotension O O
was O O
found O O
120 O O
minutes O O
post O O
ethanol B-drug B-drug
, O O
and O O
returned O O
to O O
normal O O
300 O O
minutes O O
after O O
ethanol B-drug B-drug
. O O

Since O O
bacteriostatic O B-group
drugs O I-group
, O O
such O O
as O O
the O O
tetracycline B-group B-group
class I-group I-group
of O I-group
antibiotics B-group I-group
, O O
may O O
interfere O O
with O O
the O O
bactericidal O O
action O O
of O O
penicillins B-group B-group
, O O
it O O
is O O
not O O
advisable O O
to O O
administer O O
these O O
drugs O O
concomitantly O O
. O O

In O O
healthy O O
volunteers O O
, O O
Exjade B-brand B-brand
had O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
. O O

Dexfenfluramine B-drug B-drug
should O O
not O O
be O O
administered O O
with O O
other O O
serotoninergic B-group B-group
agents I-group I-group
. O O

Nevirapine I-drug B-drug

To O O
prevent O O
stomach O O
irritation O O
, O O
subjects O O
received O O
rantidine B-drug B-drug
hydrochloride I-drug I-drug
before O O
each O O
experimental O O
session O O
. O O

Amiodarone B-drug B-drug
is O O
known O O
to O O
raise O O
serum O O
digoxin B-drug B-drug
levels O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
of O O
Aranesp B-brand B-brand
have O O
been O O
performed O O
. O O

Deaths O O
from O O
severe O O
enterocolitis O O
, O O
diarrhea O O
, O O
and O O
dehydration O O
have O O
been O O
reported O O
in O O
elderly O O
patients O O
receiving O O
weekly O O
leucovorin B-drug B-drug
and O O
fluorouracil B-drug B-drug
. O O

The O O
response O O
rates O O
were O O
similar O O
between O O
the O O
two O O
groups O O
. O O

Antacids B-group B-group
and O O
kaolin B-drug O
: O O
Antacids B-group B-group
and O O
kaolin B-drug O
can O O
reduce O O
absorption O O
of O O
chloroquine B-drug B-drug
; O O

However O O
, O O
the O O
effects O O
of O O
stress O O
and O O
glucocorticoids B-group B-group
on O O
the O O
subjective O O
and O O
behavioral O O
effects O O
of O O
psychostimulants B-group B-group
have O O
not O O
been O O
well O O
studied O O
in O O
humans O O
. O O

filipin B-drug_n B-drug_n
was O O
more O O
potent O O
in O O
lysing O O
human O O
red O O
blood O O
cells O O
, O O
whereas O O
amphotericin B-drug B-drug
B I-drug I-drug
was O O
more O O
potent O O
in O O
inhibiting O O
yeast O O
cell O O
growth O O
; O O

Oral O O
contraceptives B-group B-group
may O O
be O O
less O O
effective O O
while O O
you O O
are O O
taking O O
lymecycline B-drug B-drug
. O O

AIMS/HYPOTHESIS O O
: O O
There O O
is O O
evidence O O
that O O
insulin B-drug B-drug
and O O
glucose B-drug O
cause O O
renal O O
and O O
ocular O O
vasodilation O O
. O O

Latent O O
LCV O O
infection O O
is O O
generally O O
asymptomatic O O
, O O
but O O
can O O
lead O O
to O O
B-cell O O
lymphomas O O
when O O
animals O O
are O O
immune O O
suppressed O O
. O O

PEGASYS B-brand B-brand
should O O
be O O
assumed O O
to O O
have O O
abortifacient O O
potential O O
. O O

Adrenergic B-group B-group
Agents I-group I-group
: O O
Some O O
individuals O O
receiving O O
ZYVOX B-brand B-brand
may O O
experience O O
a O O
reversible O O
enhancement O O
of O O
the O O
pressor O O
response O O
to O O
indirect-acting O O
sympathomimetic B-group B-group
agents I-group I-group
, O O
vasopressor B-group O
or O O
dopaminergic B-group B-group
agents I-group I-group
. O O

Effect O O
of O O
Other O O
Drugs O O
on O O
the O O
Pharmacokinetics O O
of O O
Clonazepam B-drug B-drug
: O O
Literature O O
reports O O
suggest O O
that O O
ranitidine B-drug B-drug
, O O
an O O
agent O O
that O O
decreases O O
stomach O O
acidity O O
, O O
does O O
not O O
greatly O O
alter O O
clonazepam B-drug B-drug
pharmacokinetics O O
. O O

Substances O O
that O O
inhibit O O
the O O
cytochrome O O
P450 O O
isoenzyme O O
( O O
CYP3A4 O O
) O O
activity O O
may O O
decrease O O
metabolism O O
and O O
increase O O
imatinib B-drug B-drug
concentrations O O
. O O

However O O
, O O
in O O
a O O
well-controlled O O
study O O
of O O
patients O O
with O O
lymphoma O O
on O O
combination O O
therapy O O
, O O
allopurinol B-drug B-drug
did O O
not O O
increase O O
the O O
marrow O O
toxicity O O
of O O
patients O O
treated O O
with O O
cyclophosphamide B-drug B-drug
, O O
doxorubicin B-drug B-drug
, O O
bleomycin B-drug B-drug
, O O
procarbazine B-drug B-drug
and/or O O
mechlorethamine B-drug B-drug
. O O

Diabetic O O
patients O O
have O O
a O O
20 O O
% O O
higher O O
risk O O
of O O
depression O O
than O O
the O O
general O O
population O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
A O O
false-positive O O
reaction O O
for O O
ketones O O
in O O
the O O
urine O O
may O O
occur O O
with O O
tests O O
using O O
nitroprusside B-drug B-drug
, O O
but O O
not O O
with O O
those O O
using O O
nitroferricyanide B-drug B-drug
. O O

General O O
No O O
clinical O O
drug O O
interaction O O
studies O O
were O O
performed O O
. O O

The O O
interaction O O
between O O
lomefloxacin B-drug B-drug
and O O
cimetidine B-drug B-drug
has O O
not O O
been O O
studied O O
. O O

When O O
these O O
products O O
are O O
administered O O
concomitantly O O
, O O
prothrombin O O
time O O
or O O
other O O
suitable O O
coagulation O O
tests O O
should O O
be O O
closely O O
monitored O O
. O O

Beta B-group B-group
blockers I-group I-group
may O O
exacerbate O O
the O O
hypertensive O O
response O O
seen O O
with O O
clonidine B-drug B-drug
withdrawl O O
. O O

Potential O O
for O O
reduction O O
in O O
anticonvulsant B-group O
and/or O O
efavirenz B-drug B-drug
plasma O O
levels O O
; O O

Beta-blockers B-group B-group
( O O
metoprolol B-drug B-drug
, O O
propranolol B-drug B-drug
) O O
serum O O
concentrations O O
and O O
pharmacologic O O
effects O O
may O O
be O O
increased O O
. O O

Aprepitant B-drug B-drug
is O O
unlikely O O
to O O
interact O O
with O O
drugs O O
that O O
are O O
substrates O O
for O O
the O O
P-glycoprotein O O
transporter O O
, O O
as O O
demonstrated O O
by O O
the O O
lack O O
of O O
interaction O O
of O O
Aprepitant B-drug B-drug
with O O
digoxin B-drug B-drug
in O O
a O O
clinical O O
drug O O
interaction O O
study O O
. O O

Hypotension O O
: O O
Patients O O
on O O
Diuretic O B-group
Therapy O O
: O O
Patients O O
on O O
diuretics B-drug B-group
and O O
especially O O
those O O
in O O
whom O O
diuretic O B-group
therapy O O
was O O
recently O O
instituted O O
, O O
may O O
occasionally O O
experience O O
an O O
excessive O O
reduction O O
of O O
blood O O
pressure O O
after O O
initiation O O
of O O
therapy O O
with O O
enalapril B-drug B-drug
or O O
enalaprilat B-drug B-drug
. O O

Warfarin B-drug B-drug
: O O
No O O
significant O O
differences O O
were O O
observed O O
in O O
the O O
steady-state O O
pharmacokinetics O O
of O O
R-warfarin B-drug B-drug_n
or O O
S-warfarin B-drug B-drug_n
with O O
the O O
addition O O
of O O
tiagabine B-drug B-drug
given O O
as O O
a O O
single O O
dose O O
. O O

In O O
patients O O
receiving O O
FORADIL B-brand B-brand
, O O
other O O
inhaled O O
medications O O
should O O
be O O
used O O
only O O
as O O
directed O O
by O O
the O O
physician O O
. O O

With O O
the O O
exception O O
of O O
albuterol B-drug B-drug
, O O
there O O
are O O
no O O
formal O O
studies O O
fully O O
evaluating O O
the O O
interaction O O
effects O O
of O O
ATROVENT B-brand B-brand
Inhalation O O
Aerosol O O
and O O
these O O
drugs O O
with O O
respect O O
to O O
effectiveness O O
. O O

We O O
demonstrate O O
that O O
the O O
conversion O O
of O O
1,3-difluoro-2-propanol B-drug_n B-drug_n
to O O
1,3-difluoroacetone B-drug_n B-drug_n
by O O
an O O
NAD+-dependent O O
oxidation O O
is O O
the O O
rate-limiting O O
step O O
in O O
the O O
synthesis O O
of O O
the O O
toxic O O
product O O
, O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-erythro-fluorocitrate I-drug_n I-drug_n
from O O
1,3-difluoro-2-propanol B-drug_n B-drug_n
. O O

These O O
results O O
suggest O O
that O O
exposure O O
to O O
environmental O O
lead B-drug_n O
may O O
alter O O
the O O
biological O O
and O O
behavioral O O
responsiveness O O
of O O
an O O
animal O O
to O O
alcohol B-drug B-drug
. O O

No O O
drug O O
interactions O O
were O O
detected O O
except O O
for O O
an O O
increase O O
in O O
symptomatic O O
hypotension O O
in O O
patients O O
receiving O O
oral O O
ACE B-group B-group
inhibitors I-group I-group
. O O

Excessive O O
neuromuscular O O
weakness O O
may O O
be O O
exacerbated O O
by O O
administration O O
of O O
another O O
botulinum B-group B-group
toxin I-group I-group
prior O O
to O O
the O O
resolution O O
of O O
the O O
effects O O
of O O
a O O
previously O O
administered O O
botulinum B-group B-group
toxin I-group I-group
. O O

SINCE O O
THE O O
CONCOMITANT O O
ADMINISTRATION O O
OF O O
THESE O O
TWO O O
DRUGS O O
CAN O O
LEAD O O
TO O O
PHENYTOIN B-drug B-drug
INTOXICATION O O
, O O
PRIOR O O
TO O O
ADMINISTERING O O
DISULFIRAM B-drug B-drug
TO O O
A O O
PATIENT O O
ON O O
PHENYTOIN B-drug B-drug
THERAPY O O
, O O
A O O
BASELINE O O
PHENYTOIN B-drug B-drug
SERUM O O
LEVEL O O
SHOULD O O
BE O O
OBTAINED O O
. O O

Other O O
CNS B-group B-group
depressant I-group I-group
drugs I-group I-group
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
taking O O
fenfluramine B-drug B-drug
, O O
since O O
the O O
effects O O
may O O
be O O
additive O O
. O O

When O O
taken O O
concurrently O O
with O O
ethanol B-drug B-drug
, O O
a O O
pharmacological O O
interaction O O
may O O
occur O O
, O O
potentiating O O
the O O
central O O
nervous O O
system O O
depression O O
produced O O
by O O
either O O
drug O O
. O O

Cytochrome O O
P-450 O O
is O O
not O O
known O O
to O O
be O O
involved O O
in O O
the O O
metabolism O O
of O O
Plenaxis B-brand B-brand
. O O

Diuretics B-group B-group
: O O
Patients O O
on O O
diuretics B-group B-group
, O O
especially O O
those O O
with O O
intravascular O O
volume O O
depletion O O
, O O
may O O
occasionally O O
experience O O
an O O
excessive O O
reduction O O
of O O
blood O O
pressure O O
after O O
initiation O O
of O O
therapy O O
with O O
fosinopril B-drug B-drug
sodium I-drug I-drug
. O O

Drug/Laboratory O O
Test O O
Interactions O O
Acetaminophen B-drug B-drug
may O O
produce O O
false-positive O O
test O O
results O O
for O O
urinary O O
5-hydroxyindoleacetic O O
acid O O
. O O

Some O O
quinolone B-group B-group
antibiotics I-group I-group
would O O
be O O
expected O O
to O O
have O O
similar O O
effects O O
and O O
these O O
combinations O O
should O O
be O O
avoided O O
. O O

Colestipol-Concomitant B-drug O
intake O O
of O O
colestipol B-drug B-drug
and O O
vitamin B-group B-group
K I-group I-group
may O O
reduce O O
the O O
absorption O O
of O O
vitamin B-group B-group
K I-group I-group
. O O

Since O O
fondaparinux B-drug B-drug
does O O
not O O
markedly O O
inhibit O O
CYP450s O O
( O O
CYP1A2 O O
, O O
CYP2A6 O O
, O O
CYP2C9 O O
, O O
CYP2C19 O O
, O O
CYP2D6 O O
, O O
CYP2E1 O O
, O O
or O O
CYP3A4 O O
) O O
in O O
vitro O O
, O O
fondaparinux B-drug B-drug
sodium I-drug I-drug
is O O
not O O
expected O O
to O O
significantly O O
interact O O
with O O
other O O
drugs O O
in O O
vivo O O
by O O
inhibition O O
of O O
metabolism O O
mediated O O
by O O
these O O
isozymes O O
. O O

Several O O
studies O O
indicate O O
that O O
olanzapine B-drug B-drug
has O O
benefits O O
against O O
symptoms O O
of O O
aggression O O
and O O
agitation O O
, O O
while O O
other O O
studies O O
strongly O O
support O O
the O O
effectiveness O O
of O O
olanzapine B-drug B-drug
in O O
the O O
treatment O O
of O O
depressive O O
symptomatology O O
. O O

In O O
view O O
of O O
the O O
potential O O
risk O O
of O O
dehydration O O
secondary O O
to O O
vomiting O O
and/or O O
diarrhea O O
induced O O
by O O
CAMPTOSAR B-brand B-brand
, O O
the O O
physician O O
may O O
wish O O
to O O
withhold O O
diuretics B-group B-group
during O O
dosing O O
with O O
CAMPTOSAR B-brand B-brand
and O O
, O O
certainly O O
, O O
during O O
periods O O
of O O
active O O
vomiting O O
or O O
diarrhea O O
. O O

Co-administration O O
of O O
bosentan B-drug B-drug
decreased O O
the O O
plasma O O
concentrations O O
of O O
glyburide B-drug B-drug
by O O
approximately O O
40 O O
% O O
. O O

Diltiazem B-drug B-drug
: O O
In O O
patients O O
with O O
mild O O
to O O
moderate O O
hypertension O O
, O O
administration O O
of O O
aprepitant B-drug B-drug
once O O
daily O O
, O O
as O O
a O O
tablet O O
formulation O O
comparable O O
to O O
230 O O
mg O O
of O O
the O O
capsule O O
formulation O O
, O O
with O O
diltiazem B-drug B-drug
120 O O
mg O O
3 O O
times O O
daily O O
for O O
5 O O
days O O
, O O
resulted O O
in O O
a O O
2-fold O O
increase O O
of O O
aprepitant B-drug B-drug
AUC O O
and O O
a O O
simultaneous O O
1.7-fold O O
increase O O
of O O
diltiazem B-drug B-drug
AUC O O
. O O

This O O
increase O O
is O O
greatest O O
in O O
the O O
evening O O
. O O

Drugs O O
That O O
Should O O
Not O O
Be O O
Coadministered O O
With O O
INVIRASE/Ritonavir B-brand B-drug_n

Concomitant O O
administration O O
of O O
drugs O O
known O O
to O O
induce O O
cytochrome O O
P450 O O
enzymes O O
may O O
decrease O O
the O O
plasma O O
levels O O
of O O
clozapine B-drug B-drug
. O O

Digoxin B-drug B-drug
is O O
eliminated O O
renally O O
. O O

However O O
, O O
LDL-C O O
reduction O O
was O O
not O O
altered O O
. O O

There O O
was O O
no O O
apparent O O
pharmacokinetic O O
interaction O O
between O O
zaleplon B-drug B-drug
and O O
ibuprofen B-drug B-drug
following O O
single O O
dose O O
administration O O
( O O
10 O O
mg O O
and O O
600 O O
mg O O
, O O
respectively O O
) O O
of O O
each O O
drug O O
. O O

In O O
controlled O O
clinical O O
trials O O
, O O
however O O
, O O
beta B-drug B-group
blockers I-drug I-group
including O O
metoprolol B-drug B-drug
were O O
concurrently O O
administered O O
with O O
felodipine B-drug B-drug
and O O
were O O
well O O
tolerated O O
. O O

When O O
amiodarone B-drug B-drug
is O O
added O O
to O O
flecainide B-drug B-drug
therapy O O
, O O
plasma O O
flecainide B-drug B-drug
levels O O
may O O
increase O O
two-fold O O
or O O
more O O
in O O
some O O
patients O O
, O O
if O O
flecainide B-drug B-drug
dosage O O
is O O
not O O
reduced O O
. O O

Digoxin B-drug B-drug
: O O
Enoxacin B-drug B-drug
may O O
raise O O
serum O O
digoxin B-drug B-drug
levels O O
in O O
some O O
individuals O O
. O O

Cardiovascular O O
collapse O O
in O O
patients O O
treated O O
simultaneously O O
with O O
varapamil O B-drug
and O O
dantrolene B-drug B-drug
sodium I-drug I-drug
is O O
rare O O
. O O

tolbutamide B-drug B-drug
; O O

In O O
such O O
a O O
case O O
, O O
the O O
peripheral O O
vascular O O
resistance O O
may O O
increase O O
. O O

9 O O
. O O

The O O
effects O O
of O O
diethyl B-drug_n B-drug
pyrocarbonate I-drug_n I-drug
could O O
be O O
reversed O O
by O O
hydroxylamine B-drug_n O
treatment O O
. O O

Concomitant O O
use O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
with O O
drugs O O
that O O
can O O
inhibit O O
cytochrome O O
P450 O O
2D6 O O
may O O
require O O
lower O O
doses O O
than O O
usually O O
prescribed O O
for O O
either O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
or O O
the O O
other O O
drug O O
. O O

both O O
compounds O O
attenuate O O
morphine-induced B-drug B-drug
locomotion O O
in O O
morphine-experienced B-drug B-drug
rats O O
. O O

ACE B-group B-group
Inhibitors I-group I-group
and O O
Angiotensin B-group B-group
II I-group I-group
Receptor I-group I-group
Antagonists I-group I-group
( O O
Hypertension O O
) O O
- O O
In O O
clinical O O
studies O O
of O O
patients O O
with O O
hypertension O O
, O O
the O O
addition O O
of O O
INSPRA B-brand B-brand
50 O O
to O O
100 O O
mg O O
to O O
ACE B-group B-group
inhibitors I-group I-group
and O O
angiotensin B-group B-group
II I-group I-group
receptor I-group I-group
antagonists I-group I-group
increased O O
mean O O
serum O O
potassium O O
slightly O O
( O O
about O O
0.09-0.13 O O
mEq/L O O
) O O
. O O

Although O O
results O O
have O O
varied O O
from O O
study O O
to O O
study O O
, O O
effects O O
have O O
been O O
shown O O
on O O
furosemide-stimulated B-drug B-drug
diuresis O O
, O O
natriuresis O O
, O O
and O O
kaliuresis O O
. O O

The O O
possibility O O
of O O
reduced O O
statin B-group O
efficacy O O
should O O
be O O
considered O O
. O O

These O O
data O O
indicate O O
that O O
levetiracetam B-drug B-drug
does O O
not O O
influence O O
the O O
plasma O O
concentration O O
of O O
other O O
AEDs B-group B-group
and O O
that O O
these O O
AEDs B-group B-group
do O O
not O O
influence O O
the O O
pharmacokinetics O O
of O O
levetiracetam B-drug B-drug
. O O

Multiple-dose O O
administration O O
of O O
the O O
potent O O
CYP3A4 O O
inducer O O
rifampin B-drug B-drug
( O O
600 O O
mg O O
every O O
24 O O
hours O O
, O O
q24h O O
, O O
for O O
14 O O
days O O
) O O
, O O
however O O
, O O
reduced O O
zaleplon B-drug B-drug
Cmax O O
and O O
AUC O O
by O O
approximately O O
80 O O
% O O
. O O

. O O

In O O
vitro O O
studies O O
have O O
indicated O O
that O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
binds O O
a O O
number O O
of O O
drugs O O
. O O

Combination O O
hormonal B-group B-group
contraceptives I-group I-group
may O O
also O O
increase O O
risk O O
of O O
thromboembolic O O
disorders O O
. O O

( O O
1968 O O
, O O
1970 O O
) O O
, O O
the O O
higher O O
serum O O
concentrations O O
of O O
penicillins B-group B-group
and O O
cephaloridine B-drug B-drug
reached O O
after O O
administration O O
of O O
probenecid B-drug B-drug
are O O
due O O
not O O
only O O
to O O
slower O O
renal O O
elimination O O
but O O
also O O
to O O
an O O
altered O O
distribution O O
in O O
the O O
body O O
. O O

Caution O O
should O O
also O O
be O O
applied O O
for O O
other O O
sympathomimetics B-group B-group
, O O
and O O
for O O
aminophylline B-drug B-drug
and O O
theophylline B-drug B-drug
and O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
which O O
may O O
also O O
precipitate O O
arrhythmias O O
. O O

CNS O O
Drugs O O
- O O
Given O O
the O O
primary O O
CNS O O
effects O O
of O O
escitalopram B-drug B-drug
, O O
caution O O
should O O
be O O
used O O
when O O
it O O
is O O
taken O O
in O O
combination O O
with O O
other O O
centrally O O
acting O O
drugs O O
. O O

nc1 O O
40 O O
% O O
decrease O O
[ O O
CI O O
: O O
17 O O
% O O
decrease O O
, O O
57 O O
% O O
decrease O O
] O O

approximately O O
one-hundredth O O
of O O
the O O
human O O
recommended O O
dose O O
based O O
on O O
body O O
surface O O
area O O
[ O O
BSA O O
] O O
) O O
, O O
fulvestrant B-drug B-drug
caused O O
a O O
reversible O O
reduction O O
in O O
female O O
fertility O O
, O O
as O O
well O O
as O O
effects O O
on O O
embryo/fetal O O
development O O
consistent O O
with O O
its O O
anti-estrogenic O O
activity O O
. O O

The O O
appropriate O O
doses O O
for O O
this O O
combination O O
, O O
with O O
respect O O
to O O
efficacy O O
and O O
safety O O
, O O
have O O
not O O
been O O
established O O
. O O

Morphine B-drug B-drug
analgesia O O
and O O
pupil O O
constriction O O
were O O
unaffected O O
by O O
ADL B-drug B-drug
8-2698 I-drug I-drug
and O O
differed O O
from O O
placebo O O
( O O
P O O
< O O
.002 O O
) O O
. O O

Survanta B-brand B-brand
increased O O
the O O
extent O O
of O O
dissolution O O
of O O
budesonide B-drug B-drug
in O O
proportion O O
to O O
the O O
added O O
concentration O O
, O O
which O O
was O O
also O O
verified O O
by O O
equilibrium O O
solubilization O O
studies O O
. O O

Each O O
volunteer O O
was O O
administered O O
one O O
400-mg O O
ceftibuten B-drug B-drug
capsule O O
. O O

Other O O
drugs O O
have O O
not O O
been O O
studied O O
. O O

Dimenhydrinate B-drug B-drug
may O O
decrease O O
emetic B-group B-group
response O O
to O O
apomorphine B-drug B-drug
. O O

Electrocardiograms O O
were O O
done O O
at O O
baseline O O
and O O
on O O
the O O
last O O
day O O
of O O
the O O
washout O O
period O O
and O O
phase O O
2 O O
. O O

Because O O
of O O
the O O
variability O O
of O O
individual O O
patient O O
response O O
, O O
multiple O O
interacting O O
mechanisms O O
with O O
some O O
drugs O O
, O O
the O O
dependency O O
of O O
the O O
extent O O
of O O
the O O
interaction O O
on O O
the O O
dosage O O
and O O
duration O O
of O O
therapy O O
, O O
and O O
the O O
possible O O
administration O O
of O O
several O O
interacting O O
drugs O O
simultaneously O O
, O O
it O O
is O O
difficult O O
to O O
predict O O
the O O
direction O O
and O O
degree O O
of O O
the O O
ultimate O O
effect O O
of O O
concomitant O O
medications O O
on O O
anticoagulant B-group B-group
response O O
. O O

However O O
, O O
caution O O
should O O
be O O
exercised O O
because O O
there O O
have O O
been O O
a O O
few O O
spontaneous O O
reports O O
of O O
prolonged O O
prothrombin O O
times O O
, O O
with O O
or O O
without O O
bleeding O O
, O O
in O O
etodolac-treated B-drug B-drug
patients O O
receiving O O
concomitant O O
warfarin B-drug B-drug
therapy O O
. O O

Doxepin B-drug B-drug
is O O
primarily O O
metabolized O O
by O O
CYP2D6 O O
( O O
with O O
CYP1A2 O O
and O O
CYP3A4 O O
as O O
minor O O
pathways O O
) O O
. O O

Release O O
of O O
arachidonic O O
acid O O
from O O
membrane O O
phospholipids O O
as O O
well O O
as O O
subsequent O O
synthesis O O
and O O
release O O
of O O
vasoconstrictor O O
thromboxane O O
A2 O O
are O O
also O O
regulated O O
by O O
movement O O
of O O
calcium O O
ions O O
. O O

DESIGN O O
: O O
Cross-sectional O O
descriptive O O
study O O
. O O

Finasteride B-drug B-drug
does O O
not O O
appear O O
to O O
affect O O
the O O
cytochrome O O
P450-linked O O
drug-metabolizing O O
enzyme O O
system O O
. O O

We O O
have O O
shown O O
that O O
MCF-7 O O
cells O O
treated O O
with O O
100 O O
nM O O
1,25 B-drug O
( I-drug O
OH I-drug O
) I-drug O
2D3 I-drug O
exhibit O O
characteristic O O
apoptotic O O
morphology O O
( O O
pyknotic O O
nuclei O O
, O O
chromatin O O
and O O
cytoplasmic O O
condensation O O
, O O
nuclear O O
matrix O O
protein O O
reorganization O O
) O O
within O O
48 O O
h O O
. O O

Therefore O O
, O O
the O O
potential O O
exists O O
for O O
a O O
drug O O
interaction O O
between O O
WELLBUTRIN B-brand B-brand
and O O
drugs O O
that O O
affect O O
the O O
CYP2B6 O O
isoenzyme O O
( O O
e.g. O O
, O O
orphenadrine B-drug B-drug
and O O
cyclophosphamide B-drug B-drug
) O O
. O O

Dose O O
adjustment O O
of O O
Sensipar B-brand B-brand
may O O
be O O
required O O
and O O
PTH O O
and O O
serum O O
calcium O O
concentrations O O
should O O
be O O
closely O O
monitored O O
if O O
a O O
patient O O
initiates O O
or O O
discontinues O O
therapy O O
with O O
a O O
strong O O
CYP3A4 O O
inhibitor O O
( O O
e.g. O O
, O O
ketoconazole B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
itraconazole B-drug B-drug
; O O

There O O
were O O
no O O
significant O O
differences O O
between O O
the O O
two O O
groups O O
, O O
achieving O O
a O O
maximum O O
relaxation O O
of O O
> O O
95 O O
% O O
at O O
a O O
concentration O O
of O O
35 O O
micromol/l O O
. O O

It O O
was O O
concluded O O
that O O
, O O
although O O
gentamycin B-drug B-drug
did O O
augment O O
the O O
neuromuscular O O
blockade O O
of O O
atracurium B-drug B-drug
, O O
the O O
effect O O
was O O
minimal O O
. O O

Whether O O
this O O
interaction O O
also O O
occurs O O
with O O
the O O
intravenous O O
, O O
topical O O
or O O
vaginal O O
preparations O O
of O O
miconazole B-drug B-drug
is O O
not O O
known O O
. O O

The O O
mode O O
of O O
toxic O O
action O O
of O O
the O O
pesticide O B-group
gliftor B-drug_n I-group
: O O
the O O
metabolism O O
of O O
1,3-difluoroacetone B-drug_n B-drug_n
to O I-drug_n
( B-drug_n I-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-erythro-fluorocitrate I-drug_n I-drug_n
. O O

. O O

Rare O O
cases O O
of O O
elevated O O
plasma O O
concentrations O O
of O O
digoxin B-drug B-drug
have O O
been O O
reported O O
. O O

At O O
75 O O
% O O
recovery O O
of O O
fade O O
, O O
hoof O O
twitch O O
was O O
87 O O
+/- O O
3 O O
% O O
for O O
atracurium B-drug B-drug
alone O O
and O O
82 O O
+/- O O
4 O O
% O O
for O O
atracurium B-drug B-drug
plus O O
gentamycin B-drug B-drug
. O O

CYP3A4 B-drug B-drug
Inhibitors O I-drug
Felodipine O B-drug
is O O
metabolized O O
by O O
CYP3A4 B-drug O
. O O

therefore O O
, O O
if O O
glucocorticoid B-group B-group
replacement O O
is O O
needed O O
, O O
hydrocortisone B-drug B-drug
should O O
be O O
prescribed O O
. O O

Hepatic O O
Impairment O O
There O O
are O O
currently O O
no O O
clinical O O
studies O O
with O O
SPRYCEL B-brand B-brand
in O O
patients O O
with O O
impaired O O
liver O O
function O O
( O O
clinical O O
studies O O
have O O
excluded O O
patients O O
with O O
ALT O O
and/or O O
AST O O
2.5 O O
times O O
the O O
upper O O
limit O O
of O O
the O O
normal O O
range O O
and/or O O
total O O
bilirubin O O
2 O O
times O O
the O O
upper O O
limit O O
of O O
the O O
normal O O
range O O
) O O
. O O

Digoxin B-drug B-drug
: O O
Studies O O
of O O
concomitant O O
administration O O
of O O
flurbiprofen B-drug B-drug
and O O
digoxin B-drug B-drug
to O O
healthy O O
men O O
( O O
n= O O
14 O O
) O O
did O O
not O O
show O O
a O O
change O O
in O O
the O O
steady O O
state O O
serum O O
levels O O
of O O
either O O
drug O O
. O O

Thus O O
, O O
when O O
ibuprofen B-drug B-drug
and O O
lithium B-drug B-drug
are O O
administered O O
concurrently O O
, O O
subjects O O
should O O
be O O
observed O O
carefully O O
for O O
signs O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

Acarbose B-drug B-drug
may O O
affect O O
digoxin B-drug B-drug
bioavailabillty O O
and O O
may O O
require O O
dose O O
adjustment O O
of O O
digoxin B-drug B-drug
by O O
16 O O
% O O
( O O
90 O O
% O O
confidence O O
interval O O
: O O
8-23 O O
% O O
) O O
, O O
decrease O O
mean O O
C O O
max O O
digoxin B-drug B-drug
by O O
26 O O
% O O
( O O
90 O O
% O O
confidence O O
interval O O
: O O
16-34 O O
% O O
) O O
and O O
decrease O O
mean O O
trough O O
concentrations O O
of O O
digoxin B-drug B-drug
by O O
9 O O
% O O
( O O
90 O O
% O O
confidence O O
limit O O
: O O
19 O O
% O O
decrease O O
to O O
2 O O
% O O
increase O O
) O O
. O O

According O O
to O O
Gibaldi O O
et O O
al O O
. O O

Concurrent O O
use O O
of O O
hydroxyurea B-drug B-drug
and O O
other O O
myelosuppressive O B-group
agents O I-group
or O O
radiation O O
therapy O O
may O O
increase O O
the O O
likelihood O O
of O O
bone O O
marrow O O
depression O O
or O O
other O O
adverse O O
events O O
. O O

Ketoconazole B-drug B-drug
: O O
Ketoconazole B-drug B-drug
may O O
inhibit O O
both O O
synthetic O O
and O O
catabolic O O
enzymes O O
of O O
vitamin B-group B-group
D I-group I-group
. O O

Due O O
to O O
the O O
frequent O O
occurrence O O
of O O
severe O O
and O O
prolonged O O
thrombocytopenia O O
, O O
the O O
potential O O
benefits O O
of O O
medications O O
which O O
interfere O O
with O O
platelet O O
function O O
and/or O O
anticoagulation O O
should O O
be O O
weighed O O
against O O
the O O
potential O O
increased O O
risks O O
of O O
bleeding O O
and O O
hemorrhage O O
. O O

Carbamazepine B-drug_n B-drug
epoxide I-drug_n I-drug
steady-state O O
Cmin O O
concentrations O O
increased O O
57 O O
% O O
from O O
1.0 O O
0.3 O O
to O O
1.6 O O
0.4 O O
micrograms/mL O O
with O O
the O O
addition O O
of O O
felbamate B-drug B-drug
. O O

LABORATORY O O
TEST O O
FINDINGS O O
Asymptomatic O O
, O O
transitory O O
changes O O
in O O
serum O O
iron O B-drug
have O O
been O O
observed O O
. O O

In O O
separate O O
single O O
or O O
multiple O O
dose O O
pharmacokinetic O O
interaction O O
studies O O
with O O
chlorthalidone B-drug B-drug
, O O
nifedipine B-drug B-drug
, O O
propanolol B-drug B-drug
, O O
hydrochlorothiazide B-drug B-drug
, O O
cimetidine B-drug B-drug
, O O
metoclopramide B-drug B-drug
, O O
propantheline B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
and O O
warfarin B-drug B-drug
, O O
the O O
bioavailability O O
of O O
fosinoprilat B-drug_n B-drug
was O O
not O O
altered O O
by O O
coadministration O O
of O O
fosinopril B-drug B-drug
with O O
any O O
one O O
of O O
these O O
drugs O O
. O O

Caution O O
, O O
however O O
, O O
is O O
advised O O
in O O
patients O O
taking O O
tricyclic B-group B-group
antidepressants I-group I-group
which O O
can O O
affect O O
the O O
metabolism O O
and O O
uptake O O
of O O
circulating O O
amines O O
. O O

Caution O O
should O O
be O O
exercised O O
if O O
tacrolimus B-drug B-drug
and O O
bosentan B-drug B-drug
are O O
used O O
together O O
. O O

Patients O O
taking O O
isoniazid B-drug B-drug
when O O
disulfiram B-drug B-drug
is O O
given O O
should O O
be O O
observed O O
for O O
the O O
appearance O O
of O O
unsteady O O
gait O O
or O O
marked O O
changes O O
in O O
mental O O
status O O
; O O

ADL-8-2698 B-drug B-drug_n
is O O
a O O
novel O O
peripherally B-group O
restricted I-group O
opioid I-group B-group
antagonist I-group I-group
that O O
may O O
selectively O O
prevent O O
opioid-induced B-group B-group
gastrointestinal O O
effects O O
without O O
reversing O O
analgesia O O
. O O

This O O
was O O
due O O
to O O
reductions O O
in O O
both O O
renal O O
clearance O O
( O O
from O O
105 O O
+/- O O
39 O O
to O O
84 O O
+/- O O
15 O O
ml/min O O
) O O
( O O
p O O
less O O
than O O
0.05 O O
) O O
and O O
nonrenal O O
clearance O O
( O O
from O O
130 O O
+/- O O
38 O O
to O O
88 O O
+/- O O
20 O O
ml/min O O
) O O
( O O
p O O
less O O
than O O
0.01 O O
) O O
. O O

Use O O
with O O
caution O O
. O O

Diabetics O O
should O O
discuss O O
the O O
use O O
of O O
these O O
supplements O O
with O O
their O O
physicians O O
and O O
note O O
if O O
the O O
supplements O O
affect O O
their O O
glycemic O O
control O O
. O O

Infusion O O
of O O
arginine B-drug B-drug
alone O O
markedly O O
decreased O O
the O O
amount O O
of O O
extractable O O
pancreatic O O
insulin O O
and O O
glucagon O O
. O O

Aspirin B-brand B-brand
: O O
Vardenafil B-drug B-drug
( O O
10 O O
mg O O
and O O
20 O O
mg O O
) O O
did O O
not O O
potentiate O O
the O O
increase O O
in O O
bleeding O O
time O O
caused O O
by O O
aspirin B-brand B-brand
( O O
two O O
81 O O
mg O O
tablets O O
) O O
. O O

In O O
a O O
12-week O O
endoscopy O O
study O O
conducted O O
in O O
OA O O
patients O O
there O O
was O O
no O O
difference O O
in O O
the O O
cumulative O O
incidence O O
of O O
endoscopic O O
gastroduodenal O O
ulcers O O
in O O
patients O O
taking O O
low-dose O O
( O O
81 O O
mg O O
) O O
enteric O O
coated O O
aspirin B-brand B-brand
plus O O
VIOXX B-brand B-brand
25 O O
mg O O
daily O O
, O O
as O O
compared O O
to O O
those O O
taking O O
ibuprofen B-drug B-drug
2400 O O
mg O O
daily O O
alone O O
. O O

Patients O O
receiving O O
both O O
drugs O O
should O O
be O O
under O O
careful O O
observation O O
. O O

Cmax O O
and O O
AUC O O
values O O
are O O
3 O O
% O O
to O O
4 O O
% O O
lower O O
, O O
respectively O O
, O O
after O O
administration O O
of O O
125 O O
mg O O
Neurontin B-brand B-brand
and O O
21 O O
% O O
to O O
22 O O
% O O
lower O O
, O O
respectively O O
, O O
after O O
administration O O
of O O
500 O O
mg O O
Neurontin B-brand B-brand
. O O

The O O
concomitant O O
use O O
of O O
INDOCIN B-brand B-brand
with O O
other O O
NSAIDs B-group B-group
is O O
not O O
recommended O O
due O O
to O O
the O O
increased O O
possibility O O
of O O
gastrointestinal O O
toxicity O O
, O O
with O O
little O O
or O O
no O O
increase O O
in O O
efficacy O O
. O O

Concomitant O O
treatment O O
with O O
coumarin B-group B-group
derivatives I-group I-group
( O O
vitamin B-group B-group
K I-group I-group
antagonists I-group I-group
) O O
and O O
drugs O O
that O O
affect O O
platelet O O
function O O
may O O
also O O
increase O O
the O O
risk O O
of O O
bleeding O O
. O O

1,25-Dihydroxycholecalciferol B-drug B-drug_n
D3 I-drug I-drug_n
( O O
1,25 B-drug O
( I-drug O
OH I-drug O
) I-drug O
2D3 I-drug O
) O O
, O O
the O O
active O O
metabolite O O
of O O
vitamin B-group B-group
D I-group I-group
, O O
is O O
a O O
potent O O
inhibitor O O
of O O
breast O O
cancer O O
cell O O
growth O O
both O O
in O O
vivo O O
and O O
in O O
vitro O O
. O O

cmaxSS O O
( O O
Peak O O
plasma O O
concentration O O
) O O

Dexbrompheniramine B-drug B-drug
can O O
interact O O
with O O
alcohol B-drug B-drug
or O O
other O O
CNS B-group B-group
depressants I-group I-group
( O O
may O O
potentiate O O
the O O
CNS O O
depressant O O
effects O O
of O O
either O O
these O O
medications O O
or O O
antihistamines B-group B-group
) O O
, O O
anticholinergics B-group B-group
or O O
other O O
medications O O
with O O
anticholinergic O O
activity O O
( O O
anticholinergic O O
effects O O
may O O
be O O
potentiated O O
when O O
these O O
medications O O
are O O
used O O
concurrently O O
with O O
antihistamines B-group B-group
) O O
, O O
and O O
monoamine B-group B-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
( O O
concurrent O O
use O O
with O O
antihistamines B-group B-group
may O O
prolong O O
and O O
intensify O O
the O O
anticholinergic O O
and O O
CNS O O
depressant O O
effects O O
of O O
antihistamines B-group B-group
) O O
. O O

These O O
reactions O O
include O O
fever O O
, O O
chills O O
, O O
nausea O O
, O O
vomiting O O
, O O
pruritus O O
, O O
rash O O
, O O
diarrhea O O
, O O
hypotension O O
, O O
edema O O
, O O
and O O
oliguria O O
. O O

Increases O O
of O O
22 O O
% O O
with O O
MHD B-drug_n B-drug_n
and O O
47 O O
% O O
with O O
oxcarbazepine B-drug B-drug
were O O
observed O O
. O O

Interaction O O
of O O
the O O
constituents O O
of O O
alcoholic O B-drug
beverages O O
in O O
the O O
promotion O O
of O O
liver O O
damage O O
. O O

Resistance O O
was O O
measured O O
near O O
the O O
placental O O
margin O O
after O O
spontaneous O O
term O O
delivery O O
. O O

Elevated O O
serum O O
levels O O
of O O
cyclosporine B-drug B-drug
have O O
been O O
reported O O
with O O
concomitant O O
use O O
of O O
cyclosporine B-drug B-drug
with O O
norfloxacin B-drug B-drug
. O O

Warfarin B-drug B-drug

Geriatric O O
Use O O
Younger O O
patients O O
have O O
higher O O
virologic O O
response O O
rates O O
than O O
older O O
patients O O
. O O

Rifampin B-drug B-drug

The O O
magnitude O O
and O O
relative O O
importance O O
of O O
the O O
effects O O
noted O O
below O O
are O O
likely O O
to O O
be O O
patient O O
specific O O
and O O
may O O
vary O O
by O O
such O O
factors O O
as O O
age O O
, O O
gender O O
, O O
race O O
, O O
intercurrent O O
illnesses O O
, O O
dose O O
of O O
either O O
agent O O
, O O
additional O O
concomitant O O
medications O O
, O O
and O O
timing O O
of O O
drug O O
administration O O
. O O

Phenothiazine-related B-group O
compounds I-group O
and O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
may O O
have O O
additive O O
hypotensite O O
effects O O
due O O
to O O
the O O
inhibition O O
of O O
each O O
other O O
s O O
metabolism O O
. O O

Lethargy O O
and O O
somnolence O O
have O O
been O O
reported O O
following O O
doses O O
of O O
REVIA B-brand B-brand
and O O
thioridazine B-drug B-drug
. O O

Coadministration O O
of O O
amprenavir B-drug B-drug
and O O
methadone B-drug B-drug
as O O
compared O O
to O O
a O O
non-matched O O
historicalcontrol O O
group O O
resulted O O
in O O
a O O
30 O O
% O O
, O O
27 O O
% O O
, O O
and O O
25 O O
% O O
decrease O O
in O O
serum O O
amprenavir B-drug B-drug
AUC O O
, O O
Cmax O O
, O O
andCmin O O
, O O
respectively O O
. O O

MAO B-group B-group
inhibitors I-group I-group
prolong O O
and O O
intensify O O
the O O
anticholinergic O O
( O O
drying O O
) O O
effects O O
of O O
antihistamines B-group B-group
. O O

In O O
vitro O O
metabolism O O
studies O O
have O O
suggested O O
that O O
decitabine B-drug B-drug
is O O
not O O
a O O
substrate O O
for O O
the O O
human O O
liver O O
cytochrome O O
P450 O O
enzymes O O
. O O

For O O
the O O
identification O O
of O O
" O O
limit O O
values O O
" O O
, O O
it O O
has O O
generally O O
been O O
suggested O O
in O O
the O O
literature O O
that O O
the O O
possible O O
effects O O
deriving O O
from O O
multiple O O
exposure O O
be O O
considered O O
as O O
additive O O
. O O

Cancer O O
in O O
the O O
elderly O O
: O O
basic O O
science O O
and O O
clinical O O
aspects O O
. O O

Rare O O
cases O O
of O O
serious O O
cardiovascular O O
adverse O O
events O O
, O O
including O O
electrocardiographic O O
QT/QTc O O
interval O O
prolongation O O
, O O
cardiac O O
arrest O O
, O O
torsades O O
de O O
pointes O O
, O O
and O O
other O O
ventricular O O
arrhythmias O O
have O O
been O O
observed O O
. O O

Other O O
Agents O O
: O O
PRINIVIL B-brand B-brand
has O O
been O O
used O O
concomitantly O O
with O O
nitrates B-group B-group
and/or O O
digoxin B-drug B-drug
without O O
evidence O O
of O O
clinically O O
significant O O
adverse O O
interactions O O
. O O

Animal O O
studies O O
also O O
suggest O O
an O O
increased O O
potential O O
for O O
seizures O O
when O O
these O O
2 O O
drugs O O
are O O
given O O
concomitantly O O
. O O

It O O
is O O
important O O
that O O
patients O O
understand O O
how O O
to O O
use O O
FORADIL B-brand B-brand
( O O
formoterol B-drug B-drug
fumarate I-drug I-drug
) O O
capsules O O
with O O
the O O
supplied O O
AerolizerTM O O
inhalation O O
device O O
and O O
how O O
it O O
should O O
be O O
used O O
in O O
relation O O
to O O
other O O
asthma O O
or O O
COPD O O
medications O O
they O O
are O O
taking O O
. O O

Coadministration O O
of O O
alosetron B-drug B-drug
and O O
strong O O
CYP3A4 O O
inhibitors O O
, O O
such O O
as O O
clarithromycin B-drug B-drug
, O O
telithromycin B-drug B-drug
, O O
protease B-group B-group
inhibitors I-group I-group
, O O
voriconazole B-drug B-drug
, O O
and O O
itraconazole B-drug B-drug
has O O
not O O
been O O
evaluated O O
but O O
should O O
be O O
undertaken O O
with O O
caution O O
because O O
of O O
similar O O
potential O O
drug O O
interactions O O
. O O

In O O
vitro O O
studies O O
suggest O O
that O O
coadministration O O
of O O
cytochrome O O
P450 O O
inhibitors O O
to O O
PMs O O
will O O
not O O
increase O O
the O O
plasma O O
concentrations O O
of O O
atomoxetine B-drug B-drug
. O O

Effect O O
of O O
dofetillide B-drug B-drug
on O O
the O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
. O O

. O O

miconazole B-drug B-drug
; O O

An O O
individual O O
who O O
is O O
stable O O
on O O
a O O
given O O
dose O O
of O O
TCA B-group B-group
may O O
become O O
abruptly O O
toxic O O
when O O
given O O
one O O
of O O
these O O
inhibiting O O
drugs O O
as O O
concomitant O O
therapy O O
. O O

Caution O O
should O O
be O O
exercised O O
when O O
anticoagulants B-group B-group
are O O
given O O
in O O
conjunction O O
with O O
Atromid-S B-brand B-brand
. O O

Because O O
tetracyclines B-group B-group
have O O
been O O
shown O O
to O O
depress O O
plasma O O
prothrombin O O
activity O O
, O O
patients O O
who O O
are O O
on O O
anticoagulant B-group B-group
therapy O O
may O O
require O O
downward O O
adjustment O O
of O O
their O O
anticoagulant B-group B-group
dosage O O
. O O

Caspofungin B-drug B-drug
is O O
not O O
a O O
substrate O O
for O O
P-glycoprotein O O
and O O
is O O
a O O
poor O O
substrate O O
for O O
cytochrome O O
P450 O O
enzymes O O
. O O

When O O
such O O
drugs O O
are O O
administered O O
to O O
a O O
patient O O
receiving O O
Acarbose B-drug B-drug
, O O
the O O
patient O O
should O O
be O O
closely O O
observed O O
for O O
loss O O
of O O
blood O O
glucose O O
control O O
. O O

Antacids B-group B-group
containing O O
aluminum B-drug B-drug
hydroxide I-drug I-drug
and O O
magnesium B-drug B-drug
hydroxide I-drug I-drug
reduce O O
the O O
oral O O
absorption O O
of O O
enoxacin B-drug B-drug
by O O
75 O O
% O O
. O O

Green B-drug O
tea I-drug O
polyphenols I-drug B-group
as O O
potent O O
enhancers B-drug O
of O O
glucocorticoid-induced O O
mouse O O
mammary O O
tumor O O
virus O O
gene O O
expression O O
. O O

1- O O
nc O O
denotes O O
a O O
mean O O
change O O
of O O
less O O
than O O
10 O O
% O O
2- O O
Pediatrics O O
3- O O
Mean O O
increase O O
in O O
adults O O
at O O
high O O
Trileptal B-brand B-brand
doses O O
In O O
vivo O O
, O O
the O O
plasma O O
levels O O
of O O
phenytoin B-drug B-drug
increased O O
by O O
up O O
to O O
40 O O
% O O
, O O
when O O
Trileptal B-brand B-brand
was O O
given O O
at O O
doses O O
above O O
1200 O O
mg/day O O
. O O

- O O
Androgens B-group B-group
( O O
male O O
hormones O O
) O O
or O O

Cimetidine B-drug B-drug
( O O
400 O O
mg O O
b.i.d O O
. O O
) O O
had O O
no O O
effect O O
on O O
vardenafil B-drug B-drug
bioavailability O O
( O O
AUC O O
) O O
and O O
maximum O O
concentration O O
( O O
Cmax O O
) O O
of O O
vardenafil B-drug B-drug
when O O
co-administered O O
with O O
20 O O
mg O O
Vardenafil B-drug B-drug
in O O
healthy O O
volunteers O O
. O O

Furosemide B-drug B-drug
: O O
In O O
normal O O
volunteers O O
, O O
the O O
concomitant O O
administration O O
of O O
diflunisal B-drug B-drug
and O O
furosemide B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
diuretic O O
activity O O
of O O
furosemide B-drug B-drug
. O O

While O O
the O O
effects O O
of O O
chronic O O
phenytoin B-drug B-drug
or O O
carbamazepine B-drug B-drug
therapy O O
on O O
the O O
action O O
of O O
NIMBEX B-brand B-brand
are O O
unknown O O
, O O
slightly O O
shorter O O
durations O O
of O O
neuromuscular O O
block O O
may O O
be O O
anticipated O O
and O O
infusion O O
rate O O
requirements O O
may O O
be O O
higher O O
. O O

Animal O O
toxicology O O
studies O O
showed O O
increased O O
DEET B-drug O
toxicity O O
when O O
DEET B-drug O
was O O
included O O
as O O
proof O O
of O O
the O O
formulation O O
. O O

Itraconazole B-drug B-drug
Ketoconazole I-drug B-drug
Erythromycin I-drug I-drug
Clarithromycin I-drug B-drug
Telithromycin I-drug I-drug
HIV B-group B-group
protease I-group I-group
inhibitors I-group I-group
Nefazodone B-drug B-drug
Cyclosporine I-drug I-drug
Large O O
quantities O O
of O O
grapefruit O O
juice O O
( O O
1 O O
quart O O
daily O O
) O O

The O O
fluoroquinolones B-group B-group
for O O
urinary O O
tract O O
infections O O
: O O
a O O
review O O
. O O

A O O
clinical O O
study O O
in O O
healthy O O
male O O
volunteers O O
( O O
n=24 O O
) O O
demonstrated O O
that O O
mixing O O
NovoLog B-brand B-brand
with O O
NPH B-drug O
human I-drug O
insulin I-drug B-drug
immediately O O
before O O
injection O O
produced O O
some O O
attenuation O O
in O O
the O O
peak O O
concentration O O
of O O
NovoLog B-brand B-brand
, O O
but O O
that O O
the O O
time O O
to O O
peak O O
and O O
the O O
total O O
bioavailability O O
of O O
NovoLog B-brand B-brand
were O O
not O O
significantly O O
affected O O
. O O

Therefore O O
, O O
when O O
INDOCIN B-brand B-brand
and O O
digoxin B-drug B-drug
are O O
used O O
concomitantly O O
, O O
serum O O
digoxin B-drug B-drug
levels O O
should O O
be O O
closely O O
monitored O O
. O O

Hyperglycaemia O O
increased O O
all O O
the O O
renal O O
and O O
ocular O O
parameters O O
studied O O
. O O

Increase O O
daily O O
dose O O
of O O
rifabutin B-drug B-drug
by O O
50 O O
% O O
. O O

After O O
30 O O
min O O
, O O
fasting O O
glycemia O O
was O O
measured O O
. O O

Co-administration O O
of O O
celecoxib B-drug B-drug
with O O
drugs O O
that O O
are O O
known O O
to O O
inhibit O O
2C9 O O
should O O
be O O
done O O
with O O
caution O O
. O O

Potassium B-drug O
Supplements O O
and O O
Potassium-Sparing B-group B-group
Diuretics I-group I-group
Lotensin O B-brand
can O O
attenuate O O
potassium O O
loss O O
caused O O
by O O
thiazide B-group B-group
diuretics I-group I-group
. O O

In O O
case O O
of O O
theophylline B-drug B-drug
toxicity O O
and/or O O
elevated O O
serum O O
theophylline B-drug B-drug
levels O O
, O O
the O O
dose O O
of O O
theophylline B-drug B-drug
should O O
be O O
reduced O O
while O O
the O O
patient O O
is O O
receiving O O
concomitant O O
erythromycin B-drug B-drug
therapy O O
. O O

Phenytoin B-drug B-drug
: O O
In O O
post-marketing O O
experience O O
, O O
there O O
have O O
been O O
reports O O
of O O
both O O
increases O O
and O O
decreases O O
in O O
phenytoin B-drug B-drug
levels O O
with O O
dexamethasone B-drug B-drug
co-administration O O
, O O
leading O O
to O O
alterations O O
in O O
seizure O O
control O O
. O O

In O O
vitro O O
binding O O
studies O O
with O O
human O O
serum O O
proteins O O
indicate O O
that O O
glipizide B-drug B-drug
binds O O
differently O O
than O O
tolbutamide B-drug B-drug
and O O
does O O
not O O
interact O O
with O O
salicylate B-group B-group
or O O
dicumarol B-drug B-drug
. O O

It O O
is O O
not O O
known O O
if O O
hormonal B-group B-group
contraceptives I-group I-group
differ O O
in O O
their O O
effectiveness O O
when O O
used O O
with O O
Accutane B-brand B-brand
. O O

Administration O O
of O O
dantrolene B-drug B-drug
may O O
potentiate O O
vecuronium-induced B-drug B-drug
neuromuscular O O
block O O
. O O

This O O
decrease O O
in O O
bioavailability O O
was O O
about O O
5 O O
% O O
when O O
gabapentin B-drug B-drug
was O O
administered O O
2 O O
hours O O
after O O
Maalox B-brand B-brand
. O O

Folic B-drug B-drug
acid I-drug I-drug
supplements O O
can O O
correct O O
the O O
anemia O O
associated O O
with O O
vitamin O B-drug
B12 O O
deficiency O O
. O O

Taking O O
amyl B-drug B-drug
nitrite I-drug I-drug
after O O
drinking O O
alcohol B-drug B-drug
may O O
worsen O O
side O O
effects O O
and O O
may O O
cause O O
severe O O
hypotension O O
and O O
cardiovascular O O
collapse O O
. O O

Indomethacin B-drug B-drug
was O O
also O O
ineffective O O
in O O
altering O O
resveratrol B-drug_n O
activity O O
in O O
arteries O O
from O O
both O O
lean O O
and O O
dietary-obese O O
rats O O
. O O

INDOCIN B-brand B-brand
given O O
concomitantly O O
with O O
digoxin B-drug B-drug
has O O
been O O
reported O O
to O O
increase O O
the O O
serum O O
concentration O O
and O O
prolong O O
the O O
half-life O O
of O O
digoxin B-drug B-drug
. O O

Considerable O O
caution O O
should O O
be O O
exercised O O
if O O
PEGANONE B-brand B-brand
is O O
administered O O
concurrently O O
with O O
Phenurone B-brand B-brand
( O O
phenacemide B-drug B-drug
) O O
since O O
paranoid O O
symptoms O O
have O O
been O O
reported O O
during O O
therapy O O
with O O
this O O
combination O O
. O O

Paroxetine B-drug B-drug
produced O O
only O O
minor O O
changes O O
in O O
the O O
levels O O
of O O
clozapine B-drug B-drug
and O O
its O O
metabolites O O
. O O

Formulation O O
of O O
fluorescence O O
labelled O O
bacitracin B-drug B-drug
and O O
insulin B-drug B-drug
in O O
unconjugated O O
NaCMC B-drug_n B-drug_n
( O O
1 O O
% O O
m/v O O
) O O
did O O
not O O
significantly O O
improve O O
the O O
permeation O O
, O O
however O O
in O O
the O O
presence O O
of O O
1 O O
% O O
( O O
m/v O O
) O O
CMC-Cys7.3 B-drug_n O
a O O
significantly O O
improved O O
permeation O O
was O O
observed O O
( O O
R= O O
1.3 O O
) O O
. O O

Interaction O O
of O O
ketamine B-drug B-drug
and O O
halothane B-drug B-drug
in O O
rats O O
. O O

Thus O O
, O O
if O O
a O O
patient O O
has O O
been O O
titrated O O
to O O
a O O
stable O O
dosage O O
on O O
one O O
of O O
the O O
agents O O
in O O
this O O
category O O
, O O
and O O
then O O
begins O O
a O O
course O O
of O O
treatment O O
with O O
EQUETROTM B-brand B-brand
, O O
it O O
is O O
reasonable O O
to O O
expect O O
that O O
a O O
dose O O
increase O O
for O O
the O O
concomitant O O
agent O O
may O O
be O O
necessary O O
. O O

PEGASYS B-brand B-brand
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
with O O
creatinine O O
clearance O O
50 O O
mL/min O O
and O O
COPEGUS B-brand B-brand
should O O
not O O
be O O
administered O O
to O O
patients O O
with O O
creatinine O O
clearance O O
50 O O
mL/min O O

Other O O
binding O O
proteins O O
may O O
be O O
elevated O O
in O O
serum O O
, O O
( O O
i.e. O O
, O O
corticosteroid O O
binding O O
globulin O O
( O O
CBG O O
) O O
, O O
sex O O
hormone O O
binding O O
globulin O O
( O O
SHBG O O
) O O
) O O
leading O O
to O O
increased O O
total O O
circulating O O
corticosteroids B-group B-group
and O O
sex B-group B-group
steroids I-group I-group
, O O
respectively O O
. O O

Decreases O O
in O O
TBg O O
concentrations O O
are O O
observed O O
in O O
nephrosis O O
, O O
acromegaly O O
and O O
after O O
androgen B-group O
or O O
corticosteroid B-group B-group
therapy O O
. O O

Concomitant O O
administration O O
of O O
clarithromycin B-drug B-drug
with O O
pimozide B-drug B-drug
is O O
contraindicated O O
. O O

In O O
comparison O O
with O O
haloperidol B-drug B-drug
, O O
the O O
adverse O O
events O O
reported O O
significantly O O
more O O
frequently O O
with O O
olanzapine B-drug B-drug
in O O
> O O
or O O
= O O
3.5 O O
% O O
of O O
patients O O
were O O
dry O O
mouth O O
, O O
bodyweight O O
gain O O
and O O
increased O O
appetite O O
and O O
compared O O
with O O
risperidone B-drug B-drug
, O O
only O O
bodyweight O O
gain O O
occurred O O
significantly O O
more O O
frequently O O
with O O
olanzapine B-drug B-drug
. O O

These O O
medications O O
have O O
included O O
heparin B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
beta-adrenergic B-group B-group
receptor I-group I-group
blockers I-group I-group
, O O
calcium B-group B-group
channel I-group I-group
antagonists I-group I-group
, O O
angiotensin B-group B-group
converting I-group I-group
enzyme I-group I-group
inhibitors I-group I-group
, O O
intravenous O O
and O O
oral O O
nitrates B-group B-group
, O O
ticlopidine B-drug B-drug
, O O
and O O
aspirin B-brand B-brand
. O O

Pretreatment O O
of O O
rats O O
with O O
allopurinol B-drug B-drug
( O O
100 O O
mg/kg O O
, O O
ip O O
) O O
or O O
Vitamin B-drug B-drug
E I-drug I-drug
( O O
100 O O
mg/kg O O
per O O
day O O
, O O
ig O O
, O O
for O O
3 O O
days O O
and O O
a O O
dose O O
of O O
40 O O
mg/kg O O
on O O
the O O
4th O O
day O O
) O O
provided O O
significant O O
protection O O
against O O
the O O
elevation O O
of O O
TBARS O B-brand
levels O O
in O O
cerebral O O
and O O
hepatic O O
tissues O O
, O O
induced O O
by O O
single O O
high O O
dose O O
of O O
oral O O
cypermethrin B-drug B-drug
administration O O
within O O
4 O O
h O O
. O O

These O O
would O O
include O O
a O O
variety O O
of O O
preparations O O
which O O
contain O O
androgens B-group B-group
, O O
estrogens B-group B-group
, O O
progestins B-group B-group
, O O
or O O
glucocorticoids B-group B-group
. O O

Theophylline B-drug B-drug
: O O
Theophylline B-drug B-drug
clearance O O
may O O
decrease O O
in O O
hypothyroid O O
patients O O
and O O
return O O
toward O O
normal O O
when O O
a O O
euthyroid O O
state O O
is O O
achieved O O
. O O

These O O
data O O
suggest O O
that O O
rofecoxib B-drug B-drug
may O O
produce O O
a O O
modest O O
inhibition O O
of O O
cytochrome O O
P450 O O
( O O
CYP O O
) O O
1A2 O O
. O O

Because O O
many O O
drugs O O
are O O
excreted O O
in O O
human O O
milk O O
, O O
and O O
because O O
of O O
the O O
potential O O
for O O
serious O O
adverse O O
reactions O O
from O O
FASLODEX B-brand B-brand
in O O
nursing O O
infants O O
, O O
a O O
decision O O
should O O
be O O
made O O
whether O O
to O O
discontinue O O
nursing O O
or O O
to O O
discontinue O O
the O O
drug O O
taking O O
into O O
account O O
the O O
importance O O
of O O
the O O
drug O O
to O O
the O O
mother O O
. O O

A O O
return O O
to O O
normal O O
menstrual O O
rhythm O O
followed O O
cessation O O
of O O
treatment O O
. O O

The O O
higher O O
verografine B-drug B-drug
and O O
iodamide B-drug B-drug
excretion O O
was O O
due O O
to O O
their O O
increased O O
renal O O
tubular O O
secretion O O
. O O

Opioids B-group B-group
are O O
strong O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
, O O
but O O
regular O O
users O O
develop O O
physiological O O
tolerance O O
allowing O O
gradually O O
increased O O
dosages O O
. O O

Calcium B-group B-group
Channel I-group I-group
Blockers I-group I-group
, O O
Dihydropyridine B-group B-drug
: O O
e.g. O O
, O O
felodipine B-drug B-drug
, O O
nifedipine B-drug B-drug
, O O
nicardipine B-drug B-drug

Additionally O O
, O O
paroxetine B-drug B-drug
did O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
Sonata B-brand B-brand
, O O
reflecting O O
the O O
absence O O
of O O
a O O
role O O
of O O
CYP2D6 O O
in O O
zaleplon B-drug B-drug
s O O
metabolism O O
. O O

Therefore O O
, O O
monitoring O O
of O O
plasma O O
digoxin B-drug B-drug
levels O O
may O O
be O O
indicated O O
in O O
patients O O
receiving O O
similar O O
combination O O
chemotherapy O O
regimens O O
. O O

Concomitant O O
use O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
with O O
drugs O O
that O O
can O O
inhibit O O
cytochrome O O
P450 O O
2D6 O O
may O O
require O O
lower O O
doses O O
than O O
usually O O
prescribed O O
for O O
either O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
or O O
the O O
other O O
drug O O
. O O

Dolasetron B-drug B-drug
has O O
been O O
safely O O
coadministered O O
with O O
drugs O O
used O O
in O O
chemotherapy O O
and O O
surgery O O
. O O

Phenobarbital B-drug B-drug
: O O
Coadministration O O
of O O
felbamate B-drug B-drug
with O O
phenobarbital B-drug B-drug
causes O O
an O O
increase O O
in O O
phenobarbital B-drug B-drug
plasma O O
concentrations O O
, O O
In O O
12 O O
otherwise O O
healthy O O
male O O
volunteers O O
ingesting O O
phenobarbital B-drug B-drug
, O O
the O O
steady-state O O
trough O O
( O O
Cmin O O
) O O
phenobarbital B-drug B-drug
concentration O O
was O O
14.2 O O
micrograms/mL O O
. O O

Antihypertensives B-group B-group
: O O
Amphetamines B-group B-group
may O O
antagonize O O
the O O
hypotensive O O
effects O O
of O O
antihypertensives B-drug B-group
. O O

In O O
these O O
subjects O O
, O O
celecoxib B-drug B-drug
did O O
not O O
alter O O
the O O
anticoagulant O O
effect O O
of O O
warfarin B-drug B-drug
as O O
determined O O
by O O
prothrombin O O
time O O
. O O

Repeating O O
the O O
study O O
with O O
6 O O
healthy O O
male O O
volunteers O O
in O O
the O O
absence O O
of O O
glibenclamide B-drug B-drug
did O O
not O O
detect O O
an O O
effect O O
of O O
acitretin B-drug B-drug
on O O
glucose O O
tolerance O O
. O O

Two O O
weeks O O
after O O
bilateral O O
ovariectomy O O
, O O
female O O
rats O O
received O O
a O O
s.c O O
. O O

( O O
Effectiveness O O
may O O
be O O
decreased O O
when O O
used O O
concurrently O O
with O O
thiazide B-group B-group
diuretics I-group I-group
because O O
of O O
alkalinization O O
of O O
the O O
urine O O
. O O
) O O

Although O O
not O O
studied O O
with O O
alosetron B-drug B-drug
, O O
inhibition O O
of O O
N-acetyltransferase O O
may O O
have O O
clinically O O
relevant O O
consequences O O
for O O
drugs O O
such O O
as O O
isoniazid B-drug B-drug
, O O
procainamide B-drug B-drug
, O O
and O O
hydralazine B-drug B-drug
. O O

However O O
, O O
if O O
Argatroban B-drug B-drug
is O O
to O O
be O O
initiated O O
after O O
cessation O O
of O O
heparin B-drug B-drug
therapy O O
, O O
allow O O
sufficient O O
time O O
for O O
heparins O O
effect O O
on O O
the O O
aPTT O O
to O O
decrease O O
prior O O
to O O
initiation O O
of O O
Argatroban B-drug B-drug
therapy O O
. O O

- O O
Antidiabetics B-group B-group
, O O
oral O O
( O O
diabetes O O
medicine O O
you O O
take O O
by O O
mouth O O
) O O
Use O O
of O O
oral O O
antidiabetics B-group B-group
with O O
sulfapyridine B-drug B-drug
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
affecting O O
the O O
blood O O
and/or O O
the O O
side O O
effects O O
or O O
oral O O
antidiabetics B-group B-group

Data O O
suggest O O
that O O
coadministration O O
of O O
oral O O
ketoconazole B-drug B-drug
and O O
cisapride B-drug B-drug
can O O
result O O
in O O
prolongation O O
of O O
the O O
QT O O
interval O O
on O O
the O O
ECG O O
. O O

If O O
you O O
are O O
taking O O
a O O
tricyclic B-group B-group
antidepressant I-group I-group
, O O
talk O O
to O O
your O O
doctor O O
before O O
taking O O
this O O
medicine O O
. O O

Carbamazepine B-drug B-drug
: O O
Isoniazid B-drug B-drug
is O O
known O O
to O O
slow O O
the O O
metabolism O O
of O O
carbamazepine B-drug B-drug
and O O
increase O O
its O O
serum O O
levels O O
Carbamazepine B-drug B-drug
levels O O
should O O
be O O
determined O O
prior O O
to O O
concurrent O O
administration O O
with O O
isoniazid B-drug B-drug
, O O
signs O O
and O O
symptoms O O
of O O
carbamazepine B-drug B-drug
toxicity O O
should O O
be O O
monitored O O
closely O O
, O O
and O O
appropriate O O
dosage O O
adjustment O O
of O O
the O O
anticonvulsant B-group B-group
should O O
be O O
made O O
. O O

Furosemide B-drug B-drug
: O O
Clinical O O
studies O O
, O O
as O O
well O O
as O O
post O O
marketing O O
observations O O
, O O
have O O
shown O O
that O O
NSAIDs B-group B-group
can O O
reduce O O
the O O
natriuretic O O
effect O O
of O O
furosemide B-drug B-drug
and O O
thiazides B-group B-group
in O O
some O O
patients O O
. O O

Butyrophenones B-group B-group
( O O
such O O
as O O
haloperidol B-drug B-drug
) O O
and O O
phenothiazines B-group B-group
can O O
suppress O O
the O O
dopaminergic B-drug O
renal O O
and O O
mesenteric O O
vasodilation O O
induced O O
with O O
low O O
dose O O
dopamine O O
infusion O O
. O O

Erythromycin I-drug B-drug
( O O
500 O O
mg O O
q8h O O
) O O
+ O O
40 O O
% O O
+46 O O
% O O

Also O O
, O O
due O O
to O O
the O O
potential O O
for O O
additive O O
effects O O
such O O
as O O
bradycardia O O
and O O
AV O O
block O O
, O O
caution O O
is O O
warranted O O
in O O
patients O O
receiving O O
clonidine B-drug B-drug
with O O
agents O O
known O O
to O O
affect O O
sinus O O
node O O
function O O
or O O
AV O O
nodal O O
conduction O O
( O O
e.g. O O
, O O
digitalis B-group B-group
, O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
, O O
and O O
beta-blockers B-group B-group
. O O
) O O

The O O
size O O
of O O
wheal O O
and O O
flare O O
were O O
significantly O O
larger O O
when O O
fexofenadine B-drug B-drug
hydrochloride I-drug I-drug
was O O
administered O O
with O O
either O O
grapefruit O O
or O O
orange O O
juices O O
compared O O
to O O
water O O
. O O

Effects O O
of O O
Lapatinib B-drug B-drug
on O O
Drug O O
Metabolizing O O
Enzymes O O
and O O
Drug O O
Transport O O
Systems O O
Lapatinib B-drug B-drug
inhibits O O
CYP3A4 O O
and O O
CYP2C8 O O
in O O
vitro O O
at O O
clinically O O
relevant O O
concentrations O O
. O O

Certain O O
drugs O O
tend O O
to O O
produce O O
hyperglycemia O O
and O O
may O O
lead O O
to O O
loss O O
of O O
control O O
. O O

Administration O O
of O O
epinephrine B-drug B-drug
to O O
patients O O
receiving O O
cyclopropane B-drug B-drug
or O O
halogenated B-group B-group
hydrocarbon I-group I-group
general I-group O
anesthetics I-group B-group
such O O
as O O
halothane B-drug B-drug
which O O
sensitize O O
the O O
myocardium O O
, O O
may O O
induce O O
cardiac O O
arrhythmia.. O O

AZOPT B-brand B-brand
( O O
brinzolamide B-drug B-drug
ophthalmic O O
suspension O O
) O O
1 O O
% O O
contains O O
a O O
carbonic B-group B-group
anhydrase I-group I-group
inhibitor I-group I-group
. O O

All O O
20 O O
strains O O
of O O
enterococcus O O
, O O
three O O
strains O O
of O O
Clostridium O B-drug_n
, O O
three O O
strains O O
of O O
Escherichia O O
coli O O
, O O
and O O
one O O
strain O O
of O O
Proteus O O
rettgeri O O
were O O
resistant O O
to O O
both O O
clindamycin B-drug B-drug
( O O
minimal O O
inhibitory O O
concentration O O
greater O O
than O O
3.1 O O
mug/ml O O
) O O
and O O
gentamicin B-drug B-drug
( O O
minimal O O
inhibitory O O
concentration O O
greater O O
than O O
6.2 O O
mug/ml O O
) O O
. O O

In O O
combination O O
with O O
other O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
, O O
heroin B-drug_n B-drug
may O O
still O O
kill O O
even O O
experienced O O
users O O
, O O
particularly O O
if O O
their O O
tolerance O O
to O O
the O O
drug O O
has O O
reduced O O
or O O
the O O
strength O O
of O O
their O O
usual O O
dose O O
has O O
increased O O
. O O

Caution O O
is O O
advised O O
when O O
TRISENOX B-brand B-brand
is O O
coadministered O O
with O O
other O O
medications O O
that O O
can O O
prolong O O
the O O
QT O O
interval O O
( O O
e.g O O
. O O
certain O O
antiarrhythmics B-group B-group
or O O
thioridazine B-drug B-drug
) O O
or O O
lead O O
to O O
electrolyte O O
abnormalities O O
( O O
such O O
as O O
diuretics B-group B-group
or O O
amphotericin B-drug B-drug
B I-drug I-drug
) O O
. O O

Available O O
data O O
indicate O O
that O O
platelet O O
function O O
and O O
arachidonic O O
acid O O
metabolism O O
are O O
important O O
factors O O
in O O
hemostasis O O
and O O
regulation O O
of O O
vascular O O
tone O O
. O O

All O O
patients O O
in O O
whom O O
this O O
effect O O
was O O
observed O O
remained O O
asymptomatic O O
. O O

Combination O O
of O O
amiodarone B-drug B-drug
with O O
other O O
antiarrhythmic B-drug B-drug
therapy O O
should O O
be O O
reserved O O
for O O
patients O O
with O O
life-threatening O O
ventricular O O
arrhythmias O O
who O O
are O O
incompletely O O
responsive O O
to O O
a O O
single O O
agent O O
or O O
incompletely O O
responsive O O
to O O
amiodarone B-drug B-drug
. O O

RESULTS O O
: O O
During O O
treatment O O
with O O
fluvoxamine B-drug B-drug
, O O
there O O
was O O
a O O
statistically O O
significant O O
decrease O O
in O O
the O O
median O O
of O O
the O O
total O O
clearance O O
of O O
tolbutamide B-drug B-drug
, O O
from O O
845 O O
mL/h O O
to O O
688 O O
mL/h O O
, O O
among O O
the O O
volunteers O O
who O O
received O O
75 O O
mg/d O O
. O O

Disopyramide B-drug B-drug
increases O O
QT O O
prolongation O O
which O O
could O O
cause O O
arrhythmia O O
. O O

When O O
combined O O
with O O
ofloxacin B-drug B-drug
, O O
KRM-1648 B-drug_n B-drug_n
exhibited O O
strong O O
synergistic O O
activity O O
while O O
only O O
additive O O
effects O O
were O O
observed O O
with O O
the O O
combination O O
of O O
rifampicin B-drug B-drug
( O O
or O O
rifabutin B-drug B-drug
) O O
and O O
ofloxacin B-drug B-drug
. O O

Clarithromycin B-drug B-drug
exposure O O
was O O
significantly O O
decreased O O
by O O
nevirapine B-drug B-drug
; O O

Pregnancies O O
have O O
been O O
reported O O
by O O
users O O
of O O
combined B-group O
hormonal I-group B-group
contraceptives I-group I-group
who O O
also O O
used O O
some O O
form O O
of O O
St. O O
Johns O O
Wort O O
. O O

Patients O O
currently O O
receiving O O
diltiazem B-drug B-drug
therapy O O
should O O
be O O
carefully O O
monitored O O
for O O
a O O
change O O
in O O
pharmacological O O
effect O O
when O O
initiating O O
and O O
discontinuing O O
therapy O O
with O O
cimetidine B-drug B-drug
. O O

Anticoagulants B-group B-group
, O O
oral O O
: O O
Co-administration O O
of O O
corticosteroids B-group B-group
and O O
warfarin B-drug B-drug
usually O O
results O O
in O O
inhibition O O
of O O
response O O
to O O
warfarin B-drug B-drug
, O O
although O O
there O O
have O O
been O O
some O O
conflicting O O
reports O O
. O O

- O O
a O O
phenothiazine B-group B-group
such O O
as O O
chlorpromazine B-drug B-drug
( O O
Thorazine B-brand B-brand
) O O
, O O
fluphenazine B-drug B-drug
( O O
Prolixin B-brand B-brand
, O O
Permitil B-brand B-brand
) O O
, O O
prochlorperazine B-drug B-drug
( O O
Compazine B-brand B-brand
) O O
, O O
promethazine B-drug B-drug
( O O
Phenergan B-brand B-brand
) O O
, O O
and O O
others O O
; O O

Rifampin B-drug B-drug
: O O
Following O O
concomitant O O
administration O O
of O O
a O O
single O O
dose O O
of O O
ARAVA B-brand B-brand
to O O
subjects O O
receiving O O
multiple O O
doses O O
of O O
rifampin B-drug B-drug
, O O
M1 O O
peak O O
levels O O
were O O
increased O O
( O O
~40 O O
% O O
) O O
over O O
those O O
seen O O
when O O
ARAVA B-brand B-brand
was O O
given O O
alone O O
. O O

sulfonamides B-group B-group
, O O
long O O
acting O O
; O O

In O O
both O O
plasma O O
and O O
KHT O O
tumour O O
the O O
peak O O
concentration O O
and O O
" O O
early O O
" O O

The O O
monoamine O O
oxidase O O
inhibitory O O
effects O O
of O O
Isocarboxazid B-drug B-drug
may O O
persist O O
for O O
a O O
substantial O O
period O O
after O O
discontinuation O O
of O O
the O O
drug O O
, O O
and O O
this O O
should O O
be O O
borne O O
in O O
mind O O
when O O
another O O
drug O O
is O O
prescribed O O
following O O
Isocarboxazid B-drug B-drug
. O O

When O O
cholestyramine B-drug B-drug
resin B-group B-group
is O O
given O O
for O O
long O O
periods O O
of O O
time O O
, O O
concomitant O O
supplementation O O
with O O
water-miscible O O
( O O
or O O
parenteral O O
) O O
forms O O
of O O
fat-soluble B-group B-group
vitamins I-group I-group
should O O
be O O
considered O O
. O O

Drugs O O
That O O
Induce O O
CYP3A4 O O
( O O
Rifampicin B-drug B-drug
) O O
Racemic O O
zopiclone B-drug B-drug
exposure O O
was O O
decreased O O
80 O O
% O O
by O O
concomitant O O
useof O O
rifampicin B-drug B-drug
, O O
a O O
potent O O
inducer O O
of O O
CYP3A4 O O
. O O

Prothrombin O O
time O O
was O O
not O O
affected O O
. O O

400-2000 O O

The O O
concomitant O O
administration O O
of O O
rifampin B-drug B-drug
and O O
warfarin B-drug B-drug
resulted O O
in O O
the O O
need O O
for O O
an O O
unusually O O
high O O
maintenance O O
dose O O
of O O
warfarin B-drug B-drug
( O O
20 O O
mg O O
per O O
day O O
) O O
in O O
order O O
to O O
produce O O
a O O
therapeutic O O
effect O O
. O O

Cyclosporin B-drug B-drug
: O O
After O O
introduction O O
of O O
chloroquine B-drug B-drug
( O O
oral O O
form O O
) O O
, O O
a O O
sudden O O
increase O O
in O O
serum O O
cyclosporin B-drug B-drug
level O O
has O O
been O O
reported O O
. O O

Although O O
a O O
dose O O
adjustment O O
of O O
azithromycin B-drug B-drug
is O O
not O O
recommended O O
when O O
administered O O
in O O
combination O O
with O O
nelfinavir B-drug B-drug
, O O
close O O
monitoring O O
for O O
known O O
side O O
effects O O
of O O
azithromycin B-drug B-drug
, O O
such O O
as O O
liver O O
enzyme O O
abnormalities O O
and O O
hearing O O
impairment O O
, O O
is O O
warranted O O
. O O

Special O O
consideration O O
should O O
be O O
given O O
to O O
the O O
administration O O
of O O
ETHYOL B-brand B-brand
in O O
patients O O
receiving O O
antihypertensive B-group B-group
medications I-group I-group
or O O
other O O
drugs O O
that O O
could O O
cause O O
or O O
potentiate O O
hypotension O O
. O O

Synergism O O
between O O
xanthine B-group B-group
bronchodilators I-group I-group
( O O
e.g. O O
, O O
theophylline B-drug B-drug
) O O
, O O
ephedrine B-drug B-drug
, O O
and O O
other O O
sympathomimetic B-group B-group
bronchodilators I-group I-group
has O O
been O O
reported O O
. O O

Promethazine B-drug B-drug
: O O
Coadministration O O
of O O
a O O
single O O
dose O O
of O O
zaleplon B-drug B-drug
and O O
promethazine B-drug B-drug
( O O
10 O O
and O O
25 O O
mg O O
, O O
respectively O O
) O O
resulted O O
in O O
a O O
15 O O
% O O
decrease O O
in O O
maximal O O
plasma O O
concentrations O O
of O O
zaleplon B-drug B-drug
, O O
but O O
no O O
change O O
in O O
the O O
area O O
under O O
the O O
plasma O O
concentration-time O O
curve O O
. O O

Although O O
no O O
specific O O
drug O O
interactions O O
with O O
topical O O
glaucoma O O
drugs O O
or O O
systemic O O
medications O O
were O O
identified O O
in O O
clinical O O
studies O O
of O O
IOPIDINE B-brand B-brand
0.5 O O
% O O
Ophthalmic O O
Solution O O
, O O
the O O
possibility O O
of O O
an O O
additive O O
or O O
potentiating O O
effect O O
with O O
CNS B-group B-group
depressants I-group I-group
( O O
alcohol B-drug B-drug
, O O
barbiturates B-group B-group
, O O
opiates B-group B-group
, O O
sedatives B-group B-group
, O O
anesthetics B-group B-group
) O O
should O O
be O O
considered O O
. O O

CONCLUSIONS O O
: O O
It O O
is O O
important O O
to O O
identify O O
the O O
medications O O
most O O
commonly O O
involved O O
in O O
the O O
PICR O O
so O O
as O O
to O O
establish O O
corrective O O
measures O O
to O O
minimise O O
the O O
risks O O
arising O O
from O O
multiple O O
medication O O
. O O

Lithium B-drug B-drug
: O O
Lithium B-drug B-drug
toxicity O O
has O O
been O O
reported O O
in O O
patients O O
receiving O O
lithium B-drug B-drug
concomitantly O O
with O O
drugs O O
which O O
cause O O
elimination O O
of O O
sodium O B-drug
, O O
including O O
ACE B-group B-group
inhibitors I-group I-group
. O O

Effect O O
on O O
Concentration O O
of O O
Nevirapine B-drug B-drug
or O O
Concomitant O O
Drug O O

Additionally O O
, O O
higher O O
than O O
expected O O
tricyclic B-group B-group
antidepressant I-group I-group
levels O O
have O O
been O O
observed O O
when O O
they O O
are O O
begun O O
in O O
patients O O
already O O
taking O O
cimetidine B-drug B-drug
. O O

Interactions O O
may O O
occur O O
between O O
EPA B-drug B-drug
supplements O O
and O O
aspirin B-brand B-brand
and O O
other O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
and O O
herbs O O
such O O
as O O
garlic O O
( O O
Allium O B-brand
sativum O I-brand
) O O
and O O
ginkgo B-drug O
( O O
Ginkgo B-drug O
biloba I-drug O
) O O
. O O

Theoretically O O
, O O
it O O
may O O
decrease O O
hepatic O O
toxicity O O
in O O
the O O
case O O
of O O
other O O
potential O O
hepatotoxic O O
drugs O O
, O O
as O O
well O O
. O O

On O O
the O O
basis O O
of O O
the O O
principles O O
observed O O
the O O
concentrations O O
fo O O
these O O
hormones O O
were O O
investigated O O
in O O
the O O
plasma O O
of O O
dogs O O
deprived O O
of O O
water O O
for O O
3 O O
days O O
and O O
then O O
allowed O O
to O O
drink O O
. O O

Ocupress B-brand O
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
who O O
are O O
receiving O O
a O O
beta-adrenergic B-group B-group
blocking I-group I-group
agent I-group I-group
orally O O
because O O
of O O
the O O
potential O O
for O O
additive O O
effects O O
on O O
systemic O O
beta-blockade O O
. O O

In O O
diabetics O O
, O O
blood-sugar O O
levels O O
should O O
be O O
monitored O O
very O O
carefully O O
. O O

Ketoconazole B-drug B-drug
: O O
Co-administration O O
of O O
bosentan B-drug B-drug
125 O O
mg O O
b.i.d O O
. O O
and O O
ketoconazole B-drug B-drug
, O O
a O O
potent O O
CYP3A4 O O
inhibitor O O
, O O
increased O O
the O O
plasma O O
concentrations O O
of O O
bosentan B-drug B-drug
by O O
approximately O O
2-fold O O
. O O

clarithromycin I-drug B-drug
concentration O O
indinavir B-drug B-drug
concentration O O

Further O O
, O O
no O O
effects O O
on O O
either O O
warfarin B-drug B-drug
levels O O
or O O
prothrombin O O
times O O
were O O
observed O O
in O O
a O O
study O O
involving O O
concomitant O O
administration O O
of O O
warfarin B-drug B-drug
and O O
fluvastatin B-drug B-drug
. O O

The O O
amplitude O O
data O O
from O O
this O O
study O O
suggest O O
that O O
ethanol B-drug B-drug
's O O
augmentation O O
of O O
component O O
P2 O O
may O O
result O O
, O O
at O O
least O O
in O O
part O O
, O O
from O O
alterations O O
in O O
cholinergic O O
functions O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
with O O
DOXIL B-brand B-brand
. O O

The O O
effect O O
may O O
be O O
mediated O O
by O O
cimetidines B-drug O
known O O
inhibition O O
of O O
hepatic O O
cytochrome O O
P-450 O O
, O O
the O O
enzyme O O
system O O
responsible O O
for O O
the O O
first-pass O O
metabolism O O
of O O
diltiazem B-drug B-drug
. O O

Therefore O O
, O O
a O O
lower O O
total O O
daily O O
dosage O O
of O O
INDOCIN B-brand B-brand
may O O
produce O O
a O O
satisfactory O O
therapeutic O O
effect O O
. O O

Drug O O
interaction O O
studies O O
with O O
decitabine B-drug B-drug
have O O
not O O
been O O
conducted O O
. O O

It O O
is O O
recommended O O
not O O
to O O
exceed O O
a O O
single O O
5 O O
mg O O
dose O O
of O O
Vardenafil B-drug B-drug
in O O
a O O
24-hour O O
period O O
when O O
used O O
in O O
combination O O
with O O
erythromycin B-drug B-drug
. O O

The O O
concomitant O O
administration O O
of O O
griseofulvin B-drug B-drug
has O O
been O O
reported O O
to O O
reduce O O
the O O
efficacy O O
of O O
oral O O
contraceptives B-group B-group
and O O
to O O
increase O O
the O O
incidence O O
of O O
breakthrough O O
bleeding O O
. O O

Fluvoxamine B-drug B-drug
is O O
a O O
known O O
strong O O
inhibitor O O
of O O
CYP1A2 O O
and O O
also O O
inhibits O O
CYP3A4 O O
, O O
CYP2C9 O O
, O O
and O O
CYP2C19 O O
. O O

No O O
information O O
is O O
available O O
. O O

Greater O O
fecal O O
blood O O
loss O O
results O O
from O O
concomitant O O
administration O O
of O O
both O O
drugs O O
than O O
from O O
either O O
drug O O
alone O O
. O O

Concomitant O O
use O O
with O O
other O O
oxytocic B-group B-group
agents I-group I-group
is O O
not O O
recommended O O

Data O O
from O O
in O O
vitro O O
studies O O
of O O
alprazolam B-drug B-drug
suggest O O
a O O
possible O O
drug O O
interaction O O
with O O
alprazolam B-drug B-drug
for O O
the O O
following O O
: O O
sertraline B-drug B-drug
and O O
paroxetine B-drug B-drug
. O O

Concurrent O O
use O O
of O O
rifampin B-drug B-drug
increases O O
the O O
metabolic O O
clearance O O
of O O
ZEBETA B-brand B-brand
, O O
resulting O O
in O O
a O O
shortened O O
elimination O O
half-life O O
of O O
ZEBETA B-brand B-brand
. O O

Urinary O O
Alkalinizers O O
: O O
Decrease O O
aspirin B-brand B-brand
effectiveness O O
by O O
increasing O O
the O O
rate O O
of O O
salicylate B-group B-group
renal O O
excretion O O
. O O

When O O
concomitant O O
administration O O
of O O
ketoconazole B-drug B-drug
with O O
aripiprazole B-drug B-drug
occurs O O
, O O
aripiprazole B-drug B-drug
dose O O
should O O
be O O
reduced O O
to O O
one-half O O
of O O
its O O
normal O O
dose O O
. O O

Therefore O O
, O O
the O O
dose O O
of O O
corticosteroid B-group B-group
should O O
be O O
titrated O O
to O O
avoid O O
steroid O B-group
toxicity O O
. O O

In O O
patients O O
taking O O
an O O
anticonvulsant B-group B-group
( O O
eg O O
, O O
valproic B-drug B-drug
acid I-drug I-drug
, O O
carbamazepine B-drug B-drug
, O O
phenobarbital B-drug B-drug
or O O
phenytoin B-drug B-drug
) O O
, O O
the O O
concomitant O O
use O O
of O O
Mefloquine B-drug B-drug
may O O
reduce O O
seizure O O
control O O
by O O
lowering O O
the O O
plasma O O
levels O O
of O O
the O O
anticonvulsant B-group B-group
. O O

Moreover O O
, O O
the O O
mechanisms O O
underlying O O
the O O
development O O
of O O
dependence O O
may O O
be O O
similar O O
for O O
alcohol B-drug B-drug
and O O
nicotine B-drug B-drug
. O O

May O O
interact O O
with O O
cefamandole B-drug B-drug
naftate I-drug I-drug
, O O
cephalothin B-drug B-drug
sodium I-drug I-drug
, O O
magnesium B-drug B-drug
sulfate I-drug I-drug
, O O
prednisolone B-drug B-drug
sodium I-drug I-drug
succinate I-drug I-drug
, O O
and O O
prochlorperazine B-drug B-drug
edisylate I-drug I-drug
. O O

- O O
Etretinate B-drug B-drug
( O O
e.g. O O
, O O
Tegison B-brand B-brand
) O O
or O O

In O O
patients O O
taking O O
furosemide B-drug B-drug
, O O
nifedipine B-drug B-drug
, O O
diltiazem B-drug B-drug
, O O
ACE B-group B-group
inhibitors I-group I-group
, O O
verapamil B-drug B-drug
, O O
glyburide B-drug B-drug
, O O
propranolol B-drug B-drug
, O O
and O O
various O O
chemotherapy O O
agents O O
, O O
no O O
effect O O
was O O
shown O O
on O O
the O O
clearance O O
of O O
hydrodolasetron B-drug_n B-drug_n
. O O

The O O
depression O O
of O O
cardiac O O
contractility O O
, O O
conductivity O O
, O O
and O O
automaticity O O
as O O
well O O
as O O
the O O
vascular O O
dilation O O
associated O O
with O O
anesthetics B-group B-group
may O O
be O O
potentiated O O
by O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
. O O

Nifedipine B-drug B-drug
did O O
not O O
alter O O
the O O
plasma O O
levels O O
of O O
Vardenafil B-drug B-drug
when O O
taken O O
in O O
combination O O
. O O

No O O
evidence O O
of O O
interaction O O
of O O
PROCRIT B-brand B-brand
with O O
other O O
drugs O O
was O O
observed O O
in O O
the O O
course O O
of O O
clinical O O
trials O O
. O O

The O O
drug O O
interaction O O
between O O
warfarin B-drug B-drug
and O O
rifampin B-drug B-drug
is O O
not O O
well O O
known O O
. O O

However O O
, O O
due O O
to O O
possible O O
pharmacodynamic O O
interactions O O
, O O
when O O
co-administered O O
with O O
PRECEDEX B-brand B-brand
, O O
a O O
reduction O O
in O O
dosage O O
of O O
PRECEDEX B-brand B-brand
on O O
the O O
concomitant O O
anesthetic B-group B-group
, O O
sedative B-group B-group
, O O
hypnotic B-group B-group
or O O
opioid B-group B-group
may O O
be O O
required O O
. O O

Drugs O O
which O O
inhibit O O
this O O
metabolic O O
pathway O O
may O O
have O O
a O O
profound O O
effect O O
on O O
the O O
clearance O O
of O O
alprazolam B-drug B-drug
. O O

Enoxacin B-drug B-drug
does O O
not O O
affect O O
the O O
clearance O O
of O O
the O O
active O O
S-isomer O O
, O O
and O O
changes O O
in O O
clotting O O
time O O
have O O
not O O
been O O
observed O O
when O O
enoxacin B-drug B-drug
and O O
warfarin B-drug B-drug
were O O
coadministered O O
. O O

Anticoagulants B-group B-group
( O O
Oral O O
) O O
: O O
In O O
patients O O
receiving O O
oral O O
anticoagulants B-group B-group
, O O
the O O
coagulation O O
times O O
were O O
increased O O
in O O
some O O
cases O O
. O O

AUC O O
for O O
total O O
nitrosoureas B-group B-group
were O O
about O O
1.4-1.5 O O
fold O O
greater O O
for O O
the O O
oral O O
compared O O
to O O
the O O
i.p O O
. O O

Because O O
the O O
tetracyclines B-group B-group
have O O
been O O
shown O O
to O O
depress O O
plasma O O
prothrombin O O
activity O O
, O O
patients O O
who O O
are O O
on O O
anticoagulant B-group B-group
therapy O O
may O O
require O O
downward O O
adjustment O O
of O O
their O O
anticoagulant B-group B-group
dosage O O
. O O

Oxytocin B-drug B-drug
or O O
other O O
oxytocics B-group B-group
( O O
concurrent O O
use O O
with O O
dinoprost B-drug B-drug
may O O
result O O
in O O
uterine O O
hypertonus O O
, O O
possibly O O
causing O O
uterine O O
rupture O O
or O O
cervical O O
laceration O O
, O O
especially O O
in O O
the O O
absence O O
of O O
adequate O O
cervical O O
dilatation O O
; O O

The O O
single-dose O O
nature O O
of O O
this O O
study O O
and O O
the O O
lack O O
of O O
correlation O O
between O O
glyburide B-drug B-drug
blood O O
levels O O
and O O
pharmaco-dynamic O O
effects O O
, O O
makes O O
the O O
clinical O O
significance O O
of O O
this O O
interaction O O
uncertain O O
. O O

The O O
incidence O O
of O O
TBg O O
deficiency O O
approximates O O
1 O O
in O O
9000 O O
. O O

If O O
midazolam B-drug B-drug
is O O
administered O O
parenterally O O
, O O
special O O
precaution O O
is O O
required O O
since O O
the O O
sedative O O
effect O O
may O O
be O O
prolonged O O
. O O

Caffeine B-drug B-drug
: O O
Enoxacin B-drug B-drug
is O O
a O O
potent O O
inhibitor O O
of O O
the O O
cytochrome O O
P-450 O O
isozymes O O
responsible O O
for O O
the O O
metabolism O O
of O O
methylxanthines B-group B-group
. O O

Poor O O
metabolizers O O
have O O
higher O O
than O O
expected O O
plasma O O
concentrations O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
( O O
TCAs B-group B-group
) O O
when O O
given O O
usual O O
doses O O
. O O

Dexamethasone O B-drug
suppression O O
test O O
( O O
DST O O
) O O
: O O
False-negative O O
results O O
in O O
the O O
dexamethasone O B-drug
suppression O O
test O O
( O O
DST O O
) O O
in O O
patients O O
being O O
treated O O
with O O
indomethacin B-drug B-drug
have O O
been O O
reported O O
. O O

Use O O
with O O
Angiotensln B-group B-group
Converting I-group I-group
Enzyme I-group I-group
Inhibitors I-group I-group
: O O
The O O
use O O
of O O
angiotensin B-group B-group
converting I-group I-group
enzyme I-group I-group
inhibitors I-group I-group
to O O
control O O
hypertension O O
in O O
patients O O
on O O
azathioprine B-drug B-drug
has O O
been O O
reported O O
to O O
induce O O
severe O O
leukopenia O O
. O O

In O O
addition O O
, O O
other O O
quinolones B-group B-group
have O O
been O O
reported O O
to O O
decrease O O
the O O
CYP3A4-mediated O O
metabolism O O
of O O
cyclosporine B-drug B-drug
. O O

Imipramine B-drug B-drug
and O O
clonazepam B-drug B-drug
did O O
not O O
change O O
fasting O O
or O O
overload O O
glycemia O O
. O O

The O O
concurrent O O
administration O O
of O O
allopurinol B-drug B-drug
and O O
ampicillin B-drug B-drug
increases O O
substantially O O
the O O
incidence O O
of O O
rashes O O
in O O
patients O O
receiving O O
both O O
drugs O O
as O O
compared O O
to O O
patients O O
receiving O O
ampicillin B-drug B-drug
alone O O
. O O

The O O
initial O O
dose O O
of O O
levorphanol B-drug B-drug
should O O
be O O
reduced O O
by O O
approximately O O
50 O O
% O O
or O O
more O O
when O O
it O O
is O O
given O O
to O O
patients O O
along O O
with O O
another O O
drug O O
affecting O O
respiration O O
. O O

Cerivastatin B-drug B-drug
plasma O O
concentrations O O
were O O
also O O
not O O
affected O O
by O O
co-administration O O
of O O
digoxin B-drug B-drug
. O O

Betaseron B-brand B-brand
administration O O
to O O
three O O
cancer O O
patients O O
over O O
a O O
dose O O
range O O
of O O
0.025 O O
mg O O
to O O
2.2 O O
mg O O
led O O
to O O
a O O
dose-dependent O O
inhibition O O
of O O
antipyrine B-drug B-drug
elimination.14 O O
The O O
effect O O
of O O
alternate-day O O
administration O O
of O O
0.25 O O
mg O O
of O O
Betaseron B-brand B-brand
on O O
drug O O
metabolism O O
in O O
MS O O
patients O O
is O O
unknown O O
. O O

- O O
Acetohydroxamic B-drug B-drug
acid I-drug I-drug
( O O
e.g. O O
, O O
Lithostat B-brand B-brand
) O O
or O O

Indinavir B-drug B-drug
is O O
metabolized O O
by O O
CYP3A4 O O
. O O

Plasma O O
was O O
analyzed O O
for O O
tolbutamide B-drug B-drug
, O O
and O O
urine O O
was O O
analyzed O O
for O O
tolbutamide B-drug B-drug
and O O
its O O
two O O
metabolites O O
, O O
4-hydroxytolbutamide B-drug_n B-drug_n
and O O
carboxytolbutamide B-drug_n B-drug
by O O
means O O
of O O
HPLC O O
. O O

No O O
clinically O O
relevant O O
drug-drug O O
interactions O O
have O O
been O O
observed O O
with O O
drugs O O
likely O O
to O O
be O O
co-administered O O
with O O
anidulafungin B-drug B-drug
. O O

Nelfinavir B-drug B-drug
is O O
metabolized O O
in O O
proof O O
by O O
C.P.A O O
. O O

. O O

Curariform B-brand B-group
muscle I-brand I-group
relaxants I-brand I-group
( O O
eg O O
, O O
tubocurarine B-drug B-drug
) O O
and O O
other O O
drugs O O
, O O
including O O
ether O B-drug
, O O
succinylcholine B-drug B-drug
, O O
gallamine B-drug B-drug
, O O
decamethonium B-drug B-drug
and O O
sodium B-drug B-drug
citrate I-drug I-drug
, O O
potentiate O O
the O O
neuromuscular O O
blocking O O
effect O O
and O O
should O O
be O O
used O O
with O O
extreme O O
caution O O
in O O
patients O O
being O O
treated O O
with O O
Coly-Mycin B-brand B-brand
M I-brand O
Parenteral O O
. O O

The O O
MPTP-induced B-drug B-drug_n
neuronal O O
damage O O
produced O O
a O O
tolerance O O
to O O
the O O
disruptive O O
effects O O
of O O
amphetamine B-drug B-drug
and O O
a O O
supersensitivity O O
to O O
the O O
disruptive O O
effects O O
of O O
apomorphine B-drug B-drug
in O O
rats O O
responding O O
in O O
a O O
schedule O O
controlled O O
paradigm O O
. O O

Since O O
chronic O O
dosing O O
is O O
required O O
for O O
therapeutic O O
efficacy O O
of O O
antipsychotics B-group B-group
, O O
future O O
studies O O
should O O
focus O O
on O O
investigation O O
of O O
chronic O O
dosing O O
effects O O
of O O
these O O
drugs O O
in O O
combination O O
with O O
PCP B-drug_n B-drug_n
. O O

When O O
carbamazepine B-drug B-drug
is O O
added O O
to O O
aripiprazole B-drug B-drug
therapy O O
, O O
aripiprazole B-drug B-drug
dose O O
should O O
be O O
doubled O O
. O O

Effect O O
of O O
Probenecid B-drug B-drug
: O O
Probenecid B-drug B-drug
is O O
a O O
blocker O O
of O O
renal O O
tubular O O
secretion O O
. O O

Post-marketing O O
reports O O
of O O
changes O O
in O O
prothrombin O O
measures O O
have O O
been O O
received O O
among O O
patients O O
on O O
concomitant O O
warfarin B-drug B-drug
and O O
esomeprazole B-drug B-drug
therapy O O
. O O

To O O
determine O O
whether O O
probenecid B-drug B-drug
has O O
a O O
direct O O
effect O O
on O O
the O O
distribution O O
of O O
cloxacillin B-drug B-drug
, O O
the O O
elimination O O
and O O
distribution O O
of O O
cloxacillin B-drug B-drug
was O O
studied O O
in O O
six O O
patients O O
, O O
five O O
lacking O O
kidney O O
function O O
and O O
one O O
with O O
a O O
partially O O
impaired O O
renal O O
function O O
, O O
in O O
the O O
presence O O
or O O
absence O O
of O O
probenecid B-drug B-drug
. O O

Accordingly O O
, O O
diazepam B-drug B-drug
and O O
fluvoxamine B-drug B-drug
should O O
not O O
ordinarily O O
be O O
co-administered O O
. O O

A O O
potential O O
interaction O O
between O O
oral O O
miconazole B-drug B-drug
and O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
leading O O
to O O
severe O O
hypoglycemia O O
has O O
been O O
reported O O
. O O

Calcium B-drug B-group
Supplements/Antacids B-group I-group

Fluoxetine B-drug B-drug
and O O
its O O
active O O
metabolite O O
, O O
norfluoxe-tine O B-drug
, O O
have O O
long O O
half-lives O B-group
( O O
4 O O
to O O
16 O O
days O O
for O O
norfluoxetine B-drug_n B-drug
) O O
, O O
that O O
may O O
affect O O
strategies O O
during O O
conversion O O
from O O
one O O
drug O O
to O O
the O O
other O O
. O O

In O O
vitro O O
displacement O O
studies O O
with O O
highly O O
protein-bound O O
drugs O O
such O O
as O O
furosemide B-drug B-drug
, O O
propranolol B-drug B-drug
, O O
captopril B-drug B-drug
, O O
nicardipine B-drug B-drug
, O O
pravastatin B-drug B-drug
, O O
glyburide B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
, O O
tolbutamide B-drug B-drug
, O O
and O O
metformin B-drug B-drug
showed O O
no O O
influence O O
on O O
the O O
extent O O
of O O
nateglinide B-drug B-drug
protein O O
binding O O
. O O

In O O
those O O
patients O O
in O O
whom O O
renal O O
insufficiency O O
was O O
documented O O
, O O
however O O
, O O
the O O
recommendation O O
to O O
lower O O
the O O
dose O O
of O O
allopurinol B-drug B-drug
was O O
not O O
followed O O
. O O

Serum O O
potassium O O
levels O O
and O O
cardiac O O
function O O
should O O
be O O
closely O O
monitored O O
and O O
any O O
deficit O O
promptly O O
corrected O O
. O O

More O O
specific O O
applications O O
of O O
the O O
assay O O
of O O
thio O O
compounds O O
in O O
urine O O
allow O O
development O O
of O O
selective O O
methods O O
that O O
may O O
be O O
useful O O
for O O
biological O O
monitoring O O
. O O

. O O

In O O
a O O
small O O
( O O
n=30 O O
) O O
combination O O
study O O
of O O
ARAVA B-brand B-brand
with O O
methotrexate B-drug B-drug
, O O
a O O
2- O O
to O O
3-fold O O
elevation O O
in O O
liver O O
enzymes O O
was O O
seen O O
in O O
5 O O
of O O
30 O O
patients O O
. O O

In O O
the O O
absence O O
of O O
formal O O
clinical O O
drug O O
interaction O O
studies O O
, O O
caution O O
should O O
be O O
exercised O O
when O O
administering O O
TAXOL B-brand B-brand
concomitantly O O
with O O
known O O
substrates O O
or O O
inhibitors O O
of O O
the O O
cytochrome O O
P450 O O
isoenzymes O O
CYP2C8 O O
and O O
CYP3A4 O O
. O O

pentoxifylline B-drug B-drug
; O O

and O O
clinical O O
implications O O
. O O

Sedative/hypnotics B-group B-group
: O O
midazolam B-drug B-drug
, O O
triazolam B-drug B-drug

Other O O
kits O O
, O O
such O O
as O O
the O O
Coat-A-Count O O
RIA O O
Kit O O
, O O
may O O
be O O
used O O
. O O

The O O
effects O O
, O O
if O O
any O O
, O O
on O O
the O O
pituitary-gonadal O O
axis O O
in O O
premenopausal O O
women O O
are O O
unknown O O
. O O

The O O
clinical O O
significance O O
of O O
this O O
increase O O
in O O
doxazosin B-drug B-drug
AUC O O
is O O
unknown O O
. O O

Ketoconazole B-drug B-drug
: O O
Potential O O
interaction O O
of O O
Ketoconazole B-drug B-drug
and O O
Isoniazid B-drug B-drug
may O O
exist O O
. O O

Close O O
supervision O O
and O O
careful O O
adjustment O O
of O O
dosage O O
are O O
required O O
when O O
Anafranil B-brand B-brand
is O O
administered O O
with O O
anticholinergic B-group B-group
or O O
sympathomimetic B-group B-group
drugs I-group I-group
. O O

Prolonged O O
recovery O O
time O O
may O O
occur O O
if O O
barbiturates B-group B-group
and/or O O
narcotics B-group B-group
are O O
used O O
concurrently O O
with O O
ketamine B-drug B-drug
. O O

It O O
was O O
observed O O
that O O
contortrostatin B-drug_n B-drug_n
had O O
a O O
dramatic O O
effect O O
on O O
the O O
tyrosine O O
phosphorylation O O
status O O
of O O
several O O
proteins O O
in O O
T24 O O
human O O
bladder O O
cancer O O
cells O O
, O O
including O O
robust O O
induction O O
of O O
phosphorylation O O
of O O
proteins O O
in O O
the O O
range O O
of O O
120-140 O O
kDa O O
. O O

The O O
safety O O
and O O
efficacy O O
of O O
AMEVIVE B-brand B-brand
in O O
pediatric O O
patients O O
have O O
not O O
been O O
studied O O
. O O

Coadministration O O
of O O
glyburide B-drug B-drug
with O O
doses O O
higher O O
than O O
40 O O
mg O O
valdecoxib B-drug B-drug
( O O
e.g. O O
, O O
40 O O
mg O O
BID O O
) O O
have O O
not O O
been O O
studied O O
. O O

The O O
dextrorotatory O O
isomer O O
, O O
on O O
the O O
other O O
hand O O
, O O
had O O
effects O O
similar O O
to O O
those O O
of O O
PCP B-drug_n B-drug_n
in O O
both O O
species O O
. O O

Antacids B-group B-group
increase O O
the O O
rate O O
of O O
absorption O O
of O O
pseudoephedrine B-drug B-drug
, O O
while O O
kaolin B-drug O
decreases O O
it O O
. O O

Thyroid B-group O
hormone I-group O
activity O O
may O O
also O O
be O O
enhanced O O
. O O

Ritonavir B-drug B-drug

Methotrexate B-drug B-drug
Renal O O
tubular O O
transport O O
of O O
methotrexate B-drug B-drug
may O O
be O O
inhibited O O
by O O
concomitant O O
administration O O
of O O
ciprofloxacin B-drug B-drug
, O O
potentially O O
leading O O
to O O
increased O O
plasma O O
levels O O
of O O
methotrexate B-drug B-drug
. O O

A O O
number O O
of O O
drugs O O
, O O
including O O
ethacrynic B-drug B-drug
acid I-drug I-drug
, O O
have O O
been O O
shown O O
to O O
displace O O
warfarin B-drug B-drug
from O O
plasma O O
protein O O
; O O

Milk O O
, O O
milk O O
products O O
, O O
and O O
calcium-rich B-drug O
foods O O
or O O
drugs O O
may O O
impair O O
the O O
absorption O O
of O O
EMCYT B-brand B-brand
. O O

Anticoagulants B-group B-group
: O O
Combination O O
hormonal B-group B-group
contraceptives I-group I-group
may O O
increase O O
or O O
decrease O O
the O O
effects O O
of O O
coumarin B-group B-group
derivatives I-group I-group
. O O

Concomitant O O
administration O O
of O O
gemfibrozil B-drug B-drug
with O O
Targretin B-brand B-drug
capsules O O
is O O
not O O
recommended O O
. O O

No O O
formal O O
drug-drug O O
interaction O O
studies O O
have O O
been O O
performed O O
. O O

Therefore O O
, O O
indomethacin B-drug B-drug
and O O
diflunisal B-drug B-drug
should O O
not O O
be O O
used O O
concomitantly O O
. O O

Drug O O
interaction O O
studies O O
with O O
SUSTIVA B-brand B-brand
and O O
these O O
imidazole O B-group
and O O
triazole B-group B-group
antifungals I-group I-group
have O O
not O O
been O O
conducted B-group O
. I-group O

In O O
addition O O
, O O
administration O O
of O O
Sonata B-brand B-brand
to O O
a O O
patient O O
taking O O
another O O
drug O O
that O O
is O O
highly O O
protein O O
bound O O
should O O
not O O
cause O O
transient O O
increase O O
in O O
free O O
concentrations O O
of O O
the O O
other O O
drug O O
. O O

When O O
taken O O
orally O O
, O O
imidazole B-group B-group
compounds I-group I-group
like O O
ketoconazole B-drug B-drug
may O O
enhance O O
the O O
anticoagulant O O
effect O O
of O O
coumarin-like B-group B-group
drugs O I-group
. O O

Anticholinergic B-group B-group
agents I-group I-group
may O O
affect O O
gastrointestinal O O
absorption O O
of O O
various O O
drugs O O
, O O
such O O
as O O
slowly O O
dissolving O O
dosage O O
forms O O
of O O
digoxin B-drug B-drug
; O O

However O O
, O O
no O O
clinically O O
or O O
statistically O O
significant O O
differences O O
in O O
prothrombin O O
time O O
ratio O O
or O O
warfarin B-drug B-drug
enantiomer O I-drug
pharmacokinetics O O
were O O
observed O O
in O O
a O O
small O O
study O O
of O O
7 O O
healthy O O
males O O
who O O
received O O
both O O
warfarin B-drug B-drug
and O O
lomefloxacin B-drug B-drug
under O O
steady-state O O
conditions O O
. O O

All O O
of O O
these O O
also O O
resolved O O
, O O
2 O O
with O O
continuation O O
of O O
both O O
drugs O O
and O O
3 O O
after O O
discontinuation O O
of O O
leflunomide B-drug B-drug
. O O

Optimal O O
designs O O
for O O
the O O
individual O O
and O O
joint O O
exposure O O
general O O
logistic O O
regression O O
models O O
. O O

The O O
following O O
drug O O
interactions O O
have O O
been O O
reported O O
with O O
etomidate B-drug B-drug
. O O

The O O
renal O O
plasma O O
flow O O
, O O
glomerular O O
filtration O O
rate O O
and O O
pulsatile O B-drug
choroidal O O
blood O O
flow O O
were O O
measured O O
using O O
the O O
paraaminohippurate O O
method O O
, O O
the O O
inulin O O
method O O
and O O
a O O
laser O O
interferometric O O
measurement O O
of O O
fundus O O
pulsation O O
amplitude O O
, O O
respectively O O
. O O

Potassium-sparing B-group B-group
diuretics I-group I-group
such O O
as O O
spironolactone B-drug B-drug
, O O
triamterene B-drug B-drug
, O O
or O O
amiloride B-drug B-drug
, O O
or O O
potassium B-drug B-drug
supplements O O
should O O
be O O
given O O
only O O
for O O
documented O O
hypokalemia O O
, O O
and O O
then O O
with O O
caution O O
, O O
since O O
they O O
may O O
lead O O
to O O
a O O
significant O O
increase O O
of O O
serum O O
potassium O O
. O O

Optimal O O
conditions O O
, O O
kinetics O O
, O O
equilibrium O O
, O O
and O O
the O O
mechanism O O
of O O
this O O
acid-catalyzed O O
ethanolysis O O
are O O
reported O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
. O O

Dosage O O
of O O
the O O
anticoagulant B-group B-group
may O O
require O O
reduction O O
in O O
order O O
to O O
maintain O O
satisfactory O O
therapeutic O O
hypoprothrombinemia O O
. O O

The O O
histology O O
of O O
the O O
liver O O
was O O
altered O O
in O O
the O O
three O O
groups O O
which O O
were O O
submitted O O
to O O
treatment O O
with O O
the O O
hydroalcoholic O B-drug
solutions O O
, O O
with O O
quantitative O O
and O O
qualitative O O
differences O O
between O O
the O O
groups O O
. O O

The O O
following O O
laboratory O O
tests O O
have O O
been O O
found O O
to O O
be O O
abnormal O O
in O O
a O O
few O O
patients O O
receiving O O
baclofen B-drug B-drug
: O O
increased O O
SGOT O O
, O O
elevated O O
alkaline O O
phosphatase O O
, O O
and O O
elevation O O
of O O
blood O O
sugar O O
. O O

Analgesic O O
effects O O
of O O
antihistaminics B-group B-group
. O O

Combined O O
effects O O
may O O
induce O O
serious O O
cardiac O O
arrhythmias O O
. O O

Oral O O
Hypoglycemic B-group B-group
Agents I-group I-group
: O O
In O O
one O O
study O O
, O O
flurbiprofen B-drug B-drug
was O O
given O O
to O O
adult O O
diabetics O O
who O O
were O O
already O O
receiving O O
glyburide B-drug B-drug
( O O
n=4 O O
) O O
, O O
metformin B-drug B-drug
( O O
n=2 O B-drug
) O O
chlorpropamide B-drug B-drug
with O O
phenformin B-drug B-drug
( O O
n= O B-brand
3 O I-brand
) O O
or O O
glyburide B-drug B-drug
with O O
phenformin B-drug B-drug
( O O
n=6 O O
) O O
. O O

CELEBREX B-brand B-brand
should O O
be O O
introduced O O
at O O
the O O
lowest O O
recommended O O
dose O O
in O O
patients O O
receiving O O
fluconazole B-drug B-drug
. O O

The O O
incidence O O
of O O
akathisia O O
in O O
clinical O O
trials O O
of O O
the O O
weekly O O
dosage O O
schedule O O
was O O
greater O O
( O O
8.5 O O
% O O
, O O
4/47 O O
patients O O
) O O
when O O
prochlorperazine B-drug B-drug
was O O
administered O O
on O O
the O O
same O O
day O O
as O O
CAMPTOSAR B-brand B-brand
than O O
when O O
these O O
drugs O O
were O O
given O O
on O O
separate O O
days O O
( O O
1.3 O O
% O O
, O O
1/80 O O
patients O O
) O O
. O O

To O O
avoid O O
phenytoin B-drug B-drug
intoxication O O
, O O
appropriate O O
adjustment O O
of O O
the O O
anticonvulsant B-group B-group
should O O
be O O
made O O
. O O

however O O
, O O
no O O
significant O O
difference O O
in O O
the O O
maximum O O
concentration O O
in O O
plasma O O
or O O
the O O
area O O
under O O
the O O
concentration-time O O
curve O O
from O O
time O O
zero O O
to O O
8 O O
h O O
was O O
observed O O
. O O

Orlistat-Orlistat B-drug O
may O O
decrease O O
the O O
absorption O O
of O O
vitamin B-group B-group
K I-group I-group
. O O

However O O
, O O
in O O
vivo O O
drug O O
interaction O O
studies O O
of O O
ketoconazole B-drug B-drug
with O O
vitamin B-group B-group
D I-group I-group
have O O
not O O
been O O
investigated O O
. O O

Clinical O O
Comment O O

When O O
used O O
in O O
therapeutic O O
doses O O
, O O
azithromycin B-drug B-drug
had O O
a O O
modest O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
atorvastatin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
cetirizine B-drug B-drug
, O O
didanosine B-drug B-drug
, O O
efavirenz B-drug B-drug
, O O
fluconazole B-drug B-drug
, O O
indinavir B-drug B-drug
, O O
midazolam B-drug B-drug
, O O
rifabutin B-drug B-drug
, O O
sildenafil B-drug B-drug
, O O
theophylline B-drug B-drug
( O O
intravenous O O
and O O
oral O O
) O O
, O O
triazolam B-drug B-drug
, O O
trimethoprim/sulfamethoxazole B-drug B-drug
or O O
zidovudine B-drug B-drug
. O O

HMG-CoA B-group B-group
Reductase I-group I-group
Inhibitors I-group I-group
: O O
lovastatin B-drug B-drug
, O O
simvastatin B-drug B-drug
WARNING O O
potential O O
for O O
serious O O
reactions O O
such O O
as O O
risk O O
of O O
myopathy O O
including O O
rhabdomyolysis O O
. O O

In O O
addition O O
to O O
established O O
drug O O
interactions O O
, O O
there O O
may O O
be O O
potential O O
pharmacokinetic O O
interactions O O
between O O
nevirapine B-drug B-drug
and O O
other O O
drug O O
classes O O
that O O
are O O
metabolized O O
by O O
the O O
cytochrome O O
P450 O O
system O O
. O O

Drug/Laboratory O O
Test O O
Interaction O O
After O O
treatment O O
with O O
ampicillin B-drug B-drug
, O O
a O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
may O O
occur O O
with O O
copper B-drug_n O
sulfate I-drug_n O
tests O O
( O O
Benedicts O O
solution O O
, O O
Fehlings O O
solution O O
, O O
or O O
Clinitest O O
tablets O O
) O O
but O O
not O O
with O O
enzyme O O
based O O
tests O O
such O O
as O O
Clinistix O O
and O O
Glucose O O
Enzymatic O O
Test O O
Strip O O
USP O O
. O O

Lovastatin B-drug B-drug
therapy O O
has O O
not O O
been O O
associated O O
with O O
bleeding O O
or O O
with O O
changes O O
in O O
prothrombin O O
time O O
in O O
patients O O
not O O
taking O O
anticoagulants B-group B-group
. O O

. O O

Note O O
: O O

Olanzapine B-drug B-drug
, O O
a O O
thienobenzodiazepine B-group O
derivative I-group O
, O O
is O O
a O O
second B-group O
generation I-group O
( I-group O
atypical I-group B-group
) I-group I-group
antipsychotic I-group I-group
agent I-group I-group
which O O
has O O
proven O O
efficacy O O
against O O
the O O
positive O O
and O O
negative O O
symptoms O O
of O O
schizophrenia O O
. O O

Other O O
Drug O O
Interaction O O
Information O O
Digoxin B-drug B-drug
: O O
Studies O O
in O O
healthy O O
volunteers O O
have O O
shown O O
that O O
TIKOSYN B-brand B-brand
does O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
. O O

Caution O O
, O O
however O O
, O O
is O O
advised O O
in O O
patients O O
taking O O
tricyclic B-group B-group
antidepressants I-group I-group
which O O
can O O
affect O O
the O O
metabolism O O
and O O
uptake O O
of O O
circulating O O
amines O O
. O O

Propanolol B-drug B-drug
: O O
The O O
pharmacokinetics O O
of O O
almotriptan B-drug B-drug
were O O
not O O
affected O O
by O O
coadministration O O
of O O
propranolol B-drug B-drug
. O O

phase O O
1 O O
( O O
days O O
1-6 O O
) O O
: O O
cisapride B-drug B-drug
10 O O
mg O O
4 O O
times/day O O
; O O

Compared O O
with O O
risperidone B-drug B-drug
, O O
olanzapine B-drug B-drug
has O O
also O O
been O O
reported O O
to O O
decrease O O
overall O O
treatment O O
costs O O
, O O
despite O O
the O O
several-fold O O
higher O O
daily O O
acquisition O O
cost O O
of O O
the O O
drug O O
. O O

Alcohol B-drug B-drug
- O O
Although O O
LEXAPRO B-brand B-brand
did O O
not O O
potentiate O O
the O O
cognitive O O
and O O
motor O O
effects O O
of O O
alcohol B-drug B-drug
in O O
a O O
clinical O O
trial O O
, O O
as O O
with O O
other O O
psychotropic B-group B-group
medications I-group I-group
, O O
the O O
use O O
of O O
alcohol B-drug B-drug
by O O
patients O O
taking O O
LEXAPRO B-brand B-brand
is O O
not O O
recommended O O
. O O

- O O
When O O
Bezalip B-brand B-brand
or O O
Bezalip B-brand B-brand
retard I-brand I-brand
is O O
used O O
concurrently O O
with O O
anion-exchange B-group B-group
resins I-group I-group
( O O
e.g O O
. O O
cholestryramine B-drug B-drug
) O O
, O O
an O O
interval O O
of O O
at O O
least O O
2 O O
hours O O
should O O
be O O
maintained O O
between O O
the O O
two O O
medicines O O
, O O
since O O
the O O
absorption O O
of O O
Bezalip B-brand B-brand
or O O
Bezalip B-brand B-brand
retard I-brand I-brand
is O O
impaired O O

However O O
, O O
initial O O
dose O O
modification O O
is O O
generally O O
not O O
necessary O O
. O O

4 O O
. O O

These O O
behavioral O O
changes O O
may O O
be O O
related O O
with O O
the O O
negative O O
symptoms O O
of O O
schizophrenia O O
. O O

metronidazole B-drug B-drug
; O O

Other O O
quinolones B-group B-group
have O O
demonstrated O O
moderate O O
to O O
marked O O
interference O O
with O O
the O O
metabolism O O
of O O
caffeine B-drug B-drug
, O O
resulting O O
in O O
a O O
reduced O O
clearance O O
, O O
a O O
prolongation O O
of O O
plasma O O
half-life O O
, O O
and O O
an O O
increase O O
in O O
symptoms O O
that O O
accompany O O
high O O
levels O O
of O O
caffeine B-drug B-drug
. O O

METHODS O O
: O O
From O O
the O O
beginning O O
of O O
the O O
experiment O O
, O O
rats O O
were O O
given O O
10 O O
weekly O O
subcutaneous O O
injections O O
of O O
AOM B-drug_n B-drug_n
( O O
7.4 O O
mg/kg O O
body O O
weight O O
) O O
and O O
subcutaneous O O
injections O O
of O O
bombesin B-drug_n B-drug_n
( O O
40 O O
microg/kg O O
body O O
weight O O
) O O
every O O
other O O
day O O
, O O
and O O
from O O
week O O
16 O O
, O O
intraperitoneal O O
injections O O
of O O
verapamil B-drug B-drug
( O O
10 O O
or O O
20 O O
mg/kg O O
body O O
weight O O
) O O
every O O
other O O
day O O
until O O
the O O
end O O
fo O O
the O O
experiment O O
in O O
week O O
45 O O
. O O

The O O
exact O O
length O O
of O O
time O O
may O O
vary O O
and O O
is O O
dependent O O
upon O O
the O O
particular O O
MAO B-group B-group
inhibitor I-group I-group
being O O
used O O
, O O
the O O
length O O
of O O
time O O
it O O
has O O
been O O
administered O O
, O O
and O O
the O O
dosage O O
involved O O
. O O

Saquinavir B-drug B-drug

Interaction O O
between O O
lomefloxacin B-drug B-drug
and O O
cyclosporine B-drug B-drug
has O O
not O O
been O O
studied O O
. O O

this O O
effect O O
is O O
at O O
least O O
balanced O O
by O O
decreased O O
metabolism O O
of O O
corticosteroids B-group B-group
. O O

Although O O
metoclopramide B-drug B-drug
may O O
increase O O
the O O
bioavailability O O
of O O
levodopa B-drug B-drug
by O O
increasing O O
gastric O O
emptying O O
, O O
metoclopramide B-drug B-drug
may O O
also O O
adversely O O
affect O O
disease O O
control O O
by O O
its O O
dopamine O O
receptor O O
antagonistic O O
properties O O
. O O

This O O
increase O O
may O O
be O O
clinically O O
relevant O O
as O O
adverse O O
experiences O O
are O O
related O O
to O O
dose O O
and O O
exposure O O
; O O

Increasing O O
the O O
indinavir B-drug B-drug
dose O O
to O O
1000 O O
mg O O
every O O
8 O O
hours O O
does O O
not O O
compensate O O
for O O
the O O
increased O O
indinavir B-drug B-drug
metabolism O O
due O O
to O O
efavirenz B-drug B-drug
. O O

Internal O O
application O O
of O O
InsP B-drug_n B-drug_n
( I-drug_n I-drug_n
3 I-drug_n I-drug_n
) I-drug_n O
( O O
100 O O
microM O O
) O O
increased O O
intracellular O O
Ca O O
( O O
2+ O O
) O O
concentration O O
( O O
[ O O
Ca O O
( O O
2+ O O
) O O
] O O
( O O
i O O
) O O
) O O
and O O
activated O O
the O O
Ca O O
( O O
2+ O O
) O O
-dependent O O
K O O
( O O
+ O O
) O O
current O O
. O O

If O O
treatment O O
with O O
inhibitors O O
of O O
CYP3A4 O O
activity O O
( O O
such O O
as O O
ketoconazole B-drug B-drug
, O O
intraconazole B-drug B-drug
, O O
ritonavir B-drug B-drug
, O O
indinavir B-drug B-drug
, O O
saquinavir B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
etc O O
. O O
) O O
is O O
indicated O O
, O O
reduction O O
of O O
the O O
budesonide B-drug B-drug
dose O O
should O O
be O O
considered O O
. O O

The O O
core O O
temperature O O
returned O O
to O O
normal O O
300 O O
minutes O O
after O O
ethanol B-drug B-drug
. O O

St. O O
Johns O O
wort O O
( O O
Hypericum O O
perforatum O O
) O O
may O O
decrease O O
SPRYCEL B-brand B-brand
plasma O O
concentrations O O
unpredictably O O
. O O

In O O
a O O
multiple O O
dose O O
study O O
of O O
theophylline B-drug B-drug
( O O
400 O O
mg O O
once O O
daily O O
for O O
3 O O
days O O
) O O
and O O
cetirizine B-drug B-drug
( O O
20 O O
mg O O
once O O
daily O O
for O O
3 O O
days O O
) O O
, O O
a O O
16 O O
% O O
decrease O O
in O O
the O O
clearance O O
of O O
cetirizine B-drug B-drug
was O O
observed O O
. O O

Patients O O
taking O O
low-dose O O
aspirin B-brand B-brand
plus O O
ibuprofen B-drug B-drug
were O O
not O O
studied O O
. O O

These O O
drugs O O
include O O
the O O
thiazides B-group B-group
and O O
other O O
diuretics B-group B-group
, O O
corticosteroids B-group B-group
, O O
phenothiazines B-group B-group
, O O
thyroid B-group B-group
products I-group I-group
, O O
estrogens B-group B-group
, O O
oral O O
contraceptives B-group B-group
, O O
phenytoin B-drug B-drug
, O O
nicotinic B-drug B-drug
acid I-drug I-drug
, O O
sympathomimetics B-group B-group
, O O
calcium B-group B-group
channel I-group I-group
blocking I-group I-group
drugs I-group I-group
, O O
and O O
isoniazid B-drug B-drug
. O O

However O O
, O O
iloprost B-drug B-drug
has O O
the O O
potential O O
to O O
increase O O
the O O
hypotensive O O
effect O O
of O O
vasodilators B-group B-group
and O O
antihypertensive B-group B-group
agents I-group I-group
. O O

Specific O O
drug O O
interaction O O
studies O O
have O O
not O O
been O O
conducted O O
with O O
Levofloxacin B-drug B-drug
. O O

These O O
reports O O
are O O
more O O
frequent O O
for O O
women O O
who O O
use O O
only O O
a O O
single O O
method O O
of O O
contraception O O
. O O

Other O O
medicines O O
- O O
Although O O
certain O O
medicines O O
should O O
not O O
be O O
used O O
together O O
at O O
all O O
, O O
in O O
other O O
cases O O
two O O
different O O
medicines O O
may O O
be O O
used O O
together O O
even O O
if O O
an O O
interaction O O
might O O
occur O O
. O O

Most O O
cases O O
of O O
serious O O
or O O
fatal O O
adverse O O
events O O
involving O O
Levo-Dromoran B-brand B-brand
reported O O
to O O
the O O
manufacturer O O
or O O
the O O
FDA O O
have O O
involved O O
either O O
the O O
administration O O
of O O
large O O
initial O O
doses O O
or O O
too O O
frequent O O
doses O O
of O O
the O O
drug O O
to O O
nonopioid O O
tolerant O O
patients O O
, O O
or O O
the O O
simultaneous O O
administration O O
of O O
levorphanol B-drug B-drug
with O O
other O O
drugs O O
affecting O O
respiration O O
. O O

The O O
results O O
demonstrate O O
a O O
high O O
degree O O
of O O
stereoselectivity O O
in O O
the O O
behavioral O O
effects O O
of O O
NANM B-drug_n B-drug_n
. O O

cimetidine B-drug B-drug
) O O
and O O
many O O
that O O
are O O
substrates O O
for O O
P450 O O
2D6 O O
( O O
many O O
other O O
antidepressants B-group B-group
, O O
phenothiazines B-group B-group
, O O
and O O
the O O
Type O B-group
1C O I-group
antiarrhythrnics O I-group
propatenone O B-drug
and O O
flecainide B-drug B-drug
) O O
. O O

The O O
effect O O
of O O
ceftibuten B-drug B-drug
on O O
the O O
pharmacokinetics O O
of O O
theophylline B-drug B-drug
administered O O
orally O O
has O O
not O O
been O O
investigated O O
. O O

Cimetidine B-drug B-drug

As O O
a O O
precursor O O
to O O
this O O
effort O O
, O O
optimal O O
and O O
minimal O O
experimental O O
designs O O
for O O
the O O
case O O
in O O
which O O
a O O
single O O
compound O O
is O O
administered O O
have O O
also O O
been O O
developed O O
. O O

co-administration O O
of O O
phenobarbital B-drug B-drug
may O O
produce O O
a O O
synergistic O O
anticonvulsant O O
action O O
. O O

If O O
used O O
in O O
combination O O
with O O
saquinavir B-drug B-drug
hard O O
gelatin O B-drug
capsules O O
at O O
the O O
recommended O O
dose O O
of O O
600 O O
mg O O
tid O O
, O O
no O O
dose O O
adjustments O O
are O O
needed O O
. O O

It O O
is O O
not O O
known O O
if O O
REGRANEX B-brand B-brand
Gel O O
interacts O O
with O O
other O O
topical O O
medications O O
applied O O
to O O
the O O
ulcer O O
site O O
. O O

. O O

Possible O O
extrarenal O O
mechanisms O O
of O O
action O O
of O O
cimetidine B-drug B-drug
on O O
verografine B-drug B-drug
and O O
iodamide B-drug B-drug
transport O O
were O O
also O O
examined O O
. O O

[ O O
Hippocampus O O
as O O
interaction O O
sites O O
between O O
cerebral O O
memory O O
systems O O
] O O
Most O O
of O O
the O O
current O O
theories O O
assume O O
that O O
there O O
are O O
multiple O O
forms O O
of O O
memory O O
that O O
are O O
supported O O
by O O
separate O O
brain O O
systems O O
and O O
have O O
different O O
characteristics O O
. O O

Concomitant O O
medications O O
should O O
be O O
carefully O O
assessed O O
. O O

Periodic O O
measurement O O
of O O
serum O O
PSA O O
levels O O
may O O
also O O
be O O
considered O O
. O O

Recovery O O
of O O
hoof O O
twitch O O
from O O
50 O O
% O O
to O O
75 O O
% O O
took O O
7.7 O O
+/- O O
0.7 O O
min O O
for O O
atracurium B-drug B-drug
alone O O
and O O
11.5 O O
+/- O O
2.7 O O
min O O
for O O
atracurium B-drug B-drug
plus O O
gentamycin B-drug B-drug
( O O
P O O
= O O
0.03 O O
) O O
. O O

Inducers O O
and O O
Inhibitors O O
of O O
Hepatic O O
Metabolism O O
: O O
Rifampin B-drug B-drug
reduced O O
plasma O O
concentrations O O
of O O
carvedilol B-drug B-drug
by O O
about O O
70 O O
% O O
. O O

The O O
fluoroquinolones B-group B-group
are O O
a O O
rapidly O O
growing O O
class O O
of O O
antibiotics B-group B-group
with O O
a O O
broad O O
spectrum O O
of O O
activity O O
against O O
gram-negative O O
and O O
some O O
gram-positive O O
aerobic O O
bacteria O O
. O O

The O O
mean O O
minimum O O
lithium B-drug B-drug
concentration O O
increased O O
15 O O
% O O
and O O
the O O
renal O O
clearance O O
of O O
lithium B-drug B-drug
was O O
decreased O O
by O O
19 O O
% O O
during O O
this O O
period O O
of O O
concomitant O O
drug O O
administration O O
. O O

Because O O
escitalopram B-drug B-drug
is O O
metabolized O O
by O O
multiple O O
enzyme O O
systems O O
, O O
inhibition O O
of O O
a O O
single O O
enzyme O O
may O O
not O O
appreciably O O
decrease O O
escitalopram B-drug B-drug
clearance O O
. O O

Some O O
drugs/substances B-drug O
are O O
known O O
to O O
accelerate O O
the O O
metabolism O O
of O O
amiodarone B-drug B-drug
by O O
stimulating O O
the O O
synthesis O O
of O O
CYP3A4 B-drug O
( O O
enzyme O O
induction O O
) O O
. O O

Methotrexate B-drug B-drug
: O O
HUMIRA B-brand B-brand
has O O
been O O
studied O O
in O O
rheumatoid O O
arthritis O O
patients O O
taking O O
concomitant O O
MTX B-drug B-drug
. O O

Some O O
disorders O O
unrelated O O
to O O
sexual O O
dysfunction O O
( O O
eg O O
, O O
esophageal O O
motility O O
dysfunction O O
) O O
may O O
also O O
respond O O
to O O
sildenafil B-drug B-drug
. O O

Co-administration O O
of O O
irbesartan B-drug B-drug
reduced O O
aliskiren B-drug B-drug
Cmax O O
up O O
to O O
50 O O
% O O
after O O
multiple O O
dosing O O
. O O

Disulfiram B-drug B-drug
alone O O
in O O
the O O
rat O O
s O O
diet O O
did O O
not O O
lead O O
to O O
such O O
tumors O O
. O O

Platelet O O
function O O
studies O O
in O O
these O O
patients O O
have O O
not O O
demonstrated O O
any O O
significant O O
platelet O O
dysfunction O O
. O O

Paclitaxel B-drug B-drug
- O O
In O O
one O O
report O O
, O O
L-glutamine B-drug B-drug
at O O
a O O
dose O O
of O O
10 O O
grams O O
three O O
times O O
daily O O
, O O
given O O
24 O O
hours O O
after O O
receiving O O
paclitaxel B-drug B-drug
, O O
appeared O O
to O O
prevent O O
the O O
development O O
of O O
myalgia O O
and O O
arthralgia O O
, O O
adverse O O
reactions O O
of O O
paclitaxel B-drug B-drug
. O O

METH B-drug B-drug
induced O O
arc O O
mRNA O O
in O O
layers O O
IV O O
and O O
VI O O
of O O
the O O
cortex O O
which O O
dopamine O O
receptor O O
are O O
localized O O
to O O
. O O

Carbamazepine B-drug B-drug
: O O
Tiagabine B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
steady-state O O
plasma O O
concentrations O O
of O O
carbamazepine B-drug B-drug
or O O
its O O
epoxide O O
metabolite O O
in O O
patients O O
with O O
epilepsy O O
. O O

Table O O
4 O O
Potential O O
Drug O O
Interactions O O
: O O
Use O O
With O O
Caution O O
, O O
Dose O O
Adjustment O O
of O O
Co-administered O O
Drug O O
May O O
Be O O
Needed O O
due O O
to O O
Possible O O
Decrease O O
in O O
Clinical O O
Effect O O

Other O O
concomitant O O
therapies O O
: O O
In O O
clinical O O
trials O O
, O O
the O O
safety O O
profile O O
in O O
subjects O O
treated O O
with O O
Acamprosate B-drug B-drug
concomitantly O O
with O O
anxiolytics B-group B-group
, O O
hypnotics B-group B-group
and O O
sedatives B-group B-group
( O O
including O O
benzodiazepines B-group B-group
) O O
, O O
or O O
non-opioid B-group B-group
analgesics I-group I-group
was O O
similar O O
to O O
that O O
of O O
subjects O O
taking O O
placebo O O
with O O
these O O
concomitant O O
medications O O
. O O

could O O
not O O
be O O
confirmed O O
for O O
cloxacillin B-drug B-drug
in O O
patients O O
lacking O O
kidney O O
function O O
. O O

Drugs O O
Metabolized O O
by O O
P450 O O
2D6 O O
- O O
The O O
biochemical O O
activity O O
of O O
the O O
drug O O
metabolizing O O
isozyme O O
cytochrome O O
P450 O O
2D6 O O
( O O
debrisoquin O O
hydroxylase O O
) O O
is O O
reduced O O
in O O
a O O
subset O O
of O O
the O O
caucasian O O
population O O
( O O
about O O
7-10 O O
% O O
of O O
caucasians O O
are O O
so O O
called O O
poor O O
metabolizers O O
) O O
; O O

Chapter O O
3 O O
covers O O
pharmacology O O
( O O
pharmacokinetics O O
, O O
pharmacodynamics O O
and O O
potency O O
, O O
and O O
clinical O O
implications O O
) O O
. O O

Slow-channel B-group B-group
calcium I-group I-group
blockers I-group I-group
, O O
such O O
as O O
verapamil B-drug B-drug
, O O
diltiazem B-drug B-drug
and O O
nifedipine B-drug B-drug
, O O
inhibit O O
platelet O O
activation O O
in O O
vitro O O
, O O
and O O
decrease O O
platelet O O
adhesion O O
intravascularly O O
. O O

Magnesium- B-drug B-drug
and O O
aluminum-containing B-drug B-drug
antacids B-group B-group
, O O
administered O O
concomitantly O O
with O O
lomefloxacin B-drug B-drug
, O O
significantly O O
decreased O O
the O O
bioavailability O O
( O O
48 O O
% O O
) O O
of O O
lomefloxacin B-drug B-drug
. O O

The O O
regulation O O
of O O
topoisomerases O O
is O O
no O O
doubt O O
complex O O
and O O
multifaceted O O
and O O
is O O
probably O O
accomplished O O
through O O
redundancy O O
at O O
many O O
control O O
levels O O
. O O

clinical O O
significance O O
unknown O O
. O O

Narcotic B-group B-group
analgesics I-group I-group
may O O
potentiate O O
the O O
hypotensive O O
effects O O
of O O
clonidine B-drug B-drug
. O O

Lithium B-drug B-drug
: O O
Valdecoxib B-drug B-drug
40 O O
mg O O
BID O O
for O O
7 O O
days O O
produced O O
significant O O
decreases O O
in O O
lithium B-drug B-drug
serum O O
clearance O O
( O O
25 O O
% O O
) O O
and O O
renal O O
clearance O O
( O O
30 O O
% O O
) O O
with O O
a O O
34 O O
% O O
higher O O
serum O O
exposure O O
compared O O
to O O
lithium B-drug B-drug
alone O O
. O O

Clidinium B-drug B-drug
may O O
decrease O O
the O O
effect O O
of O O
phenothiazines B-group B-group
, O O
levodopa B-drug B-drug
, O O
and O O
ketoconazole B-drug B-drug
. O O

Coadministration O O
of O O
valdecoxib B-drug B-drug
( O O
40 O O
mg O O
BID O O
( O O
day O O
1 O O
) O O
and O O
40 O O
mg O O
QD O O
( O O
days O O
2-7 O O
) O O
) O O
with O O
glyburide B-drug B-drug
( O O
10 O O
mg O O
glyburide B-drug B-drug
BID O O
) O O
resulted O O
in O O
21 O O
% O O
increase O O
in O O
glyburide B-drug B-drug
AUC0-12 O O
and O O
a O O
16 O O
% O O
increase O O
in O O
glyburide B-drug B-drug
Cmax O O
leading O O
to O O
a O O
16 O O
% O O
decrease O O
in O O
glucose O O
AUC0-24 O O
. O O

Nursing O O
Mothers O O
Fulvestrant B-drug B-drug
is O O
found O O
in O O
rat O O
milk O O
at O O
levels O O
significantly O O
higher O O
( O O
approximately O O
12-fold O O
) O O
than O O
plasma O O
after O O
administration O O
of O O
2 O O
mg/kg O O
. O O

dose-dependently O O
increased O O
the O O
number O O
of O O
defecation O O
episodes O O
and O O
induced O O
a O O
soft O O
and O O
watery O O
stool O O
in O O
cecectomized O O
rats O O
. O O

Intermediate O O
doses O O
of O O
( B-drug_n B-drug_n
+ I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
or O O
PCP B-drug_n B-drug_n
produced O O
transient O O
increases O O
in O O
FI O O
responding O O
in O O
monkeys O O
and O O
sustained O O
increases O O
in O O
FI O O
responding O O
in O O
pigeons O O
; O O

The O O
basal O O
colonic O O
fluid O O
contents O O
and O O
transits O O
were O O
the O O
same O O
in O O
cecectomized O O
and O O
in O O
control O O
rats O O
. O O

Co-administration O O
of O O
nelfinavir B-drug B-drug
at O O
steady-state O O
with O O
a O O
single O O
dose O O
of O O
azithromycin B-drug B-drug
( O O
2 O O
x O O
600 O O
mg O O
tablets O O
) O O
results O O
in O O
increased O O
azithromycin B-drug B-drug
serum O O
concentrations O O
. O O

Drug O O
monitoring O O
may O O
be O O
of O O
assistance O O
in O O
detecting O O
alterations O O
in O O
carbamazepine B-drug B-drug
plasma O O
concentrations O O
. O O

Pharmacological/Pharmacodynamic O O
Interactions O O
with O O
Carbamazepine B-drug B-drug
Concomitant O O
administration O O
of O O
carbamazepine B-drug B-drug
and O O
lithium B-drug B-drug
may O O
increase O O
the O O
risk O O
of O O
neurotoxic O O
side O O
effects O O
. O O

The O O
reaction O O
after O O
norepinephrine B-drug B-drug
remained O O
the O O
same O O
in O O
both O O
groups O O
of O O
experiments O O
. O O

CONCLUSIONS O O
: O O
Olanzapine B-drug B-drug
demonstrated O O
superior O O
antipsychotic O O
efficacy O O
compared O O
with O O
haloperidol B-drug B-drug
in O O
the O O
treatment O O
of O O
acute O O
phase O O
schizophrenia O O
, O O
and O O
in O O
the O O
treatment O O
of O O
some O O
patients O O
with O O
first-episode O O
or O O
treatment-resistant O O
schizophrenia O O
. O O

In O O
clinical O O
studies O O
where O O
patients O O
were O O
on O O
chronic O O
theophylline B-drug B-drug
therapy O O
, O O
lomefloxacin B-drug B-drug
had O O
no O O
measurable O O
effect O O
on O O
the O O
mean O O
distribution O O
of O O
theophylline B-drug B-drug
concentrations O O
or O O
the O O
mean O O
estimates O O
of O O
theophylline B-drug B-drug
clearance O O
. O O

No O O
cases O O
of O O
rhabdomyolysis O O
were O O
reported O O
in O O
this O O
trial O O
. O O

No O O
information O O
is O O
available O O
about O O
the O O
use O O
of O O
butorphanol B-drug B-drug
concurrently O O
with O O
MAO B-group B-group
inhibitors I-group I-group
. O O

Cromolyn B-drug B-drug
sodium I-drug I-drug
alone O O
in O O
doses O O
up O O
to O O
540 O O
mg/kg/day O O
( O O
approximately O O
340 O O
times O O
the O O
maximum O O
recommended O O
daily O O
inhalation O O
dose O O
in O O
adults O O
on O O
a O O
mg/m2 O O
basis O O
) O O
did O O
not O O
cause O O
significant O O
increases O O
in O O
resorptions O O
or O O
major O O
malformations O O
. O O

Caution O O
is O O
advised O O
in O O
patients O O
receiving O O
chronic O O
concomitant O O
therapy O O
. O O

Methamphetamine B-drug B-drug
, O O
like O O
MPTP B-drug_n B-drug_n
, O O
produced O O
depletions O O
of O O
striatal O O
dopamine O O
but O O
these O O
actions O O
were O O
potentiated O O
by O O
pargyline B-drug B-drug
pretreatment O O
. O O

Amiodarone B-drug B-drug
is O O
metabolized O O
to O O
desethylamiodarone B-drug O
by O O
the O O
cytochrome O O
P450 O O
( O O
CYP450 O O
) O O
enzyme O O
group O O
, O O
specifically O O
cytochromes O O
P450 O O
3A4 O O
( O O
CYP3A4 O O
) O O
and O O
CYP2C8 O O
. O O

Tricyclic B-group B-group
antidepressants I-group I-group
have O O
been O O
reported O O
to O O
blunt O O
the O O
hypotensive O O
effect O O
of O O
systemic O O
clonidine B-drug B-drug
. O O

Antagonism O O
was O O
never O O
observed O O
. O O

When O O
coadministered O O
with O O
SUSTIVA B-brand B-brand
in O O
treatment-naive O O
patients O O
, O O
the O O
recommended O O
dose O O
of O O
atazanavir B-drug B-drug
is O O
300 O O
mg O O
with O O
ritonavir B-drug B-drug
100 O O
mg O O
and O O
SUSTIVA B-brand B-brand
600 O O
mg O O
( O O
all O O
once O O
daily O O
) O O
. O O

Vaccines B-group B-group
: O O
Patients O O
on O O
corticosteroid B-group B-group
therapy O O
may O O
exhibit O O
a O O
diminished O O
response O O
to O O
toxoids O B-group
and O O
live O O
or B-group O
inactivated I-group B-group
vaccines I-group I-group
due O O
to O O
inhibition O O
of O O
antibody O O
response O O
. O O

In O O
rats O O
, O O
simultaneous O O
ingestion O O
of O O
disulfiram B-drug B-drug
and O O
nitrite B-drug O
in O O
the O O
diet O O
for O O
78 O O
weeks O O
has O O
been O O
reported O O
to O O
cause O O
tumors O O
, O O
and O O
it O O
has O O
been O O
suggested O O
that O O
disulfiram B-drug B-drug
may O O
react O O
with O O
nitrites B-group B-group
in O O
the O O
rat O O
stomach O O
to O O
form O O
a O O
nitrosamine O B-drug
, O O
which O O
is O O
tumorigenic O O
. O O

Therophylline O B-drug
: O O
A O O
recent O O
study O O
has O O
shown O O
that O O
concomitan O B-drug
administration O O
of O O
isoniazid B-drug B-drug
and O O
theophylline B-drug B-drug
may O O
cause O O
elevated O O
plasma O O
levels O O
of O O
theophylline B-drug B-drug
, O O
and O O
in O O
some O O
instances O O
a O O
slight O O
decrease O O
in O O
the O O
elimination O O
of O O
isoniazid B-drug B-drug
. O O

and O O
( O O
ii O O
) O O
the O O
effects O O
of O O
filipin B-drug_n B-drug_n
were O O
more O O
efficiently O O
inhibited O O
by O O
added O O
cholesterol O O
, O O
the O O
major O O
membrane O O
sterol O O
in O O
human O O
cells O O
, O O
whereas O O
the O O
effects O O
of O O
amphotericin B-drug B-drug
B I-drug I-drug
were O O
more O O
efficiently O O
inhibited O O
by O O
ergosterol O B-drug
, O O
the O O
major O O
membrane O O
sterol O O
in O O
yeast O O
. O O

Some O O
of O O
the O O
cases O O
of O O
collapse/respiratory O O
arrest/cardiac O O
arrest O O
during O O
initial O O
treatment O O
occurred O O
in O O
patients O O
who O O
were O O
being O O
administered O O
benzodiazepines B-group B-group
; O O

For O O
comprehensive O O
information O O
concerning O O
laboratory O O
test O O
alterations O O
associated O O
with O O
ritonavir B-drug B-drug
, O O
physicians O O
should O O
refer O O
to O O
the O O
complete O O
prescribing O O
information O O
for O O
NORVIR B-brand B-brand
( O O
ritonavir B-drug B-drug
) O O
. O O

The O O
effects O O
of O O
ERGOMAR B-brand B-brand
may O O
be O O
potentiated O O
by O O
triacetyloleandomycin B-drug B-drug
which O O
inhibits O O
the O O
metabolism O O
of O O
ergotamine B-drug B-drug
. O O

In O O
2 O O
separate O O
studies O O
, O O
fexofenadine B-drug B-drug
hydrochloride I-drug I-drug
120 O O
mg O O
twice O O
daily O O
( O O
240 O O
mg O O
total O O
daily O O
dose O O
) O O
was O O
co-administered O O
with O O
either O O
erythromycin B-drug B-drug
500 O O
mg O O
every O O
8 O O
hours O O
or O O
ketoconazole B-drug B-drug
400 O O
mg O O
once O O
daily O O
under O O
steady-state O O
conditions O O
to O O
healthy O O
volunteers O O
( O O
n=24 O O
, O O
each O O
study O O
) O O
. O O

HMG-CoA B-group B-group
Reductase I-group I-group
inhibitors I-group I-group
: O O
lovastatin B-drug B-drug
, O O
simvastatin B-drug B-drug

Oral O O
Anticoagulants B-group B-group
CAUTION O O
SHOULD O O
BE O O
EXERCISED O O
WHEN O O
COUMARIN B-group B-brand
ANTICOAGULANTS I-group B-group
ARE O O
GIVEN O O
IN O O
CONJUNCTION O O
WITH O O
TRICOR B-brand B-brand
. O O

High-dose O O
cisplatin B-drug B-drug
with O O
sodium B-drug B-drug
thiosulfate I-drug I-drug
protection O O
. O O

There O O
have O O
been O O
rare O O
reports O O
of O O
significant O O
respiratory O O
depression O O
, O O
stupor O O
and/or O O
hypotension O O
with O O
the O O
concomitant O O
use O O
of O O
loxapine B-drug B-drug
and O O
lorazepam B-drug B-drug
. O O

The O O
latter O O
might O O
arise O O
from O O
a O O
hit O O
in O O
a O O
genetically O O
initiated O O
cell O O
, O O
the O O
result O O
of O O
which O O
is O O
a O O
more O O
rapid O O
progression O O
in O O
tumor O O
type O O
. O O

Coadministration O O
of O O
CRIXIVAN B-brand B-brand
and O O
other O O
drugs O O
that O O
inhibit O O
CYP3A4 O O
may O O
decrease O O
the O O
clearance O O
of O O
indinavir B-drug B-drug
and O O
may O O
result O O
in O O
increased O O
plasma O O
concentrations O O
of O O
indinavir B-drug B-drug
. O O

Probenecid B-drug B-drug
: O O
As O O
with O O
other O O
b-lactams B-group O
, O O
the O O
renal O O
excretion O O
of O O
cephalexin B-drug B-drug
is O O
inhibited O O
by O O
probenecid B-drug B-drug
. O O

Therefore O O
, O O
when O O
using O O
doses O O
of O O
Trileptal B-brand B-brand
greater O O
than O O
1200 O O
mg/day O O
during O O
adjunctive O O
therapy O O
, O O
a O O
decrease O O
in O O
the O O
dose O O
of O O
phenytoin B-drug B-drug
may O O
be O O
required O O
. O O

oxolinic B-drug B-drug
acid I-drug I-drug
; O O

Cimetidine B-drug B-drug
: O O
In O O
the O O
presence O O
of O O
cimetidine B-drug B-drug
at O O
300 O O
mg O O
QID O O
( O O
N=12 O O
) O O
the O O
mean O O
apparent O O
oral O O
clearance O O
of O O
gabapentin B-drug B-drug
fell O O
by O O
14 O O
% O O
and O O
creatinine O O
clearance O O
fell O O
by O O
10 O O
% O O
. O O

The O O
toxicity O O
of O O
cadmium O O
, O O
zinc B-drug B-drug
, O O
and O O
cadmium/zinc O O
mixtures O O
at O O
concentrations O O
ranging O O
from O O
10000 O O
to O O
10 O O
microg/l O O
was O O
investigated O O
. O O

Vecuronium B-drug B-drug
: O O
When O O
used O O
in O O
the O O
perioperative O O
period O O
, O O
piperacillin B-drug B-drug
has O O
been O O
implicated O O
in O O
the O O
prolongation O O
of O O
the O O
neuromuscular O O
blockade O O
of O O
vecuronium B-drug B-drug
. O O

The O O
agent O O
was O O
found O O
to O O
produce O O
some O O
inhibiting O O
activity O O
against O O
hepatic O O
microsomal O O
7-ethoxycoumarine O O
deethylase O O
in O O
male O O
Wistar O O
rats O O
in O O
vitro O O
and O O
in O O
vivo O O
experiments O O
. O O

Other O O
strong O O
inhibitors O O
of O O
CYP3A4 O O
( O O
itraconazole B-drug B-drug
) O O
would O O
be O O
expected O O
to O O
have O O
similar O O
effects O O
and O O
need O O
similar O O
dose O O
reductions O O
; O O

- O O
a O O
monoamine B-group B-group
oxidase I-group I-group
inhibitor I-group I-group
( O O
MAOI B-group B-group
) O O
such O O
as O O
isocarboxazid B-drug B-drug
( O O
Marplan B-brand B-brand
) O O
, O O
tranylcypromine B-drug B-drug
( O O
Parnate B-brand B-brand
) O O
, O O
or O O
phenelzine B-drug B-drug
( O O
Nardil B-brand B-brand
) O O
; O O

The O O
mean O O
percentage O O
increase O O
in O O
the O O
glipizide B-drug B-drug
AUC O O
after O O
fluconazole B-drug B-drug
administration O O
was O O
56.9 O O
% O O
( O O
range O O
: O O
35 O O
to O O
81 O O
) O O
. O O

A O O
potential O O
interaction O O
between O O
oral O O
miconazole B-drug B-drug
and O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
leading O O
to O O
severe O O
hypoglycemia O O
has O O
been O O
reported O O
. O O

Additive O O
adverse O O
effects O O
resulting O O
from O O
cholinergic O O
blockade O O
may O O
occur O O
when O O
LEVSIN B-brand B-brand
is O O
administered O O
concomitantly O O
with O O
other O O
antimuscarinics B-group B-group
, O O
amantadine B-drug B-drug
, O O
haloperidol B-drug B-drug
, O O
phenothiazines B-group B-group
, O O
monoamine B-group B-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
, O O
tricyclic B-group B-group
antidepressants I-group I-group
or O O
some O O
antihistamines B-group B-group
. O O

Additional O O
drugs O O
that O O
are O O
not O O
recommended O O
for O O
coadministration O O
with O O
INVIRASE B-brand B-brand
and O O
ritonavir B-drug B-drug
are O O
included O O
below O O
. O O

The O O
physician O O
is O O
advised O O
to O O
monitor O O
plasma O O
levels O O
of O O
phenytoin B-drug B-drug
and O O
to O O
decrease O O
the O O
dose O O
if O O
necessary O O
. O O

Benazepril B-drug B-drug
, O O
like O O
other O O
ACE B-group B-group
inhibitors I-group I-group
, O O
has O O
had O O
less O O
than O O
additive O O
effects O O
with O O
beta-adrenergic B-group B-group
blockers I-group I-group
, O O
presumably O O
because O O
both O O
drugs O O
lower O O
blood O O
pressure O O
by O O
inhibiting O O
parts O O
of O O
the O O
renin-angiotensin O O
system O O

Fifteen O O
to O O
30 O O
minutes O O
of O O
exposure O O
to O O
1.25 O O
MAC O O
isoflurane B-drug B-drug
or O O
enflurane B-drug B-drug
had O O
minimal O O
effects O O
on O O
the O O
duration O O
of O O
action O O
of O O
initial O O
doses O O
of O O
NIMBEX B-brand B-brand
and O O
therefore O O
, O O
no O O
adjustment O O
to O O
the O O
initial O O
dose O O
should O O
be O O
necessary O O
when O O
NIMBEX B-brand B-brand
is O O
administered O O
shortly O O
after O O
initiation O O
of O O
volatile O O
agents O O
. O O

In O O
vitro O O
studies O O
with O O
several O O
drugs O O
which O O
may O O
be O O
administered O O
concomitantly O O
showed O O
that O O
the O O
extent O O
of O O
flecainide B-drug B-drug
binding O O
to O O
human O O
plasma O O
proteins O O
is O O
either O O
unchanged O O
or O O
only O O
slightly O O
less O O
. O O

N-methyllevallorphan B-drug_n B-drug_n
( O O
5 O O
mg/kg O O
, O O
s.c. O O
) O O
completely O O
antagonized O O
the O O
inhibitory O O
effect O O
of O O
loperamide B-drug B-drug
and O O
partly O O
antagonized O O
the O O
effect O O
of O O
morphine B-drug B-drug
. O O

At O O
a O O
median O O
follow-up O O
of O O
33 O O
months O O
, O O
the O O
combination O O
of O O
ARIMIDEX B-brand B-brand
and O O
tamoxifen B-drug B-drug
did O O
not O O
demonstrate O O
any O O
efficacy O O
benefit O O
when O O
compared O O
with O O
tamoxifen B-drug B-drug
in O O
all O O
patients O O
as O O
well O O
as O O
in O O
the O O
hormone O O
receptor-positive O O
subpopulation O O
. O O

The O O
effect O O
of O O
dofetilide B-drug B-drug
on O O
the O O
steady-state O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
was O O
evaluated O O
in O O
a O O
randomized O O
, O O
double-blind O O
study O O
. O O

increased O O
platelet O O
count O O
; O O

The O O
effects O O
of O O
DCG-IV B-drug_n B-drug_n
and O O
L-CCG-1 B-drug_n B-drug_n
upon O O
phencyclidine B-drug_n B-drug_n
( O O
PCP B-drug_n B-drug_n
) O O
-induced O O
locomotion O O
and O O
behavioral O O
changes O O
in O O
mice O O
. O O

Serious O O
anticholinergic O O
symptoms O O
( O O
severe O O
dry O O
mouth O O
, O O
urinary O O
retention O O
, O O
blurred O O
vision O O
) O O
have O O
been O O
associated O O
with O O
elevations O O
in O O
the O O
serum O O
levels O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
when O O
cimetidine B-drug B-drug
is O O
added O O
to O O
the O O
drug O O
regimen O O
. O O

Concurrent O O
use O O
of O O
butorphanol B-drug B-drug
with O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
( O O
e.g. O O
, O O
alcohol B-drug B-drug
, O O
barbiturates B-group B-group
, O O
tranquilizers B-group B-group
, O O
and O O
antihistamines B-group B-group
) O O
may O O
result O O
in O O
increased O O
central B-group O
nervous I-group O
system I-group O
depressant I-group O
effects O O
. O O

Atromid-S B-brand B-brand
may O O
displace O O
acidic O O
drugs O O
such O O
as O O
phenytoin B-drug B-drug
or O O
tolbutamide B-drug B-drug
from O O
their O O
binding O O
sites O O
. O O

- O O
Corticosteroids B-group B-group
, O O
ACTH B-drug B-drug
: O O
Intensified O O
electrolyte O O
depletion O O
, O O
particularly O O
hypokalemia O O

Because O O
of O O
the O O
risk O O
of O O
serious O O
ventricular O O
arrhythmias O O
and O O
sudden O O
death O O
potentially O O
associated O O
with O O
elevated O O
plasma O O
levels O O
of O O
thioridazine B-drug B-drug
, O O
Duloxetine B-drug B-drug
and O O
thioridazine B-drug B-drug
should O O
not O O
be O O
co-administered O O
. O O

It O O
is O O
essentially O O
completely O O
metabolised O O
, O O
therefore O O
little O O
is O O
excreted O O
unchanged O O
. O O

Atazanavir B-drug B-drug

Alcohol B-drug B-drug
: O O
In O O
post-marketing O O
experience O O
, O O
there O O
have O O
been O O
rare O O
reports O O
of O O
adverse O O
neuropsychiatric O O
events O O
or O O
reduced O O
alcohol B-drug B-drug
tolerance O O
in O O
patients O O
who O O
were O O
drinking O O
alcohol B-drug B-drug
during O O
treatment O O
with O O
WELLBUTRIN B-brand B-brand
. O O

Such O O
an O O
interaction O O
can O O
potentially O O
lead O O
to O O
higher O O
free O O
fractions O O
of O O
either O O
tiagabine B-drug B-drug
or O O
the O O
competing O O
drug O O
. O O

PROSTIN B-brand B-brand
E2 I-brand I-brand
may O O
augment O O
the O O
activity O O
of O O
other O O
oxytocic B-group B-group
drugs I-group I-group
. O O

Single O O
dose O O
bioavailability O O
studies O O
in O O
normal O O
volunteers O O
have O O
failed O O
to O O
wshow O O
an O O
effect O O
of O O
aspirin B-brand B-brand
on O O
ibuprofen B-drug B-drug
blood O O
levels O O
. O O

Ergot O B-group
derivatives O I-group
: O O
dihydroergotamine B-drug B-drug
, O O
ergonovine B-drug B-drug
, O O
ergotamine B-drug B-drug
, O O
methylergonovine B-drug B-drug

fluoxetine B-drug B-drug
, O O
fluvoxamine B-drug B-drug
, O O
paroxetine B-drug B-drug
, O O
sertraline B-drug B-drug
) O O
. O O

In O O
vitro O O
studies O O
show O O
significant O O
inhibition O O
of O O
the O O
formation O O
of O O
oxidized O O
irbesartan O B-drug
metabolites O O
with O O
the O O
known O O
cytochrome O O
CYP O O
2C9 O O
substrates/inhibitors O O
sulphenazole B-drug B-drug
, O O
tolbutamide B-drug B-drug
and O O
nifedipine B-drug B-drug
. O O

Other O O
drugs O O
that O O
are O O
specific O O
substrates O O
, O O
inhibitors O O
, O O
or O O
inducers O O
of O O
the O O
enzyme O O
system O O
may O O
have O O
a O O
significant O O
impact O O
on O O
the O O
efficacy O O
and O O
side O O
effect O O
profile O O
of O O
diltiazem B-drug B-drug
. O O

[ O O
Quantitative O O
approach O O
to O O
treatment O O
with O O
incisive O O
neuroleptics B-group B-group
by O O
therapeutic O O
monitoring O O
] O O
; O O
The O O
problems O O
encountered O O
during O O
the O O
longterm O O
treatment O O
of O O
psychotic O O
patients O O
with O O
neuroleptics B-group B-group
are O O
illustrated O O
by O O
six O O
typical O O
case O O
reports O O
. O O

The O O
effect O O
of O O
BREVIBLOC B-drug B-brand
on O O
the O O
duration O O
of O O
succinylcholine-induced B-drug B-drug
neuromuscular O O
blockade O O
was O O
studied O O
in O O
patients O O
undergoing O O
surgery O O
. O O

In O O
treatment-experienced O O
patients O O
, O O
available O O
uncontrolled O O
data O O
suggest O O
these O O
agents O O
contribute O O
to O O
regimen O O
efficacy O O
in O O
NNRTI-na B-group O
ve O O
, O O
treatment-experienced O O
patients O O
. O O

While O O
all O O
the O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
( O O
SSRIs B-group B-group
) O O
, O O
e.g. O O
, O O
fluoxetine B-drug B-drug
, O O
sertraline B-drug B-drug
, O O
paroxetine B-drug B-drug
, O O
and O O
fluvoxamine B-drug B-drug
, O O
inhibit O O
P450 O O
2D6 O O
, O O
they O O
may O O
vary O O
in O O
the O O
extent O O
of O O
inhibition O O
. O O

Haloperidol B-drug B-drug
: O O
Haloperidol B-drug B-drug
blocks O O
dopamine O O
receptors O O
, O O
thus O O
inhibiting O O
the O O
central O O
stimulant O O
effects O O
of O O
amphetamines B-group B-group
. O O

No O O
drug O O
interactions O O
have O O
been O O
reported O O
between O O
Prostin B-brand B-brand
VR I-brand I-brand
Pediatric I-brand O
and O O
the O O
therapy O O
standard O O
in O O
neonates O O
with O O
restricted O O
pulmonary O O
or O O
systemic O O
blood O O
flow O O
. O O

Amiodarone B-drug B-drug
taken O O
concomitantly O O
with O O
procainamide B-drug B-drug
for O O
less O O
than O O
seven O O
days O O
increases O O
plasma O O
concentrations O O
of O O
procainamide B-drug B-drug
and O O
n-acetyl O B-drug_n
procainamide B-drug B-drug
by O O
55 O O
% O O
and O O
33 O O
% O O
, O O
respectively O O
. O O

In O O
some O O
patients O O
, O O
the O O
administration O O
of O O
INDOCIN B-brand B-brand
can O O
reduce O O
the O O
diuretic O B-group
, O O
natriuretic O O
, O O
and O O
antihypertensive B-group O
effects O O
of O O
loop O O
, O O
potassium-sparing O O
, O O
and O O
thiazide B-group B-group
diuretics I-group I-group
. O O

Improvements O O
in O O
general O O
cognitive O O
function O O
seen O O
with O O
olanzapine B-drug B-drug
treatment O O
in O O
a O O
1-year O O
controlled O O
study O O
of O O
patients O O
with O O
early-phase O O
schizophrenia O O
, O O
were O O
significantly O O
greater O O
than O O
changes O O
seen O O
with O O
either O O
risperidone B-drug B-drug
or O O
haloperidol B-drug B-drug
. O O

Intravenous O O
Pentamidine B-drug B-drug
: O O
Treatment O O
with O O
HIVID B-drug B-drug
should O O
be O O
interrupted O O
when O O
the O O
use O O
of O O
a O O
drug O O
that O O
has O O
the O O
potential O O
to O O
cause O O
pancreatitis O O
is O O
required O O
. O O

Studies O O
to O O
evaluate O O
possible O O
interactions O O
between O O
REVIA B-brand B-brand
and O O
drugs O O
other O O
than O O
opiates B-group B-group
have O O
not O O
been O O
performed O O
. O O

nalidixic B-drug O
acid I-drug O
; O O

The O O
findings O O
suggest O O
that O O
the O O
agent O O
has O O
slight O O
effects O O
on O O
the O O
tested O O
activities O O
. O O

Drug O O
Effect O O

Aminosalicylic B-drug B-drug
acid I-drug I-drug
may O O
decrease O O
the O O
amount O O
of O O
digoxin B-drug B-drug
( O O
Lanoxin B-brand B-brand
, O O
Lanoxicaps B-drug B-drug
) O O
that O O
gets O O
absorbed O O
into O O
your O O
body O O
. O O

Clinical O O
Comment O O

Quinidine B-drug B-drug
and O O
procainamide O B-drug
doses O O
should O O
be O O
reduced O O
by O O
one-third O O
when O O
either O O
is O O
administered O O
with O O
amiodarone B-drug B-drug
. O O

However O O
, O O
halothane B-drug B-drug
anesthetic O O
requirement O O
( O O
i.e. O O
, O O
MAC O O
) O O
was O O
depressed O O
in O O
a O O
dose-dependent O O
fashion O O
as O O
much O O
as O O
56 O O
% O O
1-2 O O
hours O O
and O O
as O O
much O O
as O O
14 O O
% O O
5-6 O O
hours O O
after O O
injection O O
of O O
ketamine B-drug B-drug
, O O
50 O O
mg/kg O O
, O O
im O O
. O O

CONCLUSIONS O O
: O O
The O O
combination O O
of O O
CHOP O O
plus O O
HAART O O
is O O
feasible O O
and O O
may O O
reduce O O
the O O
morbidity O O
from O O
OIs O O
in O O
HIV-NHL O O
patients O O
. O O

The O O
administration O O
of O O
local O O
anesthetic B-group B-group
solutions I-group O
containing O O
epinephrine B-drug B-drug
or O O
norepinephrine B-drug B-drug
to O O
patients O O
receiving O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
or O O
tricyclic B-group B-group
antidepressants I-group I-group
may O O
produce O O
severe O O
, O O
prolonged O O
hypertension O O
. O O

Phenobarbital B-drug B-drug
: O O
Decreases O O
aspirin B-brand B-brand
effectiveness O O
by O O
enzyme O O
induction O O
. O O

Orthostatic O O
hypotension O O
in O O
patients O O
taking O O
clozapine B-drug B-drug
can O O
, O O
in O O
rare O O
cases O O
( O O
approximately O O
1 O O
case O O
per O O
3,000 O O
patients O O
) O O
, O O
be O O
accompanied O O
by O O
profound O O
collapse O O
and O O
respiratory O O
and/or O O
cardiac O O
arrest O O
. O O

The O O
use O O
of O O
dextromethorphan B-drug B-drug
hydrobromide I-drug I-drug
may O O
result O O
in O O
additive O O
CNS O O
depressant O O
effects O O
when O O
coadministered O O
with O O
alcohol B-drug B-drug
, O O
antihistamines B-group B-group
, O O
psychotropics B-group B-group
or O O
other O O
drugs O O
that O O
produce O O
CNS O O
depression O O
. O O

However O O
, O O
in O O
vivo O O
drug O O
interaction O O
studies O O
of O O
ketoconazole B-drug B-drug
with O O
vitamin B-group B-group
D I-group I-group
have O O
not O O
been O O
investigated O O
. O O

No O O
inhibition O O
of O O
any O O
of O O
the O O
other O O
isoforms O O
tested O O
was O O
observed O O
at O O
gabapentin B-drug B-drug
concentrations O O
up O O
to O O
171 O O
mg/mL O O
( O O
approximately O O
15 O O
times O O
the O O
Cmax O O
at O O
3600 O O
mg/day O O
) O O
. O O

Dose O O
modification O O
is O O
recommended O O
for O O
patients O O
who O O
are O O
also O O
receiving O O
a O O
potent O O
CYP O O
3A4 O O
inducer O O
. O O

Following O O
a O O
10 O O
g O O
bolus O O
of O O
AMICAR B-brand B-brand
, O O
transient O O
peak O O
plasma O O
concentrations O O
of O O
4.6 O O
mMol/L O O
or O O
0.60 O O
mg/mL O O
have O O
been O O
obtained O O
. O O

Butalbital B-drug B-drug
, O O
acetaminophen B-drug B-drug
and O O
caffeine B-drug B-drug
may O O
enhance O O
the O O
effects O O
of O O
: O O
other O O
narcotic B-group B-group
analgesics O I-group
, O O
alcohol B-drug B-drug
, O O
general O O
anesthetics B-group B-group
, O O
tranquilizers B-group B-group
such O O
as O O
chlordiazepoxide B-drug B-drug
, O O
sedative-hypnotics B-group B-group
, O O
or O O
other O O
CNS B-group B-group
depressants I-group I-group
, O O
causing O O
increased O O
CNS O O
depression O O
. O O

Reduced O O
efficacy O O
and O O
increased O O
incidence O O
of O O
breakthrough O O
bleeding O O
and O O
menstrual O O
irregularities O O
have O O
been O O
associated O O
with O O
concomitant O O
use O O
of O O
rifampin B-drug B-drug
. O O

Discontinuation O O
of O O
cimetidine B-drug B-drug
in O O
well-controlled O O
patients O O
receiving O O
tricyclic B-drug B-group
antidepressants I-drug I-group
and O O
cimetidine B-drug B-drug
may O O
decrease O O
the O O
plasma O O
levels O O
and O O
efficacy O O
of O O
the O O
antidepressants B-drug B-group
. O O

Nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
have O O
been O O
reported O O
to O O
decrease O O
the O O
tubular O O
secretion O O
of O O
methotrexate B-drug B-drug
and O O
to O O
potentiate O O
its O O
toxicity O O
. O O

Pharmacokinetic O O
data O O
indicate O O
that O O
oral O O
ketoconazole B-drug B-drug
inhibits O O
the O O
metabolism O O
of O O
astemizole B-drug B-drug
, O O
resulting O O
in O O
elevated O O
plasma O O
levels O O
of O O
astemizole B-drug B-drug
and O O
its O O
active O O
metabolite O O
desmethylastemizole B-drug_n O
which O O
may O O
prolong O O
QT O O
intervals O O
. O O

Flurbiprofen B-drug B-drug
did O O
not O O
appear O O
to O O
affect O O
the O O
beta-blocker-mediated O O
reduction O O
in O O
heart O O
rate O O
. O O

In O O
patients O O
receiving O O
HCTZ B-drug B-drug
alone O O
, O O
dofetilide B-drug B-drug
AUC O O
increased O O
by O O
27 O O
% O O
and O O
Cmax O O
by O O
21 O O
% O O
. O O

descending O O
epsilon O O
and O O
mu O O
systems O O
for O O
beta-endorphin B-drug_n B-drug
and O O
morphine B-drug B-drug
, O O
respectively O O
, O O
are O O
proposed O O
. O O

Both O O
steady-state O O
maximum O O
concentration O O
and O O
AUC O O
were O O
dose O O
proportional O O
over O O
the O O
full O O
dose O O
range O O
when O O
assessed O O
on O O
day O O
1 O O
, O O
as O O
well O O
as O O
for O O
the O O
full O O
duration O O
of O O
the O O
study O O
at O O
steady O O
state O O
. O O

Non-steroidal B-group B-group
Anti-inflammatory I-group I-group
Agents I-group I-group
: O O
In O O
some O O
patients O O
with O O
compromised O O
renal O O
function O O
who O O
are O O
being O O
treated O O
with O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
, O O
the O O
co-administration O O
of O O
lisinopril B-drug B-drug
may O O
result O O
in O O
a O O
further O O
deterioration O O
of O O
renal O O
function O O
. O O

Drugs O O
which O O
may O O
potentiate O O
the O O
release O O
of O O
neutrophils O O
, O O
such O O
as O O
lithium B-drug B-drug
, O O
should O O
be O O
used O O
with O O
caution O O
. O O

bone O O
density O O
; O O

Treatment O O
with O O
entacapone B-drug B-drug
coadministered O O
with O O
levodopa/dopa B-drug B-drug
decarboxylase B-group B-group
inhibitor I-group I-group
does O O
not O O
change O O
these O O
effects O O
. O O

Pimozide B-drug B-drug
and O O
Celexa B-brand B-brand
- O O
In O O
a O O
controlled O O
study O O
, O O
a O O
single O O
dose O O
of O O
pimozide B-drug B-drug
2 O O
mg O O
co-administered O O
with O O
racemic O O
citalopram B-drug B-drug
40 O O
mg O O
given O O
once O O
daily O O
for O O
11 O O
days O O
was O O
associated O O
with O O
a O O
mean O O
increase O O
in O O
QTc O O
values O O
of O O
approximately O O
10 O O
msec O O
compared O O
to O O
pimozide B-drug B-drug
given O O
alone O O
. O O

Oral O O
Contraceptives B-group B-group
: O O
Multiple O O
dose O O
administration O O
of O O
tiagabine B-drug B-drug
( O O
8 O O
mg/day O O
monotherapy O O
) O O
did O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
oral O O
contraceptives B-group B-group
in O O
healthy O O
women O O
of O O
childbearing O O
age O O
. O O

The O O
clinical O O
significance O O
of O O
this O O
property O O
is O O
unknown O O
. O O

Cephalosporins B-group B-group
are O O
known O O
to O O
occasionally O O
induce O O
a O O
positive O O
direct O O
Coombs O O
test O O
. O O

Loperamide B-drug B-drug
and O O
morphine B-drug B-drug
( O O
0.1 O O
and O O
1.0 O O
mg/kg O O
, O O
s.c O O
. O O
) O O

As O O
with O O
other O O
cephalosporins B-group B-group
, O O
high O O
concentrations O O
of O O
cefotetan B-drug B-drug
may O O
interfere O O
with O O
measurement O O
of O O
serum O O
and O O
urine O O
creatinine O O
levels O O
by O O
Jaffe O O
reaction O O
and O O
produce O O
false O O
increases O O
in O O
the O O
levels O O
of O O
creatinine O O
reported O O
. O O

Profound O O
hypotensive O O
episodes O O
may O O
occur O O
when O O
diazoxide B-drug B-drug
infection O O
and O O
hydralazine B-drug B-drug
are O O
used O O
concomitantly O O
. O O

However O O
, O O
concomitant O O
administration O O
of O O
5 O O
mg O O
b.i.d O O
. O O
isradipine B-drug B-drug
and O O
40 O O
mg O O
b.i.d O O
. O O

Two O O
groups O O
( O O
SH/DA O O
; O O
SH/FA O B-brand
) O O
were O O
submitted O O
to O O
daily O O
treatment O O
with O O
synthetic O B-group
hydroalcoholic O B-drug
solutions O O
containing O O
ethanol B-drug B-drug
, O O
methanol B-drug_n B-drug
, O O
higher O O
alcohols B-drug_n B-drug
and O O
acetaldehyde B-drug_n B-drug
in O O
the O O
same O O
proportions O O
as O O
those O O
found O O
in O O
most O O
common O O
distilled O O
and O O
fermented O O
alcoholic O B-drug
beverages O O
; O O

This O O
interaction O O
should O O
be O O
given O O
consideration O O
in O O
patients O O
taking O O
VIOXX B-brand B-brand
concomitantly O O
with O O
ACE B-group B-group
inhibitors I-group I-group
. O O

Esomeprazole B-drug B-drug
inhibits O O
gastric O O
acid O O
secretion O O
. O O

Antihistamines B-group B-group

Anesthetics B-group B-group

Acetaminophen B-drug B-drug
: O O
A O O
report O O
of O O
severe O O
acetaminophen B-drug B-drug
toxicity O O
was O O
reported O O
in O O
a O O
patient O O
receiving O O
Isoniazid B-drug B-drug
. O O

Interaction O O
between O O
glycine B-drug B-drug
and O O
glutamate B-drug B-drug
in O O
the O O
development O O
of O O
spontaneous O O
motility O O
in O O
chick O O
embryos O O
. O O

The O O
interaction O O
was O O
pharmacodynamic O O
with O O
no O O
alteration O O
of O O
the O O
pharmacokinetics O O
of O O
either O O
drug O O
. O O

The O O
pharmacokinetics O O
of O O
theophylline B-drug B-drug
were O O
not O O
altered O O
. O O

b O O
This O O
table O O
is O O
not O O
all-inclusive O O
. O O

